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Angiogenesis (formation of new blood vessels) is essential for tissue growth and
development. The adult vasculature is generally quiescent, except in the ovaries and
uterus, which undergo cyclical angiogenesis to ensure adequate provision of nutrients
and hormone precursors essential for establishment and maintenance of pregnancy.
These tissues provide excellent models in which to study angiogenesis. Clinically,
inadequate luteal vascularisation may cause reduced luteal function and insufficient
progesterone production, resulting in early embryo loss or failure of the blastocyst to
implant directly resulting from an inadequately prepared endometrium. This thesis
investigated angiogenesis in the primate corpus luteum and endometrium of early
pregnancy.
The coipus luteum is a transient endocrine gland responsible for progesterone
production to induce changes in uterine endometrium necessary for implantation of
the developing blastocyst and establishment of pregnancy. In the absence of
conception, progesterone declines resulting in endometrial destabilisation. Should
conception occur, the corpus luteum is rescued by chorionic gonadotrophin
synthesised by the developing trophoblast, and retains its functional capacity to
synthesise and secrete progesterone until such time as this role is transferred to the
placenta.
The first experiment investigated whether there exists a further burst of
angiogenesis in the corpus luteum of early pregnancy at the time of luteal rescue
which may be involved in prolonging its lifespan. Ovaries were collected from non¬
pregnant animals in the late luteal phase at day 21 after ovulation and from pregnant
animals at day 21 and day 28 post ovulation. In vivo luteal angiogenesis was assessed
by quantitative immunocytochemistry of 1) Bromodeoxyuridine (BrdU)
incorporation, 2) Assessment of the microvascular network by CD31 endothelial cell
marker and 3) Pericyte recruitment by smooth muscle a-actin staining. Molecular
regulation of angiogenesis was assessed by in situ hybridisation of mRNA for
Vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 and VEGFR-
2, followed by image analysis of grain density and grain area. No increase in any
xxi
cellular or molecular angiogenic parameter was observed in the marmoset corpus
luteum during luteal rescue. It was concluded that the vasculature already established
by the late luteal phase is all that is required to maintain early pregnancy.
At the uterine level, early pregnancy is associated with changes that allow
implantation and give rise to an environment capable of supporting early embryonic
development.
The metabolic demands of a newly implanted blastocyst are met by diffusion
from the endometrial vasculature, as such, a stable and well developed maternal
vascular network is an essential prerequisite for successful implantation and early
pregnancy. The second experiment aimed to elucidate the angiogenic events
occurring during the peri-implantation period and in early pregnancy. Uteri were
studied at day 14, 21 and 28 of pregnancy, together with non-pregnant uteri from day
14 and day 21 post-ovulation. Cellular parameters were studied by volume fraction
analyses of uterine sections dual stained with BrdU and CD31. Increased
angiogenesis was observed in the endometrium at this time. VEGF, VEGFR-1,
VEGFR-2, Angiopoietin-1, Angiopoietin-2 and Tie-2 mRNA's were localised by in
situ hybridisation to describe the spatial and temporal expression of these factors and
to indicate putative mechanisms by which the observed changes in the vasculature
occur. Messenger RNA for VEGF and its receptors increased from the time of
implantation throughout pregnancy, as did Angiopoietin-1. Particularly high levels of
expression were observed at a focal point immediately adjacent to the implantation
site. This work provides evidence that angiogenesis, regulated by VEGF and the
angiopoietins, may be involved in the preparation of endometrium for implantation,
remodelling of the maternal vasculature during the peri-implantation period and
trophoblast invasion.
This thesis has improved our understanding of the angiogenic events occurring
in the corpus luteum and endometrium of early pregnancy and its molecular
regulation.
Chapter 1 Introduction 1
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1 Introduction
1.1 Overview
Angiogenesis refers to formation of new blood vessels, or neovascularisation
and is an essential component of tissue growth and development. Apart from wound
healing, the adult vasculature is generally quiescent, with vascular endothelium
representing an extremely stable population of cells with low mitotic rate. Intense or
persistent capillary growth is associated with several pathological conditions
including tumour growth, retinopathies, hemangiomas, fibroses and rheumatoid
arthritis. Notable exceptions of physiological angiogenesis occur in the female
reproductive tract, ovaries, uterus and placenta. These tissues undergo cyclical
angiogenesis to ensure adequate provision of nutrients and hormone precursors
essential for establishment and maintenance of pregnancy. As such the female
reproductive tissues provide excellent models in which to study angiogenesis. It is
the regulation of angiogenesis in the primate corpus luteum and endometrium of
early pregnancy which form the subject of this thesis.
The corpus luteum is a transient endocrine gland principally responsible for
progesterone production. One function of progesterone is to induce changes in
uterine endometrium necessary for implantation of the developing blastocyst and
establishment of pregnancy. The corpus luteum is formed from the dominant follicle
after ovulation and persists throughout the luteal phase until such time as it
undergoes functional and structural regression. Luteal regression results in declining
progesterone production causing endometrial destabilisation and menstruation in the
human.
The human luteal phase or functional lifespan of the corpus luteum is 14 days
and 21 days in the marmoset. Should conception occur, the corpus luteum is rescued
by chorionic gonadotrophin (humans and non-human primates) synthesised by the
developing trophoblast, and retains its functional capacity to synthesise and secrete
progesterone until such time as this role is transferred to the placenta.
During the follicular phase the follicular granulosa layer remains avascular,
separated from the vascularised theca by a basement membrane. After ovulation, the
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granulosa layer becomes vascularised transforming the newly formed corpus luteum
into a highly active endocrine gland. Extensive angiogenesis occurs in the early
luteal phase gradually decreasing throughout the lifespan of the corpus luteum. In a
non-fertile cycle the corpus luteum undergoes functional and structural regression.
Functional luteolysis is associated with a decline in progesterone production after
which structural luteolysis occurs, associated with vessel atrophy, and formation of a
relatively avascular structure, visible within the ovary in subsequent cycles.
In a fertile cycle, the maintenance or rescue of the corpus luteum ensures
continued presence of progesterone, maintaining the intrauterine environment and
preventing menstruation.
Progesterone acts on the endometrium as a differentiation factor. Oestrogens
induce endometrial proliferation during the follicular phase, a process inhibited by
progesterone in the luteal phase. Progesterone induces stromal differentiation,
stimulates glandular secretions and changes the pattern of proteins secreted by
endometrial cells. All these events prepare the uterus for implantation and give rise
to an environment capable of supporting early embryonic development. Progesterone
also inhibits myometrial contractility.
Many factors thought to be involved in the regulation of angiogenesis, with the
exception of VEGF and bFGF, have been determined largely from gene knockout
studies investigating embryonic vascularisation in transgenic mice, in vitro studies
and from analysis of tumour angiogenesis. Luteal angiogenesis has been widely
studied throughout the luteal phase in human and primates but the role of
angiogenesis in luteal rescue in vivo in the primate has yet to be elucidated. The
corpus luteum, being one of the exceptional adult tissues to undergo cyclic
angiogenesis forms a unique model for studying the dynamic processes involved in
such a rapid onset and tightly controlled process.
The clinical implications of angiogenesis research are paramount. Inadequate
luteal vascularisation may be a cause of reduced luteal function and insufficient
progesterone production. This could result in early embryo loss or indeed failure of
the blastocyst to implant directly resulting from an inadequately prepared
endometrium. There are many pathological conditions associated with unregulated
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angiogenesis such as retinopathies, rheumatoid arthritis, tumour growth and
psoriasis, therefore clinical research into this field remains important. Also,
manipulation of luteal angiogenesis in both pregnant and non-pregnant cycles could
lead to novel strategies in post-ovulatory or post-coital fertility control.
This chapter reviews the current understanding of 1) The formation and
control of the corpus luteum in fertile and non-fertile cycles with regard to
angiogenesis and 2) Cyclic changes in the endometrium and those associated with
early pregnancy. Firstly, the ovarian cycle will be discussed: Folliculogenesis
culminating in ovulation, subsequent luteal development, luteolysis, the maternal
recognition of pregnancy and luteal rescue with emphasis on functional relevance of
ovarian vascularisation. Molecular control of angiogenesis will then be discussed
with reference to current understanding of its role in early pregnancy. Cyclic changes
in endometrium, menstruation, implantation and placentation will also be addressed,
again with emphasis on the angiogenic process. Finally the clinical relevance of the
study of in vivo angiogenesis in early pregnancy in the corpus luteum and
endometrium will be evaluated with details of current understanding ofmanipulation
of angiogenesis.
This chapter serves to introduce the field of clinical angiogenesis research
and to evaluate current knowledge in order that rationale for the succeeding
experimental chapters be appreciated.
In each section I have tried to give an overall review referring to human, non-
human primates, rodents and domestic species. However, it should not be assumed
that mechanisms occurring in one species will be the same in another and so unless
experiments have been conducted to confirm species similarities or differences, I
have not extrapolated from one to another.
1.2 Experimental models
With the exception of data presented in Chapter 4, all results presented in this
thesis were obtained using the marmoset monkey (Callithrix jacchus) as an
experimental model for this in vivo investigation into angiogenesis and tissue
remodelling at the time of implantation and in subsequent early pregnancy in corpus
luteum and uterus. Using a primate model allows the identification and manipulation
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of angiogenic factors that may be important in the human therefore forming a bridge
between basic research in the laboratory and clinical application. Mechanisms by
which luteal function is regulated are markedly different in rodents compared to
primates (Fraser and Lunn, 2001). In the non-fertile cycle in the rodent, the corpus
luteum is active for less than a day making it difficult to discern discrete phases of
vessel maturation and vessel regression that follow the angiogenic phase of the
corpus luteum. In contrast, the marmoset corpus luteum remains active for 2-3 weeks
allowing the stages of the luteal phase to be accurately dissected out and studied
(Augustin, 2000). Another advantage is that the marmoset ovulatory cycle can be
reliably synchronised by PGF2« administration, any time after luteal day 8, causing
luteal regression and subsequent ovulation 10 days later (Summers, et ah, 1985).
Marmosets also have a high fertility rate, short gestation (Fraser et al., 1994) and
unlike the human and bovine are not a monovulatory species, ovulating two to three
ova per cycle. Rodents, however, are multiple ovulators and are therefore arguably
more dissimilar to the human than the marmoset (Augustin, 2000).
1.3 The marmoset ovulatory cycle
The marmoset ovulatory cycle lasts approximately 28 days and there are
usually two to three ova shed at ovulation. The follicular phase lasts about 8 days
followed by a luteal phase of about 20 days (Harding, 1982). At the end of the luteal
phase, structural and functional regression of the corpus luteum occurs in non¬
pregnant cycles while in pregnancy, the corpus luteum is rescued by the presence of
chorionic gonadotrophin.
Implantation in the marmoset occurs on day 11 after ovulation and the
blastocyst remains in loose attachment to the surface epithelium without epithelial
fusion. Penetration of trophoblast into maternal vessels occurs at around day 45 to 60
of gestation (Enders, 1993).
For the purposes of this thesis, pregnant marmosets were studied at day 14
(around the peri-implantation period), day 21 and day 28 of the luteal phase, together
with non-pregnant animals from day 14 and day 21.
As a model for the human, the marmoset presents some differences. It is not a
mono-ovulatory species, it has a luteal phase length of approximately 21 days, as
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opposed to 14 days in the human, and the structure of its corpus luteum differs to that
of the human. It displays subtly different implantation and placentation and does not
menstruate. However, it has allowed for the first time, the study of physiological
pregnancy as opposed to pharmacological pregnancy, by hCG treatment, in a primate
model. Such invasive investigations of endometrial angiogenesis and structure of the
early implantation site could not be carried out in higher primates. Its high fecundity,
greater that 70% fertility rate, offers a considerable advantage over other commonly
studied non-human primates, where fertility rate is in the region of 30%. The
marmoset has an ovulatory cycle more analogous to the human than any rodent
species, and so is an appropriate animal model.
In order to investigate angiogenesis in the marmoset and to compare this to
the human, it is necessary to understand what is happening at this time in both
species. Progesterone is a key player in early pregnancy. Maintenance of pregnancy
in mammals requires progesterone production by the ovarian corpus luteum and in
most species, the functional lifespan of the CL is extended to maintain this
production (Zeleznik and Benyo, 1994). In humans, the CL remains the primary
source of progesterone for 4-5 weeks after implantation until placental production
becomes sufficient to maintain pregnancy. The mechanisms of luteal rescue vary
among species. In rodents, coitus initiates rescue whereas in human and primates,
rescue is initiated by the conceptus through its production of chorionic
gonadotroophin.
The general pattern of progesterone production during the first trimester of
pregnancy has been described in the human. Luteal rescue by hCG is associated with
increased luteal progesterone secretion both in normal (Lenton and Woodward,
1988) and simulated early pregnancy (Mendizabal et al., 1984, Tay and Lenton,
2000). This observation forms the first discrepancy between these two species, for in
the marmoset, progesterone levels are maintained in early pregnancy at levels
already attained in the luteal phase but are not further augmented during luteal rescue
(See chapter 3).
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1.4 Folliculogenesis
The corpus luteum is pivotal to the control of the menstrual cycle and is formed
from ovulation of the pre-ovulatory cycle; Once formed the corpus luteum secretes
progesterone throughout the luteal phase and its regression signifies the beginning of
the follicular phase of the subsequent cycle. Maturational changes occurring during
the follicular phase are essential for adequate luteal function therefore it is important
to firstly discuss events prior to ovulation in order to fully appreciate the role of this
endocrine gland. The involvement of pituitary gonadotrophin secretion on
folliculogenesis will also be considered as gonadotrophins play a fundamental and
essential role in reproductive function at all levels.
During the follicular phase of the human menstrual cycle, the follicle destined to
ovulate increases in size from a diameter of 2-5mm to over 20mm and becomes the
major ovarian source of secreted oestrogen. This oestrogen synthesising capacity
accompanies a programmed sequence of cell growth and differentiation in the follicle
which terminates in ovulation and formation of the corpus luteum (Hillier, 1991).
The sequence of events which transpire during folliculogenesis will be discussed in
more detail in the subsequent section but Figure 1.1 highlights the main stages.
PRIMORDIAL Essentiallyquiescent; Verylittleatresia PRE-ANTRAL Committedfollicl
GCproliferation Antralformation Thecal vascularisation




















c o o" 3
Gonadotrophin- dependent
(X)
Chapter 1 Introduction 9
1.4.1 Pre-antral development
Individual follicles within the primordial follicle reserve are stimulated to
commence development in a process known as folliculogenesis. The primordial
follicle consists of an oocyte surrounded by a single layer of flattened epithelial cells
and is essentially devoid of a capillary network. At this stage there is very little
evidence of atresia and cell turnover rates are low (Hirshfield, 1991). Primordial
follicles are recruited to undergo follicular maturation in an ordered sequence
thought to commence with those from the innermost regions of the ovarian cortex
(Smith et al., 1993). On leaving the primordial pool, follicles are irreversibly
committed to growth and can no longer return to a quiescent state. Several theories
have been suggested to explain initiation of follicle recruitment, but the stimulus for
follicle growth still remains unclear (Baird, 1991). However, evidence from studies
of hypophysectomised sheep indicate that pituitary hormones are not required
(McNatty et al., 1992).
The first detectable events in the transformation from a primordial follicle to a
committed follicle include RNA synthesis by the oocyte, formation of the zona
pellucida, a change in shape of the granulosa cells from flat to cuboidal and
granulosa proliferation which continues in concentric circles around the oocyte.
When two or three layers of granulosa cells are formed, thecal cells differentiate
from the surrounding stroma with a concentric alignment to the basement membrane
(Scaramuzzi et al., 1993). Fluid subsequently accumulates in spaces between the
epithelial cells and the follicle becomes vesicular. Once the granulosa layer has
become two, three and then four layered, blood capillaries invade the fibrous layer of
the theca externa and thus the theca becomes vascularised. These capillaries remain
the only source of nutrients and hormone precursors to both the granulosa layer and
oocyte by diffusion until ovulation and concurrent collapse of the basement
membrane separating the two layers occurs (Baker, 1972).
During each reproductive cycle, under the influence of pituitary FSH, a pool of
growing follicles are stimulated to undergo further growth and maturation. This
pituitary dependent phase of follicular growth involves further multiplication in the
number of granulosa cells and also passage of fluid into the spaces between them
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(liquor folliculi). As the quantity of fluid increases so do the cavities that it occupies
and they become confluent to form the antrum. The follicle is now of the Graafian
type.
1.4.2 Antral development
By the time an antrum is formed (in women at a follicular diameter of 0.2mm),
the gonadotrophins, follicle stimulating hormone (FSH) and luteinising hormone
(LH) are required although relative amounts vary depending on stage of
development. This concept will be further discussed below (Baird, 1991). Follicles
entering the last 14 days of pre-ovulatory development, corresponding to the first
halfof the menstrual cycle, are between 2 and 4mm in diameter (Baird, 1991).
1.4.3 Selection of the dominant follicle
From the pool of small antral follicles (2-5mm diameter) a single follicle is
selected for further development in the human and the rest become atretic. The
trigger for this is still not fully understood. It may be that all these follicles are at
subtly different stages of development despite being a similar size, not all receptive
to the gonadotrophin milieu of high LH and FSH, following luteal regression
(McNatty, 1982). In multiple ovulators for example the pig and marmoset, it is
assumed that development of such follicles is synchronous so that several can
concurrently be selected to undergo further maturation (Baird, 1987).
FSH is known to play a crucial role in selection. Large healthy follicles in
women all contain easily detectable levels of FSH while those with lower FSH levels
have much lower steroidogenic output (Zeleznik and Hillier, 1996). It is thought that
local paracrine factors may play a role in selecting the dominant follicle while locally
produced steroidal and non-steroidal factors probably modulate the responsiveness of
the ovarian cells to gonadotrophins.
Once selected, it is the chosen follicle that ensures suppression of
development of other follicles. It is thought that this is mediated by suppression of
FSH due to the rise in oestradiol levels secreted by this dominant follicle. Inhibin
and oestradiol both have the potential to negatively regulate pituitary FSH secretion
(Groome et ah, 1995), but there is evidence that it is the oestradiol that is the primary
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regulator of FSH secretion during the follicular phase of the human and non-human
primate ovarian cycles (Zeleznik and Kubik, 1986). As a result of this negative
feedback, FSH levels fall too low to sustain the development of other follicles within
the cohort and they become non-ovulatory and undergo atresia (Zeleznik and Hillier,
1996). The dominant follicle is thought to be protected from atresia as it is more
sensitive to FSH than other less favoured follicles and thus can survive in FSH levels
below the 'threshold' necessary to recruit further follicles. The presence of LH
receptors on granulosa cells of the maturing follicle could also contribute to its
protection from declining FSH levels (Yong et al., 1992). In addition to changes in
the density of gonadotrophin receptors, vascularisation of the dominant follicle could
also contribute to its survival, where gonadotrophins are preferentially delivered to it.
In rhesus monkeys, the dominant follicle has a capillary supply three times more
dense than subordinate follicles (Zeleznik et ah, 1981). The dominant follicle may
also secrete angiogenic mitogens causing its selective vascularisation. Vascular
endothelial growth factor (VEGF) for example, is apparently selectively expressed
by the maturing follicle (Ravindranath et ah, 1992). There also exist a number of
paracrine and autocrine regulators of FSH action which could serve a role in
providing increased sensitivity of the dominant follicle to FSH, however details of
these will not be provided at this point (Zeleznik and Hillier, 1996).
The follicle which will eventually ovulate is now approaching a diameter of
about 10mm and is beginning to secrete increasing amounts of oestradiol (Baird,
1991). Over 95% of the oestradiol produced in the follicular phase of the cycle
comes from the dominant follicle, thus by the mid-follicular phase, the selected
follicle can dictate to the hypothalamo-pituitary unit, to secrete an optimal
gonadotrophin cocktail, for its further development.
1.4.4 Gonadotrophin control of pre-ovulatory follicular
development
Ovarian cyclicity is controlled by a feedback system involving the
hypothalamus, anterior pituitary and the ovaries. FSH and LH are secreted by
gonadotrophs in the anterior pituitary in response to gonadotrophin-releasing
12Chapter 1 Introduction
hormone (GnRH) that interacts with specific receptors on the surface of the
gonadotroph. Serum levels of LH and FSH are shown in Figure 1.2.
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Figure 1.2 Gonadotrophin levels throughout the human menstrual cycle
(Clarke, 1996)
1.4.4.1 FSH
As the corpus luteum regresses, steroid and inhibin mediated negative
feedback to the pituitary are removed and consequent increased pituitary FSH
secretion occurs at the beginning of a subsequent cycle. This increased FSH
production by the pituitary constitutes the primary signal for pre-ovulatory follicular
development to commence (Hsueh et al., 1989). A 5mm antral follicle will require
10-12 days of sustained stimulation by FSH to attain a full pre-ovulatory diameter of
approximately 20mm. During which time the number of granulosa cells increase to
reach over 50 million (McNatty, 1981). It is FSH which stimulates granulosa cell
proliferation directly and also induces LH-responsive mechanisms on these cells
previously limited to the thecal layer (Channing and Tsafriri, 1977). FSH stimulation
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to granulosa cells also causes increased synthesis of steroids (progesterone and
oestrogen) (McNatty, 1981) and overall increased responsiveness to FSH and LH
(Hillier, 1985, Hsueh et ah, 1984, Richards, 1980).
There exist several FSH inducible genes. These include the LH receptor itself
(Segaloff et al., 1990) and some major steroidogenic enzymes including aromatase
(P450arom) crucial in conversion of androstenedione and testosterone to oestradiol
in granulosa cells of the small antral follicle (Mendelson et al., 1988). Proteases such
as plasminogen activator and regulatory peptides, such as inhibin and follistatin may
also be induced by FSH (Hillier, 1991).
1.4.4.2 LH
Steroidogenesis in the antral follicle is critically dependent on LH, as is the
corpus luteum. In the early follicular phase of the cycle the concentration of LH rises
as the suppressive effect of progesterone is removed following luteal regression.
Follicular oestrogen synthesis occurs in the second half of the follicular phase when
frequency of pituitary LH pulses increases and FSH declines. This occurs until mid-
cycle where oestrogen secretion is suppressed by the ovulatory LH surge.
Granulosa LH receptors develop in response to FSH stimulation. LH
receptors are also located on thecal cells and androgen synthesis in these cells is
under direct LH control mediated through adenylyl cyclase signalling (Golos et al.,
1987, Magoffin, 1989, Marsh, 1976).
1.4.5 Putative Intraovarian regulators
Despite the widely accepted role of gonadotrophins in folliculogenesis, the
continued variable fate of follicles exposed to the same hormone milieu suggests the
existence of other intraovarian modulatory systems (Adashi and Rohan, 1994).
It is thought that most intraovarian communication is autocrine or paracrine
in nature. Paracrine communication involves local diffusion of regulators from their
site of production to their designated target cells within the same organ. The
adequate endocrine function of the follicle in terms of oestradiol synthesis depends
upon the ability of the theca to provide the granulosa cells with androgenic substrate
(Adashi and Rohan, 1994). The granulosa therefore may produce regulators which
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could alter the function of the neighbouring theca. It has been suggested that
granulosa-theca cell interactions are paramount in maintenance of follicular structure
and function. Theca cells secrete inhibitory factors to suppress differentiation of
immature granulosa cells while promoting that of mature cells during co-culture of
bovine theca and granulosa cells; granulosa cells were also shown to secrete factors
promoting both growth and differentiation of thecal cells (Yada et ah, 1999).
Autocrine communication is based upon a cell modulating its activity by
detecting its own message at surface receptors. In the ovary, the granulosa cells
produce local autocrine factors which may alter granulosa cell function. Steroids may
exert intracrine effects (regulation within the cell of origin), but there is little
evidence for juxtacrine (contact-dependent regulation between immediately adjacent
cells) mediators in the ovary (Adashi and Rohan, 1992).
Most studies of intraovarian regulation of folliculogenesis have been in rats
or from in vitro experiments. From which several putative peptidergic intraovarian
regulators have been discovered, some ofwhich will be discussed briefly below.
Insulin-like growth factor-I for example, is produced in the rat granulosa cell
and its receptors are located on both granulosa and theca cells. This signal molecule
has been indicated to have many roles within the ovary including amplification of
gonadotrophin action (Adashi and Rohan, 1994). Depletion of IGF action may be
necessary for the onset of atresia and thus IGF may confer follicular survival.
Conversely, transforming growth factor a has been put forward as a candidate
attenuator of gonadotrophin action. Other peptidergic regulators of gonadotrophins
include activin, inhibin and the interleukin-I system, details of which will not be
given here.
Steroids can also act as paracrine regulators of ovarian function. Locally
produced androgens act via granulosa cell androgen receptors to modulate follicular
responsiveness to gonadotrophins and thus serve as paracrine regulators of ovarian
function (Hillier et al., 1997). Androgen receptor is down regulated during FSH-
induced pre-ovulatory follicular development in the rat (Tetsuka and Hillier, 1996)
and marmoset (Hillier, et al., 1997), suggesting that paracrine androgen action is
influenced by development-related changes in granulosa cell androgen receptor
expression.
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1.4.6 Steroidogenesis- Mechanisms of follicular oestrogen synthesis
Both theca and granulosa cells are required for oestrogen synthesis by the antral
follicle. Androstenedione and testosterone are produced by the theca interna under
positive regulation by LH (Erickson et al., 1985). They are produced from
cholesterol transported to the follicle by the vascularised thecal layer in a reaction
catalysed by P450cl7. This enzyme is expressed exclusively by thecal/interstitial
cells and theca lutein cells and has both 17-hydroxylase and C-17,20-lyase activities
(Richards et al., 1987, Sasano et al., 1989). These androgens act as precursors for
oestrogen synthesis in the granulosa cells which are thought to be the exclusive
source of oestradiol synthesis in the follicle (Dorrington and Armstrong, 1979). It has
been calculated that over 99% of aromatase activity lies in this layer (Hillier et al.,
1981). It is worth noting that despite these very specific roles of individual cell types,
oestradiol production depends both on FSH and LH. FSH does indeed stimulate
granulosa cell aromatase activity in antral follicles, but without the androgen
precursors produced by the theca upon stimulation by LH this would not be possible.
Follicular steroidogenesis is in fact a complex and tightly controlled event involving
both cell types of small antral follicles. In this way, the granulosa cells are activated
to utilize efficiently the increased amounts of androgen produced by the theca in
response to the LH rise following luteal regression (Baird, 1991).








Figure 1.3 Two-cell, two-gonadotrophin theory of steroidogenesis, adapted from
(Zeleznik and Hillier, 1996). Androgen synthesis occurs in the theca interna
regulated by LH. This is the rate limiting step where C21 substrates are hydrolysed to
C19 androgens catalysed by 17-hydroxylase/Ci7_2o-lyase (P450cl7). Aromatase
(P450arom) is the granulosa cell enzyme that converts C19 androgens
(androstenedione and testosterone) to Cig oestrogens (estrone and oestradiol)-
induced by FSH. FSH also induces granulosa LH receptors which are coupled to
aromatase. Thus androgen is synthesised in thecal cells and aromatised to oestrogen
in granulosa cells.
Progesterone synthesis is only a minor granulosa cell function before the
onset of the LH surge. However, LH responsive steroidogenic enzymes crucial to
progesterone synthesis in the corpus luteum are induced by FSH during pre¬
ovulatory granulosa cell development, notably P450scc (Funkenstein et al., 1984,
Richards et al., 1987). FSH-responsive aromatase activity and progesterone synthesis
in granulosa cells increase markedly during preovulatory follicular development in
rat (Hillier et al., 1978, Zeleznik et al., 1977), human (Hillier, et al., 1981) and non-
human primate ovaries (Harlow et al., 1988). This is thought to be mediated by
amplification of cAMP intracellular signalling and could further contribute to the
dominant follicle's ability to continue to synthesise and secrete oestrogen in the face
of declining levels of FSH.
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1.4.7 Termination of follicular oestrogen synthesis
Several hours after the onset of the ovulatory LH surge, thecal androgen
synthesis is suppressed resulting in reduced oestradiol output. The exact mechanism
for this discontinuation of androgen synthesis is not fully understood but is thought
to be a consequence of thecal desensitisation to LH brought about by the rapid and
extreme increase in circulating LH levels characteristic of this stage of the ovulatory
cycle. Desensitisation appears to involve impaired coupling of the LH receptor to the
guanine nucleotide binding regulatory protein Gs (Ekstrom and Hunzicker-Dunn,
1989).
Once the LH surge subsides and ovulation has occurred, thecal androgen
synthesis is reinitiated in the CL (Hillier, 1991). The LH surge does not suppress
granulosa cell aromatase activity, it may in fact even enhance it. Progesterone
synthesis in the granulosa layer is also enhanced by the LH surge in preparation for
the progesterone secreting role of the corpus luteum (Hillier, 1985).
1.4.8 Atresia
Folliculogenesis occurs continually throughout life until the stock of oocytes
is exhausted (Gougeon, 1982). The majority of follicles become atretic at the antral
stage of development but the number attaining ovulatory status is more or less fixed
for a given species by the levels of circulating gonadotrophins. A follicle is described
as being functionally atretic when it has sustained irreversible degeneration
preventing it from further development and ovulation (Scaramuzzi, et al., 1993).
1.5 Ovulation
Ovulation marks the pivotal point in the ovarian cycle. It marks the terminal
step in the growth and differentiation of the follicle and an essential prerequisite for
corpus luteum formation.
1.5.1 The LH Surge
Ovulation occurs in response to a massive discharge of LH from the anterior
pituitary. It is the action of oestrogen on the hypothalamo-pituitary unit that
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stimulates this pre-ovulatory LH discharge via a GnRH surge. How oestrogen exerts
this positive feedback mechanism remains to be fully understood but it is thought to
exert an effect at both the hypothalamus and pituitary.
Oestrogen sensitises the gonadotrophs to the effects of GnRH resulting in
progressively more and more LH released throughout the follicular phase following
GnRH injection, reviewed by Baird, 1991. Restoration of ovarian cyclicity and
subsequent ability to ovulate can be restored to hypogonadotrophic rhesus monkeys
by hourly pulses of GnRH (Wildt et al., 1981). The LH surge is likely to be due to
pulsatile GnRH release from the hypothalamus, acting on a hypersensitive pituitary.
Ovulation can also be induced in FSH primed pre-ovulatory follicles by
administration of exogenous HCG as an LH substitute (Zeleznik and Hillier, 1996).
Circulating levels of progesterone rise prior to ovulation at about the same
time as the onset of the LH surge. This is caused by cessation of follicular growth
and increased expression of P450 see, the major steroidogenic enzyme required for
progesterone synthesis, in granulosa cells (Yong, et ah, 1992). Oestrogen synthesis
declines as a result of inhibition of thecal P450cl7 and subsequent lack of androgen
as a substrate for aromatase in the granulosa cells. Thus as ovulation approaches, the
ovary increasingly produces progesterone while oestrogen levels transiently decline
(Hillier, 1985). In the rat, progesterone facilitates the ability of oestrogen to provoke
a discharge of LH (Fink, 1979). In rabbit (Kanayama et ah, 1996), monkey (Collins
and Hodgen, 1986, Wolf et ah, 1989) and women (Ho, 2001, Liu et ah, 1987),
treatment with progesterone antagonist prevents the pre-ovulatory LH surge.
Progesterone is also thought to further enhance the positive feedback effects of
oestradiol at this time in women (Liu and Yen, 1983).
Progesterone levels continue to rise in follicular fluid following the LH surge
and it is thought that this preovulatory increase is essential to follicular rupture, by
accelerating the net loss of collagen fibres in the follicular wall as demonstrated in
vitro in human (Tjugum et ah, 1984). This loss of collagen fibres is caused by the
upregulation of plasminogen activator synthesis by progesterone which in turn
activates collagenase thereby facilitating follicular wall breakdown, reviewed by
(Zeleznik and Hillier, 1996). There is further evidence for a specific action of
progesterone in ovulation in rats and pigs where LH/hCG has been demonstrated to
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stimulate transient expression of progesterone receptor mRNA in granulosa cells of
preovulatory follicles (Park-Sarge and Mayo, 1994). Progesterone receptors have
also been localised in granulosa cells of women (Chaffkin et al., 1993) and rhesus
monkey (Duffy et ah, 1994).
1.5.2 Follicle rupture
The LH surge provokes a proteolytic cascade within the preovulatory follicle
resulting in its rupture approximately 36 hours later (Zeleznik and Hillier, 1996),
earlier in sheep (Scaramuzzi, et ah, 1993). During the final stages of folliculogenesis,
a small area of the wall of the Graafian follicle becomes weaker, usually mediated by
reduced blood flow to the apex or stigma, and increased proteolytic enzyme activity
induced by second messenger systems which become activated in the thecal and
granulosa cells. This area becomes the ovulation point. Similarly, disintegration of
the follicle wall, basement membrane and theca also occurs, eventually leaving a
single layer of granulosa cells separating the follicular fluid from the peri-ovarian
space. In pigs and other species this breakdown is brought about by the action of
prostaglandin F2a from granulosa cells produced in response to the LH surge (Evans
et ah, 1983). It is these locally produced prostaglandins which are primarily
responsible for the increase in vascular permeability, that sustains positive
intrafollicular pressure with the onset of follicular fluid leakage. VEGF could also be
involved in this increase in permeability, but this will be discussed later. Just prior to
ovulation the stigma becomes raised and resembles a fluid filled blister on the
ovarian surface. With the onset of ovulation, follicular fluid and vascular transudate
flow out of the ruptured follicle carrying the cumulus-enclosed oocyte onto the
ovarian surface from which point it passes into the oviduct (Johnson and Everitt,
1995). The collapsed follicle now transforms into a progesterone secreting corpus
luteum.
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1.6 The corpus luteum
1.6.1 Corpus luteum formation and luteinisation
The luteal phase of the ovulatory cycle commences in response to the mid-
cycle gonadotrophin surge resulting in follicular rupture and transformation of the
follicular granulosa cells into luteal cells in a process known as luteinisation
(Zeleznik, 1991). The corpus luteum is usually formed from the preovulatory follicle
but ovulation is not a necessary prerequisite for luteinisation as corpora lutea can
develop from non-ovulated follicles (Behrman et al., 1993). In antral follicles, the
theca and granulosa cell layers are separated by a basement membrane consisting of
collagen IV and laminin (Paulsson, 1992, Yurchenco and Schittny, 1990). This
excludes capillaries, white blood cells and nerve processes from the granulosa layer
until ovulation at which time this basal lamina is degraded. As such, degradation of
the follicular membrane can be used as an early marker of luteinisation (Rodgers et
al., 1998). In an in vitro study of cultured marmoset large antral non-luteinised
follicles, Wehrenberg et al, using dissociation of the basement membrane, decrease
of the gap junction protein connexin-43, expression of a luteal specific member of
the integrin family and the expression of TGF-P receptor type II as markers of
luteinisation, demonstrated that antral follicles can spontaneously luteinise without
necessarily having undergone ovulation (Wehrenberg and Rune, 2000). These
spontaneously luteinised follicles are termed accessory corpora lutea.
1.6.2 Neovascularisation
An adequate vascular supply is paramount in efficient steroid synthesis and
secretion. Before such mechanisms of steroid biosynthesis are further discussed, the
dramatic events associated with neovascularisation of the newly formed corpus
luteum will first be addressed. The detailed mechanism of angiogenesis will follow
in section 1.11. This is purely an introduction.
After follicle rupture at ovulation, newly formed blood vessels invade the
avascular granulosa and within about 5 days, the CL becomes one of the most highly
vascularised organs on a tissue-weight basis (Zeleznik and Benyo, 1994). New
vessels originate as sprouts from small capillaries, the basement membrane of the
endothelium is broken down and endothelial cells migrate into the granulosa layer as
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a cord. This cord then forms a lumen, mitosis begins and growth occurs just behind
the tip of the advancing vessel. Formation of the vessel is completed by the laying
down of a basement membrane and migration of pericytes along the length of the
vessel (Folkman, 1992). The CL has one of the highest blood flows per unit mass of
any gland in the body (Baird, 1991, Bruce, 1976, Reynolds and Redmer, 1999). It is
not surprising therefore that endothelial cells make a substantial contribution to total
cells in the mature human corpus luteum, around 50% in fact. The capillary network
of the CL is so extensive that in the mature corpus luteum, every steroid producing
cell is in contact with a capillary. Endothelial cells increase in number from the early
to mid luteal phase. Cellular proliferation is greatest in the early corpus luteum,
resulting in a mitotic rate comparable to that of rapidly growing tumours (Jablonka-
Shariff et al., 1993). This rate of proliferation gradually decreases throughout the
luteal phase (Dickson and Fraser, 2000). Greater than 80% of these proliferating cells
have been identified as endothelial in sheep (Jablonka-Shariff, et al., 1993), rat
(Gaede et al., 1985), pig (Ricke et al., 1999), cow (Zheng et al., 1994), macaque
(Christenson and Stouffer, 1996) and marmoset (Dickson and Fraser, 2000).
The mature corpus luteum receives most of the ovarian blood flow which is
highly correlated with progesterone secretion (Redmer and Reynolds, 1996). An
inadequate blood supply to the corpus luteum is associated with decreased luteal
function. CL expected to be short lived have reduced LH receptor number and
reduced luteal vascularity (Smith et al., 1996). Reduced progesterone secretion
resulting from inadequate luteal development results in inadequate development of
the endometrium for secure implantation of fertilised ova. This is clinically
significant in infertility (Andrews, 1979, Crosignani, 1988).
1.6.3 Luteal steroidogenesis
The corpus luteum is fundamental to the control of the menstrual cycle and
once formed, it has a functional lifespan of 14 to 16 days in women. During this time
its major secretory products are progesterone and oestradiol.
During the follicular phase, granulosa and theca cells of the follicle co-
ordinately produce oestrogens. Luteinisation of the follicle alters the steroidogenic
pathway so that progesterone is the primary steroid hormone produced. Synthesis of
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progesterone occurs in both theca-lutein cells and granulosa-lutein cells, although
predominantly in the latter, and is the least complex biosynthetic pathway in the













Figure 1.4. Pathway for progesterone biosynthesis in a generic luteal cell
(Niswender et al., 2000). Three sources of cholesterol can be utilised for substrate: 1)
Low-density lipoprotein (LDL) 2) High-density lipoprotein (HDL), or 3) hydrolysis
of stored cholesterol esters by cholesterol esterase. Free cholesterol is transported to
mitochondria, thought to involve StAR 4). Cholesterol is converted to pregnenolone
by cytochrome P-450 side-chain cleavage enzyme (P-450scc); 5). Pregenenolone is
then transported out of mitochondria and converted to progesterone by 3P-
hydroxysteroid dehydrogenase (3P- HSD) 6), present in smooth endoplasmic
reticulum. 7) Progesterone diffuses from luteal cell.
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The substrate for steroidogenesis is cholesterol which predominantly comes
from low density- and high density- lipoproteins (LDL and HDL respectively) in the
blood stream. Either source can be utilised for steroid biosynthesis by most species
but for simplicity only LDL will be considered further here. The uptake of LDL by
luteal cells occurs by receptor mediated endocytosis (Brown and Goldstein, 1986).
Once internalised, the endosomes combine with lysosomes where LDL dissociates
from the receptor and is degraded making free cholesterol available to the cell. This
free cholesterol in the cell is now transported to mitochondria where the cholesterol
side-chain cleavage enzyme, P-450 complex (P450scc) cleaves the side chain from
cholesterol to form pregnenolone. This is the rate limiting step in this process and
appears to the primary site of acute positive and negative regulation of
steroidogenesis by second messenger systems (Niswender, et al., 2000).
Stimulation of the steroidogenic pathway by trophic hormones requires the
synthesis of a short-lived protein which when phosphorylated, upregulates steroid
secretion. This protein is termed steroidogenic acute regulatory protein (StAR) and is
thought to aid internalisation of cholesterol at the mitochondrial membrane. Once
formed, pregnenolone is transported to the endoplasmic reticulum where it is
converted to progesterone by 3f3-hydroxysteroid dehydrogenase A5,A4 isomerase
(3P-HSD). Progesterone is then thought to diffuse from the cell (Niswender, et al.,
2000).
In the uterus, progesterone acts on the endometrium as a differentiation factor
(Cummings and Yochim, 1984). Oestrogens induce endometrial cell proliferation
during the follicular phase which is inhibited by progesterone in the luteal phase
(Padykula et al., 1989). Progesterone induces stromal differentiation, stimulates
glandular secretions and changes the pattern of proteins secreted by endometrial
cells. This process is known as decidualisation. These uterine proteins provide an
environment that supports early embryonic development (Niswender, et al., 2000).
Progesterone also inhibits myometrial contractility.
Other products of this newly formed endocrine gland include androgens and
peptides such as relaxin and oxytocin. Inhibin-A, eicosanoids, cytokines, growth
factors and oxygen radicals have also been identified as luteal products but their
function has yet to be elucidated (Behrman, et al., 1993). It should be noted that in
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the primate, pig and rat, the corpus luteum retains the ability to secrete oestrogen in
the luteal phase in addition to progesterone.
Progesterone, oestradiol and inhibin-A, secreted by the corpus luteum
collectively exert negative feedback regulation on pituitary FSH secretion thereby
preventing preovulatory follicular development (Zeleznik and Hillier, 1996). It has
been demonstrated that the health of the dominant follicle from a subsequent cycle is
superior when it develops in the contralateral ovary where no ovulation took place in
the preceeding cycle rather than in the ovary where the preceding ovulation took
place (Fukuda et al., 1996). Further to this work it was proposed that the corpus
luteum may exert a local negative effect on follicular growth during the luteal phase
by secreting local ovarian factors which negatively affect follicular health of the
responsive cohort of follicles of the next menstrual cycle (Fukuda et al., 1997). Due
to the various levels of negative feedback exerted by the corpus luteum, both locally
and at the level of the pituitary, its regression becomes a pivotal event in order that a
new menstrual cycle and subsequent follicular development may occur (Zeleznik and
Hillier, 1996).
As the corpus luteum matures and plasma progesterone levels rise, the
capacity for luteal cells to biosynthesise progesterone declines, illustrated by Figure
1.5 (Zeleznik and Hillier, 1996). Cellular levels of 3P-HSD and P450scc mRNA's
are also highest shortly after ovulation, declining progressively throughout the luteal
phase. This declining rate of steroid production and biosynthetic potential may occur
due to the fact that the newly formed CL is incompletely vascularised such that
access to blood-borne cholesterol in the form of low density lipoprotein as a
progesterone precursor is limiting. However, by the mid-luteal phase when the luteal
vasculature is fully developed, this is no longer true so progesterone secretion rate
progressively increases during the early to mid-luteal phase despite a decline in
steroidogenic potential at the cellular level (Zeleznik, 1991).
Increased vascularisation also benefits oestradiol synthesis. It is thought that
the two cell model for oestrogen synthesis is preserved in the primate corpus luteum
with small theca-derived luteal cells producing androgens that serve as a substrate for
the large granulosa-derived cells producing oestrogens (Sanders and Stouffer, 1997).
Luteal oestrogen levels mimic those of progesterone, reaching a maximum in the
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mid-luteal phase despite declining activity of aromatase. This can be explained by
the fact that granulosa-lutein cells require precursor androgen from the theca-lutein
cells in order that it may be aromatised to oestradiol. Therefore this process can also
only benefit from increased vascularity (Zeleznik, 1991).
1.6.4 Cell types in the corpus luteum
Luteinisation includes several structural events and endocrinological
components that shift a predominantly FSH regulated, oestrogen secreting organ to
an organ dominated by LH whose function is predominantly progesterone secretion.
(Behrman, et al., 1993). Over the last few years it has been extensively reported that
the CL of several species, including the human is composed of several cell
subpopulations which are either steroidogenic or non-steroidogenic (Vega and
Devoto, 1997). It is widely accepted that steroidogenic cells are derived from both
the granulosa and theca layers of the follicle. In women, these are easily recognised,
with the theca lutein cells, also termed small lutein cells, at the periphery and cortical
infoldings of the gland and the granulosa lutein cells, or large lutein cells, internal to
this area (Behrman, et al., 1993).
Large luteal cells contain numerous mitochondria, well developed
endoplasmic reticulum and secretory granules, all characteristic of a secretory cell. It
is here that most of the progesterone is synthesised and on these cells there exist
prostaglandin F2« receptors. The small lutein cells however, have reduced
mitochondrial numbers and a well developed endoplasmic reticulum lacking
secretory granules (Vega and Devoto, 1997). Small lutein cells are the site of action
of LH. Both theca and granulosa lutein cells are capable of progesterone, androgen
and oestrogen production, but the regulatory mechanisms involved differ between the
two cell types. In several domestic species and human, the majority of luteal LH and
hCG receptors exist on small lutein cells (Niswender et al., 1985, Retamales et al.,
1994). Large lutein cells are the sites where most steroidogenesis occurs even though
they show poor response to several regulatory factors. Thus it is most likely that the
regulation of the steroidogenic capacity of the human CL is by response of small
lutein cells to different endocrine, paracrine and autocrine regulators (Vega and
Devoto, 1997). In addition to steroidogenic cells, the corpus luteum contains non-
Chapter 1 Introduction 26
steroidogenic cell types including endothelial cells, fibroblasts, pericytes and
immune cells. Despite serving as an endocrine organ principally responsible for
progesterone secretion in the luteal phase and early pregnancy, the human corpus
luteum contains more non luteal cells than luteal cells, also evident in bovine species
(Lei, 1991). In most non-primate animals, follicular tissue is extensively reorganised
during migration of luteal cells during development of the corpus luteum (Niswender
and Nett, 1994), where large and small luteal cells, fibroblasts and endothelial cells
are in close proximity (Niswender, et al., 2000). Figure 1.5 illustrates development




Figure 1.5. Development of the corpus luteum from a follicle (Niswender, et ah,
2000). The follicle is organised into distinct layers, The Antrum (A), is a fluid fdled
lumen surrounded by a granulosa layer (GL). This layer and the oocyte are separated
from the rest of the follicle by a basement membrane (BM). Outside the BM are the
theca interna (TI) and theca externa (TE) layers of the follicle. Capillaries (C) are
present in the thecal layer but not in the granulosa layer. LH causes breakdown of the
follicular wall and release of the oocyte at ovulation (1). After ovulation the
granulosa layer becomes vascularised as the basement membrane degrades and the
follicular tissue develops into the corpus luteum (2). The Corpus luteum contains a
heterogeneous population of cells including large and small luteal cells (LLC and
SLC respectively). There are many capillaries indicative of the high degree of
vascularisation of the CL.
Of the non-steroidogenic cells, leukocytes, particularly macrophages are of
fundamental importance because of their capacity for secretion of growth factors,
cytokines and reactive oxygen species increasingly recognised as intraluteal
regulators of luteal function (Brannstrom and Friden, 1997). Macrophage numbers
are highest at the end of the mid luteal phase, having tripled from initial numbers.
These cells represent a greater proportion of total cells than fibroblasts which also
increase in number from the mid to late luteal phase. (Lei, 1991). Besides their
involvement in regressing corpora lutea (Gaytan et al., 1998), macrophages are
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putative cells involved in luteal angiogenesis and progesterone synthesis (Vega and
Devoto, 1997).
1.6.5 Trophic regulation of the corpus luteum
1.6.5.1 LH
LH is historically recognised as playing a fundamental and critical role in
formation and maintenance of the CL (Niswender, et al., 2000) by its action at LH
receptors. The number of LH receptors increases during the early to midluteal phase
and declines progressively in the late luteal phase becoming undetectable after
menstruation. Therefore, regulation of this receptor may in itself be an important
mechanism controlling the function of the CL throughout the menstrual cycle
(Nakano, 1997). From studies conducted on stumptailed macaque, it was found that
the corpus luteum is relatively unresponsive to high serum LH concentrations in the
early luteal phase and that this responsiveness increases as the luteal phase
progresses. However, the corpus luteum is sensitive to LH withdrawal regardless of
stage of luteal phase (Fraser et al., 1986). It is possible that other luteotrophic factors
such as prolactin may be involved in maintaining the morphological integrity of the
CL but this is unlikely as inhibition of prolactin secretion does not result in reduced
luteal function, reviewed by (Baird, 1991).
The overwhelming evidence would suggest that primates and women depend
absolutely upon LH throughout the entire luteal phase to maintain secretion of
progesterone by the corpus luteum (Zeleznik, 1991). GnRH antagonist administration
has been shown to prevent normal luteal development and reduce progesterone
synthesis (Hutchison and Zeleznik, 1984, Ravindranath et al., 1992, Webley et al.,
1991). In hypophysectomised women, injection of HCG has been demonstrated to
maintain the secretory activity of the corpus luteum for its normal lifespan of 14-16
days (Gemzell, 1965, Vande Wiele et al., 1970).
Dependence on LH for adequate luteal function has also been addressed in
other species but the findings are somewhat less uniform. Ewes and pregnant swine
treated with LH antisera have lower luteal weights and reduced luteal progesterone
production (Fuller and Hansel, 1970, Reimers and Niswender, 1975, Snook et al.,
1969, Spies and Niswender, 1971). Pulsatile release of LH is necessary for luteal
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development in cattle (Peters et al., 1994), but once fully developed, the bovine CL is
no longer LH dependent. Sheep do not appear to be critically dependent on LH at all
as treatment with GnRH antagonist had no effect on luteal function in either the
developing or mature CL (McNeilly et al., 1992).
It would appear therefore that LH support is critical in primates for normal
luteal function and in development of the CL in cows. However, it appears not to be
important for maintained progesterone secretion in the cow and not at all critical in
formation or maintained CL function in ewes. Thus requirement for gonadotrophin
support in the luteal phase is variable between species.
A close temporal association exists between bursts of LH and the subsequent
secretion of progesterone by the corpus luteum (Ellinwood et al., 1984, Filicori et al.,
1984, Mais et al., 1986). The speed of response in progesterone secretion following
each pulse of LH implies an acute effect of LH on precursor cholesterol metabolism
through existing steroidogenic pathways rather than upregulation of steroidogenic
enzyme production, exactly how this is mediated is still unknown (Zeleznik and
Hillier, 1996). It is thought to include the cyclic AMP-dependent mobilisation of
cholesterol to the inner mitochondrial membrane for conversion into pregnenolone
by P450scc (Strauss, 1991). A longer term effect of LH on steroidogenesis is exerted
through maintaining cellular levels of 3(1-HSD and P450scc mRNA's (Bassett et al.,
1991, Ravindranath, et al., 1992).
1.6.5.2 FSH
Luteal function itself is not directly regulated by FSH but does depend on
development of the follicle. FSH induces appearance of LH receptors on granulosa
cells but does not appear to stimulate progesterone secretion. The fact that exogenous
LH and hCG can maintain luteal function and steroidogenic capacity in
hypophysectomised women indicate that FSH does not play an obligatory role in
regulation of the primate corpus luteum (Gemzell, 1965).
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1.6.6 Autocrine/Paracrine regulation of human luteal function and
development
Human corpora lutea undergo an extremely rapid period of growth,
development and regression during the course of non-fertile cycles. Having discussed
the dependence on pituitary-derived LH for steroidogenesis in women and other
primates, there also exists intra-luteal regulation of steroid synthesis. Steroidogenic
luteal cells and non-steroidogenic cells interact via endocrine and paracrine
pathways, and by contact-dependent pathways (gap junctions). Thus, hormones and
locally produced factors including steroids, growth factors, cytokines, reactive
oxygen species and nitric oxide may modulate luteal lifespan and as such will be
discussed briefly below (Devoto et al., 2000).
1.6.6.1 Oestradiol
The primate CL synthesises oestradiol where it has been implicated as an
intraovarian regulator of luteal regression (Stouffer, 1996). In some species such as
the rat, rabbit and pig, oestrogens are luteotrophic, however the dependence of the
corpus luteum on oestradiol for support varies in these species. In rabbit and rat,
where oestradiol is the major luteotrophic hormone, removing it causes cessation of
progesterone synthesis (Niswender, et al., 2000). It is stimulation by oestrogen in
these species that causes luteal cell hypertrophy during pregnancy (Holt, 1989). In
the pig the luteotrophic role of oestrogen is ill-defined however it does inhibit
PGF2a, thus preventing luteolysis (Ford et al., 1982). Oestrogen receptor mRNA
was found to be absent from rhesus monkey CL suggesting an apparent absence of a
role for oestradiol in this species (Chandrasekher et al., 1994) despite localisation of
specific androgen and progesterone receptors (Vega and Devoto, 1997).
Administration of large amounts of oestradiol suppresses plasma LH levels and
results in premature luteal regression in human. Also, following administration of
antioestrogens such as clomiphene or tamoxifen there is an increase in frequency,
though not amplitude of LH pulses suggesting that oestradiol enhances the
suppressive effect of progesterone on GnRH pulse frequency during the luteal phase.
Thus, during the luteal phase under the combined effects of oestradiol and
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progesterone the concentration of LH is suppressed to the lowest levels throughout
the cycle (Baird, 1991).
1.6.6.2 Progesterone
Progesterone has been implicated as a universal luteotrophin for the
mammalian CL and has been demonstrated as a potent regulator of its own secretion
in rat (Rothchild, 1981). Besides important roles in periovulatory events,
progesterone promotes synthesis of both LH receptor and luteotrophic prostaglandins
in the bovine (Vega and Devoto, 1997). In the rhesus monkey, appearance of the
progesterone receptor is driven by the LH peak. Luteinising granulosa cells from
patients undergoing in vitro fertilisation undergo differentiation in response to
progestins which in turn upregulate progesterone production (Rothchild, 1981).
Furthermore, the observed rise in progesterone is maintained by progesterone itself
and as such may be considered as a broader regulator of the functional lifespan of the
primate CL (Vega and Devoto, 1997).
1.6.6.3 Prostaglandins
The role of prostaglandins as luteal regulators has long been
postulated. The highest secretion of prostaglandins has been reported in the early
luteal phase decreasing by the late luteal phase and as such their putative role in
luteal function has been the subject of much research (Niswender, et al., 2000).
Production of both luteotrophic and luteolytic prostaglandins has been
documented in the non-primate and primate CL over the years. Prostacyclin (PGH) is
a major product of endothelial cells and has an implicated role in vasodilation. It is
thought to be lutetrophic as its inhibition during luteal development has been shown
to decrease progesterone production and bovine luteal lifespan (Milvae and Hansel,
1985). In women and non-human primates, stimulation of progesterone secretion by
PGE2 has been demonstrated in vitro and in vivo (Stouffer et al., 1979, Zelinski-
Wooten et al., 1990, Zelinski-Wooten and Stouffer, 1990). In contrast, PGF2a has
been shown to reduce concentrations of progesterone in vivo (Auletta and Kelm,
1994, Sargent et al., 1988). In the marmoset, in vivo administration of cloprostenol, a
synthetic PGF2a analogue induces luteolysis during the mid-late luteal phases
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(Summers et al., 1985). Treatment with PGE2 can prevent PGF2ct induced premature
functional luteolysis in the rhesus monkey but not spontaneous luteal regression
(Zelinski-Wooten and Stouffer, 1990).
As such luteal function is thought to be regulated by complex interactions of
luteotrophic and luteolytic prostaglandins (Fehrenbach et ah, 1999). However the
role of PGF 2a in luteolysis will be further discussed in a subsequent section.
1.6.7 Cellular interactions
Cellular interactions in the CL are mediated by several mechanisms including
humoral (endocrine and paracrine) and contact-dependent (gap-junctional) pathways
and involve heterogeneous cell populations including steroidogenic and non-
steroidogenic cells. The existing interactions between cells in the corpus luteum are
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Figure 1.6 Cellular interactions in the corpus luteum adapted from (Pate, 1996).
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1.6.8 Humoral cellular interactions
1.6.8.1 Cellular interactions among small and large steroidogenic luteal cells
Data from several studies suggest that cellular interactions are involved in the
production of progesterone and luteolysis in the CL of several species, reviewed by
(Grazul-Bilska et al., 1997). Numerous hormones and growth factors are produced
by luteal cells that may mediate cellular interactions in a paracrine manner (Del-
Vecchio, 1997). Steroidogenic luteal cells produce oxytocin, relaxin, inhibin and
prostaglandins E2, F2a and I2 in several species (Ackland et al., 1992, Auletta and
Flint, 1988, Einspanier et al., 1997, Einspanier et al., 1999, Fields, 1991, Hansel et
al., 1991, Hansel, 1986, Khan-Dawood et al., 1997, Nappi et al., 1994, Stouffer and
Brannian, 1993, Yamamoto et al., 1997). Large luteal cells contain the majority of
PGF2oc receptors and as such may respond to PGF2c( produced by small luteal cells
resulting in reduced LH-induced progesterone secretion. Oxtocin is also produced by
large luteal cells and has an effect on progesterone secretion. In small concentrations
it appears to be stimulatory becoming inhibitory with higher doses. It has also been
implicated in luteinisation in the marmoset (Einspanier, et al., 1997) and has been
shown to induce luteolysis by either stimulation of uterine PGF2a or by acting
directly on the CL as a paracrine down-regulator of steroidogenesis in sheep (Grazul-
Bilska, et al., 1997). Oxytocin also stimulates oestradiol synthesis, which may effect
expression of the gap-junction protein connexin-43 allowing interaction between
large and small luteal cells (Khan-Dawood, 1997).
1.6.8.2 Cellular interactions among steroidogenic and endothelial cells
Interactions between steroidogenic and endothelial cells may be important for
growth, differentiation and regression of luteal tissues. After the process of ovulation
endothelial cells of the vascularised theca layer invade the previously avascular
granulosa layer. Proliferation and migration of these endothelial cells are critical
components of the angiogenic process. Under the influence of LH, steroidogenic
tissues produce angiogenic factors, principally VEGF which target receptors on
endothelial cells causing their migration towards this angiogenic stimulus (Grazul-
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bilska et al., 1995, Redmer et al., 1988, Redmer et al., 1996, Redmer and Reynolds,
1996, Smith et al., 1994). The angiogenic process will be discussed more thoroughly
in later sections. Steroidogenic cells also produce tissue inhibitors of matrix
metalloproteinases which may regulate endothelial cell migration during this process.
Just as luteal cells appear to regulate endothelial cells, the reverse is also true.
Endothelial cells produce vasoactive compounds which have profound and unique
effects on the steroidogenic functions of the CL for example endothelin (Meidan and
Girsh, 1997).
Interactions between steroidogenic cells and endothelial cells may not only be
humoral, but also contact dependent. In vitro these two cell types develop contact
dependent communication which can be regulated by LH and PGFkx (Grazul-Bilska,
et al., 1997).
1.6.8.3 Cellular interactions among steroidogenic and immune cells
Cytokines secreted by immune cells eg. Interferons, tumor necrosis factor or
interleukins exert effects on luteal cells. Additionally cytokines enhance expression
of major histocompatibility complex molecules on luteal cells and may be cytotoxic
in certain conditions (Pate, 1996).
1.6.9 Gap junctional (contact-dependent) cellular interactions
The mammalian gap junction is a junction of communication or electrical
coupling between adjacent cells, which when open, allows exchange of nutrients,
ions and regulatory molecules (Grazul-Bilska, et al., 1997). Gap junctions have been
demonstrated in corpora lutea of numerous species by electron microscopy and more
recently by detection of gap junctional proteins or connexins (Beyer et al., 1990).
The structure and function of gap junctions are thought to be regulated by
numerous factors including hormones, growth factors and intracellular regulators
(Grazul-Bilska, et al., 1997). The stage of luteal development affects gap junctional
intercellular communication. The rate of gap junctional intercellular communication
between small and large luteal cells is significantly greater in the early and mid-
luteal phases in cows, when the CL is undergoing rapid growth and differentiation
compared to the late luteal phase, when the CL is regressing (Grazul-Bilska et al.,
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1996). The rate of gap junctional exchange between bovine or ovine luteal cells is
increased by LH, indicating that the luteotrophic effects of LH extend to control of
luteal interactions (Grazul-Bilska et al., 1996, Grazul-Bilska et ah, 1997, Grazul-
Bilska, 1996). In ewes and cows, PGF2a affects basal and LH stimulated gap
junctional intercellular communication so not only does it contribute to functional
and structural luteolysis, but also modulates cell to cell communication among luteal
cell types, reviewed by (Grazul-Bilska, et ah, 1997). Current knowledge of the
function of gap junctions in luteal function however, is limited.
1.7 Luteolysis
In a non-fertile cycle, 10-12 days after its formation, obligatory demise of the
corpus luteum occurs in order that the negative effects of progesterone, oestrogen
and inhibin on FSH secretion are removed. The removal of these inhibitors allows
continued maturation of subordinate follicles culminating in follicular rupture in the
subsequent cycle.
Corpus luteum regression or luteolysis is defined as lysis or structural demise
of the corpus luteum. During normal luteolysis, two closely related events occur.
Firstly, there is a loss of the capacity to synthesise and secrete progesterone, referred
to as functional luteolysis followed by loss of the cells that comprise the corpus
luteum, known as structural luteolysis (Niswender, et ah, 2000). In rat and human,
functional and structural luteolysis are separate events under separate endocrine
control as corpora lutea of previous cycles are evident within the ovary. (Malven and
Sawyer, 1966, Wang et ah, 1993). The interval between loss of functional activity
and the induction of structural involution is not known exactly in the human, but in
rat, corpora lutea are known to persist for up to five oestrous cycles, reviewed by
(Behrman, et ah, 1993).
1.7.1 Functional luteolysis
This refers to suppression of progesterone synthesis and secretion, a process
that precedes structural luteolysis. Several features characterise the decrease in
progesterone secretion during functional luteolysis in the primate and other species.
Functional luteolysis resembles the effects of LH withdrawal, such as those produced
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by hypophysectomy or chronic treatment with gonadotrophin releasing hormone
(GnRH) antagonist.
The mechanism of luteolysis remains unclear. LH is the principal
luteotrophin and therefore has been implemented to play a role in luteolysis.
However, it is not necessarily changes in LH secretion that appear to be responsible
for luteal regression. The major change in LH secretion during the luteal phase is a
progesterone-mediated reduction in the frequency of pulsatile LH secretion from the
anterior pituitary. The number of pulses falls from 1 pulse per hour during the early
luteal phase to as little as 1 pulse every 4-8 hours during the mid-late luteal phases
(Ellinwood, et al., 1984, Filicori, et al., 1984). This cannot be the direct cause of
luteal regression however, because administration of hourly LH pulses throughout
the luteal phase does not prolong luteal lifespan (Knobil et al., 1980, Leyendecker et
al., 1980) nor does reduction of the LH pulse frequency to 1 every 8 hours in the
early luteal phase cause premature luteal regression (Hutchison et al., 1986).
Complete withdrawal of LH however causes rapid cessation of luteal progesterone
secretion and onset of premature menses, however, the regulatory action of LH on
luteal progesterone secretion can be dissociated from its influence on luteal lifespan
(Zeleznik, 1991).
The best explanation for induction of luteolysis in primates, is that the corpus
luteum loses its sensitivity to LH with age, such that a progressively higher plasma
level of LH is needed to sustain luteal function. It has been reported that the number
of LH receptors decreases markedly in the late luteal phase of the cycle (Duncan et
al., 1998, McNeilly et al., 1980).The corpus luteum therefore regresses due to its ever
declining ability to perceive the low levels of plasma LH that prevail throughout the
luteal phase (Zeleznik and Hillier, 1996). However, studies in non-primates have
shown that the corpus luteum degenerates as a result of the action of various
luteolytic factors including oestrogen, oxytocin, prostaglandins and various other
polypeptides and growth factors (Braden et al., 1994). However, the luteolytic factor
in primates remains unclear.
PGF2cx, produced by the uterus after priming with oestradiol and progesterone
at the end of the cycle, serves as the main luteolytic factor in several mammals
including sheep, pig, guinea pig and cow. Hysterectomy of heifers, ewes, pigs and
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guinea pigs, results in delayed luteolysis (Baird, 1991). PGF2a reaches the ovary by a
local counter-current mechanism between the utero-ovarian vein and the ovarian
artery. On reaching the ovary, it stimulates the secretion of oxytocin from the corpus
luteum which acts on the uterus to provoke further release of oxytocin in a positive
feedback fashion which ensures the demise of the corpus luteum (Flint and
Sheldrick, 1982 nature ovarian secretion (Cao and Chan, 1993).
In women and monkeys however, the uterus does not appear to play a role in
luteolysis as hysterectomy does not affect the luteal phase (Neill et al., 1969,
Niswender, et al., 2000), nor do women with congenital absence of the uterus, have
prolonged luteal lifespan (Baird, 1991). PGF2a may still be a luteolytic factor in
these species as a shortening of the luteal phase was observed in women given direct
injections of PGF2a into the CL (Korda et al., 1975). Locally produced PGF2a acts
via paracrine and/or autocrine mechanisms to induce luteolysis (Auletta and Flint,
1988, Bennegard et al., 1991). The corpus luteum is most sensitive to the luteolytic
effects of PGF2a in the late luteal phase (Messinis, 1997). PGF2a decreases luteal
progesterone synthesis in cows, ewes, sows, monkeys, humans and
pseudopregnant/pregnant rats and rabbits, reviewed by (Niswender and Nett, 1994).
There are several possible intracellular effects of PGF2a; 1) Down regulation of
receptors for luteotrophic hormones, although this does not appear to be the case as it
does reduce LH receptor levels in ewes but this occurs after progesterone levels have
already declined (Diekman et al., 1978). It may however interfere with the ability of
LH to activate PKA as adenylate cyclase activity decreases after PGF2(X
administration (Niswender, et al., 2000). 2) Decreased cellular uptake of cholesterol,
although this does not appear to be the case. 3) Decreased transport of cholesterol
through the cell and/or across mitochondrial membranes. Treatment of ewes or cows
with PGF2ot dramatically reduces concentrations of StAR mRNA, followed by a
decline in StAR production, an essential component of cholesterol transport (Juengel
et al., 1995, Pescador et al., 1996). 4) Decreased activity of the steroidogenic
enzymes responsible for progesterone biosynthesis, P-450scc and 3P-HSD, but again
this has been demonstrated not to be true, as doses of PGF2a that reduce progesterone
secretion were not seen to decrease levels of P-450scc mRNA or activity of the
P450scc complex in several species, reviewed by (Niswender, et al., 2000).
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Another potential luteolytic factor is oestrogen. Oestrogen is known to impair
luteal function in the primate by suppression of LH secretion (Schoonmaker et al.,
1982). On the nonhuman primate, oestrogen does not induce luteal regression when
LH secretion is maintained by pulsatile GnRH administration (Hutchison et al.,
1987). Thus oestrogen-induced luteal regression in the primate is thought to be due
to suppression of LH secretion (Behrman, et al., 1993).
Evidence for many other putative intraovarian substances involved in
luteolysis has been produced. Oxytocin is stimulated by PGF2a and has been
demonstrated to inhibit progesterone production in high doses in human luteal cell
cultures (Tan et al., 1982). Progesterone itself may also play an autocrine role in
luteolysis (Duffy, et al., 1994). Nitric oxide is a free radical gas and has been shown
to participate in functional luteal regression by inhibition of steroid synthesis (Friden
et al., 2000, Olson et al., 1996, Vega and Devoto, 1997). A characteristic feature of
luteal regression is the infiltration of leucocytes that is documented in the human
(Adams and Hertig, 1969) and other species including guinea pig (Paavola, 1979)
and rabbit (Bagavandoss et al., 1990).These leucocytes are prominent generators of
prostaglandins and cytokines as well as antioxidants and hydrogen peroxide. Thus
infiltration and activation of leucocytes appears to be an essential process for the
induction of luteolysis (Behrman, et al., 1993, Bukovsky et al., 1995). Cytokines that
evoke antigonadotrophic or luteolytic actions include TNFa, IFNy and IL's. IFNy
activates macrophages and monocytes which in turn release TNFa and IL-1. These
then evoke downstream activation of eosinophils and neutrophils to produce H2O2,
other radicals and cytotoxic peptides (Behrman, et al., 1993). These can cause matrix
dissolution by induction of collagenase activity and disrupt the actin cytoskeleton.
Control of collagenases is by tissue inhibitors of matrix metalloproteinases (TIMP's)
released at the same time as collagenases to block activity. It is suggested that TIMP-
1 may serve to prevent luteolysis (Behrman, et al., 1993, Duncan et al., 1996). In the
rat a decrease in TIMP mRNA occurs at the time of functional luteolysis (Tanaka et
al., 1992), and interestingly LH and hCG stimulate TIMP expression in follicular
granulosa cells (Mann et al., 1991). In the rat, prolactin induces structural luteolysis
(Malven and Sawyer, 1966).
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In summary, immune cells and cytokines appear to play a role in luteolysis by
regulating PGF2a synthesis, steroidogenesis and phagocytosis.
1.7.2 Structural luteolysis
Structural luteolysis is defined as involution of the corpus luteum and is a
distinct event occurring after functional regression. Several different patterns of
structural luteolysis exist in the human (Morales, 2000). Luteal regression is
generally associated with a dramatic decrease in luteal weight and cell size as well as
with an increase in the number of dying cells (Plendl, 2000). The diameter of the
corpus luteum decreases and connective tissue or stromal elements greatly increase.
At the end of the luteal phase, in the human corpus luteum, granulosa cells are seen
to have large vacuoles occupying almost all of the cytoplasm. Small densely stained
pyknotic nuclei are evident and an occasional nucleus has degenerated into a dense
irregular mass. This degeneration is even more advanced in the theca (Corner, 1956).
Luteal cell degeneration is accompanied by a massive regression of blood vessels.
Some blood vessels are retained and are thought to play an important role in
resorption of the luteal tissue (Plendl, 2000). It has been reported in bovine that
reduced ovarian blood flow plays a critical role in luteal regression and that
endothelial cells are important in the luteolytic process (Girsh et al., 1995). In a study
conducted on sheep, it was demonstrated that vascular changes involved both
luminal contents and capillary walls. Endothelial cell degeneration was observed
leading to ultimate degradation of vessels (O'Shea et ah, 1977). PGF2a has been
implicated in this reduction in blood flow to the corpus luteum and may therefore
cause luteolysis by depriving the gland of nutrients, steroidogenic substrates and
luteotrophic support in bovine. It is thought in this species, that PGF2a exerts its
effects at endothelial cells as these possess PGF2a receptors by causing endothelial
cell degradation (Mamluk et ah, 1998). Endothelial cell deletion during luteolysis has
been widely reported in many species (Azmi and O'Shea, 1984, Gaytan et ah, 1999,
Hossain and O'Shea, 1981, O'Shea, et ah, 1977, Zheng, et ah, 1994) resulting in
marked reduction in capillary density thereby reducing blood flow to the luteal
parenchyma.. Recently, endothelin-1 has been implicated as a putative mediator of
the effects of PGF2ct on luteal blood flow in bovine. PGF2ct stimulates endothelial
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cells to produce endothelin-1 in vitro (Girsh et al., 1996) and in vivo (Ohtani et al.,
1998). Endothelin-1 is a potent vasoconstrictor and inhibits the steroidogenic activity
of luteal cells (Girsh, et al., 1996). It may also reduce blood flow during early
luteolysis by causing arteriole constriction in this species (Ohtani, et al., 1998). The
resultant hypoxic environment may cause additional endothelin-1 release thus
generating a positive feedback response (Rakugi et al., 1990). Thus endothelial cells
play an essential role in luteal steroidogenic activity by being involved in both
luteotrophic and luteolytic processes (Meidan and Girsh, 1997).
PGF2a elicits a series of morphological changes in rat, sheep, cow and
marmoset. The proportion and size of luteal cells in the CL decreases within 24 hours
of treatment with PGF2a in ewes (Braden et al., 1988). However, these
morphological changes in steroidogenic cells do not become evident until after the
steroidogenic capacity of the cells is markedly reduced. PGF2a acts by binding to
specific receptors localised to large steroidogenic cells (Fitz et al., 1982). Upon
binding to its receptor, PGF2&1 induces activation of membrane bound phospholipase
C which ultimately leads to increased cytosolic concentrations of IP3. This in turn
causes release of free calcium ions from the smooth endoplasmic reticulum into the
cytoplasm and stimulation of protein kinase C. Activation of PKC is believed to
mediate many of the antisteroidogenic actions of PGF2a in large luteal cells and
induces expression and activation of many proteins involved in apoptosis, reviewed
by (Niswender, et al., 2000).
Apoptosis is thought to play a major role in luteolysis in many species,
(Bacci et al., 1996, Fraser et al., 1995, McCormack et al., 1998, Shikone et al., 1996,
Young et al., 1997, Young et al., 1998, Yuan and Giudice, 1997), although the
process of structural regression in the primate is poorly understood and thought to
consist ofmultiple cell death pathways (Fraser et al., 1999). Endothelial cells have
been documented to be the first cell type to be eliminated during luteolysis with
apoptosis taking place 24 to 48 hours after administration of cloprostenol in guinea
pig (Azmi and O'Shea, 1984). Apoptosis is an active, energy dependent process by
which nonessential populations of cells delete themselves from a tissue. Several
biochemical and morphological changes are characteristic of apoptotic cells
including nuclear fragmentation, appearance of membrane-bound vesicles of
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cytoplasmic contents, ladderlike DNA fragmentation and changes in gene expression
(Niswender, et al., 2000). The involution ofmany endocrine glands after removal of
a trophic hormone occurs by apoptotic mechanisms. Human granulosa cells deprived
of FSH undergo apoptosis during follicular atresia and epithelial cells of the human
endometrium experience apoptosis when progesterone and oestrogen support
declines (Hopwood and Levison, 1976)
The first morphological evidence that a cell is apoptotic is the appearance of
nuclear fragments containing degenerate chromatin, cell shrinkage, and appearance
of membrane-bound cytosolic fragments. These cell fragments or apoptotic bodies
are targets for the phagocytic cells of the immune system. Macrophages augment the
apoptotic process in populations of luteal cells by phagocytosing membrane-enclosed
fragments of those cells (Gemmell et al., 1976).
1.8 Luteal rescue
If pregnancy is to become successfully established, the maintenance of the
corpus luteum and continued secretion of progesterone is essential. Although
mechanisms by which progesterone secretion is maintained vary between species,
there exist a few general types of signal. Timing of this signal is crucial. In general,
the conceptus secretes factors that either prevent the secretion or luteolytic actions of
PGF2a or that are directly luteotrophic. Around the start of implantation, about 7
days after ovulation in the human (Baird, 1991), and 11 days in the marmoset
(Enders, 1993), the embryo secretes chorionic gonadotrophin (CG) which stimulates
increased secretion of progesterone by the corpus luteum. The amounts of hCG
secreted by the trophoblastic cells in the implanting blastocyst increase
exponentially, reaching maximal levels in the first trimester. Structurally and
functionally, the hCG molecule is similar to LH and both interact with the same cell-
surface receptor. hCG very rapidly reaches levels that might be expected to down
regulate LH receptor synthesis. However, LH receptors are maintained at luteal
phase levels in the corpus luteum of early pregnancy in both the human and
nonhuman primate unlike in the rat, although >90% of them are occupied by hCG
rather than LH (Duncan et al., 1996). hCG increases luteal function when
administered in the luteal phase and is used therapeutically for such purposes. hCG is
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thought to not only act as a surrogate for LH in stimulating progesterone secretion,
but also has a more generalised luteotrophic role by inhibiting processes involved in
luteal regression (Baird, 1991). The fact that hCG and LH are so similar begs the
question why can hCG unlike LH prevent luteal regression? It may be that hCG
provides a more intense and sustained gonadotrophic stimulus to the ageing corpus
luteum overriding its diminished responsiveness to LH. Also, the substantially longer
half life of hCG compared to LH would serve to further enhance the strength of hCG
as a luteotrophic signal (Monfort et al., 1989). In the rhesus monkey, hCG has been
shown to completely abolish the luteolytic effect of PGF2a (Auletta and Kelm, 1994),
and cell degradation enzymes which are normally upregulated in luteolysis are down
regulated, for example MMP's (Duncan et al., 1998). hCG has also been
demonstrated to prevent the normal influx of macrophages into the CL in the late
luteal phase (Duncan et al., 1998) and to prevent apoptotic luteal cell death (Shikone,
et al., 1996).
It has been suggested that there may be a point of no return at the mid-luteal
phase, beyond which, the corpus luteum can no longer be maintained by hCG (Baird
et al., 1991). The cellular mechanisms responsible for the loss of responsiveness to
LH and hCG that occur as the CL ages remain largely unknown. It is thought that
this is by an impairment of the gonadotrophin receptor adenylyl cyclase system in
luteal cells and a reduction in enzyme activity necessary for progesterone synthesis
in rhesus monkeys (Stouffer et al., 1978).
In ruminants, trophoblast proteins are produced that belong to the IFNa
family of proteins. These are thought to 'rescue1 the corpus luteum in these species
by blocking synthesis of PGF2« (Imakawa et al., 1987). In rodents, stimulation of the
cervix during copulation causes activation of a neuroendocrine reflex arc that results
in a dramatic release of prolactin, FSH and LH on the morning of oestrous. The
biphasic release of prolactin from the anterior pituitary continues for 8-10 days and
extends the function of the corpus luteum for 10-12 days. This occurs in a
pseudopregnant situation. In a true pregnancy where an embryo is present, biphasic
release of hypophysial prolactin is also extended for 8-10 days (Niswender, et al.,
2000).
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Progesterone secretion by the corpus luteum is maintained in early pregnancy
until such time as the role is assumed by the placenta. The luteo-placental shift
occurs near the end of the third week of gestation in rhesus monkeys (Goodman and
Hodgen, 1979) at five to six weeks in women (Stouffer, 1996), and around six weeks
in the marmoset (Hodges et ah, 1983).
1.9 The endometrium
For the purposes of this literature review, the following sections focus on the
human and primate with little referral to the rodent or domestic species because of
widespread species differences.
1.9.1 The role of steroids throughout the menstrual cycle
The uterus undergoes prominent steroid-dependent cyclic changes in
structure and function. During each cycle, the uterus first prepares to receive and
transport the spermatozoa from the cervix to the oviduct, and subsequently, it
prepares to receive the conceptus from the oviduct and nourish it. The uterus consists
of an outer peritoneal and serosal investiture, overlaying a thick myometrium of
smooth muscle. Internally, the endometrium consists of a stromal matrix over which
a simple, low columnar epithelium with glandular extensions penetrating into the
stroma is found (Johnson and Everitt, 1995).
The dependence of the uterus on ovarian steroids is paramount to its function,
and the cyclical regulation of the two are intimately regulated. The ovarian steroid
profile throughout the human menstrual cycle is illustrated in Figure 1.7 (Johnson
and Everitt, 1995).









Figure 1.7 Changes in human endometrium during the menstrual cycle. Underlying
steroid changes are indicated below and basal body temperature is indicated above.
Thickness of arrows (oestrogens:stippled; progestagens:white) indicate strength of
action (Johnson and Everitt, 1995).
After ovariectomy, and subsequent progesterone withdrawal, the uterus
hypertrophies and its blood supply is reduced. Administration of oestrogen reverses
this effect, with massive increases in RNA and protein synthesis, cellular division
and growth. In human and non-human primates, the period during which oestrogen
rises rapidly coincides with the latter half of the follicular phase of the menstrual
cycle. In non-primates oestrogen rises are associated with the entire follicular phase.
During this phase a similar uterotrophic effect of oestrogen is observed. Oestrogen
causes the myometrium to increase its contractility and its excitability,
accompanying increased spontaneous activity.
In the endometrium, stromal thickening occurs partly in reponse to stromal
cell proliferation, hence the follicular phase, a term used in conjunction with the
ovary, is called the proliferative phase when referring to the uterine cycle, and partly
due to oedema.
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Steroids interact with their target organs via specific nuclear receptors. The
expression of endometrial sex steroid receptors, progesterone, oestrogen and
androgen, varies both spatially and temporally across the menstrual cycle (Garcia et
al., 1988, Lessey et ah, 1988, Slayden et ah, 2001, Snijders et ah, 1992). Expression
of both the oestrogen and progesterone receptors (ER and PR, respectively) are under
the control of oestrogen and progesterone. Both are upregulated during the follicular
phase by oestrogen and down regulated in the luteal phase by progesterone. The
presence of a progesterone receptor is evidence that a functional oestrogen mediated
pathway is in place. Administration of RU486, an anti-gestogen, in the early luteal
phase blocks the progesterone-induced down regulation of both ER and PR in non¬
pregnant human endometrium (Cameron et ah, 1996, Maentausta et ah, 1993).
There are two distinct types of the human progesterone receptor (Clarke and
Sutherland, 1990), that arise from a single gene and function as transcriptional
regulators of progesterone responsive genes.The PRA is the shorter isoform, missing
164 amino acids at the N-terminus of the B subtype (Tung et ah, 1993). PR
expression declines significantly in the secretory phase compared to the proliferative
phase, in the glands of the functionalis, (the region shed at menstruation). PR
expression remains in the stroma, at particularly high levels cells in close proximity
to the uterine vasculature. The basalis layer is differently regulated in that the glands
of this layer continue to express PR throughout the cycle. These differences between
the superficial and basal layers of the endometrium are likely to contribute functional
importance when only the upper zones are shed at menstruation (Critchley et ah,
2001).
The two forms of oestrogen receptor ERa and ER|3 have also been described
(Green et ah, 1986, Kuiper et ah, 1996). Both genes are encoded by eight exons with
highest homology between the two present in the DNA and ligand binding domains
(Enmark et ah, 1997). The functionof ERP in the uterus is unknown. ERa expression
increases in both glandular and stromal cells in the functionalis during the
proliferative phase, and declines in the secretory phase as a consequence of
increasing levels of progesterone which suppress it. In the basalis, ERa expression
like PR remains unchanged throughout the cycle (Garcia, et ah, 1988). In human and
non-human primate, ERP expression like ERa, is expressed in the nuclei of
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glandular epithelial and stromal cells, declining in the secretory phase in the
functionalis. However, ER(3, unlike ERa has been detected in endothelial cells,
indicating that oestrogen may act directly on endometrial blood vessels and may thus
be involved in angiogenesis and vascular permeability changes throughout the cycle
(Critchley et al., 2001). Progesterone receptor is absent form the vascular
endothelium (Critchley, et al., 2001) of the spiral arteries, suggesting that the effects
of progesterone withdrawal on these vessels, which play a key role in menstrual
induction, is directly mediated by the PR-positive peri-vascular stromal cells.
1.9.2 Menstruation
The endometria of humans and menstruating primates are
subcompartmentalised (Rune et al., 1992). This compartmentalisation was described
as follows: zone 1, luminal epithelium; zone 2, uppermost gland segments; zone 3,
middle gland segments; and zone 4, basal gland segments. This definition was
thought to provide a key to deciphering the mechanisms that underlie repetitive
cycliclity (Rune, et al., 1992). The uterine experiments conducted for this thesis were
performed using marmosets. Marmosets do not menstruate, and thus, according to
(Padykula et al., 1984), are not expected to show endometrial zonation or to be
suitable as primate models for the study of uterine cyclicity. This group were able to
distinguish 4 zones in the rhesus monkey. In marmoset only 3 zones are detectable, a
basal area, bordering on the myometrium, an adluminal region and the luminal zone
based on morphological parameters. In a cross section through the endometrium, the
glands of the basal region appear long and thin. Glands in the adluminal and luminal
zone appear more rounded. The stroma of these zones appears more compact
compared to the basal area. It would seem therefore that the subdivision of the basal
area into 2 zones, seen in the human and rhesus endometrium seems to be absent in
the marmoset (Rune, et al., 1992). They concluded that the existence of zonation per
se in the marmoset endometrium is an integral feature that is independent of
hormonal influences, whereas the differential behaviours of these zones throughout
the cycle is due to varying steroid levels. Consequently, zonation of the endometrium
is not a unique feature of menstruating species and thus not directly related to
menstruation. Therefore the marmoset has the same zonal compartmentalisation of
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the endometrium as the human and so despite it being a non-menstruating species is
still an appropriate model to study the endometrium.
Menstruation involves the shedding of the superficial two thirds of the
endometrium (the superficialis). Endometrial repair usually begins by the second day
after bleeding has started, but proliferation begins around the fifth day of the cycle
under oestrogen influence from the developing follicles (Ludwig and Metzger,
1976).
Menstruation is induced by the fall in concentration of progesterone that
follows luteal regression. The molecular mechanisms by which steroids induce these
changes, involve interactions between the endocrine and immune systems (Critchley,
et al., 2001). In addition to the epithelial, stromal and endothelial cells that
participate in cyclic proliferation, differentiation and desquamation, there is a
dynamic population of leucocytes within the endometrium that plays an important
role in the menstrual breakdown process. Details of this leucocyte population in
terms of cell types and cell numbers will not be provided for the purposes of this
thesis.
There exists a complex dialogue between the sex steroid honnones and the
leukocytic cells of the immune system, locally produced cytokines and growth
factors. These leucocytes are likely to be controlled directly by paracrine mediators
and not by sex steroids directly as nuclear steroid receptors are not detectable in any
of the macrophages, neutrophils found within the uterus (King, 2000, Poropatich et
al., 1987). However, ERP expression has been reported in uterine natural killer (NK)
cells (Henderson et al., 2003). Progesterone withdrawal causes a unique cascade of
events that include expression of uterine cytokines that attract leucocytes into the
uterine environment and a complex set of interactions between these cells and their
products that ultimately result in the tissue sloughing and bleeding, characteristic of
the menstrual process. This leucocytic invasion and production of inflammatory
cytokines has led to menstruation being described as an inflammatory event (Finn,
1986, Kelly, 1994).
Transplanting explants of endometrium to the anterior chamber of the eye of
the rhesus macaque causes vasoconstriction of spiral arteries induced by
progesterone withdrawal (Markee, 1940). This constriction was associated with the
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regression of stromal tissue and onset of degradation of the extracellular matrix. This
vasoconstriction causes anoxia in the zones closest to the uterine lumen. MMP's are
secreted by stromal cells in the upper zones after 48h following progesterone
withdrawal (Rudolph-Owen et al., 1998). There has been much speculation as to
what these endometrial vasoconstrictors are. As well as prostaglandins, there are
other locally produced agents that have a vasoconstrictor action in the endometrium
including endothelins (O'Reilly et ah, 1992) and angiotensin II (Hunt et ah, 1995).
Another unexpected observation was that KDR, one of the receptors for
VEGF was upregulated in the stromal cells of the superficial endometrial zones
during the pre-menstrual phase of both human and macaque endometrium (Nayak et
ah, 2000). VEGF itself can be upregulated by hypoxia as it has a hypoxia inducible
factor in its promoter (Goldberg and Schneider, 1994). The KDR promoter however,
lacks this response element and so it is therefore unlikely that hypoxia will regulate
expression of this recetptor (Gerber et ah, 1997). It may be possible that hypoxia is
upregulatingVEGF and that this is in turn upregulating KDR expression (Critchley,
et ah, 2001).
In summary, demise of the corpus luteum causes a decline in progesterone.
As a consequence of progesterone withdrawal, in cells that contain progesterone
receptor, inflammatory mediators and locally produced prostaglandins are elevated.
Spiral arteries are constricted, causing hypoxia in the uppermost endometrial zones.
This in turn induces VEGF which may induce its own receptor KDR within stromal
cells of this compartment. VEGF interaction with its receptor can augment MMP
expression by stromal cells, while the inflammatory mediators induce a large influx
of leucocytes. Therefore progesterone withdrawal would appear to firstly effect cells
with progesterone receptors. Early events in the menstrual process are
vasoconstriction and cytokine upregulation. Activation of lytic events occurs later,
and involves cells that may lack progesterone receptors eg uterine leucocytes and
epithelial cells (Kelly et ah, 2001). Figure 1.8 illustrates the current understanding
of menstrual induction (Critchley, et ah, 2001).





Figure 1.8 Menstrual Induction hypothesis (Critchley, et ah, 2001)
1.10 Implantation
1.10.1 Adaptations of the uterus for implantation
The uterus, at the appropriate phase of the menstrual cycle, provides a
hospitable and privileged environment for implantation of the blastocyst. This period
of time is known as the "receptive window" and appears to be primarily regulated by
ovarian steroids. Embryo implantation is the natural culmination of this period, and
successful nidation requires the precise preparation of both the blastocyst and the
endometrium. Enders and Schlafe (Enders and Schlafke, 1969) defined the
morphological changes associated with implantation into three distinct stages:
1 Opposition of the trophoblast and epithelium, 2) adhesion, involving the formation
of junctional complexes between the two cell types, and 3) Epithelial penetration,
which includes the spreading of trophoblast within the endometrium, regression of
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1.10.1.1 Morphological adaptations
Detailed ultrastructural investigations into the morphology of the
endometrium in response to pregnancy have been conducted (Cornillie et ah, 1985,
Wynn, 1974). Comparative morphological studies in the rhesus macaque and baboon
(Fazleabas et al., 1995, Kraemer et al., 1977, MacLennan and Wynn, 1971).
demonstrated that the non-human primate endometrium undergoes cyclic changes
similar to that described for humans, with one notable exception. In humans,
differentiation of periarteriolar stromal cells, referred to as the predecidual response,
(Bell, 1983) begins during the final week of the menstrual cycle and spreads through
the upper two thirds of the endometrium (Wynn, 1974). In contrast, stromal changes
in the macaque (Brenner and Slayden, 1994) and baboon (Kraemer, et ah, 1977) are
minimal, and only those stromal cells that surround the spiral arteries enlarge
substantially. Thus, it seems that only the human and chimpanzee show
"predecidual" modifications of stromal fibroblasts in the absence of implantation
and/or trauma (Enders, 1991, Graham, 1973).
1.10.1.2 Decidualisation
As discussed previously, the primate endometrium is a target tissue for
oestrogen and progesterone. In response to these steroids and in the presence of a
trophoblast, the endometrium is modified into the decidua of pregnancy. In a fertile
cycle, blastocyst attachment to surface epithelium and its subsequent implantation is
associated with local remodelling of the maternal stroma, smooth muscle and
endothelium of the blood vessels by the trophoblast (Aplin, 1991). In addition, the
glandular epithelium becomes highly secretory (Bell, 1988, Fazleabas et al., 1993),
and the stromal cells differentiate into decidual cells, the major cell type of the
gestational endometrium (Bell, 1983).
Ultrastructural studies on the human decidual cell indicate that they possess
all the characteristics of a secretory cell (Wynn, 1974). While gap junctions are
present on these cells, they do not join neighbouring cells, (Lawn et al., 1971) which
may be advantageous for trophoblast invasion. It is thought the decidua has multiple
functions during pregnancy, but its true function remains to be elucidated. It has been
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suggested that the decidua may nourish the developing embryo, protect maternal
tissue from excessive trophoblast invasion and/or protect the embryo against
immunological rejections in utero (Beer and Boillingham, 1974).
Stromal cells of the rhesus monkey and baboon undergo cellular swelling
during implantation (Ramsey et al., 1976), but the process is far more rapid in the
human, where decidualisation is evident about 5 days following blastocyst
implantation (Hertig et al., 1956). Also in non-human primates, the cells do not
enlarge to the same extent as in the human, nor can decidualisation be induced by
hormonal treatment, without the presence of a blastocyst (Fazleabas et al., 1993,
Tarantino et al., 1992). In human, however, stromal cells obtained from non pregnant
women will decidualise in the presence of steroids, relaxin and growth factors (Irwin
et al., 1989, Irwin et al., 1991, Tseng et al., 1992). One characteristic of decidual
cells is their ability to synthesise and secrete IGFBP-1, and while this can be induced
in vitro, in vivo studies in the human suggest that the presence of the conceptus does
enhance expression of IGFBP-1 and TGF-|3 in the decidualised endometrium (Selick
et al., 1994). Therefore it would appear that despite the ability of human stromal cells
to "predecidualise" in vivo and the fact that they can be induced to undergo
decidualisation in vivo, decidual transformation in the human and non-human
primate is far more efficiently regulated during pregnancy.
Despite the divergence in the timing of the onset of decidualisation between
the human and non-human primate, in both, the starting cell, the stromal fibroblast,
and the transformed secretory decidual cell are biochemically and morphologically
similar (Fazleabas, et al., 1993). The regulation of this transformation could reflect
the differences in the implantation process between these species (Enders, 1993,
Ramsey, et al., 1976).
In the human, as soon as the blatocyst adheres to and begins to penetrate the
uterine epithelium, the endometrium by definition is termed the decidua. The area
underlying the blastocyst is called the decidua basalis, the endometrium overlying
the blastocyst the decidua capsularis, and the rest of the endometrium becomes the
decidua vera or the decidua parietalis.
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1.10.1.3 Immune responses to implantation
It is not just stromal fibroblasts that respond to an implanting blastocyst by
undergoing a decidual reaction, uterine epithelial cells, vascular endothelial cells and
endometrial granular cells or large granular lymphocytes also respond.
The presence of a granulated mononuclear cells in the endometrium of the
human and of the rhesus monkey was noted and associated originally with the
premenstrual portion of the cycle and early pregnancy, reviewed by (Enders, 1991).
It is now clear that these cells, which are the predominant mononuclear cells
of the basal plate in early pregnancy, belong to a subset of T-lymphocytes that
constitute only a very small percentage of the peripheral blood large granular
lymphocytes (King and Loke, 1990). These express markers of NK cells, and are
generally CD3 and CD 16 negative, and CD56 positive (King et al., 1989). These NK
cells appear rounded with a kidney shaped nucleus, characterised by a cluster of
large dense granules. The granules surround a cell centre composed of compact golgi
apparatus and a pair of centrioles associated with the indented region of the nucleus
(Cardell et al., 1969).
NK cells are in close association with the trophoblast cells which invade into
the uterus and are often associated with decidual cells that surround small vessels
(Enders, 1991). The function of these cells remains unclear. Many functions have
been proposed, but there is no evidence to support any single proposal nor indeed
whether these cells have single or multiple functions. They do appear to have a
cytotoxic capability (Stewart, 1998). It has been postulated that these cells are
involved in removal of labyrinthine cytotrophoblast which might otherwise lead to
placental dysfunction in mouse (Stewart and Mukhtar, 1988).
In rodents, these NK cells are termed granulated metrial gland (GMG) cells
and are by far the most remarkable population of cells in the decidualised uterine
tissue. The observations that GMG cells are present in non-pregnant decidua where
no foetus is present suggests that the origin of these cells is maternal (Zheng et al.,
1991). They vary in number and maturation during pregnancy, suggesting that
hormones, particularly progesterone and oestrogen, play a crucial role in controlling
their differentiation (Sharma et al., 1986, Stewart, 1987). However, non-hormonal
factors for example cytokines may also be important. Several cytokines, including
Chapter 1 Introduction 53
interleukin (IL)-2, IL-6, IL-7, IL-12 and IL-15 have been shown to be capable of
inducing the differentiation and activation ofNK cells, reviewed by (Liu and Young,
2001).
Human uterine NK cells are smaller than GMG cells of the rodent, but the
proliferation and differentiation of these cells parallel those of the rodent. In human,
these cells become prominent in the late secretory phase (Liu and Young, 2001), a
status appropriate for implantation, provided conception occurs (King, et al., 1989).
In the absence of conception, NK cells undergo apoptosis a few days prior to the
onset ofmenstruation (King, et al., 1989). In a pregnant cycle, these cells persist and
then increase remarkably in number in the decidua as gestation advances in the first
trimester. At this stage uterine NK cells may account for up to 70% of the decidual
leukocytes localised most densely at the implantation site where foetal trophoblasts
infiltrate into maternal tissues (King et al., 1996, Starkey et al., 1988). These cells
become less conspicuous by 20 weeks of pregnancy and virtually vanish by
parturition. Unlike in the rodent, these cells in the human do not accumulate in
specific regions of the pregnant uterus, rather they distribute throughout the decidual
tissue but are more noticeable around the spiral arteries and near degenerative
endometrial glands (Bulmer et al., 1983).
The exact role of uterine NK cells in pregnancy remains unclear. They may
have a role in the implantation process and the subsequent orderly growth and
development of the placenta (King et al., 1998). Additionally, they may modulate the
growth, differentiation, breakdown and regeneration of the cycling uterine mucosa in
a manner analogous to that proposed for regulation of the gut epithelium by resident
lymphocytes (Boismenu and Havran, 1994). However, the presence of granulated
lymphocytes at the maternal-foetal interface appears to be a common feature ofmany
species during pregnancy (King, et al., 1998), suggesting that placental trophoblast
cells are potential targets for uterine NK cells (King, et al., 1998). It has recently also
been proposed that NK cells may play a role in endometrial angiogenesis after the
finding that they produce VEGF-C and P1GF (Li et al., 2001).
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1.10.1.4 Vascular endothelial cells
One of the more striking transformations that occurs during implantation in a
number of non-human primates is the modification of the superficial capillaries and
venules of the endometrium. The endothelial cells of these vessels become cuboidal,
often with distinctive apically-situated nuclei. This transformation results in a series
of anastomotic channels lined by tall endothelial cells (Enders, 1991). Endothelial
cell hypertrophy is localised in vessels of the decidua basalis, and clearly involves all
of the superficial vessels except the arterioles.
Arterioles directly beneath the placenta appear to be blocked by endovascular
cells, the anastomotic complex of vessels lined by tall endothelial cells is probably
the major pathway of blood both entering and leaving the intervillous spaces in the
early stages of implantation and formation of the placenta (Enders, 1991).
1.11 Morphology of implantation in primates
Detailed descriptions of the morphological changes associated with
implantation in human and non-human primates are available (Enders, 1993). While
the same maternal and foetal tissues seem to be involved, the structure of the
implantation site differs between species. A summary taken from (Enders, 1993) is
given below in Table. 1.
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8 Attachment Attachment Hatching blastocyst
9 Epithelial penetration Penetration to basal lamina Attachment, penetration to
basal lamina
10 Expanding site, amnion distinct Penetration of maternal vessels Trophoblastic plate
11 Recruitment of parietal trophoblast Trophoblast cleft and lacuna
formation
Penetration of maternal vessels,
secondary implantation
Attachment to uterus




















Primary villi, primitive streak
Secondary villi
Tertiary villi
Penetration to basal lamina
Trophoblastic plate
Fusion of parietal trophoblast
p-'
45
Spread of trophoblast shell
Maternal vessels surround
Tertiary villi
60 Penetration of maternal
vessels
Table 1.1 Relative time sequence of some developmental sites in the peri-
implantation period (Enders, 1993).
Apposition and adhesion
Implantation is not a single event, rather a series of events in the continued
development and association of the blastocyst and the endometrium. Even if
implantation is defined as starting when the blastocyst assumes a relatively fixed
position within the uterus and a more intimate contact with the endometrium
established, there is still a period of time between apposition of an adhesive
blastocyst to the uterus and the time at which adhesion of the trophoblast to the
uterine surface actually occurs. The lumen of the simplex uterus of primates is
virtually closed at the time of implantation. This is thought to allow apposition of the
endometrial epithelium to trophoblast of the blastocyst and is thought to be a result
of the shape of the uterus, muscular activity, paucity of luminal fluid and endometrial
oedema (Enders, 1993). Initial adhesion of the blastocyst to the uterine luminal
epithelium occurs in the peri-inner cell mass region. In human, baboon, macaque
and marmoset, the syncytial trophoblast developing in the peri-inner cell mass region
invades the uterine epithelium (Enders et ah, 1983). It would appear that the
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adhesion stage prior to epithelial penetration is a short stage in primates. However,
very little information regarding this stage of implantation is available.
Invasion ofendometrial Epithelium
More information is available concerning invasion of the uterine epithelium
by trophoblast. The initial invasion has been suggested to occur in the macaque and
marmoset by intrusion of processes of syncytial trophoblast between epithelial cells
(Enders, et al., 1983, Smith et ah, 1987). This is followed by coalescence of the area
of penetration to form a trophoblastic plate, which usually spreads in the plane of the
epithelium (Enders, 1993). Epithelial invasion occurs within a day of adhesion in the
baboon (Enders and King, 1991), 1-2 days in the macaque and a similar 1-2 days in
the marmoset (Hearn et ah, 1991). No information is available on the human yet,
suggesting that epithelial penetration takes place over a very short space of time.
In the marmoset, the trophoblast intervenes between epithelial cells without
apparent cellular damage. Syncytium is usually described as cytolytic implying its
ability to erode the uterine epithelium and thereby penetrate to underlying vessels
(Moore et ah, 1985).
Trophoblast-Epithelial cellfusion
During the trophoblastic plate stage in the macaque and baboon, some fusion
of syncytial trophoblast with maternal epithelial cells takes place. At the margin of
the implantation site, cytoplasm that is confluent with syncytial trophoblast has
apical vesicles similar to those in maternal epithelial cells. Second, in macaques,
some masses of syncytium contain nuclei that have intranuclear channels similar to
those seen in epithelial plaque cells. Third, near the basal lamina between nuclei,
whorls and pockets of cell membrane suggest fusion of lateral cell membranes
between cells (Enders, 1993).
Between days 13 and 15, the marmoset implantation site expands peripherally
with areas of syncytial penetration between uterine luminal epithelial cells. Such
penetrating masses bridge openings of endometrial glands, share junctional
complexes with the uterine epithelial cells between which they are infiltrating and
subsequently reach the basal lamina of the uterine luminal epithelium (Enders, 1993).
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Stromal invasion and invasion ofmaternal vessels
With expansion of the trophoblastic plate, the epithelial basal lamina is
penetrated as is the underlying stroma, followed by penetration of subepithelial
maternal vessels. During these processes, variation between species increases.
Trophoblast penetrates maternal blood vessels most readily in the baboon (Enders
and King, 1991). Subepithelial stromal cells are dilated, and ectoplasmic processes
from the syncytial trophoblast penetrate the vessels almost as soon as they have
passed through the epithelial basal lamina (Enders, 1993). At the other extreme is the
marmoset (Smith, et al., 1987), in which maternal vessels are slowly surrounded by
trophoblast and penetration of trophoblast into vessels does not occur until 45 days to
60 days (Smith, et ah, 1987) of gestation. In the macaque, penetration of vessels
occurs almost as soon as epithelial basal lamina penetration, but a day or so later than
in the baboon (Enders, 1993). It appears therefore that the trophoblast penetrates
deeper into the stroma before breaching maternal vessels in marmoset (Enders and
Lopata, 1999).
Trophoblast differentiation
While the trophoblast is tapping maternal vessels, profound changes are
occurring in syncytial trophoblast in the macaque, baboon and human. The majority
of this trophoblast converts from a multinucleate invasive tissue to a unilaminar
microvillous absorptive tissue (Enders, 1989). This conversion occurs towards the
end of the initial invasion of endometrium and during the early stages of formation of
blood filled spaces within the trophoblast (Enders, 1993). The formation of an
extensive series of clefts facilitates the subsequent expansion of these spaces into
blood-filled intrasyncytial lacunae. In human, this conversion corresponds to the time
of change in the rate of hCG production (Lenton and Woodward, 1988).
Expansion of the Implantation site
Once maternal vessels are tapped, there again exists variation between
species (Enders, 1993). In the baboon, clefts in syncytial trophoblast develop rapidly
into lacunae, and rapid growth of trophoblast lifts the placenta off the surface of the
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endometrium (Tarara et al., 1987). During this time, most of the growth is within the
placenta; little is within the endometrium (Enders, 1993).
In human, all of the trophoblast, including the abembryonic trophoblast, is
converted into syncytial and cytotrophoblast with clefts and lacunae (Enders, 1989).
This expansion of the lacunar area is largely contained within the endometrium
(Enders, 1993).
In the macaque, abembryonic trophoblast forms a secondary implantation site
on the opposite surface of the endometrium. As such, both placental discs lift from
the surface of the endometrium. In the marmoset, the abembryonic trophoblast of
twins and triplets fuses so that there comes to be a shared exocelom (Smith, et al.,
1987).
In summary, it would appear that the human previllous stage is most deeply
embedded in the endometrium because the trophoblast grows within the stroma for a
longer period of time before tapping vessels and because all of the trophoblast
becomes involved (Enders, 1993).
The trophoblastic plate of the macaque and the baboon is a mixture of
syncytium and cytotrophoblast. Vessels are initially penetrated by syncytial
trophoblast, but as lacunae form, maternal blood comes into contact with both
syncytium and cytotrophoblast. At this point, the border of trophoblast on the
endometrium becomes smoother, and the cytotrophoblast cells become segregated
largely to the embryonic side of the trophoblastic plate (Enders, 1993). In the
macaque and baboon, cytotrophoblastic cells from the trophoblastic plate enter
maternal vessels shortly after initial vessel penetration and become situated in the
superficial arterioles that they at least partially plug (Enders and King, 1991).
At the end of the lacunar or previllous stage, proliferation of cytotrophoblast
cells in clusters adjacent to the blastocyst cavity (human) or between lacunae
(macaque and baboon) results in formation of the primary villi. Almost immediately,
these become secondary villi once mesenchyme begins to grow into them. Despite
vessels forming very quickly within these villi, no blood circulates in the vessels
until an embryonic heartbeat is established (Enders, 1993). Thus, a period of placenta
formation follows implantation for about 1 week. The reorganisation of trophoblast
at the endometrial junction, results in establishment of more permanent structures
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that persist for weeks or months rather than days. These structures are tenned the
anchoring villi. It is only at this stage (that of formation of the trophoblastic shell)
that invasion ofmaternal arterioles occurs in the human (Enders, 1993).
Cytotrophoblast invasion into maternal stroma and blood vessels is a very
dynamic process, associated with cell-cell and cell-matrix interactions (Tarara, et al.,
1987). Several factors are secreted by decidual cells such as laminin, typelV
collagen, fibronectin, heparin and proteoglycans. These probably have a role in
maintaining decidual integrity and enhancement of implantation (Charpin et ah,
1985). It has been demonstrated in vitro that invading trophoblast cells require
fibronectin to facilitate attachment, and that they adhere preferentially to laminin
coated surfaces (Fazleabas, et ah, 1995). The current evidence in the human (Aplin,
1991, Damsky et ah, 1993) and the rhesus macaque (Blankenship and Enders, 1997)
suggests that trophoblast invasion into the maternal endometrium and uterine
vasculature is regulated by cell-cell and cell-matrix interactions.
As can be seen from Table 1. the marmoset embryo adheres to the uterine
epithelium at a later gestational age than other primates. However, the maternal
vascular bed beneath the surface epithelium of the endometrium is present
throughout the uterus at the time of implantation. Sinuses enlarge in the vicinity of
the embryo attachment as trophoblast extends along the uterine surface. The
relatively slow development of the marmoset post-implantation embryo is therefore
unlikely due to limitations of the initial placentation, but instead, probably an
inherent developmental characteristic (Moore, et al., 1985). Marmoset implantation
has been described as less invasive than that in the human and other primates
because of the superficial position of the marmoset embryo in the uterine lumen
(Hertig, et al., 1956).
Figure 1.9 is a diagram to illustrate expansion of the early implantation site
in the marmoset. It illustrates differences in trophoblast-endometrial relationships
during expansion of the site.
Chapter 1 Introduction 60
Figure 1.9 Expansion of the marmoset early implantation site (Enders and Lopata,
1999).
1.11.1 Steroid receptors during pregnancy
Regulation of ER during pregnancy is controlled by steroids. It is down
regulated in glands and stroma as early as day 18 of pregnancy by progesterone as in
the secretory phase of the non-pregnant cycle (Brenner et al., 1990). However, it
does persist in spiral arteries throughout pregnancy where it may have a role in
regulating blood flow, allowing the spiral arteries to adapt to trophoblast invasion
and vessel occlusion (Enders, 1993) by increasing vasodilation to permit the
unrestricted delivery of maternal blood to the developing embryo.
PR is also hormonally regulated during pregnancy but in a different way to
that of the ER (Hild-Petito et al., 1992). In baboon, by day 18 of pregnancy, PR was
absent form all glandular epithelium, but was in stroma surrounding the glands and
spiral arteries. Stromal cells further away from the basal membrane of the glandular
epithelium contained few PR positive cells, suggesting that the progesterone
mediated glandular secretory activity may be regulated in a paracrine manner by
adjacent stromal cells (Fazleabas, et al., 1993, Tarantino, et al., 1992). Furthermore,
in baboon, PR expression in cells that do not contain ER suggests that PR
maintenance in the primate endometrium during pregnancy is not via an ER-
mediated mechanism. Insulin, IGF, EGF and cAMP have all been demonstrated to
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increase PR expression in the absence of oestrogen in vitro (Aronica and
Katzenellenbogen, 1991, Sumida et al., 1988, Sumida and Pasqualini, 1989).
Following complete decidualisation, PR and IGFBP-1 are coexpressed in the same
cells in the baboon uterus (Fazleabas et al., 1989, Hild-Petito, et al., 1992). It may be
therefore, that IGF bound to IGFBP-1 can regulate PR expression in an autocrine
manner in the pregnant baboon.
1.12 Vascular growth
1.12.1 Uterine and placental tissues
The mucosal, innermost layer of the uterus is termed the endometrium. In
primates, growth of the endometrial vasculature begins during the proliferative
(follicular) phase and continues throughout the secretory (luteal) phase of the
menstrual cycle (Reynolds et al., 1992). Associated with endometrial capillary
proliferation, is increased DNA synthesis of vascular endothelial cells (Ferenczy et
al., 1979). Endometrial growth and development in response to systemic
concentrations of ovarian steroids was demonstrated by classic experiments of
Markee, 1932 and 1940 (as cited in (Reynolds and Redmer, 1992)). In these studies,
endometrial explants of rabbits or monkeys were transplanted to the anterior chamber
of the eye. Not only were these explants shown to quickly recruit a vascular supply,
but they also underwent cyclic periods of growth and regression, which were
associated with changes in systemic concentrations of steroids. Rapid vascularisation
and cyclic growth of human endometrial explants that were transplanted to the
hamster cheek pouch has been observed (Abel, 1985).
Rate of blood flow to uterine tissues also varies throughout the non pregnant
cycle, being greatest at or just before ovulation when systemic oestrogen levels are
greatest, and least during the luteal phase of the cycle when systemic levels of
progesterone are highest. These regular patterns in uterine blood flow are temporarily
associated with the ratio of oestrogemprogesterone in systemic blood (Reynolds, et
al., 1992).
In eutherian mammals, the definitive placenta consists of maternal
(endometrial) and fetal (chorioallantoic) tissues and is the site of physiological
exchange between the maternal and foetal systems. Placental vascular growth begins
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in early pregnancy and continues throughout gestation in association with a continual
and dramatic increase in rates of uterine and umbilical blood flows (Ferrell, 1989).
Increased blood flow to placental tissues satisfies the steadily increasing metabolic
demands of foetal growth. The importance of placental vascular development means
that any dysfunction may be a major contributor to embryonic wastage and reduced
birth weights, two major socio-economic problems associated with pregnancy.
Angiogenesis affects numerous pathologic processes of the endometrium.
These include, dysfunctional uterine bleeding and endometrial response to
exogenous hormonal treatment (such as subdermal continuous released
levonorgestrel or orally administered medroxyprogesterone acetate). Also, bleeding
associated with an intrauterine device, uterine leiomyomata, endometriosis, complex
endometrial hyperplasia and endometrial carcinoma in which greater depth of
invasion and higher tumour grade are directly associated with increased angiogenic
activity (Abulafia and Sherer, 1999).
1.12.2 The ovary
Before or soon after birth, the ovary of most mammals contains a stock pile
of non-growing primordial follicles, each of which is composed of an oocyte
surrounded by a layer of squamous pregranulosa cells (Greenwald and Terranova,
1988). In the postpubertal female, primordial follicles continually leave this non-
growing pool. As they approach ovulation, the growing follicles begin to produce
large quantities of oestrogens. A majority of these follicles undergo atresia, and
regulation of growth and development of ovarian follicles therefore has long been
recognised as a means to reduce or enhance fertility. After ovulation, the remaining
cells of the ruptured follicle form a transient endocrine gland, the corpus luteum
(CL). This is critical for successful maintenance of pregnancy in mammals because it
is the primary source of the progestational hormone progesterone. In addition, the
lifespan of the corpus luteum may be a primary determinant of the length of the non-
fertile cycle. The extensive development of ovarian vascular beds has been well
documented over the years, and it is recognised that capillary growth may be of
primary importance in the growth and selection of ovulatory follicles as well as in
the subsequent development and function of CL (Reynolds, et al., 1992). It has been
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suggested that growth of the ovarian follicle and its corpus luteum may be governed
by increased angiogeneis that occurs in the dominant follicle (Gospodarowicz and
Thakral, 1978, Ravindranath, et al., 1992)
It has been demonstrated that reduced DNA synthesis of follicular endothelial
cells, in association with reduced follicular vascularity, was one of the earliest signs
of atresia (Greenwald, 1989), in addition, atretic follicles will regenerate when
placed into culture. As such, decreased vascularity may limit access of atretic
follicles to nutrients, substrates and trophic hormones, thus maintaining these
follicles in an atretic state in vivo (Moor and Seamark, 1986). The extent to which
angiogenesis governs follicular atresia and selection of the dominant follicle is of
great interest. In some species a relationship has been demonstrated. The density of
microvessels in the dominant, or selected follicle is at least twice that of other
follicles in the rhesus ovary (Ravindranath, et ah, 1992, Zeleznik, et ah, 1981). This
increased vessel density greatly increases the level of gonadotrophic hormone that is
delivered to the dominant follicle in vivo suggesting that angiogenesis itself plays a
role in selection of the preovulatory follicle. However, differences in follicle
vasculature from one follicle to another are not obvious in the human ovary (Suzuki
et ah, 1998).
During the process of ovulation, the basement membrane loses its integrity
and the thecal blood vessels access the granulosa cell layer. Subsequently, fonnation
of the corpus luteum is associated with intense angiogenesis (Rodger et ah, 1997).
The formation and maintenance of the CL are essential for the support of early
pregnancy, but the mechanisms that control these processes are unclear. In a fertile
cycle in women, the corpus luteum persists in the presence of human chorionic
gonadotrophin and secretes progesterone to maintain the developing conceptus. In a
non-fertile cycle, the corpus luteum undergoes structural and functional regression.
Approximately 50-70% of cells in the mature CL are endothelial cells and pericytes
(Farin et ah, 1989, Lei, 1991) resulting in the majority of steroidogenic cells being in
contact with at least one capillary (Redmer and Reynolds, 1996, Reynolds, et ah,
1992, Reynolds and Redmer, 1998). By the mid-luteal phase, when the CL is fully
functional, blood flow is among the greatest of any tissue in the body, and ovarian
blood flow is highly correlated with the rate of progesterone production (Niswender
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et al., 1994). Proliferation of endothelial cells continues at a moderate rate decreasing
towards the end of the cycle, so that, by the mid-luteal phase the microvascular tree
is fully established. Phannacological rescue of the corpus luteum of the CL in early
pregnancy is associated with further angiogenesis in women (Wulff et al., 2001).
Luteolysis in the sheep is associated with a rapid diminishment in luteal blood flow
at a much faster rate than tissue weight, implying that luteal regression is preceded
by changes in the vasculature (Bruce and Moor, 1976).
The newly ovulated follicle produces diffusible angiogenic substances that
direct capillary proliferation into the newly formed corpus luteum (Gospodarowicz
and Thakral, 1978). More recently, several angiogenic growth factors and their
receptors have been shown to be present in the corpus luteum such as VEGF, KDR,
Fit, Ang-1 and Ang-2 (Reynolds et al., 1994), (Goede et al., 1998, Hazzard et al.,
1999, Maisonpierre et al., 1997, Redmer and Reynolds, 1996). More specific detail
about expression of these factors and molecular regulation of angiogenesis will be
included in the relevant experimental chapters.
1.13 Angiogenesis
Angiogenesis refers to formation of new blood vessels, or neovascularisation,
and is an essential component of tissue growth and development (Folkman and
Klagsbrun, 1987, Klagsbrun and D'Amore, 1991). It differs from vasculogenesis in
which new embryonic microvessels arise in situ and endothelial cells are produced
from progenitor cell types (Risau, 1991). It is regulated by a complex series of
growth factor interactions, including stimulatory, modulatory and inhibitory
regulators. This section will discuss physiological and pathological angiogenesis, the
angiogenic process and its molecular regulation.
1.13.1 Pathological angiogenesis
Apart from during tumour growth and wound healing, the adult vascular
endothelium is generally quiescent, representing an extremely stable population of
cells with low mitotic rate. Rampant or persistent capillary growth is associated with
numerous pathological conditions including tumour growth, retinopathies,
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hemangiomas and rheumatoid arthritis (reviewed by Reynolds, et al., 1992).
Conversely, insufficient capillary growth occurs in several disease states, including
delayed wound healing, nonhealing fractures and chronic varicose ulcers. Due to the
fact that regulation of the angiogenic process could become the primary method of
treatment for these angiogenic disorders, and because capillary growth occurs
infrequently in normal adult tissues, most work on angiogenesis and its regulation
has focused on developmental or pathological processes (Klagsbrun and D'Amore,
1991).
1.13.2 Physiological angiogenesis
The notable exceptions of physiological angiogenesis are within the female
reproductive tract; the ovaries uterus and placenta (Folkman, 1992). These tissues
undergo cyclic changes in angiogenesis necessary to supply the nutrients and
hormone precursors essential for the establishment and maintenance of pregnancy.
During the menstrual cycle this physiological angiogenesis in the corpus luteum and
endometrium is distinctive in that, in the absence of conception, it is followed by
tissue regression and re-initiation of cyclicity. This tight physiological control
contrasts to the situation in tumours, and raises the possibility that endogenous
inhibitors of angiogenesis play an integral role in the reproductive tract.
Growth and regression of these tissues is extremely rapid. In the cow, for
example, the ruptured ovulatory follicle, which represents less than 200mg of tissue,
forms a mature corpus luteum weighing about 5-6g, in a period of about 10 days.
Similar rapid growth is observed in uterine and placental tissues (Reynolds, et al.,
1992). Rapid growth and regression of female reproductive tissues are accompanied
by equally rapid changes in rates of blood flow. When fully functional, ovarian,
uterine and placental tissues receive some of the greatest rates of blood flow, on a
weight-specific basis, of any tissues in the body (Ford et al., 1982). Tissues of the
female reproductive system are so dynamic that they provide a unique model for
studying regulation of angiogenesis during the processes of growth, differentiation
and regression in normal adult tissues. Understanding the mechanisms of control of
angiogenesis in the reproductive system and the harnessing ofmajor advances in the
development of angiogenic inhibitors and stimulators may reveal new approaches to
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regulation of reproductive function and treatment of pathological conditions of the
female reproductive tract.
This section will discuss the current state of knowledge regarding the physiology
of the angiogenic processes and their regulation in female reproductive tissues.
1.13.3 The angiogenic process
The angiogenic process begins with endothelial cell proliferation and
culminates in the formation of a new microcirculatory bed composed of arterioles,
capillaries and venules. The initial component of angiogenesis, capillary formation
has been shown to consist of three processes:-
1) Fragmentation of the basal lamina of the existing vessel
2) Migration of endothelial cells from the existing vessel towards the angiogenic
stimulus, and
3) Proliferation of endothelial cells (Reynolds, et al., 1992)
Neovascularisation is completed by formation of capillary lumina, by cessation
of endothelial cell proliferation, curvature of the endothelial cell and adherence to
each other to form the capillary lumen. The newly formed vessels differentiate into
arterioles and venules, as pericytes emerge along the length of the sprout. Blood flow
begins slowly. Newly formed vessels are highly permeable until the new basement
membrane is formed and stabilisation by pericytes is complete (Findlay, 1986).
1.13.4 Endothelial cell proliferation
Endothelial cell proliferation forms the major component of capillary growth.
Endothelial cells are generally quiescent and unresponsive to angiogenic stimuli. One
important question in angiogenesis research is what maintains endothelial cells in
this quiescent state and how are these barriers overcome during the initiation of
neovascularisation? (Folkman, 1992). One of these barriers is cellular. Pericytes in
the microvasculature appear to inhibit endothelial cell proliferation. In co-cultures of
pericytes and endothelial cells, cell-cell contact results in production of latent TGF-P
produced by both cell types (Antonelli-Orlidge et al., 1989). Interestingly, retinal
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neovascularisation involves a process of "pericyte drop-out", whereby the normal
number of pericytes is reduced (Folkman, 1992).
Another barrier to neovascularisation is the endothelial cell itself. In culture,
endothelial cells do not respond to growth factors when they are confluent. Increased
sensitivity to bFGF, for example, only occurs by endothelial cell spreading or
elongation (Ingber and Folkman, 1989). In vivo, small venules from which capillary
sprouts arise under angiogenic stimulation appear to contain crowded endothelial
cells analogous to a confluent cell culture (Folkman, 1992).
Vasodilation has been implicated as a possible first step in initiation of
angiogenesis. This commonly occurs as a first step in angiogenesis before the
emergence of the first capillary sprout (Dvorak et al., 1995). It could be that
vasodilation serves to stretch endothelial cells to render them responsive to growth
factors (Folkman, 1992).
A third barrier to neovascularisation is that access to vascular endothelium by
potent angiogenic regulators may be prevented by their being sequestered by the
basement membrane.
A fourth barrier to neovascularisation consists of endogenous inhibitors of
endothelial growth that are present in the circulation and in tissues. These inhibitors
will be discussed in more detail in a later section. Under mitogenic stimulation,
endothelial cells leave the G0 resting phase of growth and re-enter the cell cycle.
Proliferation of endothelial cells can be quantified by expression of specific proteins
associated with the cell cycle for example Ki67, or by the incorporation of nucleotide
analogues during the DNA synthesis phase of growth. Studies using these
approaches have quantified luteal endothelial cell proliferation in the human (Gaytan,
et al., 1998, Rodger, et al., 1997), rhesus macaque (Christenson and Stouffer, 1996),
sheep (Jablonka-Shariff, et al., 1993) and cow (Zheng, et al., 1994). All demonstrate
peak endothelial cell proliferation in the early luteal phase associated with formation
of the corpus luteum and decreased proliferation associated with luteal regression.
As mechanisms of initiating angiogenesis are revealed in the female
reproductive tract, they may also be considered as therapeutic targets to control
dysfunctional bleeding as well as targets of novel methods of contraception.
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1.13.5Capillary stabilisation and periytes
Mature capillaries and postcapillary venules are comprised of two cell types,
endothelial cells and pericytes. Pericytes are found in intimate association with
endothelial cells, and this arrangement, unique to small vessels, is characterised by
frequent sites of contact between the two (Orlidge and D'Amore, 1987). The position
of the pericyte in the capillary and their close proximity to endothelial cells have led
to several theories regarding their function. These include, regulation of permeability
(De Oliveira, 1966) mediation of contractility (Tilton et al., 1979), maintenance of
integrity (Rhodin, 1968) and control of proliferation (Crocker et al., 1970). The
absence of pericytes has been correlated with the onset of neovascularisation. Before
the onset of new vessel growth associated with diabetes mellitus, there is a loss of
pericytes, termed "pericyte drop-out" (De Oliveira, 1966). Morphogenetic studies of
vessel development demonstrate that newly forming capillaries are characterised by
active endothelial cell proliferation and migration, and the absence of pericytes
(Ausprunk and Folkman, 1977), whereas there is a decline in endothelial cell
proliferation and migration associated with pericyte appearance (Ausprunk and
Folkman, 1977). Such observations suggest a role for pericytes in the regulation of
endothelial cell growth. In vitro, pericytes have been found to inhibit capillary
endothelial cell proliferation, (Antonelli-Orlidge, et al., 1989, Orlidge and D'Amore,
1987). This inhibitory effect of pericytes appeared to be mediated by TGF-p.
Activation of this factor requires formation of cell-cell contacts between pericytes
and endothelial cells. Furthermore, the number of cell-cell contacts between
pericytes and endothelial cells has been shown to increase with ongoing maturation
of newly formed capillaries (Wakui et al., 1989). Capillary sprouting includes
coordinated growth of both pericytes and endothelial cells rather than mere
elongation of endothelial tubes, which subsequently become occupied by pericytes.
Therefore, it may be that pericytes have a role in guiding capillary sprouts to find
each other allowing their fusion to continuous capillary loops (Nehls et al., 1992).
This has also been suggested in the sheep CL (Redmer et al., 2001). In view of these
findings, stimulation and inhibition of endothelial cell proliferation during
angiogenesis is a finely balanced process in which pericytes by an active
involvement in capillary sprouting, are likely to play a key role.
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Endothelial cells and pericytes communicate via bi-directional extracellular
exchange of soluble mediators. Endothelial cells are a source of diffusible factors,
regulating mural cell and possibly mural cell precursor proliferation and migration
(Hirschi and D'Amore, 1996). Several diffusible soluble factors are synthesised and
secreted by endothelial cells, among which are a variety of polypeptide growth
factors, including platelet-derived growth factor (PDGF) (Westermark et al., 1990)
and bFGF (Montesano et al., 1986), which function in a paracrine fashion to promote
mural cell proliferation/migration. Microcapillary endothelial cells coexpress PDGF-
B and PDGF-B receptor genes, suggesting that endothelial cell proliferation may be
stimulated in part by autocrine mediation by this molecule. Endothelial cells of larger
developing vessels however, retain high expression of PDGF-B but have no
detectable levels of PDGF-B receptor mRNA (Holmgren et al., 1991). The receptor
is detectable in surrounding fibroblast-like cells and smooth muscle cells. These data
suggest that endothelial cells can effect mural cell precursor migration and
proliferation during vessel development by paracrine stimulation by PDGF-B. In
vitro co-culture of endothelial cells and smooth muscle cell precursors has
demonstrated that endothelial cells are capable of inducing migration of smooth
muscle cells via PDGF-B. These mural precursors differentiated into smooth muscle
cells in the presence of endothelial cells. If cultured alone their differentiation is
driven by TGF-J3 (Hirschi et al., 1998). Basic fibroblast growth factor is angiogenic,
but also mitogenic (D'Amore and Smith, 1993) and chemotactic (Sato et al., 1991)
for smooth muscle cells. Although its mechanism of release remains unclear, it is
another candidate for involvement in smooth muscle cell or pericyte-precursor
recruitment by endothelial cells (Hirschi and D'Amore, 1996).
Pericytes appear to have a varied yet essential role in angiogenesis. Elevated
awareness of these cells and increasing information obtained by further investigation
will lead to better understanding of their role/s in microvascular function.
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1.14 Angiogenic growth factors
1.14.1 Angiogenic promoters
Given the physiological and pathological importance of angiogenesis, a great
deal of research has been devoted to the isolation, characterisation and purification of
factors that can either stimulate or inhibit angiogenesis. Several bioassays have been
developed to measure angiogenesis. The most common ones are endothelial cell
migration (Glaser et al., 1980) and proliferation (Folkman et al., 1979) in vitro, and
capillary growth in vivo in the developing chick chorioallantoic membrane (CAM)
(Ausprunk et al., 1974) and the cornea (Gimbrone et al., 1974). Angiogenesis is
regulated in the reproductive tract and elsewhere by at least twenty angiogenic
growth factors, which have been identified to date. A number of stimulators of
angiogenesis have been purified and characterised. One important promoter of
angiogenesis appears to be vascular endothelial growth factor (VEGF), and it is the
only angiogenic peptide that is mitogenic specifically for vascular endothelial cells.
Other angiogenic promoters include acidic and basic fibroblast growth factors,
platelet derived growth factor, which is structurally similar to VEGF, transforming
growth factor-a, transforming growth factor-|3, folliculostellate-derived growth
factor, angiotropin, angiogenin (Abulafia and Sherer, 1999), and tumour necrosis
factor-a (Okuda et al., 1999). Finally insulin-like growth factor II has been identified
as an angiogenic promoter, in that it stimulates migration and morphological
differentiation of endothelial cells (Lee et al., 2000). This is supported by earlier
work by Fraser et al (Fraser et al., 1998), where it was found that insulin-like growth
factor binding protein-3 mRNA was expressed in endothelial cells of the primate
corpus luteum. This has more recently been implicated to play a role in luteal rescue.
The regulated expression of IGFBP-3 may play a role in controlling angiogenesis
and cell responses in the CL by autocrine/paracrine mechanisms (Fraser et al., 2000).
1.14.1.1 The Fibroblast Growth Factors
An angiogenic factor was first isolated from a tumour in 1971 (Folkman et al.,
1971). This polypeptide was purified by heparin-affinity chromatography and when
subsequently sequenced, it was found to be bFGF (Esch et al., 1985). Basic fibroblast
growth factor is one of the most potent of the known angiogenic factors (Klagsbrun
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and D'Amore, 1991). It is not only an endothelial growth factor, but also a mitogen
for vascular smooth muscle, fibroblasts and for some epithelial cells. It is produced
by virtually all vascular endothelial cells and by many other cell types. Therefore it
may act as both an autocrine and paracrine growth factor. There also exists an acidic
fibroblast growth factor (aFGF) Both bFGF and aFGF are structurally related, with a
53% absolute sequence homology (Esch et al., 1985).
FGF is one of the most widely distributed growth fators in the body, and it is
synthesised by many cells in culture. It has been demonstrated to be a cellular rather
than a secreted protein (Vlodavsky et al., 1987). Both bFGF and aFGF do not contain
a consensus signal peptide in the open reading frame and are thus not secreted.
(Abraham et al., 1986). Endothelial cells synthesise large amounts of bFGF
(Schweigerer et al., 1987). Angiogenesis in vivo is a complex process involving the
degradation of the capillary basement membrane, the migration and proliferation of
endothelial cells, and tube formation. FGF in vitro is mitogenic and chemotactic for
endothelial cells. It stimulates their production of collagenase and plasminogen
activator proteases capable of degrading basement membrane, and it induces
migration of capillary endothelial cells to migrate into three-dimensional collagen
matrices to form capillary like tubes (reviewed by (Klagsbrun and D'Amore, 1991)).
Both aFGF and bFGF are angiogenic factors in the CAM and cornea bioassays at
levels as low as KMOOng (reviewed by (Klagsbrun and D'Amore, 1991)).
In summary, both aFGF and bFGF are both angiogenic mitogens. It is not
clear how they mediate angiogenesis in vivo. Since they are not secreted proteins,
they must be released from cells by alternative mechanisms, for example by
displacement by heparin or cell lysis.
1.14.1.2 Vascular Endothelial Growth factors
By far the most widely studied of these angiogenic regulators in terms of
regulation of angiogenesis is VEGF, also known as vascular permeability factor
(Ferrara and Davis-Smyth, 1997). It was identified in 1983 by its ability to elicit
vascular permeability (Senger et al., 1983), and has subsequently been shown to be a
potent inducer of angiogenesis (Ferrara and Davis-Smyth, 1997). VEGF is a potent
mitogen for micro and macrovascular endothelial cells but is devoid of appreciable
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mitogenic activity for any other cell types (Keck et al., 1989, Leung et ah, 1989). It is
also known as a vascular permeability factor based on its ability to induce vascular
leakage in the guinea pig skin (Senger, et ah, 1983). More recent studies have also
suggested that VEGF may be a factor that induces fenestrations in endothelial cells
(Roberts and Palade, 1995)
VEGF is a member of the platelet derived growth factor family, and is a
heparin-binding, secreted, dimeric glycoprotein. It exists as 5 different homodimeric
isoforms generated by alternative splicing from a single gene. The secreted forms are
composed of 121 and 165 amino acids respectively and act upon endothelial cells in
which its receptor tyrosine kinases, VEGFR-1 and VEGFR-2 (Fit-1, KDR/Flk-1
respectively) are selectively expressed (Abulafia and Sherer, 2000). The most
common secreted molecular species is VEGF|65. VEGF is an inducer of capillary
tube formation and a vascular permeability-inducing agent, stimulated by hypoxia
(Namiki et ah, 1995), cytokines and hormones (Shweiki et ah, 1992). VEGF is
expressed in the ovary in a regulated manner, and its importance in ovarian
angiogenesis has been established following studies in which its action has been
inhibited during the ovulatory cycle. Targeted inactivation of one VEGF allele in
embryonic stem cells results in abnormal formation of embryonic blood vessels
(Carmeliet et ah, 1996). Blood vessel formation is further impaired in homozygous
VEGF allele deficient embryos, resulting in death during gestation. It appears that
VEGF deficiency impairs most early steps of vascular development including in situ
differentiation of blood islands (vasculogenesis), sprouting from pre-existing vessels
(angiogenesis), lumen formation, formation of large vessels, establishment of
interconnections, and spatial organisation of intra- and extra-embryonic vessels
(Carmeliet, et ah, 1996). Abnormal organogenesis can also occur due to inhibition of
angiogenesis. This was demonstrated after exposure to thalidomide (associated with
severe limb malformations, stunted limb growth and dysmelia) even at low
concentrations in early human embryos (D'Amato et ah, 1994).
1.14.1.3 Angiopoietins
VEGF has been the focus of a great deal of research in recent years.
Particular attention has been given to the inter-relationship of VEGF with a novel
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family of angiogenic regulators, the angiopoietins -1 and -2. These consist of about
500 amino acids and act via another endothelial cell receptor tyrosine kinase, Tie-2.
Northern blot analyses of RNA from adult human tissues localised expression of
these regulators. Angiopoietin-1 (Ang-1) was widely expressed, although in small
amounts in the heart and liver. Angiopoietin-2 (Ang-2) expression was readily
detectable only in ovary, placenta and uterus, three predominant sites of vascular
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Figure 1.10 Expression of Ang-1 and Ang-2 mRNA in adult human tissues
(Maisonpierre, et al., 1997).
It can be seen that the angiopoietins are relatively highly expressed in the
ovary, uterus and placenta. Since they appear to play a major role in stabilisation of
blood vessels on one hand and endothelial cell death on the other, the angiopoietins
are attractive candidates as regulators of these divergent processes as they occur in
the female reproductive tract. When angiogenesis is occurring in the presence of
VEGF, Ang-2 acts in concert to enhance angiogenesis, while Ang-1 is involved in
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the process ofmaturation and stabilisation of new blood vessels (Maisonpierre, et ah,
1997). Paradoxically, in circumstances of reduced VEGF expression, Ang-2 may act
to destabilise blood vessels and induce vascular regression by competitive inhibition
of Ang-1. This was tested to determine if Ang-2 negatively regulates Tie-2 function
in vivo (Maisonpierre, et ah, 1997).
Transgenic mice specifically overexpressing Ang-2 in their blood vessels
were generated by the use of an expression vector containing Tie-2 transcriptional
regulatory elements, which direct expression of introduced genes to virtually all
vascular structures in a developing mouse embryo (Maisonpierre, et ah, 1997). Using
this method they demonstrated that transgenic overexpression of Ang-2 disrupts
blood vessel formation in the mouse embryo. This causes the embryo to be smaller
than that of the wild type. The transgenic embryo had a collapsed heart endocardium,
various vascular abnormalities in and around the heart and lacked a regular dendritic
capillary plexus in the head, reminiscent of embryos lacking Tie-2 or Ang-1.
Ang-2 therefore has been demonstrated to be a natural antagonist for Tie-2
that disrupts in vivo angiogenesis. Natural antagonists for vertebrate receptor tyrosine
kinases such as this are atypical, thus, the discovery of a negative regulator acting on
Tie-2 emphasises the need for exquisite regulation of this angiogenic receptor
system.
The temporal changes in the pattern of expression of VEGF and angiopoietin
mRNA in the rat ovary have shown that VEGF is expressed in the pre-ovulatory
follicle and in the hormone producing cells of the corpus luteum. Ang-2 is present in
the theca of the preovulatory follicle and in the endothelial cell sprouts of the
developing corpus luteum, suggesting an angiogenic role in concert with VEGF at
this time. Interestingly, Ang-2 is highly expressed in regressing rat CL, when VEGF
is declining, implying its involvement in the luteolytic process via destabilisation of
blood vessels (Hazzard et al., 2000). Similarly, quantitative PCR in the bovine
revealed that the Ang-2:Ang-l ratio increased during luteolysis (Goede, et al., 1998).
While luteolysis in the normal cycle is associated with endothelial cell loss,
stabilisation and maturation of blood vessels may be crucial to the maintenance of
the corpus luteum in early pregnancy. The mechanisms involved in these divergent
processes are not fully understood. If luteolysis is associated with an increase in
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Ang-2 expression and blood vessel destabilisation perhaps rescue of the corpus
luteum is associated with an increase in recruitment of pericyte cells which stabilise
the blood vessels? This has been demonstrated to be the case in CL ofwomen treated
with hCG to pharmacologically rescue their CL (Wulff, et al., 2001). However, this
does not appear to be the case in all species. In the marmoset for example, this
phenomenon was not observed (See Chapter 3).
1.14.2 Receptors involved in angiogenesis
Tie-2 knockout mice die somewhat later in embryogenesis (E9-E10.5), but
the phenotype is distinct from that of VEGF receptor knockouts. Endothelial cells are
present in normal numbers and are assembled into tubes, but the vessels are
immature, lacking branching networks and proper organisation into large and small
vessels. There is also an absence of the angiogenesis that vascularises the
neuroectoderm by capillary sprouting from the primitive vascular network. Notably,
the vessels that do form, lack an intimate encapsulation by periendothelial support
cells. Thus the Tie-2 tyrosine kinase appears to control the capability of endothelial
cells to recruit stromal cells to encase the endothelial tubes so as to stabilise the
structure and modulate the function of blood vessels (Hanahan, 1997).
The fourth endothelial cell-selective RTK, Tie-1 is very similar in structure to
Tie-2 and appears to control another aspect of vascular integrity. Knockout mice
lacking Tie-1 die over a variable period of oedema and haemorrhage, implicating the
Tie-1 signal in control of fluid exchange across capillaries in haemodynamic stress
resistance, (the ability of a capillary to withstand changes in blood pressure)
(Hanahan, 1997).
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Figure 1.11 Lessons from gene knockout mice. The endothelial cell-
selective RTK's have all been ablated in gene-knockout mice. Each RTK knockout
produced embryonic lethality with vascular defects. However, their distinctive
phenotypes indicate that each of these tyrosine kinases controls a specific,
complementary function in endothelial cells that collectively account for a significant
part of endothelial cell morphogenesis into functional vessels (Hanahan, 1997).
Summary of these interactions
1) Ang-1 is widely expressed in a variety of tissue types of adult and embryo.
Ang-2 however, although expressed widely in the embryo, is expressed only
in ovary, uterus and placenta of adult, the three tissues subject to
physiological angiogenesis.
2) In early follicles, the vasculature is quiescent, and Ang-1 is expressed with
little or no VEGF or Ang-2 expression
3) In late or preovulatory follicles and in the CL, where angiogenesis is ongoing,
both VEGF and Ang-2 are upregulated while Ang-1 expression persists.
4) Finally in non-productive follicles which show vascular regression, Ang-2 is
expressed at uniformly high levels, in the absence of VEGF expression.
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These patterns of expression, collectively suggest a model for control of
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Figure 1.12 Regulation of vascular morphogenesis, maintenance and remodelling by
RTKs and their ligands (Hanahan, 1997).
All three ligands (VEGF, Ang-1 and Ang-2) bind to RTK's that have very
similar cytoplasmic signalling domains. Yet, their downstream signals elicit
distinctive cellular responses. Only VEGF binding to VEGFR-2 sends a classical
proliferative signal. When first activated in embryogenesis, this interaction induces
the birth and proliferation of endothelial cells. In contrast, VEGF binding to VEGFR-
1 elicits endothelial cell-cell interactions and capillary tube formation, a process that
follows closely proliferation and migration of endothelial cells.
Ang-1 binding to the Tie-2 RTK recruits and likely maintains association of
peri-endothelial support cells (pericytes, smooth muscle cells, myocardiocytes), thus
solidifying and stabilising a newly formed blood vessel. Ang-2 does not activate the
Tie-2 receptor, rather, it binds and blocks kinase activation in endothelial cells, thus
it is a competitive antagonist of Ang-1. The Ang-2 negative signal causes vessel
structures to become loosened, reducing endothelial cell contacts with matrix and
disassociating peri-endothelial support cells. This loosening appears to render the
endothelial cells more accessible and responsive to the angiogenic inducer VEGF.
Finally, Ang-2 is expressed at uniformly high levels in vascular regression, in non¬
productive ovarian follicles, the lack of VEGF coexpression suggests that loosening
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of cell-matrix interactions in the absence of a growth or survival signal elicits
endothelial cell death, likely by apoptosis.
Although it will not be discussed in detail for the purposes of this literature
review, changes in the extracelular matrix (ECM) are an essential part of the
angiogenic process and are regulated by the metalloproteinases and their inhibitors.
Cell adhesion to the ECM is primarily through integrins, a family of heterodimeric
transmembrane proteins (Bazzoni et al., 1999). These mediate cell adhesion to the
ECM leading to intracellular signalling events that regulate cell survival,
proliferation and migration. During angiogenesis, it is thought that a number of
integrins expressed on the surface of activated endothelial cells regulate critical
adhesive interactions with a variety of ECM proteins (Eliceiri and Cheresh, 1999).
A complete understanding of these complex regulatory mechanisms within
the ovary and uterus will allow systemic targeting in pathologies which have a
vascular component.
1.14.3 Angiogenic inhibitors
An increasing number of angiogenesis inhibitors have been described
including angiostatic steroids, interferons and platelet factor 4, which are non¬
specific, TNF-a, thrombospondin, TGF-P and protamine, reviewed by (Klagsbrun
and D'Amore, 1991). Angiostatin, an internal fragment of plasminogen, and
endostatin, a fragment of collagen XVIII derived from a human tumour cell line, are
two examples of specific angiogenic inhibitors (O'Reilly et al., 1996, O'Reilly et al.,
1997). No specific detail about angiogenesis inhibitors will be given for the purposes
of this review.
1.15 Manipulation of angiogenesis
1.15.1 Development of antiangiogenic agents
Over 300 endogenous, natural or synthetic anti-angiogenic agents have been
described (Thompson et al., 1999). The initial development involved screening for
antiangiogenic activity in compounds developed for other pathologies. A second
group required the design of specific antagonists to known positive angiogenic
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factors and their receptors, while a third class have been identified from tumour
sources as having negative effects on angiogenesis. The table below summarises this
and is adapted from (Thompson, et ah, 1999).
VEGF immunoneutralising antibodies
Truncated soluble receptor
Tyrosine kinase receptor antagonists eg. Sugen 5416




Metalloproteinase inhibitors eg. Marimastat
Integrin inhibitors eg. Vitaxin
















Inhibition of positive regulators
VEGF inhibitors:-
Numerous studies have shown that inhibition both by broad-spectrum or
systemic targeting of the angiogenic pathway can have profound suppressive effects
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upon tumour growth in animal models. Endostatin has been shown to specifically
inhibit endothelial cell proliferation in tumours (O'Reilly, et al., 1997)
Other experiments include the effects of neutralisation of VEGF in an ovarian
cancer model, with implications for a clinical application of this knowledge in
inhibiting malignant ascites fonnation in ovarian cancer (Mesiano et al., 1998). Most
of the clinical trials on angiogenesis have employed first generation compounds such
as the fumagillin analogue, TNP-470, but as with many of these compounds, its
mechanism of action is multi-factorial and is still under investigation.
Specific angiogenic peptide or receptor antagonists are being developed for
clinical application. A humanised monoclonal antibody to VEGF is currently on a
clinical trial (Presta et al., 1997) and the VEGF receptor is also being targeted using a
soluble truncated Fit-1 receptor or tyrosine kinase inhibitors, the latter having the
advantage of oral activity. Combination treatments such as VEGF inhibitor followed
by Ang-2 may prove to be more effective in preventing angiogenesis (Hanahan,
1997).
Initial studies in experimental tumour models using negative regulators of
angiogenesis, such as recombinant angiostatin are encouraging in that they
demonstrate the successful treatment of tumours without generating resistance.
Angiostatin has been shown to induce and sustain dormancy of human primary
tumours in mice (O'Reilly, et al., 1996). Endostatin has also been shown to be an
endogenous inhibitor of angiogenesis and tumour growth (O'Reilly, et al., 1997).
As increasing numbers of specific antagonists are developed, it should
become possible to systemically target key steps in the angiogenic pathway at
selected periods of the reproductive cycle using suitable animal models and their
effects upon angiogenesis in the ovary, uterus and placenta determined. The potential
for inhibition of physiological angiogenesis is currently being explored. Critical
components of the reproductive pathway have been demonstrated to be suppressed
after mice were treated with the angiogenesis inhibitor AGM-1470 (Klauber et al.,
1997).
The importance of angiogenesis in the immature rat ovary has been shown in
studies in which VEGF was blocked using a truncated Fit receptor. Follicular
development was induced by gonadotrophin treatment and resulted in multiple
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ovulations and elevated serum progesterone in control rats, whereas those treated
with antagonist starting 4-6h prior to gonadotrophin administration showed small
antral follicles and only few corpora lutea. The latter were relatively avascular and
often demonstrated central ischaemic necrosis. While the uteri of the gonadotrophin-
treated rats demonstrated morphological evidence of steroid stimulation, such
changes were largely blocked in antagonist treated animals, presumably secondary to
the comparative lack of steroid stimulation, but also in part as a result of inhibition of
uterine VEGF (Ferrara et al., 1998). In marmoset, after treatment with a soluble
truncated form of the Fit-1 receptor, vascular endothelial growth factor trap (A40)
(VEGF trap) intense luteal endothelial proliferation was suppressed, a concomitant
decrease in endothelial cell area confirmed the inhibition of vascular development,
and a marked fall in plasma progesterone levels confirmed that luteal function was
compromised (Wulff et al., 2001). In the follicle, treatment with the same compound
resulted in an 87% decrease of proliferation in the theca of secondary and tertiary
follicles, a reduction in endothelial cell area and a marked decline in Fit-1 mRNA
expression. Granulosa cell proliferation also decreased. These results demonstrate
that onset and establishment of the follicle vasculature takes place early during
follicular development. Furthemore, the ability of VEGF trap treatment to severely
restrict follicular angiogenesis establishes that VEGF is the major regulator of this
process in the primate ovary (Wulff et al., 2001). Treatment with a VEGF
neutralising antibody, commencing on day 7 after ovulation, for 3 days markedly
suppressed luteal function as judged by a 50% reduction in plasma progesterone
concentration (Dickson et al., 2001). It was concluded that ongoing angiogenesis in
the mid-luteal phase is primarily driven by VEGF, that a proportion of endothelial
cells of the mid-luteal phase vasculature are dependent on VEGF support and that the
treatment may also be an anti-permeability agent, which would explain the decline in
progesterone.
The mechanisms which regulate luteal function in rodents and primates are
markedly different. For example, when macaques or marmosets were treated with
TNP-470 there were no apparent effects upon angiogenesis or luteal function (Fraser
et al., 1999) in contrast to the results in the mouse. However, luteal angiogenesis in
the primate can be suppressed by neutralisation ofVEGF (Fraser et al., 2000).
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Less data is available on the effects of inhibition of VEGF on uterine
function. It would appear that VEGF plays a fundamental role in implantation as an
angiogenic factor but also as a potent inducer of permeability and edema. Its
inhibition prevented implantation in rats (Rabbani and Rogers, 2001, Rockwell et al.,
2002). In mice VEGF antagonist was seen to inhibit oestrogen induced uterine edema
but had no effect on angiogenesis (Hastings et al., 2003). In marmoset, treatment
with a neutralising antibody was seen to significantly suppress progesterone but had
no significant effect on preventing establishment of early pregnancy. This result is
not included in this thesis, but forms part of a publication included in the appendix
(Rowe, et al., 2002). In this experiment, 10 marmosets were given a VEGF
neutralizing antibody. Progesterone levels and pregnancy rates were compared to 6
control animals. Five out of six control animals became pregnant, whereas five out of
ten treated animals became pregnant. This result was not significantly different
despite there being significantly lower levels of progesterone in treated animals
determined by 2-way ANOVA.
Angiogenesis is a very complex and tightly controlled process. Our
understanding of its regulation in physiological circumstances and pathology is
widening all the time. Targeted inhibition of angiogenesis and its manipulation are
allowing this system to be dissected and no doubt further interventions will continue
to improve our understanding of this vast subject.
1.15.1.1 Clinical relevance of angiogenesis research
Angiogenesis a very tightly regulated process. This review has highlighted its
involvement in selection of the dominant follicle, subsequent formation of the corpus
luteum and its role in uterus and placenta.
The corpus luteum is critical for successful maintenance of pregnancy as it is
the primary source of the progestational hormone progesterone. Angiogenesis is
intense during the early luteal phase where the previously avascular granulosa
compartment of the ovulatory follicle becomes invaded by the thecal vasculature
until such time as by the mid-luteal phase, every steroidogenic cell is in contact with
at least one capillary. This is important in order that the necessary nutrients, oxygen
and hormone precursors can be received by the gland to allow its efficient synthesis
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of progesterone, then its export to receptive organs. In non-fertile cycles, the corpus
luteum undergoes structural and functional regression accompanied by a demise of
the vasculature. Luteal angiogenesis is clearly a tightly regulated process unlike that
seen in tumours where prolonged and often unabated angiogenesis takes place.
There exist a number of endogenous inhibitors of angiogenesis that play as
much of a role in its control as angiogenic promoters therefore this tightly regulated
system represents an excellent model in which to study angiogenesis.
Inadequate progesterone production by the corpus luteum due to insufficient
vascularisation could lead to early embryo loss, therefore promoters of angiogenesis
may be of use in the follicle particularly, to help treat infertility. However, inhibition
of luteal angiogenesis by an antagonist could prevent formation of the corpus luteum
and thus act as a post-ovulatory contraceptive. Administration of the angiogenic
inhibitor TNP-470, to mice resulted in inhibition of corpus luteum formation and
endometrial maturation (Klauber, et al., 1997). TNP-470, however, has been shown
to have no effect on luteal establishment and function in the primate (Fraser, et al.,
1999). Therefore clearly not all treatments work the same way in different species
and care must be taken when extrapolating from one to another.
The endometrium also undergoes cyclical angiogenesis. A poorly developed
endometrial vasculature could have implications for successful implantation,
establishment of early pregnancy, and placentation. Manipulation of angiogenesis
here for example could have clinical implications in terms of treating women
experiencing frequent miscarriage as a result of a poorly developed vasculature with
pro-angiogenic agents or indeed conversely preventing implantation by anti-
angiogenesis inhibitors. Studies addressing this issue are to date are limited to the
rodent but form a basis for our understanding of this phenomenon (Rabbani and
Rogers, 2001, Rockwell, et al., 2002).
Growth of tumours is dependent on an ever increasing vascular supply for
provision of nutrients, oxygen and growth factors (Folkman, 1995). The study of
angiogenesis in vivo using the female reproductive tract allows a unique opportunity
to target factors involved therein that may have direct clinical relevance into several
clinical conditions, both reproductive pathologies but also in other diseases.
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1.16 Hypothesis and objectives
This thesis aims to elucidate the sites and mechanisms of angiogenesis in the
marmoset during early pregnancy. In order to do this several hypotheses will be
investigated:-
1) Based on existing evidence known about the human CL in early
pregnancy where a further burst of angiogenesis is observed in early
pregnancy (Wulff et al., 2001), it was hypothesised that this
phenomenon would also exist in the marmoset CL at this time.
2) This experiment was conducted to test the hypothesis that the
upregulation in pregnant human CL, (Wulff et al., 2001), is a
progesterone mediated event and that it does not occur in the
marmoset because progesterone levels are not significantly different
in early pregnancy compared to the late luteal phase, (Rowe et al,
2002)
3) This Chapter aimed to test the hypothesis that there would be an
upregulation of angiogenesis in the marmoset endometrium in early
pregnancy.
4) The final hypothesis was that if an upregulation in angiogenesis was
observed in the marmoset endometrium in early pregnancy, this
would be as a result of changes in local expression of the angiogenic
factors. To investigate this, the localisation of these factors and their
expression throughout the cycle in this tissue was examined.
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2 Materials and Methods
2.1 Sources of reagents, enzymes and antibodies
Unless otherwise stated, all reagents and nuclease free water were obtained
from Sigma (Poole, Dorset, UK) and all antibodies were from Dako Ltd, (High
Wycome, Bucks, UK).
2.2 Marmoset husbandry
Animals were housed in a primate centre, the R.V.Short Building, Bush
Estate, Edinburgh. Animals and the unit itself were maintained by primate centre
staff. Marmosets were housed in cages in rooms maintained between 20°C and 25°C
and artificially lit between 07.00h and 19.00h. the animals were fed daily with a
selection of fruit, SDS Mazuri (E) primate dried pellets and high protein porridge
with multivitamin supplements three times per week. Water was continuously
available. Regularly cycling adult females with no previous breeding experience,
aged between 2 and 2.5 years, weighing approximately 350g were housed together
with a prepubertal female in cages measuring 1.15m in height, 1.1m in depth and
0.6m wide. The floor of each cage was covered with wood chippings to allow
foraging and the cages contained large branches and a nest box. Blood samples were
collected three times per week by femoral venepuncture without anaesthesia while
the animals were held in a restraining device (Hearn et ah, 1978). Syringes were
sealed and centrifuged for 20 minutes at lOOOg, plasma was subsequently removed
and stored at -20°C until assayed for progesterone to determine the date of ovulation
and stage of the cycle and chorionic gonadotrophin (CG) to confirm pregnancy.
2.2.1 PGF2a administration and induction of luteolysis
Administration of treatments was carried out by staff at the primate centre.
All experiments were carried out in accordance with the Animals (Scientific
Procedures) Act, 1986. In order that the timing of ovulation could be synchronised
and subsequent day of cycle determined, all animals received lpg PGF201 analogue
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(chloprostenol, Planate, Coopers Animal Health Ltd., Crewe, UK) intramuscularly
(i.m.) during the mid-late luteal phase of the previous cycle to induce luteolysis and
subsequent ovulation 10 days later (Summers, et al., 1985). At the time of
prostaglandin administration, a fertile male was introduced. Two days prior to
expected ovulation, vaginal lavages were obtained from female marmosets to
detennine whether or not they had mated. Blood samples continued to be taken until
such time as tissues were collected. Terminal blood samples were assayed for
chorionic gonadotrophin (CG) as a pregnancy test.
One parameter used to determine angiogenesis in this study was proliferation
of endothelial cells. In order that this could be visualised and documented,
bromodeoxyuridine (BrdU; Boehringer Mannheim, Sussex, UK) (twenty milligrams
dissolved in 500pl physiological saline), was administered intravenously (i.v) lh
prior to tissue collection. BrdU is a thymidine derivative which is incorporated into
the DNA of proliferating cells during the S-phase (DNA synthesis phase) of the cell
cycle. This can then be visualised in tissue sections by immunocytochemistry. This
will be discussed later.
2.2.2 Collection of tissue
Tissue was collected in the mid- and late- luteal phases from non-pregnant
animals at days 14 (2 weeks) and 21 (3 weeks) from ovulation. Tissues from
pregnant animals were also collected at 2 and 3 weeks post-ovulation. Additionally a
final group of pregnant animals were studied at day 28 (4 weeks).
Animals were sedated using lOOpl ketamine hydrochloride (Parke-Davis
Veterinary, Pontypool, UK), i.m., and killed with an i.v. injection of 400ml Euthetal
(sodium pentobarbitone, Rhone Merieux, Harlow, Essex, UK). Ovaries and uteri
were removed immediately and weighed. Ovaries were halved at random across the
widest point and fixed in either 4% paraformaldehyde (PFA) in phosphate-buffered
saline (0.01M PBS; pH 7.4, containing 2.7mM KC1, 0.137M NaCl) or 4% neutral
buffered formalin (NBF) in PBS for paraffin wax-embedding. All uteri were fixed in
PFA.
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These tissues were used for all results presented in chapters 3,5, 6 and 7. For
Chapter 7, additional archived tissues were used from the early, mid and late
follicular phase and the early and mid luteal phase.
Collection of human granulosa cells for Chapter 4 will be described later.
Day relative to ovulation
Figure 2.1 Schematic of study groups
Prostaglandin is administered in the mid to late luteal phase of the previous cycle to
induce luteolysis (progesterone declines) and synchronise the timing of subsequent
ovulation 10 days later as seen by the rise in progesterone concentration. Levels
greater than 30nmol/l signify that ovulation has occurred. Pregnant and non-pregnant
animals were studied at day 14 (progesterone remains elevated in both) and day 21
post-ovulation (in pregnant animals, where the corpus luteum is rescued and
maintained by foetal CG, progesterone remains high, while in non-pregnant animals
in the absence of CG, the corpus luteum regresses and progesterone levels decline).
An additional group of pregnant animals were studied at day 28.
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2.2.3 Details of animals used in each experiment
Study Groups Number of animals








Pregnant Day 21 6
Pregnant Day 28 6
Angiogenesis in the
endometrium (Chapter 5)
Mid-luteal Day 14 5




Pregnant (Day 28) 5
Gene expression in the
endometrium (Chapter 6)
Late luteal (Day 21) 5 (all animals had
structurally intact CL)
Pregnant (Day14) 5
Pregnant (Day 21) 5
Pregnant (Day 28) 5
Table 2.1. Details of animals used for the thesis
2.2.4 Progesterone ELISA plate assay
Marmoset ovulatory cycles were monitored by measuring plasma
progesterone concentrations. Three blood samples were taken per week, plasma
separated and frozen at -20°C.
Ninety-six well plates were coated in a coating antibody, Rivanol purified
DARS (Donkey anti-rabbit serum, pH 9.6, SAPU, Scottish Antibody Production unit,
Carluke, Lanarkshire, UK) and left overnight at 4°C. Plates were washed 5 times
with washing solution diluted 1 in 25 before use (2.5M tris, 7M NaCl and 1.25%
Tween, pH 7.5). Marmoset plasma samples were thawed, vortexed and diluted. 2.5pl
of the plasma was added to 97.5pl of progesterone assay buffer, pH 6 (0.12M
phosphate, 0.04M citrate, 0.1% gelatin and 0.01% thiomersalate in deionised water).
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In each assay, a low, medium and high progesterone concentration quality control
(QC) was used. These were prepared in the same way as samples.
A standard curve was prepared from a progesterone standard diluted in assay
buffer to 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500 and 1000pg/50p.l. Fifty microlitres
of each standard plus 2.5pl of charcoal stripped male marmoset plasma was added to
47.5pl assay buffer. Finally, to determine maximum binding (BO), 2.5pl of charcoal
stripped male marmoset plasma was diluted in 97.5pl of buffer. All samples,
standard curve, BO and QC's were prepared in duplicate. To all wells, 50pl of
primary antibody (rabbit anti-progesterone, SAPU, Carluke, Lanarkshire, UK)
diluted 1:50,000 in assay buffer was added. In addition, to assess non-specific
binding, charcoal stripped male marmoset plasma, which does not contain
progesterone, was diluted in 147.5pl of assay buffer, primary antibody was omitted.
The total volume in all wells was 150pl. Plates were covered and left overnight at
room temperature.
After incubation overnight, 50pl per well of labelled ligand (progesterone-11-
glucuronide-biotin complex) diluted 1:20,000 in assay buffer was added with 2mg/ml
ANSA (8-anilino-l naphthalene sulphonic acid). Plates were left at room temperature
for 3h. After incubate was removed, plates were washed 10 times before lOOpl per
well of Streptavidin-Horseradish peroxidase diluted 1:2000 with normal phosphate
buffer, (pH7.4, 1% casein). After 1 hour, plates were again washed 10 times before
200pl per well of substrate OPD, (5mM O-Phenylenediamine/0.03% H2O2)
dissolved in substrate buffer, pH 5, (10.3g citric acid, 17.79g Na2HPC>4 dihydrate up
tp 1L with deionised water) was added. After approximately 15 minutes, once a
sufficiently dark enough colouration had occurred, the reaction was stopped by
adding 50pl per well of stopping solution (2N sulphuric acid). Plates were read at
490nm on a "Victor" spectrophotometer plate reader. Inter- and intra- assay
coefficients of variation were 15% and 4% at the centre of the standard curve,
becoming more varied at the extremes.
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Figure 2.2 Schematic of ELISA for progesterone
The rabbit primary antibody binds to progesterone in the sample. This complex can
then bind to the capture antibody (DARS) which is coating the plate. The biotin
labelled progesterone is essentially exactly the same as the unlabelled sample antigen
and binds to the primary antibody binding site with equal affinity. This labelled
antigen can in turn bind the streptavidin- hydrogen peroxidase which is the enzyme
responsible for the detectable substrate colour change. When in solution together, the
labelled and unlabelled progesterone compete for the same binding site. There are a
limited number of these binding sites but a proportionate amount of binding occurs
depending upon the concentration of unlabelled progesterone in the sample.
Therefore the more progesterone in the sample, the less labelled antigen can bind and
the lower the colour intensity. Hence the colouration is inversely proportional to the
amount of progesterone in the sample.
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2.2.5 Assay for serum chorionic gonadotropin
This was conducted by Ian Swanston, using the method described by
(Saltzman et ah, 1998). The assay measures LH, which in marmoset has the same
structure as CG apart from at the CHO terminus (Muller et al, 2004). The assay was
a double-antibody RIA using the monoclonal antiserum 518B7 raised in mouse
against bovine LH. The standard reference preparation was hCG CR-127 with a
range of 0.1-5.0ng/tube. To validate the assay, three different marmoset plasma pools
were assayed for parallelism. Each pool gave a displacement curve parallel to the
standard curve. Assay sensitivity was O.lng/tube and inter and intra-assay CVs of a
quality control pool were 6.88 and 5.96% respectively.
2.2.6 Classification of the stage of the ovulatory cycle
The classification of the stage of the marmoset ovulatory cycle was
determined by plasma progesterone concentrations based on sampling three times per
week, Monday, Wednesday and Friday. The follicular phase was defined as the
period when plasma progesterone concentration was <30nmol/L. The luteal phase
was classified as the stage when plasma progesterone concentration initially rose
above 30nmol/L and was followed by a sustained increase. The first day when
plasma progesterone rose above 30nmol/L being day 0, (the day of ovulation).
Pregnancy was confirmed by the presence of trophoblast in serial sections of the
uterus and plasma levels of CG greater than 20ng/ml.
2.3 Tissue fixation, processing and sectioning of paraffin
blocks
Tissue fixation was necessary in order to prevent autolysis and bacterial
degradation. Also fixation limits shape or volume changes during subsequent
procedures, and allows tissues to be maintained as closely as possible to their in vivo
state without significant loss or rearrangement of tissue morphology and RNA
quality. All uteri and one half of the bisected ovaries were fixed in 4%
parafonnaldehyde (PFA). The other half of the bisected ovaries were fixed in 4%
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neutral buffered formalin (NBF). The reason for this bisection and differing fixation
of both halves was to examine any differences observed in results obtained from the
tissues according to which fixative had been used. PFA had always been traditionally
used in our laboratory but requires being made up on the day of use. NBF however,
is more convenient as it can be stored at the primate centre ready for tissue collection
at any time. Both of these fixatives work in the same way, by forming cross-links
between proteins and aldehydes, resulting in a stable structure, without loss or
damage to enzymes and antigenic sites; clearly important in immunocytochemistry.
DNA and RNA do not react significantly with formaldehyde in their native states,
but are thought to be physically trapped by the protein matrix formed in protein
fixation.
Uteri obtained were fixed in 4% PFA for 24h then transferred to 70% EtOH
until processing into paraffin wax. Ovaries were first bisected through the maximal
part of the largest corpus luteum to ensure that the widest cross section through the
gland could be obtained then fixed as above, one half in PFA, the other in NBF. Uteri
were bisected after being fixed and transferred to EtOH. Bisection was performed
longitudinally through the luminal cavity in order that sections would contain a full
cross section of all compartments, myometrium, endometrium, luminal epithelium
and uterine lumen. Processing and paraffin wax embedding were carried out by the
MRC HRSU Histology Department. Tissue was dehydrated through a series of
graded alcohols before saturation with paraffin wax. This process was conducted
using a 17.5h automated cycle on a Leica TP-1050 processor (Leica UK Limited,
Milton Keynes, UK). The tissue was then embedded with the cut surface facing
upwards so that upon sectioning, maximal cross sections could be obtained. Five
micron sections were cut on a hand operated microtome (Jung RM2035; Leica) with
disposable blades. Super-frost plus slides, electrostatically charged for improved
binding, were used for immunocytochemistry and in situ hybridisation (BDH, Merck
Ltd., Poole, Dorset, UK). Sections were cut and floated onto a heated water bath
(approximately 50°C containing either tap water for immunocytochemistry or RNase
free water for in situ hybridisation). Sections were transferred onto slides and dried
overnight before use. Uteri from females housed with a fertile male were serially
sectioned in order to determine the presence of a trophoblast.
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2.4 Haematoxylin and eosin staining
Haematoxylin and Eosin (H&E) stains were routinely prepared in the
Histology department. Harris's haematoxylin was prepared by dissolving 2.5g of
haematoxylin (BDH) in absolute alcohol. This is then added to alum that has been
dissolved in 500ml of warmed distilled water in a 2L flask. The mixture was rapidly
brought to the boil and the mercuric oxide (1.25g) or sodium iodate (0.5g) slowly
added. The flask was then rapidly cooled by plunging into ice cold water. Once cold,
20ml glacial acetic acid was added (Stevens and Wilson, 1996). Eosin Y as a
cytoplasmic stain was prepared as a 1% solution in distilled water with 0.5ml per
litre of acetic acid.
Tissue sections for haematoxylin and eosin (H & E) staining were dewaxed in
xylene and rehydrated through a series of graded alcohols to tap water. They were
placed into Harris's haematoxylin for 5 minutes, then washed with tap water before
being differentiated in 1% acid alcohol (1% HC1 in 70% alcohol) for 5-10 seconds.
Sections were again washed in tap water then placed into Scott's tap water until a
'blue' colour had developed (approximately 20 seconds). Sections were then washed
again in tap water and placed into eosin for 20 seconds. After a final tap water wash,
sections were dehydrated through a series of graded alcohols and placed into xylene
for approximately 5 minutes before mounting in pertex (Cell Path, Hemel
Hempstead, UK).
After serial sectioning of the uteri, every 10th slide was stained with H & E to
determine the presence of trophoblast or foetal membranes.
2.5 Immunocytochemistry
Immuncytochemistry is a technique for identifying specific cellular or tissue
constituents (antigens, usually proteins) by means of antibody-antigen interactions.
The antigen is recognised within a cell by using a specific antibody raised to an
epitope (monoclonal) or epitopes (polyclonal) of the protein in question. This
technique allows specific localisation of proteins to individual cells and when
quantified, provides a powerful tool for assessing protein expression. Quantification
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is usually based upon parameters such as the number of positive cells within a given
cell population, area of staining within a given field size and /or intensity of staining.
The power of immunocytochemistry is in the magnification of a signal
produced by a bound antibody to a specific antigen by a series of secondary and
tertiary antibodies to increase the available sites for the detection system. In this
thesis, the majority of immunocytochemical techniques use either alkaline
phosphatase-anti-alkaline phosphatase (APAAP) or Horseradish peroxidase (HRP).
However, details of these specific detection systems will be provided separately.
2.5.1 Antigen retrieval
Fixation and embedding in paraffin wax to facilitate section cutting can mask
or even destroy some antigenic epitopes. As such, after tissues had been dewaxed
and rehydrated in a series of graded alcohols to water, an antigen retrieval step was
used to reveal masked antigens. All antibodies used for the purposes of this thesis
required an antigen retrieval step unless otherwise stated. Heat treatment was found
to be the best antigen retrieval method for the antibodies used here after a series of
optimisation experiments were carried out in order to ensure that no tissue damage or
loss ofmorphology occurred.
Slides were subjected to pressure cooking in 0.01M citrate buffer, pH 6, in a
Tefal Clypso pressure cooker (Tefal, Essex, UK). Two litres of citrate buffer were
heated to boiling point in the pressure cooker. Once boiling, the dewaxed and
rehydrated slides in a metal rack were lowered in. The lid was sealed and the slides
were heated for 6 minutes at high pressure from when full pressure was reached
(pressure 2). After pressure was released the slides remained in hot buffer for a
further 20 minutes before cooling and either transferred to 0.01M phosphate buffered
saline, pH 7.4, or 0.05M Tris buffered saline, pH 7.4, for 5 minutes.
2.5.2 Blocking Endogenous enzymes
If enzymes similar to those used in the tracer system are present in the tissue
they may react with the substrate used to localise the tracer and cause problems with
interpretation of results. For example, endogenous peroxidases may react with the
DAB chromagen (3,3'-diaminobenzidine tetrahydrochloride) in the same way as the
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exogenous horseradish peroxidase and give rise to non-specific staining. All
antibodies which were detected using hydrogen peroxidase were incubated in
absolute methanol containing 0.5% hydrogen peroxide for 20 minutes immediately
after pressure cooking, without being transferred to TBS or PBS first (Streefkerk,
1972). After incubation, slides were transferred to TBS or PBS (details of which will
be given in Table 2.2)
There are many types of alkaline phosphatase within tissues and most
endogenous activity can be blocked using a 1 mM concentration of levamisole in the
final incubating medium. The alkaline phosphatase used here is calf intestinal
alkaline phosphatase which is not inhibited by levamisole at this concentration so the
specific signal is not quenched.
2.5.3 Blocking non-specific binding
The main cause of non-specific background staining is non-immunological
binding of the specific immune sera by hydrophobic and electrostatic forces to
certain sites within tissue sections (Kraehenbuhl and Jamieson, 1974). Generally, it is
the first immune sera which gives rise to the highest background staining. This can
be reduced by blocking those sites which show a non-specific affinity for
immunoglobulins by incubating the section in normal whole serum (SAPU), from the
species in which the secondary antibody was raised. For example, when mouse
CD31 was localised using rabbit anti-mouse as a secondary antibody, blocking was
performed using normal rabbit serum. All slides were treated with the relevant
blocking serum diluted 1:5 in TBS with 20% bovine serum albumin (BSA) for 30
minutes at room temperature. This regime was used if no biotinylated secondary
antibody would be subsequently used for detection. (See Table 2.2 for details of
respective blocking sera)
Marmoset ovaries tend to contain high levels of endogenous biotin. Thus a
degree of non-specificity is incurred when using a biotinylated secondary antibody.
Endogenous biotin was blocked in all cases where biotinylated secondary antibodies
were used, by addition of exogenous avidin and biotin to the blocking sera. Using
this blocking regime, exogenous avidin blocks the endogenous biotin, and all biotin
binding sites on the avidin molecule were saturated with addition of excess biotin.
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Avidin (Vector Laboratories Inc., Burlingame, CA, USA) was added at a
concentration of 8 drops per ml of normal blocking serum for 30 minutes (as per kit
instructions) then washed off with TBS or PBS. Followed by a 30 minute incubation
with biotin in normal blocking serum (Vector, 8 drops per ml, as per kit instructions).
2.5.4 Immunocytochemical protocol
An automated incubation method, the Sequenza System (Shandon Scientific,
Runcorn, Cheshire, UK) was used for all incubations apart from the peroxidase
block. The Sequenza works by capillary action and reduces volumes of reagents
required. Unbound antibody is washed from the section before addition of the next
incubate. Each section is retained within its own sequenza coverslip preventing cross
contamination and antibody-antigen complexes are prevented from precipitating onto
sections giving rise to unwanted background staining.
The method detailed below is a general protocol. Detection systems vary
according to antibody, as will the block used before addition of primary antibody and
indeed whether or not TBS or PBS was used. Exact details are given in Table 2.2.
After the appropriate block had been applied and allowed to incubate for 30
minutes, sections were washed 3 times for 5 minutes each with either TBS or PBS.
The primary antibody, diluted in the appropriate blocking serum used for blocking
non-specific binding was added to the sections and incubated overnight at 4°C.
2.5.5 Detection
After 3 five minute washes with TBS or PBS, the secondary antibody, diluted
accordingly in the appropriate blocking serum was added and incubated at room
temperature for 40 minutes. At this point the standard protocol is somewhat
divergent. Thus each detection system will be briefly discussed in turn.
APAAP (Alkaline phosohatase-Anti-alkaline phosphatase)
Slides incubated with non-biotinylated secondary antibodies were
subsequently incubated with a tertiary APAAP antibody (Cordell et ah, 1984). The
secondary antibody is applied in excess so that one of its two identical binding sites
binds to the primary antibody and the other to the APAAP complex (Figure 2.3).
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The APAAP was added, again diluted in the appropriate serum block for 40 minutes
before slides were washed and transferred to TBS or PBS.
The APAAP method can be used with a variety of substrates giving rise to a
variety of colours. The two used for the purposes of this thesis were nitroblue
tetrazolium (NBT) which forms a Deep blue/black immunostain (McGadey, 1970)
and fast red TR used with naphthol AS-MX phosphate sodium which gives rise to a
bright red end product.
Where NBT was used, slides were transferred to NBT buffer for 10 minutes
at room temperature (40ml 0.5M MgCl + 40ml lMtris/lMNaCl + 320ml distilled
water). The area of the slide surrounding the tissue was then dried and NBT solution
added, 10ml NBT buffer + 45pl NBT substrate (Boehringer Mannheim, Germany) +
35pl Xphosphate (Boehringer Mannheim) +1 OjliI levamisole (Sigma). Slides were
left for colour to develop over approximately 10 minutes.
Where Fast red was to be used for detection, slides were removed from TBS
and tissues dried around. Fast red solution was added lmg/ml fast red buffer and left
for approximately 20-30 minutes until red colour developed. Reactions were stopped
in tap water. Sections were counterstained in haematoxylin for approximately 20
seconds before being dehydrated in graded alcohols cleared and mounted in pertex
(Cell Path) if stained with NBT or air dried before mounting if stained with fast red.
HRP
The favoured substrate for HRP was 3,3' diaminobenzadine
tetrahydrochloride (DAB) which yields a crisp, insoluble, stable, dark brown reaction
end product (Graham and Karnovsky, 1966). Where HRP was to be used as the
detection enzyme, biotinylated secondary antibodies were used. After incubation
with the secondary antibody, sections were washed three times for 5 minutes with
PBS or TBS then incubated for 30 minutes at room temperature with ABC-HRP
complex (one drop of solution 'A' + 1 drop of solution 'B' to 5ml 0.05M tris buffer
with no salt, Dako). Slides were washed and transferred to either TBS or PBS before
sections dried around and DAB substrate added (Dako). Staining was produced
almost immediately. Reactions were stopped in tap water and sections were
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counterstained in haematoxylin for approximately 20 seconds before being
dehydrated, cleared and mounted in pertex (Cell Path).
Avidin-Biotin techniques rely on the marked affinity of the glycoprotein
avidin for biotin. Avidin is composed of four subunits which form a tertiary structure
possessing four biotin-binding hydrophobic pockets (Miller, 1996). The ABC-HRP
complex works because 3 of the biotin binding sites on the avidin molecule are
occupied by biotin molecules complexed to HRP while one site remains empty and
can therefore bind to the biotinylated secondary antibody (Figure 2.4).
2.5.6 Dual staining
In order that two antigens can be detected and differentiated on the same
slide, two separate detection systems must be used. For the purposes of this thesis it
was required that BrdU and CD31 were dual stained. The antibodies to be used were
raised in different species, sheep and mouse respectively which is important in order
that no cross reactivity occurs. The secondary antibody to be used for both antibodies
was raised in the same species namely rabbit, thus the blocking serum is the same for
both antibodies, normal rabbit serum diluted 1 in 5 with TBS + 0.25g BSA.
Sections were dewaxed and rehydrated, then an avidin and biotin block was
applied as described in 2.7.3. The first primary antibody, CD31 diluted accordingly
in normal rabbit serum was added and incubated overnight at 4°C. This was then
detected the following day by addition of a rabbit anti-mouse secondary antibody,
followed by mouse APAAP and finally fast red as described above. Sections were
then washed and sequenzas flushed through with TBS before the second primary
antibody was added again diluted accordingly in normal rabbit serum overnight at
4°C. After post incubation washes with TBS, a biotinylated rabbit anti-mouse
secondary antibody was added, followed by ABC-AP (Dako). The principle of this is
the same as for ABC-HRP except that it uses NBT as a substrate instead of DAB.
After incubation with the ABC-AP complex, slides were transferred to NBT buffer
for 10 minutes before staining with NBT. Reactions were stopped in tap water, then
slides were counterstained with haematoxylin before being dehydrated in ascending
concentrations of alcohol, cleared in xylene and mounted in pertex (Cell Path).
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Figure 2.3. APAAP detection of immunocytochemistry
The primary antibody binds to its specific antigen. The secondary antibody is applied
in excess so that one of its two identical binding sites binds to the primary antibody
and the other to the APAAP complex. A coloured substrate is then used for
visualisation











Figure 2.4. ABC-HRP detection of immunocytochemistry
The secondary antibody is biotinylated which permits binding of the tertiary
complex, A coloured substrate, most commonly DAB is used for visualisation.
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Antibody Species raised Block Secondary Tertiary Detection Washes Counter-
in antibody antibody/complex stain
CD3I Mouse Normal Rabbit Mouse APAAP NBT TBS No
Monoclonal rabbit anti-mouse 1:100
1:20 serum 1:60
BrdU Mouse Normal Rabbit Mouse APAAP NBT TBS Yes
Monoclonal rabbit anti-mouse 1:100
1:30 serum 1:60




Mouse/Mono Rabbit Mouse APAAP Fast Red
1:20 anti mouse 1:100
1:60
Cytokeratin Rabbit Normal Swine ABC-HRP DAB PBS No
Polyclonal swine anti-rabbit
1:5000 serum 1:200
Pericytes Mouse Normal Rabbit Mouse APAAP NBT TBS No
Monoclonal rabbit anti-mouse 1:100
1:20 serum 1:60
Table 2.2 Antibodies and reagents used for immunocytochemistry and protocol. All
antibodies were used routinely in our laboratory and had been validated by
the group previously. See Wulff C, Dickson SE, Duncan WC and Fraser HM
(2001) for Pericytes, Fraser et al, 1999 for BrdU and WulffC, Wiegand SJ,
Saunders PT, Scobie GA and Fraser HM (2001) for CD31. Cytokeratin was
an antibody borrowed from Dr. Simon Riley for a single morphological
staining. Its specificity was tested on Human foetal membranes and marmoset
endometrium as positive controls. Negative controls were conducted using
rabbit IgG.
All antibodies are from DAKO apart from the sheep BrdU (Fitzgerald
Industries international, Concord, MA, USA) and the mouse BrdU (Boehringer
Mannheim). All detection reagents are from Sigma. See Appendix for details of
antibodies and specificity.
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2.5.7 Negative controls
For each antibody, negative controls were used in initial trials to determine
the specificity of the antibody. The primary antibody was replaced with




Tissue sections were examined by Digital Photomicroscopy using an
Olympus Provis microscope Olympus Optical, London, UK) and photographed using
a digital camera, Kodak DCS420 (Eastman Kodak, Rochester, NY, USA). Figures
were compiled using Adobe Photoshop 6.0 for Macintosh (Adobe Systems Inc.,
Mountain View, CA, USA) before being printed on a colour laser jet printer.
2.6.2 Quantification of immunocytochemical staining
Not all immunostains were quantified, some were purely performed for the
purposes of localisation. In the corpus luteum, BrdU, CD31 and pericyte
immunostaining were quantified using Image Pro Plus 3.0 software (Media
Cybernetics, Silver Spring, Maryland, USA). Quantification was carried out across
the complete ovarian cross section. An image is captured at x20 objective
magnification and converted to grey scale. The captured image was examined to
ensure that it mirrored the live image as closely as possible by eye. The area or
5 2number of dark objects on a white background per field of view (3.2 x 10 pm ) are
measured using a specifically designed and pre-recorded macro. In all cases, the
threshold for recognition of a "dark" object was set so that the captured image
mirrored the live image as closely as possible. The total cross section of the corpus
luteum was analysed in this way.
In the uterus the dual staining of CD31 and BrdU were quantified using a grid
system to record volume fraction measurements. Specific details of quantification
protocols will be given in the relevant experimental chapters.
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2.7 In situ hybridisation
This technique was used for the detection of specific mRNA in tissue sections
by hybridisation to complementary radiolabelled riboprobes and subsequent
detection using photographic emulsion.
I would like to thank Regeneron Pharmaceuticals, Inc., for the gift of
Angiopoietin-1, -2 and Tie-2 cDNA riboprobes supplied to our laboratory preinserted
into specific plasmids. Helen Wilson and Dr. Christine Wulff were responsible for
transfection of these plasmids into Epicurian coli (XL-1 Blue; Stratagene, La Jolla,
CA, USA) and production of glycerol stocks. I would also like to thank Dr. S.
Charnock-Jones (University of Cambridge, Department of Obstetrics and
Gynaecology) for the gifts of VEGF, VEGFR-l(Flt) and VEGFR-2 (KDR) cDNA
probes. (All inserts are human sequences)
2.7.1 Plasmid Preparation
Riboprobes were generated from plasmids containing the specific cDNA
insert of interest and RNA polymerase initiation sites. As stated above, these
plasmids were received by myself already transfected into Epicurian coli as glycerol
stocks. Details of specific plasmids used for each probe are given in Table 2.3.







VEGF-A pBluescript 383 T7/T3
VEGFR-1 (Fit) pBluescript 272 T7/T3
VEGFR-2 (KDR) pBluescript 412 T3/T7
Ang-1 pKS+ 570 T3/T7
Ang-2 pKS+ 640 T3/T7
Tie-2 pKS+ 1000 T3/T7
Table 2.3. Specific plasmids used for each cDNA insert. See appendix for specific
sequences and homology to marmoset.
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Plasmids were amplified by growth overnight on a shaking platform at 37°C
of 1 0(li1 of glycerol stock inoculated into 10ml LB Broth (Anachem, Luton Beds,
UK; 25 capsules per litre distilled water) containing 10pl Ampicillin (50m/ml, Gibco
BRL, Life Technologies Ltd., Paisley, UK). A control tube containing broth and
ampicillin was also prepared. After overnight growth, plasmids were purified from
their host bacterium if the control solution remained clear.
Purification was performed using a QIAprep Spin miniprep kit (QIAGEN
Ltd., Crawley, West Sussex, UK) according to the manufacturers instructions. Cells
were centrifuged, resuspended then lysed by treatment with an alkaline solution.
After addition of a neutralising solution and centrifugation, the supernatant was
added to a QIAprep spin column. DNA becomes adsorbed to the silica in the
presence of high salt, and is then eluted off the column. A GeneQuant Pro
spectrophotometer (Amersham Pharmacia Biotech, Cambridge Science Park,
Cambridge, UK) was used to determine the concentration and purity of the DNA.
Additionally, the quality was checked using agarose gel electrophoresis. A 1%
agarose gel was prepared by dissolving 0.5g agarose in 50ml TBE buffer (1M tris,
1M boric acid and 0.02M EDTA in distilled water). Once dissolved, lpl ethidium
bromide was added to the solution. The gel was cast and wells made with a comb.
The purified plasmid was loaded (lpl) with 2pl loading buffer and 7pl nuclease free
water. The gel was run at 100V for 45 minutes and the DNA visualised and
photographed under UV light. If PCR (polymerase chain reaction) of riboprobes was
not to commence immediately, purified plasmids were stored at -20°C.
2,7.2 Polymerase Chain Reaction (PCR) of plasmids for riboprobes
In order to amplify the sequence of interest within the plasmid. Specific
forward and reverse primers were designed to the RNA polymerase initiation sites




A standard PCR was performed using the following reaction mix:-
1 Oul 1 Ox Thermostart standard buffer (Abgene, Epson, Surrey, UK)
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6j.il MgCL2 (1.5mM)
2pl dNTP mix (20mM mixture, 5mM each ofA, C, G and T)
2pl each of forward and reverse primers (5pM each)
0.5pl Taq DNA polymerase (Abgene)
75.5pl nuclease free water
Total volume lOOpl
The Thermostart enzyme requires a heat activation step at the beginning of
the PCR. Annealing temperature for VEGF, Fit, KDR, Ang-1, Ang-2 and Tie-2 was
52°C. The following PCR protocol was used:-
95°C lOmin Enzyme activation
95°C 30secs Denature
52°C 30secs Primer annealing
72°C lmin30secs Extension
72°C lOmins Final extension
30 cycles
PCR products were then purified using a Boehringer High Pure PCR Product
purification kit (Boehringer Manheim) according to manufacturers instructions. As
with the plasmid purification column, the riboprobe is bound to the column while
plasmid template and other contaminants are washed through with a series of
washing buffers. The purified product is then eluted off the column. Concentration of
DNA was measured on a GeneQuant Pro spectrophotometer (Amersham Pharmacia
Biotech) and the product run on an agarose gel as before. The length of the expected
cDNA sequence was known (Table 2.3) and so it was possible to verify that the
correct product had been amplified by reference to the gel.
2.7.3 Synthesis of riboprobe (cold labelling)
Having purified the PCR product, it was necessary to determine whether or
not the cDNA could be transcribed into a functional sense and antisense riboprobe.
In order for this to be tested, a cold labelling was performed. Sense and antisense
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riboprobes (generated from the same purified PCR product), were made using T7 and
T3 RNA polymerases (See Table 2.3) Riboprobes were synthesised using a
MAXIscript in vitro transcription kit (Ambion Inc., Austin, Texas, USA). 300ng
purified PCR product was added to a reaction mixture containing 1 X transcription
buffer (Ambion), 0.5mM of each rNTP (ribonucleotide triphosphate; riboadenosine
triphosphate, rATP, ribocytosine triphosphate, rCTP, riboguanine triphosphate, rGTP
and ribouridine triphosphate, rUTP), 10U RNA polymerase and nuclease free water
to 20pl. This mixture was incubated at 37 °C for lh. After which 1U DNase
(deoxyribonuclease) was added for a further 15 minute incubation at 37 °C. The
product was run on a gel to check that transcription had been successful.
2.7.4 35S labelling
This is essentially the same as the cold labelling. 300ng DNA are added to the
following reaction mixture, 10U RNA polymerase, lx transcription buffer 0.4mM
rCTP, rGTP and rATP, (rUTP was added at 0.04mM concentration). This is to allow
for some incorporation of cold UTP and some incorporation of 35S labelled UTP. 3aS
labelled UTP is a large molecule and so if incorporated in close proximity to another
•> r
S labelled UTP, it may be stereoinhibited. By adding a low concentration of cold
UTP, this incorporates at random to limit this.
In addition to this standard reaction mixture 2.3MBq 35S labelled UTP was
added (NEN life science products, Boston, MA, USA) and 0.4mM Dithiothreitol
(DTT), to prevent formation of disulphide bridges, up to a final volume of 25 pi with
nuclease free water. Reaction mixtures were incubated at 37 °C for 45 minutes and
then for a further 45 minutes after addition of another 10U enzyme. Finally 1U of
DNase was added and incubated for 15 minutes at 37 °C.
After riboprobe synthesis, incorporation of 35S UTP was measured by
counting the total radioactivity (counts per minute, cpm) of 1 pi of the final reaction
mixture then spinning the remaining solution through a ChromaSpin column
(Clonetech Laboratories Inc., Palo Alto, CA, USA), according to manufacturers
instructions to retain any free radioactivity before counting lpl of the eluate. The
incorporated count was expressed as a percentage of total counts per minute.
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2.7.5 In situ hybridisation procedure
In situ hybridisation experiments were conducted for VEGF-A, Fit, KDR,
Ang-1, Ang-2 and Tie-2. For each tissue of interest, two serial sections were cut, one
was treated with the sense probe and the other with the antisense probe. Only tissues
from the same in situ experiment were compared for analysis. It was essential that
solutions and all equipment used for the experiment were ribonuclease (RNase) free.
To ensure this was the case, sterile plastics were utilised and glassware and metal
racks were baked at 180°C. Tissue sections were cut wearing disposable gloves onto
sterile slides. All solutions used on the first day of the in situ hybridisation were
made up with Diethyl pyrocarbonate (DEPC, Sigma) treated water (1ml per litre ultra
pure water), which had been autoclaved three times. After hybridisation subsequent
solutions were made up in ultra pure water. Additionally, chemicals were retained for
in situ use only with no usage without sterile equipment and gloves.
Fresh xylene and alcohols were prepared before each experiment. Tissue
sections were dewaxed and rehydrated. Then placed in 0.2N HCL (to denature
proteins) for 20 minutes followed by two 5 minute DEPC water washes. Proteolytic
digestion of tissues was performed using 5pg/ml proteinase K in 1M Tris, 0.5M
EDTA, for 30 minutes at 37°C. (Optimised for all probes). The proteinase K
digestion was stopped by transfer of slides to a 0.2% glycine solution at 4°C for 10
minutes. Slides were then transferred to 0.1M triethanolamine buffer (TEA, pH 8
with 5M NaOH) for 5 minutes before incubation in TEA buffer/0.25% acetic
anhydride for 10 minutes. Sections were then washed in 4X SSC (salt sodium
chloride containing 0.6M NaCl, 0.06M Na citrate, pH 7) for 5 minutes.
Hybridisation
Sections were dried round, laid in sterile humid boxes and incubated for 2h
at 55°C in 1 OOjliI prehybridisation buffer containing; 50% deionised formamide, 4x
SSC, lxDenhardts, 125pg/ml salmon testes DNA, 125pg/ml yeast tRNA and lOmM
DTT. Prehybridisation buffer was drained off and replaced with 50pl per slide of
hybridisation buffer (containing the same as the prehybridisation buffer plus 10%
dextran sulphate, to increase the rate of reassociation of nucleic acids, and
approximately 0.5 xlO6 cpm of probe per 50pl for VEGF-A and 1 xlO6 cpm per
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50pl for all other probes). Before addition of hybridisation buffer to slides, the probe
(in buffer) was denatured immediately before use by heating to 95°C for 10 minutes.
Sections were coverslipped (Gel Bond) and incubated overnight at 55°C in a humid
box.
The following day, RNase free conditions were no longer required. After
removal of coverslips and a subsequent 10 minute wash in fresh 4xSSC, slides
underwent RNase-A treatment (20pg/ml Rnase A in 1M Tris, 0.5M EDTA, 0.5M
NaCl buffer, pH 8) at 37°C for 30 minutes. This was followed by a wash in RNase
buffer containing no RNase-A for 30 minutes. Slides were then subjected to repeated
30 minute stringent post hybridisation washes, at room temperature unless otherwise
stated (2xSSC, 1 x SSC at 65°C and 0.1 x SSC). Finally, slides were dehydrated in
50% (v/v) ethanol/0.3M ammonium acetate, 85% ethanol/0.3M ammonium acetate
and 94% ethanol/0.3M ammonium acetate for 2 minutes each, before being allowed
to air dry for 3-4h.
Slides were dipped in G5 emulsion (Illford, H + A West, Edinburgh, UK),
diluted 1:1 in distilled water and heated until liquefied at 45°C, in a dark room.
Slides were then dried overnight in a light proof humid box at 4°C, before dessicant
was added and emulsion exposed at 4°C for a certain number of weeks depending on
probe. VEGF, Fit and KDR were exposed for 5, 9 and 9 weeks respectively for
corpus luteum and 12 weeks for uterus. Ang-1, Ang-2 and Tie-2 were exposed for 12
weeks in uterus. Exposure times were determined by inclusion of trial slides in each
in situ hybridisation experiment for each probe and tissue type that were developed at
intervals until such time as optimum hybridisation had occurred. All experimental
slides within one run were developed at the same time. Slides were developed in
filtered Kodak D19 developer (Edinburgh cameras, Edinburgh, UK) for 4 minutes at
14°C, rinsed in distilled water then fixed in Kodak GBS Fixer (Sigma), diluted 1:5 in
distilled water, for 10 minutes at room temperature. Slides were again rinsed in
distilled water, counterstained with haematoxylin for 20 seconds, cleared in xylene
and mounted in pertex as previously described for immunocytochemistry.
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2.7.6 Quantification of in situ hybridisation
Specific hybridisation to tissues was quantified by grain density
measurements. This was either carried out using an image analysis macro for corpora
lutea where the cross section of cells forms a homologous picture without zonation,
or by eye in the uterus where tissue zonation was apparent. It would be impossible to
use this image analysis macro on the uterine sections as it assumes homology of the
tissue between fields as occurs in the corpus luteum, but clearly does not occur in the
uterus where some fields may contain glands, others stroma etc. Grain area was also
measured in ovaries using an image analysis macro. The reason that grain are and
density were both used is that grain area gives an indication as to how many cells are
expressing a gene, whereas grain density gives an indication as to how highly an
individual cell is expressing a given gene. The image analysis macro was designed to
distinguish silver grains in dark field at x20 objective magnification against the black
background of the tissue. Where scoring was carried out by eye, in the case of the
uterus, two independent observers used the following classification: - (0) No
detectable specific signal above background levels, + (1) detectable but low grain
density clearly above background levels, ++ (2) Moderate grain density, +++ (3)
high grain density without grain coalescence and ++++ (4) grain coalescence.
Scoring of tissues was blind and random by each observer. Statistical analyses were
performed for the data obtained. If grain counts were conducted using a pre-designed
macro, ANOVAs were used. However, if scoring was by eye, significant differences
between groups were determined using a Kruskal-Wallis non-parametric test
followed by Dunn's multiple comparisons test.
2.8 Statistical analysis of data
Specific details of statistical analyses will be given in the relevant chapters.
Where more than two variables were being compared, an analysis of variance was
used (ANOVA) followed by a Bonferroni's post hoc test if the data was parametric.
In this thesis all data was normally distributed and hence an ANOVA was applied.
One exception was in the scoring analysis of in situ hybridisation in the marmoset
endometrium, where data was skewed towards the upper end of the distribution
across the groups studies. In this circumstance, where data was non-parametric, a
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Kruskal-Wallis, followed by Dunn's multiple comparisons test was used. If only two
data sets were to be compared two-tailed unpaired t-tests were used. In all cases, the
level of significance was P<0.05. All tests were performed using SPSS 10 for the
macintosh.
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Chapter 3
Angiogenesis in the corpus luteum of early
pregnancy
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3 Angiogenesis in the Corpus Luteum ofEarly
Pregnancy
3.1 Introduction
Angiogenesis has been shown to be intense during the first few days of the
lifespan of the corpus luteum (CL) in a large number of species studied, including
sheep, marmoset, macaque and women (Christenson and Stouffer, 1996, Dickson
and Fraser, 2000, Rodger, et al., 1997, Zheng, et al., 1994) and is stimulated
principally by vascular endothelial cell growth factor (VEGF) (Dickson, et ah, 2001,
Fraser, et ah, 2000).
In the corpus luteum of early pregnancy, the changes in angiogenesis and the
role of the luteal vasculature in the maintenance of progesterone secretion remain to
be elucidated. When pharmacological 'rescue' of the CL by human chorionic
gonadotrophin (hCG) was carried out in rhesus monkeys, no stimulation of
angiogenesis, as monitored by Ki-67 incorporation, was observed despite
maintaining plasma progesterone concentrations (Christenson and Stouffer, 1996). In
apparent contrast, in the CL from women given hCG to mimic luteal rescue of early
pregnancy, a second wave of angiogenesis, accompanied by vascular stabilisation by
pericytes was associated with luteal rescue (Wulff, et ah, 2001). This increase,
documented by analysis of luteal sections, was dependent upon an increase in luteal
cell volume being taken into account. In the study using rhesus monkeys luteal cell
volume was not considered. It was also found that mRNA for VEGF increased in the
CL after hCG rescue (Wulff et ah, 2000). These findings suggest that luteal
angiogenesis could be a component of luteal rescue which is important for
prolonging the lifespan of the corpus luteum and the establishment of early
pregnancy.
Since failure of the CL due to a malfunction of the vasculature could possibly
lead to miscarriage or infertility, it was considered important to establish a non-
human primate model of early pregnancy in which this issue could be addressed.
The marmoset monkey offers several potential advantages for such studies. Firstly,
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it has an exceptionally high rate of fertility (>70%) (Fraser, et al., 1994) when
compared to other primates, so physiological pregnancy, rather than pharmacological
hCG rescue may be studied. Secondly, the cellular and molecular regulation of
angiogenesis during the normal cycle has been described previously (Dickson and
Fraser, 2000). Angiogenesis was determined by comparing BrdU incorporation into
corpora lutea of the late luteal phase versus early pregnancy. Vascular stability was
monitored by determining pericyte area. Localisation of expression of VEGF mRNA
and its receptors, KDR and Fit were determined and changes associated with
pregnancy quantified using in situ hybridisation.
3.1.1 Specific Methods
3.1.1.1 Details of animals used for the experiment













P,21 2.19 341 6
P,28 2.68 356 6
3.1.1.2 Analysis of corpora lutea
In marmosets after ovulation, the follicle or follicles from which the ooytes
were ovulated become luteinised and are termed primary corpora lutea. Often after
ovulation, other follicles within the ovary also become luteinised. They do not differ
in morphology to the primary CL except for the fact that they are smaller. While
detailed descriptions of the analyses conducted in this experiement are given in
Chapter 2, it should be noted that all primary and accessory corpora lutea were
analysed in all cases. A comparison was conducted between the two groups for all
parameters. In all cases, no significant difference between primary and accessory CL
were found (P<0.05 using 2 way ANOVA) hence results were combined.
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3.2 Results
3.2.1 Hormone profile
Pregnancy was confirmed by the presence of a trophoblast and CG levels
greater than 20ng/ml, while non-pregnant animals had a uterus compatible with an









Figure 3.1 Mean plasma chorionic gonadotrophin (ng/ml) from animals at the
different stages studied. Pregnancy was confirmed by CG levels greater than
20ng/ml. Values are means ± SEM. (For LL n=8, and n=6 for P,21 and P,28)
Plasma progesterone profiles of pregnant and non-pregnant marmosets from
ovulation (day 0) to day 21 of the cycle are illustrated in Figure 3.2. The late luteal
non-pregnant animals have been subdivided into two groups, according to whether
functional and structural regression had taken place by day 21. The corpora lutea of 5
animals in this group remained structurally intact despite being anticipated to shortly
undergo structural regression. One of these intact CL was from an animal which was
housed in the absence of a male. Thus the non-regressed state of the CL, was not
dependent on a male being present. There was no observable difference in plasma
progesterone levels between these non-pregnant control animals and the pregnant
animals from day 0 to 21 of the cycle. Three of the late luteal control animals had
undergone functional and structural regression. In these animals, there was a
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significant difference in plasma progesterone as determined by a 2-way ANOVA
compared to both the pregnant and control animals. In all four groups there was an
initial rise in progesterone indicative of ovulation. Progesterone levels then remain
elevated (>150nmol/L) until day 10-11 which corresponds to the time of
implantation in marmosets (Enders, 1993). At day 10-11, the regressed late luteal
control animals showed declining progesterone for the remainder of the recorded
cycle, whereas a continued elevation of progesterone was observed in both groups of
pregnant animals and the structurally intact control animals. Statistical analysis (2-
way ANOVA) revealed that progesterone levels in the regressed control group were
significantly different to the structurally intact controls and 3 (day 21) and 4 (day 28)
week pregnant animals (P<0.05) from day 16. Progesterone levels remained elevated
until tissue collection in day 28 pregnant animals although Figure 3.2 only illustrates
the progesterone profile until day 21. Data up to day 28 was not included inorder that
the graph be consistent across all groups studied. Progesterone levels remained at the
same level between day 21 and 28 in day 28 pregnant animals. Progesterone levels

















Figure 3.2 Plasma progesterone concentrations from ovulation to day 21 in pregnant
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and non-pregnant animals. Values are means ± SEM. (n=6, day 21 and 28 of
pregnancy; n=5, day 21 structurally intact; and n=3 in day 21 regressed). In the five
non pregnant animals with structurally intact CL, elevated progesterone levels
continued up to day 21 despite anticipated luteal regression. Progesterone levels from
three non pregnant animals with structurally regressed CL, however, had declined to
follicular phase levels by Day 21.
3.2.2 Lutein cell area
3.2.2.1 Method of quantification
The marmoset is a multiovular species, therefore the ovary contains several
corpora lutea. 10 fields of view were randomly chosen across the largest corpus
luteum present in an ovarian cross section. Within each of these fields 10 cells were
randomly selected and cross sectional area measured by free hand drawing around
the circumference of the cell using image analysis equipment. This area was then
filled in on the screen and the area of the blackened section measured.
3.2.2.2 Results
Cross-sectional area of individual lutein cells was not significantly different
using a 1-way ANOVA (P>0.05) between structurally intact non-pregnant CL and
the pregnant animals at day 21 and 28 (492±26, 530±21 and 584±34, respectively.
Values are means ± SEM). The structural integrity of the regressed corpora lutea was
such that individual lutein cells could not be identified and thus not measured
(Figure 3.3 and Figure 3.4)
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Figure 3.3 Haematoxylin and eosin stained sections ofmarmoset corpora lutea. (A)
Structurally intact non-pregnant late luteal CL, (B) Structurally regressed non¬
pregnant late luteal CL, note absence of structural integrity, (C) CL at day 21 of
pregnancy and (D) CL from day 28 of pregnancy. (EC, Endothelial cell, SC,
Steroidogenic cell).













Figure 3.4 Cross-sectional area of lutein cells in corpora lutea of animals from the
different study groups. Values are means ± SEM. There were no significant
differences between study groups
BrdU immunostaining indicating proliferating cells was readily detected in all
corpora lutea. When quantified, by 1-way ANOVA, no significant difference
(P>0.05) was observed between structurally intact late luteal and pregnant CL,
however, proliferation indices from structurally regressed CL were significantly
higher (P<0.05) than for all other groups apart from day 14 pregnant animals (Figure
3.5 and 3.6). Previously published data (Dickson and Fraser, 2000), from the early
and mid and late-luteal phase are included in Figure 3.6 to show the changes in
endothelial cell proliferation throughout the luteal phase of the cycle. An intense
burst of angiogenesis with high endothelial cell proliferation is observed in the early
luteal phase, decreasing in the mid-luteal phase and further still towards the end of
the luteal phase. Data from 2 week (day 14) pregnant animals were included to
investigate whether or not an intense burst of angiogenesis occurred earlier than 3
weeks (day 21). Day 14 corresponds to the peri-implantation period. However,
proliferation indices were not found to be significantly different from other groups at
this stage.
3.2.3 Cell Proliferation
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The insert in Figure 3.5 illustrates the co-localisation of CD31 and BrdU
immunostaining, ie. proliferating endothelial cells. Quantification showed that
greater than 90 % of proliferating cells were endothelial cells.
Figure 3.5 Cell Proliferation in the marmoset corpus luteum (x40 objective); (A)
structurally intact late luteal CL, (B) structurally regressed late luteal, (C) Pregnant,
day 21, (D) Pregnant, day 28. Insert in (A) shows colocalisation of CD31 and BrdU.
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Figure 3.6 Mean proliferation index in corpora lutea of animals from the different
study groups, early luteal (EL, day 4), Mid-luteal (ML, day 10) and late luteal (LL,
day 21) from earlier studies, (Dickson et al., 2000); Structurally regressed late luteal
(SRLL), Structurally intact late luteal (SILL), Pregnant, day 14, 21 and 28 (P, D14,
P,D21 and P,D28, respectively). Values are means ± SEM. Mean proliferation index
from structurally regressed CL was significantly higher than all other groups, apart
from 2 week pregnant animals (P<0.05), from 2-way ANOVA. Different letters
denote significant differences.
3.2.4 Endothelial cell area
Measurement of CD31 was used to quantify endothelial cell area. There was
no significant difference between groups (P>0.05), using a 1-way ANOVA. (Figure
3.7 and Figure 3.8). By the late luteal phase, the corpus luteum is well vascularised
and from the photomicrograph (Figure 3.7) it can be seen that every lutein cell is in
contact with at least one endothelial cell. Structurally regressed CL were not included
in the quantitative analysis because of poor structural integrity leading to diffuse
staining, as can be seen in Figure 3.7B.
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Figure 3.7 Immunocytochemical localisation of endothelial cell marker CD31.
Structurally intact late luteal (A), structurally regressed late luteal (B), pregnant, day
21 (C) and pregnant, day 28 (D) corpora lutea are illustrated here. (SC) steroidogenic
cell, (EC) endothelial cell. No significant difference in area of CD3 1 staining was
observed between study groups.






Figure 3.8 Mean endothelial cell area in corpora lutea of animals from the different
study groups. Values are means ± SEM. No significant differences were observed
between groups.
3.2.5 Pericyte cell area
Immunostaining for a-smooth muscle actin was evident in all stages
observed, predominantly in large luminal vessels, but also to a lesser extent in
smaller vessels and capillaries (Figure 3.9 and 3.10). No significant difference in
endothelium coverage by pericytes (P>0.05) using 1-way ANOVA, was seen
between study groups. Again structurally regressed CL were not quantified because
of diffuse staining.
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Figure 3.9 Immunocytochemical localisation of a-smooth muscle actin. Structurally
intact late luteal (A), structurally regressed late luteal (B), pregnant, day 21 (C) and
pregnant, day 28 (D) corpora lutea are illustrated here. (SC) steroidogenic cell, (Pe)
Pericyte. No significant difference in area of a-smooth muscle actin staining was
observed between study groups.
Chapter 3 Angiogenesis in the corpus luteum of early pregnancy 125
LL P,21 P,28
Figure 3.10 Mean pericyte area in corpora lutea of animals from the different study
groups. Values are means ± SEM. No significant differences were observed between
groups.
3.2.6 VEGF
Both grain area and grain density were measured using an image analysis
macro across the whole cross section of the corpus luteum. Intense hybridisation to
VEGF mRNA was localised to lutein cells, with absence of hybridisation to
endothelial cells. Distinct, punctate hybridisation in lutein cells was clearly seen in
structurally intact control and pregnant CL (Figure 3.11). The exact cellular
localisation of the grains was done by morphology of the sections under high power
bright field microscopy. There was no significant difference using 1-way ANOVA
(P>0.05) in either mean grain area or mean grain density between these groups
(Figure 3.12). In the structurally regressed CL, most of the lutein cells were devoid
of punctate VEGF expression and there was a marked reduction in grain area and
density (Figure 3.11C and D).
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Figure 3.11 Photomicrographs illustrating localisation of VEGF mRNA to
steroidogenic cells (SC) by in situ hybridisation. (A, C,E and G are dark field images
of structurally intact, structurally regressed, pregnant, day 21 and pregnant, day 28
corpora lutea, while B, D, F and H are corresponding light field images.







































Figure 3.12 VEGF expression in marmoset CL. Mean grain density/pm and mean
grain area (pm2) in nonpregnant and pregnant CL. No significant differences were
observed between these groups by 1-way ANOVA. Values are means ± SEM.
3.2.7 KDR
Both grain area and grain density were measured using an image analysis
macro across the whole cross section of the corpus luteum. Hybridisation to KDR
mRNA was localised to endothelial cells (Figure 3.13). No significant difference in
grain area or density was observed between study groups (P>0.05) using 1-way
ANOVA as illustrated by Figure 3.14. Structurally intact and regressed non¬
pregnant CL were analysed independently but, in contrast to VEGF, KDR expression
was maintained in the regressed CL. Since grain area and density were the same in
each group, the results were combined.
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Figure 3.13 Photomicrographs illustrating localisation of KDR mRNA to endothelial
cells (EC) by in situ hybridisation. (A, C,E and G are dark field images of
structurally intact, structurally regressed, pregnant, day21 and pregnant, day 28
corpora lutea, while B, D, F and H are corresponding light field images.
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Figure 3.14 KDR expression in marmoset CL. Mean grain density/pm2 and mean
grain area (pm2) in nonpregnant and pregnant CL. No significant differences were
observed between these groups by 1-way ANOVA. Values are means ± SEM.
3.2.8 Fit
Both grain area and grain density were measured using an image analysis
macro across the whole cross section of the corpus luteum. Hybridisation to Fit
mRNA was localised to endothelial cells of the CL Figure 3.15. A significantly
lower mean grain area was observed in day 28 pregnant corpora lutea than in late
luteal animals (P<0.05) by 1-way ANOVA, as illustrated by Figure 3.16. However,
no significant difference in grain area was seen between late luteal and pregnant day
21 animals, nor was there any observable difference in grain density between groups.
As above, late luteal regressed and intact controls were combined as there was no
difference in Fit expression between them.
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Figure 3.15 Photomicrographs illustrating localisation of Fit mRNA to endothelial
cells (EC) by in situ hybridisation. (A, C,E and G are dark field images of
structurally intact, structurally regressed, pregnant, day21 and pregnant, day 28
corpora lutea, while B, D, F and H are corresponding light field images.
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Figure 3.16 Fit expression in marmoset CL. Mean grain density/pm" and mean grain
area (pm2) in nonpregnant and pregnant CL. A significantly lower mean grain area
was observed in day 28 pregnant corpora lutea compared to late luteal animals
(P<0.05) by 1-way ANOVA. No other significant differences were observed. Values
are means ± SEM.
3.2.9 Ang-1, Ang-2 and Tie-2
No photographic or data are included for Ang-1, Ang-2 and Tie-2. However it
should be noted that no expression above background levels of any of these genes
was observed in the marmoset corpora lutea studied. Marmoset endometrium was
used as a positive control in all experimental runs.
3.3 Discussion
This experimental chapter has described the cellular and morphological
changes in the corpus luteum associated with early pregnancy in the marmoset.
Neither luteal cell area, endothelial cell area, pericyte area or endothelial cell
proliferation differed in early pregnancy from the late luteal CL of the non-pregnant
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cycle. However, the proliferation index in structurally regressed CI was significantly
greater than that recorded from CL of all other groups. It may be that these rapidly
proliferating cells are white cells however, due to the disorganisation of the tissue at
this time, immunocytochemical detection of white cells not carried out. We had no
reason to believe that this was non-specific BrdU incorporation as the BrdU staining
was specific in all other sections. In addition, levels of VEGF, KDR and Fit mRNA
were largely unaltered. Thus, a further burst of angiogenesis does not occur in early
pregnancy in the marmoset. It would appear that the late, pre-regressed luteal
vasculature is equipped with the molecular and cellular components to perform the
functions of the vasculature of the CL of early pregnancy.
In the human corpus luteum, endothelial cell proliferation mirrors that of the
marmoset in the early, mid- and late luteal phase, where maximal proliferation
occurs in the early luteal phase and declines significantly in the mid- and late luteal
phase (Gaytan, et al., 1998, Rodger, et ah, 1997). This is also true in the rhesus
monkey, (Christenson and Stouffer, 1996), sheep (Jablonka-Shariff, et ah, 1993,
Jablonka-Shariff et ah, 1997) and in cattle (Zheng, et ah, 1994). During
pharmacologically-induced luteal rescue in women by hCG, an increase in luteal cell
volume, endothelial cell proliferation, pericyte recruitment and VEGF expression is
observed, indicating an increased rate in angiogenesis accompanied by vessel
stabilisation (Wulff, et ah, 2001). This appears to mirror the situation observed in rat
where endothelial cell proliferation is also seen to increase in early pregnancy
(Meyer and McGeachie, 1988, Tamura and Greenwald, 1987). In contrast, there does
not appear to be an increase in endothelial cell proliferation in early pregnancy in the
marmoset, as in sheep (Jablonka-Shariff, et ah, 1997) or in hCG-induced rescue of
the CL in the rhesus monkey (Christenson and Stouffer, 1996).
The rescue of the corpus luteum of pregnancy allows it to persist functionally
and structurally for longer than in the non-pregnant cycle. Presumably, this survival
requires a stable vasculature, with recruitment of pericytes and prolonged endothelial
cell survival, in addition to prolongation of the lifespan of the luteal cells. Since
endothelial cell proliferation did not increase after administration of hCG in the
rhesus monkey (Christenson and Stouffer, 1996), it was suggested that early
pregnancy may be associated with an increase in vessel stability, and there is recent
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evidence for hCG-induced increase in pericyte number in the human CL (Wulff, et
ah, 2001). However, no evidence for this was found here.
The increase in pericyte number in the human was dependent upon taking
account of the increase in lutein cell volume after hCG administration (Wulff, et ah,
2001). However, in the marmoset, no such increase was observed, consistent with
Webley et al, (Webley et ah, 1990), who examined cell size distribution of luteal
cells from pregnant and non-pregnant marmosets. It was concluded that there is a
significant increase in mean cell diameter between day 6 and day 14 in both pregnant
and non-pregnant animals but no further increase on day 20.
While in the structurally regressed CL, VEGF expression was markedly
reduced, there was no apparent difference in VEGF expression between structurally
intact late luteal controls and pregnant corpora lutea in the marmoset. VEGF
expression is not significantly altered throughout the functional lifespan of the
human corpus luteum, which is consistent with the high expression seen in the
marmoset in the structurally intact CL (Berisha et ah, 2000, Otani et ah, 1999, Wulff,
et ah, 2000). A significant increase in VEGF expression, in terms of both grain area
and density, compared to the late luteal phase was found in hCG rescued human CL,
using the same method as the present study (Wulff, et ah, 2001). Cell culture studies
using luteinised granulosa cells, have also revealed that hCG treatment leads to
increased VEGF mRNA levels (Neulen et ah, 1998). This reported up-regulation of
VEGF by hCG rescue supports the view that in the human, pregnancy is associated
with further angiogenesis. In the marmoset however, no evidence for up-regulation
of VEGF mRNA was found, consistent with observations in the early pregnant CL of
the cow (Berisha, et ah, 2000). It is also of interest that there is no evidence for a
decline in VEGF mRNA preceeding luteolysis, rather the decrease of VEGF mRNA
was only observed at the time of structural regression.
Levels of KDR mRNA also did not change in the pregnant animals. Fit
mRNA was unchanged in the day 21 pregnant group, but significantly decreased in
the day 28 animals compared to the non-pregnant controls. It is interesting that only
grain area was significantly reduced, not grain density. This suggests that the number
of cells expressing Fit is reduced at this time, but that the intensity of expression
within these cells is no less than in other groups. This could be explained by the fact
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that Fit is associated with proliferating endothelial cells of which there are more in
the earlier luteal phases of the cycle. Therefore by 28 days post ovulation, the
endothelial cells from these earlier phases may be beyond the stage of high Fit
expression. In the human CL, RT-PCR demonstrated that there was no increase in
KDR or Fit mRNA levels in the CL of pregnancy compared to the non-pregnant
cycle (Sugino et al., 2000). Thus, luteal rescue is not associated with an increase in
VEGF receptors. These results lead us to propose that the late luteal CL of the
marmoset retains its molecular (at least with regard to VEGF mRNA and its
receptors), morphological and structural integrity and is similar to the rescued CL
until such time as it does undergo structural regression.
In view of these results, it was considered that a period of intense
angiogenesis may be occurring earlier than day 21, for example at around day 14 of
early pregnancy, soon after implantation of the blastocyst on day 11. However,
analysis of endothelial cell proliferation in the CL at day 14 of pregnancy, failed to
demonstrate a significantly higher intensity of angiogenesis compared to non¬
pregnant structurally intact late luteal controls. While I have focussed on VEGF and
its receptors in this study, it is possible that other angiogenic factors may be involved
in regulation of the vasculature of early pregnancy. Since the angiopoietins are
thought to participate in stabilisation of blood vessels, I examined mRNA levels for
Angiopoietin-1 and -2 and their receptor Tie-2 using the same method and
riboprobes employed by Wulff et al, (Wulff, et al., 2001), and marmoset
endometrium as a positive control. However, no detectable specific signal above
background grain density was observed in ovaries of any groups, thus the
angiopoietins appear not to play a role in luteal rescue in the marmoset.
The length of the luteal phase in the non-pregnant marmosets varied greatly.
This was advantageous here, as it allowed for the study of both structurally intact
non-pregnant and structurally regressed CL, but the cause of this variation however,
is still unclear. Some animals have functionally and structurally regressed CL by day
21 whereas other non-pregnant animals are still functionally and structurally active
although anticipated to shortly undergo regression. Recent estimations from our
colony have shown luteal length to vary between 16 and 24 days which is consistent
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with previous reports on variability in luteal phase length (Harding, 1982, Harlow et
al., 1984, Summers, et ah, 1985).
It is well established that progesterone levels are maintained due to the
continued responsiveness of luteal cells to gonadotrophins via CG in pregnancy
(Stouffer, et ah, 1978). It would appear that in the marmoset, despite the absence of
CG, the late luteal CL of a non-pregnant cycle is maintained until it undergoes a
rapid regression and thus decline in progesterone production. Luteal regression in the
marmoset must therefore be a very rapidly triggered event, for up until that point the
CL of a non-fertile cycle retains its morphology and functional capacity to the same
extent as in a pregnant cycle.
These results have demonstrated that by the late luteal phase in the marmoset,
the corpus luteum has already established a mature vascular system and the
molecular capacity to synthesize VEGF and its receptors which are not further
enhanced in early pregnancy. A pregnancy induced spurt of angiogenesis does not
take place, rather a maintenance of the existing vasculature is all that is required for
establishment of pregnancy in the marmoset. Therefore, it has to be concluded that
the changing morphological and cellular events thought to be associated with early
pregnancy in the human after hCG rescue do not occur in the marmoset.
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4 The effect of progesterone on VEGF expression
in human luteal steroidogenic cells in vitro
4.1 Introduction
Chapter 3 demonstrated that there is no increase in angiogenesis associated
with early pregnancy in the marmoset corpus luteum (Rowe, et al., 2002) in apparent
contrast to the effects of hCG induced rescue of the CL in the human (Wulff, et ah,
2001). One parameter used to assess angiogenesis in both of these studies was the
level of expression of VEGF mRNA. This was unaltered in the marmoset in early
pregnancy but was seen to increase in the human after hCG rescue. This chapter aims
to investigate further this divergence between these species and to provide some
preliminary data as to potential mechanisms for this discrepancy.
In order to investigate this issue, it is necessary to understand what is
happening at this time in both species. Progesterone is a key player in early
pregnancy. Maintenance of pregnancy in mammals requires progesterone production
by the ovarian corpus luteum and in most species, the functional lifespan of the CL is
extended to maintain this production (Zeleznik and Benyo, 1994). In humans, the CL
remains the primary source of progesterone for 4-5 weeks after implantation until
placental production becomes sufficient to maintain pregnancy. The mechanisms of
luteal rescue vary among species. In rodents, coitus initiates rescue whereas in
human and primates, rescue is initiated by the conceptus through its production of
chorionic gonadotroophin.
The general pattern of progesterone production during the first trimester of
pregnancy has been described in the human. Luteal rescue by hCG is associated with
increased luteal progesterone secretion both in normal (Lenton and Woodward,
1988) and simulated early pregnancy (Mendizabal et al., 1984, Tay and Lenton,
2000). This observation forms the first discrepancy between these two species, for in
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the marmoset, progesterone levels are maintained in early pregnancy at levels
already attained in the luteal phase but are not further augmented during luteal rescue
(Rowe, et ah, 2002). This therefore gives rise to the possibility that progesterone
could be responsible for the increase in VEGF seen in the human that is not apparent
in the marmoset CL in early pregnancy. I hypothesise that the increase in VEGF
mRNA observed in hCG rescue of the human CL is a progesterone mediated effect.
This could be possible as the VEGF gene has been documented to contain a
progesterone response element (Hyder and Stancel, 2000).
In order to understand this and to address this hypothesis, reception of
progesterone in the CL will be investigated using immnocytochemistry for
progesterone receptor in the marmoset and human. In order to fully dissect the
system, an in vitro model of human luteal steroidogenic cells will be employed to
allow this system to be studied by addition and withdrawal of progesterone to
determine its role in promoting increased VEGF expression in the hCG rescued
human corpus luteum.
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4.2 Specific methods
4.2.1 Details of animals and samples used




























3 culture samples from
different women
The effect of hCG on human
luteinised granulosa cells
Varying doses of
hCG (0, 0.001, 0.01,
0.1, 1, 10 and
lOOng/ml hCG)
5 culture samples from
different women at each
dose
The effect of progesterone on








8 culture samples from
different women per
treatment
The effect of duration of treatment





5 culture samples from
different women per
treatment
Table 4.1 Details of animals and samples used in the experiment
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4.2.2 Source ofmarmoset and human tissues
Marmoset corpora lutea used in this experiment were collected from normally
cycling marmosets in the mid-luteal phase (n=3). Details of marmoset husbandry,
collection and processing of tissues are to be found in Chapter 2, sections 2.4 and
2.5. The marmoset endometrium used for the positive control was from the late
secretory phase (n=l). Again uteri were collected and processed according to
sections 2.4 and 2.5.
Human corpora lutea (n=3) were obtained from normally cycling women
undergoing hysterectomy in the mid-luteal phase and were fixed and processed
according to section 2.5. Human endometrium used for a positive control was
collected in the early secretory phase from endometrial biopsy (n=l) and processed
according to sections 2.4 and 2.5.
4.2.3 Progesterone receptor immunocytochemistry on fixed tissues
Tissues were dewaxed and rehydrated, as described in section 2.5 before
being subjected to antigen retrieval. This was performed using pressure cooking in
citrate buffer before blocking of endogenous peroxidase and endogenous biotin were
performed as described in section 2.7. The normal serum used in this case was
Normal horse serum (Vectastain ABC kit-Horse anti mouse, 3 drops of horse serum
to 10ml PBS). Progesterone receptor antibody (mouse, monoclonal, Novocastra
Laboratories Ltd., Newcastle Upon Tyne, UK. This is raised against human PR. It
detects both the A and B forms of the receptor, and does not detect non-genomic
receptors), diluted 1:20 in normal horse serum block was added to slides and
incubated overnight at 4 °C. A negative control was included and incubated with
mouse IgG (SAPU) at a similar concentration (in this case 1:6000) overnight at 4 °C.
After overnight incubation with primary antibody, slides were washed twice
in PBS before the secondary antibody was added, 1 drop of anti-mouse serum to
10ml PBS (Vectastain ABC kit- horse anti mouse). This incubate was left on for lh
at room temperature. After 2x PBS washes, previously prepared ABC-HRP solution
(2 drops of solution A and 2 drops of solution B to 10ml PBS, made up at least 20
minutes in advance, Vectastain ABC kit- horse anti mouse) was added for lh at room
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temperature before detection by DAB immunostaining, counterstaining with
haematoxylin, dehydration and mounting (see chapter 2).
4.2.4 Collection and separation of human granulosa cells
Follicular fluid was obtained from patients undergoing in vitro fertilisation
treatment after transvaginal follicular aspiration. Typically these patients followed a
long protocol down regulation with GnRH analogues for 2-3 weeks followed by
daily injection of recombinant FSH with ultrasound monitoring. When three or more
follicles were 18mm or greater, 10,000IU of urinary derived hCG was administered
and follicular aspiration for oocyte collection was organised 35-36 hours later.
Recruitment of patients and subsequent surgical procedures were performed by either
Dr. W.C Duncan or Dr. W. Ismail. This study was approved by the Reproductive
medicine subcommittee of the South East Scotland Research Ethics committee.
4.2.5 Cell culture
Follicular fluid, containing cells from within the follicle, was received after
removal of oocytes by hospital staff. It was centrifuged at 1200rpm for 10 minutes
and supernatant discarded. The gelatinous precipitate was resuspended to 5ml
volume with warmed (37°C) medium. Dulbecco's modified Eagle's medium nutrient
mixture F-12 ham, was used, supplemented with the following; To 480ml medium,
5ml each of 2mM L-glutamine, Penicillin-Streptomycin solution (100,000 units/1
penicillin, 100mg/l streptomycin), 2.5mg/l amphotericin B and insulin-transferrin-
sodium selenite media supplement (10mg/l insulin, 5.5mg/l trasferrin, 5pg/l sodium
selenite, 0.5g/l bovine serum albumin and 4.7pg/l linoleic acid).
Granulosa cells were separated over 45% percoll in culture medium. The cell
suspension was layered over the percoll (Amersham Pharmacia Biotech, Little
Chalfort, Bucks, UK) mixture and centrifuged at 252g for 30 minutes. After
centrifugation the clearly visible granulosa layer was placed in a clean test tube and
subjected to repeated washes in sterile phosphate buffered saline (PBS, 37°C) to
remove red blood cell contamination. After the cells had been resuspended in PBS
they were spun at 252g for 1 minute. Supernatant was discarded and cells
resuspended in fresh PBS. These washes were repeated up to 5 times depending on
how clean the samples were after each wash. Cells were ultimately resuspended in
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lml culture medium. Twenty microlitres of cell suspension were mixed 1:1 with
trypan blue vital dye and mixed vigorously to break up cell clumps. Half of this
mixture was placed in a haemocytometer and cells counted in each of four corner
squares from the two chambers (8 squares in total). Total cells per ml were
calculated;
Average count per square x dilution factor x 104.
Cells were plated out in culture medium onto matrigel coated 24 well plates
at a density of 75,000 cells per well. Incubation overnight at 37°C in 5% CO2
allowed cells to adhere to plates before specific treatments were added, details of
which will be discussed below. Matrigel (Beckton Dickinson UK, Ltd, Cowley,
Oxford, UK), was thawed overnight on ice then mixed 1:1 with cold culture medium.
Plates were cooled on an ice block before 50pl of the matrigel mixture was added
and spread across the base of each well. This was allowed to dry for 45 minutes
before 500pl culture medium was added per well. Plates coated in matrigel can be
used for up to 14 days.
4.2.6 Cell fixation and processing for immunocytochemistry
Human luteinised granulosa cells were plated out onto matrigel coated plates
as described in section 4.2.4 at a density of 75,000 cells per well and left to adhere
for 24 hours.
After removal of culture medium, cells were washed with PBS and removed
from the well with trypsin-EDTA solution (0.5g Trypsin, 0.2g EDTA made up to
100ml) for 2 minutes at 37°C. This puts the cells under stress and so medium
containing 10% foetal calf serum was added as this enhanced cell survival and
limited cell damage. After 900pl of culture medium containing 10% foetal calf
serum was added, cells were gently scraped off the bottom of each well and placed
into an eppendorf tube. Cells were centrifuged at 252g for 3 minutes before being
fixed in 200pl 10% neutral buffered formalin. The cell pellet was then resuspended
by vortexing and centrifuged 252g for 3 minutes.
After the supernatant was discarded, cells were resuspended in 5 to 10pl PBS,
before being added to a liquefied 2% agarose pellet. Once the pellet had solidified it
was strored in 70% ethanol until processing (as described in Chapter 2). Five micron
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sections were cut onto BDH superfrost slides ready for haematoxylin and eosin
staining as described in chapter 2, or immunocytochemistry as described below.
4.2.7 Progesterone receptor and 3|3HSD immunocytochemistry
dual staining on fixed cells.
Immunostaining for progesterone receptor was performed exactly as
described above except that 2 drops of nickel were added to the DAB substrate
solution before detection so that the resultant nuclear immunostain would be black
and thus clearly distinguishable from the cytoplasmic brown 3pHSD immunostain to
follow.
After detection of progesterone receptor, slides were incubated with normal
goat serum (3 drops of goat serum to 10ml PBS, Vectastain ABC kit - Goat anti-
rabbit), before 3pHSD antibody, (rabbit polyclonal, kindly donated by Professor Van
Luu-The (CHUL Research Centre, Quebec, Canada) diluted 1:1000 in normal goat
serum was added and incubated overnight at 4°C (Duncan et al., 1999). After
overnight incubation the secondary antibody, goat anti-rabbit was added for lh at
room temperature (1 drop biotinylated anti-rabbit serum to 10ml PBS, Vectastain
ABC kit - Goat anti-rabbit). Detection was as above (ABC-HRP, lh, room
temperature and subsequent staining with DAB substrate).
Sections were dehydrated and mounted as described in chapter 2, without
counterstaining.
4.2.8 Cell culture treatments
As stated in Section 4.2.4, human luteinised granulosa cells were plated out
onto 24 well, matrigel coated plates. These were then left at 37°C in 5% C02 for 24
hours to allow the living cells to adhere to the base of the well. After 24h, culture
medium was removed before fresh medium containing specific treatments was added
(lml medium per well). In all experiments, a lipid supplement of LDL cholesterol
(Sigma) was included in the culture medium at a concentration of 50pg/ml, all
treatments were given in duplicate and application of treatments was for 24 hours.
Under no circumstances were cells from different women mixed. If there were not
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enough cells from a sample to provide duplicate wells of at least 75,000 cells per
well, for each treatment, then the sample was discarded. The number of individual
experiments conducted for each part of this chapter ("n" number) refers to the
number of separate samples utilised.
After 24 hours treatment duration, culture medium was removed and
stored for analysis of progesterone while cells were treated with Tri reagent for RNA
extraction and real time quantitative PCR for VEGF, as described below. At this
stage, Tri reagent from duplicate wells was combined.
4.2.9 Treatment regimes
In order to determine the dose response of cultured human luteinised
granulosa cells to hCG in terms of progesterone secretion and VEGF expression and
to elucidate optimal concentrations to use for future experiments, urinary derived
hCG was added to cells at concentrations of Ong/ml, O.OOlng/ml, O.Olng/ml,
O.lng/ml, lng/ml, 1 Ong/ml and lOOng/ml.
To manipulate progesterone within this cell culture system, and to dissect out
the effects of progesterone from hCG, several different strategies were used. All
treatments were applied to cells in culture medium for 24h; (1) A control was
included that received only culture medium containing 50pg/ml low density
lipoprotein (LDL) as a substrate for progesterone synthesis. In order to increase
progesterone secretion, both hCG and LDL need to be added. This control confirms
that this is an effect of hCG rather than the LDL; (2) In order to assess the response
of human luteal steroidogenic cells to hCG alone, 1 Ong/ml hCG + 50pg/ml LDL was
added. This concentration of hCG was chosen because in dose response experiments
it was demonstrated to evoke progesterone secretion from these cells towards the
maximal range achieved, where the graph of dose response begins to flatten at
saturated levels of progesterone secretion and VEGF expression; (3) To determine
the effect of progesterone alone without addition of hCG, cells were treated with
lOpM progesterone + 50pg/ml LDL; (4) In order to assess the involvement of
progesterone in the observed upregulation of VEGF expression from human luteal
steroidogenic cells, it was necessary to remove it from the system and to determine
whether or not the previously seen upregulation of VEGF was maintained in the
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presence of hCG treatment alone. To test this, a steroidogenesis inhibitor,
aminoglutethamide, was used at appropriate concentrations previously reported
(Fowkes et al., 2001). The treatment regime employed was lOng/ml hCG + lOOpM
aminoglutethamide + 50pg/ml LDL. At this point, I wish to address the issue as to
why RU486 was not chosen as a progesterone inhibitor. If steroidogenesis is
blocked, no progesterone can be synthesised in response to hCG treatment, whereas
if progesterone action alone is blocked, and its synthesis remains unabated, it cannot
be proven in this system that RU486 is penetrating cells adequately and destroying
any intracellular progesterone effects that may remain; (5) Finally, if progesterone is
responsible for the increase in VEGF expression observed, reintroducing it
exogenously to a system where its endogenous synthesis has been blocked should not
only reinstate this effect, but evoke a further increase in VEGF expression. In order
to test this, lOng/ml hCG + lOOpM Aminoglutethamide + 10pM progesterone +
50pg/ml LDL were added.
4.2.10 Time course experiment
If the observed upregulation in VEGF expression was a progesterone
mediated effect, it would be expected that increased progesterone synthesis would
precede increased VEGF expression after hCG treatment. In order to test this
hypothesis, human luteal steroidogenic cells were treated with lOng/ml hCG for a
duration of 12 and 24 hours before medium collection and RNA extraction as
described in section 4.3. A control was also included which received only culture
medium without hCG for 24 hours.
4.2.11 Progesterone assay on culture medium
This was essentially exactly the same as the protocol used for serum
progesterone assays (Chapter 2), except that instead of 2.5pi of charcoal stripped
male marmoset plasma being added to the standards, 2.5pl of culture medium was
added.
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4.2.12 Total RNA extraction and quantification of specific mRNA
4.2.12.1 RNA extraction from cells
Total RNA was extracted from human granulosa cells using Tri-Reagent, a
mixture of guanidine thiocyanate and phenol in a mono-phase solution. This is a
quick and convenient reagent for use in the simultaneous isolation of RNA, DNA
and protein. This method is one of the most effective ways to isolate total intact RNA
with little or no contaminating DNA or protein. The resulting RNA can be used for
Northern blots, mRNA isolation, in vitro translation, RNase protection assay,
cloning and PCR.
After removal and storage of culture medium from wells, the cells were
washed in PBS to remove any dead, non-adherent cells, (live cells remained adherent
to the well surface). Subsequently, 0.5ml Tri-reagent was added to each well,
pipetted up and down to remove adherent cells and then left for approximately 5
minutes. All cell culture treatments (described in Chapter 4), were performed in
duplicate. At this stage the tri reagent from each of the duplicate wells was combined
before transfer to a clean eppendorf tube on ice. Then 200pl chloroform was added
and mixed vigorously. The tube was then centrifuged at 19064 g at 4°C for 20
minutes. Centrifugation separates the mixture into three phases, a red organic phase
containing protein, a white interphase containing DNA and a colourless upper
aqueous phase containing RNA. This upper aqueous phase was transferred to a clean
tube before 500pl isopropanol and 1 pi glycogen were added (to aid visibility of the
pellet). This was gently mixed by inversion before being left for at least one hour on
ice at 4°C. After a further 15 minute centrifugation at 19064g, 4°C, a pellet was
formed (not necessarily visible at this stage). The isopropanol was removed and
500pl 70% ethanol (made with DEPC water) added. After a gentle mix, the tube was
once again spun for 10 minutes at 19064g, 4°C. The majority of the ethanol was
removed by pipetting, while the remainder was allowed to evaporate off on ice. The
pellet was resuspended in 20pl DEPC water. Concentration (A26o) and quality
(A26o/28o) ofRNA was measured on a GeneQuant Pro spectrophotometer (Amersham
Pharmacia Biotech) and concentration adjusted to lpg/pl. Additionally the quality of
randomly selected RNA samples were assessed by heating to 70°C for 15 minutes
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followed by immediate transfer to ice and 0.7% agarose gel electrophoresis and
visualisation under UV light.
4.2.12.2 DNase treatment
In order that any contaminating genomic DNA from the extraction was
removed, the RNA was DNase treated (Promega). The following reaction mixture
was incubated at 37°C for 30 minutes:-
70pl DEPC water
lOpl DNase buffer
lOpl DNase 1 enzyme
lpl RNase inhibitor (Promega)
lOpl RNA(lOpg)
After incubation, lOpl of "stop solution" (supplied with the DNase) was added and
the mixture incubated for a further 10 minutes at 70°C. RNA was either used
immediately for reverse transcription or frozen at -70°C.
4.2.12.3 Reverse transcription (RT)
In order that expression of specific genes of interest can be assessed by
quantitative real time PCR, complementary DNA (cDNA) must be produced from
the extracted RNA. Reverse transcription was conducted using a Taqman reverse
transcription kit (Applied Biosystems, Cheshire, UK), according to manufacturers
instructions. A mixture ofbuffer, dNTP's, random hexamers, RT enzyme, MgCh,
RNase free water and RNA (200ng per 20pl reaction mixture) was incubated at room
temperature for 10 min before heating to 42°C for lh followed by a 10 min
incubation at 95°C. For every sample an RT-negative was included. This contained
everything but the reverse transcriptase.
Once the cDNA had been made, it was amplified by PCR for Glucose-6-
Phosphate Dehydrogenase (G6PDH) together with its negative control to ensure that
there was no genomic contamination. G6PDH is not regulated in the human
reproductive cycle across the stages studied here. This was tested by Julie Bell,
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another member of our group, who passed this information on to me by personal
communication). The resultant PCR product was run on a gel and visualised under
UV light. The band produced in the positive control was checked to ensure that it
was the expected size for the primers used and where bands were present in the
negative controls, the cDNA was not used for quantitative PCR.
4.2.12.4 Quantitative real time PCR
The Lightcycler (Roche, East Sussex, UK) was used to amplify the cDNA in
a cyclic process of DNA denaturation, specific primer annealing and primer
extension to exponentially increase the primer specified cDNA fragment.
Complementary DNA sequences for target genes were acquired from Genbank, on
the internet. Primers were designed by Julie Bell for earlier experiments within our
laboratory group, using Primer 3 software;
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3 www.cgi)
Primers were designed against segments of the sequence that displayed low
homology with other genes of the same family and where possible spanning an
intron. This allows identification of genomic contamination. If genomic DNA
remains in the sample even after DNase treatment, two peaks with different melt
temperatures will be produced when using a melt curve analysis or two bands will be
visible on an agarose gel. Primer sequences are given below.
VEGF (103bp)
5' TACCTCCACCATGCCAAGTG 3' (forward)
5" TAGCTGCGCTGATAGACATCCA 3' (reverse)
G6PDH(239bp)
5' CGGAAACGGTCGTACACTTC 3' (forward)
5' CCGACTGATGGAAGGCATC 3' (reverse)
Real time quantification of this process allows the cDNA synthesised after
each PCR step to be visualised. Visualisation is by fluorescence of SYBR Green I
which fluoresces when bound to double stranded DNA. The principles used in this
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Figure 4.1 Monitoring PCR with SYBR Green 1 dye.
SYBR green I is a double stranded DNA binding dye. It binds to the minor groove of
dsDNA which greatly enhances fluorescence. During the various stages of PCR,
different intensities of fluorescence signals can be detected, depending on the amount
of dsDNA that is present. (A) All DNA becomes single stranded after denaturation.
At this stage the SYBR green I dye will not bind and the intensity of fluorescence
signals is low. During annealing, the PCR primers hybridise to the target sequence
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resulting in small parts of dsDNA to which SYBR green I can bind thereby
increasing fluorescence intensity (B). In the elongation phase of the PCR, the PCR
primers are extended, and more SYBR green I dye can bind (C). At the end of the
elongation phase, all of the DNA has become double stranded and a maximum
amount of dye is bound. The fluorescence (530nm) is recorded at the end of the
elongation phase and increasing amounts of PCR product can be monitored from
cycle to cycle. Figure 4.2 illustrates the real time fluorescence readings in a typical
light cycler run.
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2 Repli. of Sample 1VEGF
3 Sample 2 VEGF
4 Repli. of Sample 2 VEGF
5 Sample 3 VEGF
6 Repli. of Sample 3 VEGF
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Figure 4.2. Real time amplification of fluorescence signal
There is some fluorescence detection form the negative control, but this only occurs
at much higher cycle numbers than the samples.
Quantification of real time PCR is based on calculations taking into account a
house keeping control gene (Glucose-6-phosphate dehydrogenase, G6PDH) in this
case) and the gene of interest. The choice of control gene is critical. It has to be
quantifiable over the same range and be amplified with the same or similar efficiency
as the gene of interest. It must be constitutively expressed (equally within all cells,
not changing according to the treatments the cells are given), and be optimally
synthesised at the same primer annealing temperature with the same magnesium
concentration as the gene of interest. VEGF and G6PDH reaction conditions were
optimised to ensure that this was the case. The reagents used per capillary tube are
listed below together with the PCR conditions (capillary tubes and reagents all
supplied by Roche):
Negative control
Chapter 4 Progesterone and VEGF expression 151
1 pi Light cycler Fast start DNA Master SYBR Green (enzyme)
6.2pl nuclease free water
0.8pl magnesium chloride (3mM)
1 pi (5pM) primer pairs
1 pi cDNA
Reaction conditions
Heat activation 95°C 10 minutes
Denature 95°C 10 seconds
Primer annealing 65°C 5 seconds
Extension 72°C 15 seconds
Take measurement 83°C 1 second
Fluorescence measurements were taken at a temperature (optimised
specifically for the gene of interest). This temperature was chosen to ensure that only
fluorescence measurements of the specific product were taken while measurements
of non-specific products such as primer-dimers were avoided. Primer dimers that
may have been formed during the PCR will have been denatured at this temperature
and are thus no longer binding SYBR green.
Measurement temperature was determined by producing "melt curve" data. A
melt curve analysis is performed at the end of every run. The samples are heated to
ensure that all double stranded DNA is denatured. The samples are then cooled and
reheated slowly, while fluorescence measurements are constantly taken. At a specific
temperature, melting of the DNA of interest occurs characterised by a sharp drop in
fluorescence. Any non-specific product, for example primer dimers will have melted
at a lower temperature. The temperature at which measurements are taken is between
melting of non-specific products and melting of specific product. Therefore only the
specific DNA of interest remains double stranded, and hence binding SYBR green I.
By checking the melt curve produced at the end of each run, any genomic
contaminants can be identified as these will produce melting peaks at different
temperatures. Only a single melt peak should be produced from each sample (Figure
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4.3). Note that the two melt curves have been combined for the purposes of this
diagram but PCR for VEGF and G6PDFI were carried out in different capillaries,
therefore for each capillary only one melting peak would be produced, either VEGF
or G6PDH.
1 Sample 1VEGF
2 Repli. of Sample 1 VEGF
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Figure 4.3 Melt curve analysis
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A specific melting peak is produced for each product made, therefore any
genomic contaminants producing non-specific products would be detectable. Primer
dimer formation gives rise to melt peaks at a lower temperature than specific
products (top diagram). The lower diagram illustrates the fluorescence profile as the
temperature is slowly increased. The red line indicates the temperature at which
fluorescence was measured at the end of each PCR cycle. This temperature is above
that at which primer dimers remain double stranded so only specific product is
measured. This temperature is the same for the specific gene of interest and
housekeeper, therefore when choosing a housekeeping gene, it is essential to ensure
that it melts in the same region as the gene of interest.
Relative quantification of specific cDNA is performed by normalisation to
known concentrations of serially diluted standards (human placental cDNA reverse
transcribed in the same reverse transcription experiment as the samples to be
measured). This eliminates any variation in RT efficiency.
A standard curve with a gradient of -3.3 signified an efficient PCR. An
efficient PCR was designed and optimised before any measurements were taken in
order that separate runs of the Lightcycler could be accurately compared (Figure
4.4). The standard curve for each run was constructed using second derivative
maximum software, supplied by Roche for the light cycler to apply a line of best fit
through the standard points. This was considered to be the best option of standard




Figure 4.4. Standard curve
Constructed using second derivative maximum software to apply a line of best fit.
The gradient of this standard curve was -3.5 from G6PDH standards.
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Where results were to be directly compared, the same master mix was used
and samples were run in duplicate for both VEGF and the housekeeping gene,
G6PDH. Using SYBR green I and specific primers, without the need for additional
specific hybridisation probes, requires that measurement of the gene of interest and
G6PDH is from separate capillaries. The Lightcycler carousel can hold a maximum
of 32 capillaries. This allows 5 separate samples to be included in each run of the
Lightcycler:-
5 samples in duplicate =10 for VEGF
5 samples in duplicate =10 for G6PDH
4 standards (100%, 50%, 25% and 12.5%) for VEGF and 1
4 standards (100%, 50%, 25% and 12.5%) for G6PDH and
Total number of capillaries per run =30
4.3 Results
4.3.1 Progesterone receptor immunohistochemistry on marmoset
and human tissues
Genomic progesterone receptors were localised by immunohistochemistry in
marmoset and human tissues (Figure 4.5). The endometrium, a major target tissue
for progesterone in both species, was used as a positive control in all runs of the
experiment. Specific nuclear staining for progesterone receptors was seen in both
stromal and glandular cells of the endometrium, as expected from previous studies
(Critchley, et al., 2001). This confirmed the ability of the anti-human progesterone
receptor antibody to detect genomic progesterone receptors in marmoset tissues.
Marmoset and human endometrial sections are illustrated in (Figure 4.5A and B,
respectively). Insert in (A) is a negative control.
As previously described, human granulosa lutein cells expressed progesterone
receptor (Sasano and Suzuki, 1997), (Figure 4.5C) However, PR could not be
immunolocalised in the steroidogenic luteal cells of the marmoset corpus luteum in
any of the ovaries examined. Interestingly, PR was detectable in the granulosa and
theca cells of the marmoset follicle, and in the ovarian stroma (Figure 4.5D).
negative control =5
1 negative control =5
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CL
100i
Figure 4.5 Progesterone receptor localisation by immunocytochemistry in human
and marmoset reproductive tract. Positive staining is brown. (A) Marmoset
endometrium, (B) Human endometrium, (C) human CL, note intense
immunostaining in steroidogenic cells of the CL, and (D), marmoset ovary, note
absence of staining in the CL, but positive staining in the follicle (F) and stroma (S).
Insert in (A) represents a negative control section ofmarmoset endometrium.
4.3.2 Progesterone receptor immunocytochemistry of human
luteinised granulosa cells
In order to confirm that the cells cultured were in fact luteal steroidogenic
cells, immunocytochemistry for progesterone receptor and 3(3HSD was performed.
Figure 4.6 illustrates dual staining of progesterone receptor, black, localised to cell
nuclei with 3PHSD expression, brown, localised to cytoplasm. The function of luteal
steroidogenic cells is to synthesise and secrete progesterone (Duncan, et al., 1999). In
order to do this these cells must contain 3[3HSD, the final enzyme in the progesterone
steroidogenic pathway responsible for the conversion of pregnenolone to
progesterone (Strauss, 1991). The immunostaining observed confirms that the
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isolated cells are luteal steroidogenic cells and that the cell separation technique is
appropriate, and that these cells continue to express genomic progesterone receptors
in culture. It should be noted that the background staining is of the matrigel matrix
used in the cell culture system and is not extracellular matrix non-specifically
staining. The negative control is a section containing steroidogenic cells from the
same culture without the addition of primary antibody.
Figure 4.6 Dual staining of progesterone receptor (black, nuclear) and 3PHSD
(brown, cytoplasmic) on human granulosa cells that have been fixed and paraffin
embedded. Insert is the negative control with absence of specific staining above
background levels.
4.3.3 The effect of hCG on luteal steroidogenic cells in vitro.
4.3.3.1 Effect of hCG on progesterone secretion
Figure 4.7 illustrates the response of luteal steroidogenic cells to increasing
, doses of hCG in terms of progesterone secretion into culture medium. No difference
in the concentration of progesterone secreted was observed at doses of hCG, below
t
O.lng/ml hCG. Doses of hCG between O.lng/ml and lOOng/ml gave rise to a
» tendency to increase levels of progesterone secretion, maximal responses occurring
, when cells were treated with 1 OOng/ml hCG.
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Figure 4.7 Dose response graph to illustrate the effect of varying hCG
concentrations (ng/ml) on progesterone secretion (nmol/1) from luteinised human
granulosa cells in vitro. Values are means ± SEM (n=5 cell cultures from individual
patients per hCG dose)
4.3.3.2 Effect of hCG on VEGF expression
I have established that these cells respond to hCG between 0.1 ng/ml and
lOOng/ml by increased secretion of progesterone. As such, Figure 4.8 depicts levels
ofVEGF expression in cells treated with these concentrations of hCG. It appears that
VEGF expression follows the same pattern as progesterone secretion in response to
increasing levels of hCG. Using Pearson's correlation test, the two data sets were
positively correlated with a correlation coefficient of 0.995, significant at the 0.01
level. From this initial dose response experiment, it was decided that lOng/ml would
be the concentration at which hCG would be used for the actual experiment. This is
not the dose where a maximal response was observed, but it evokes a response in the
upper part of the curve, before it plateaus ie. before saturation.
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Figure 4.8 Dose response graph to illustrate the effect of varying hCG
concentrations (ng/ml) on relative VEGF mRNA expression in luteinised human
granulosa cells in vitro. Values are means ± SEM (n=5 cell cultures from individual
patients per hCG dose).
4.3.4 The effect of progesterone on luteal steroidogenic cell VEGF
expression
From the previous experiment, it is clear that addition of hCG increased both
progesterone secretion and VEGF expression in luteinised granulosa cells. The
following experiments were designed to dissect the effect of hCG from that of
progesterone. The strategy involved manipulating progesterone independently from
hCG. To increase progesterone secretion from cells, either progesterone or hCG were
added. As can be seen from Figure 4.9, both of these treatments significantly
increased the progesterone concentration in cell medium as determined by l-way
ANOVA (P<0.05). This effect was abolished when a steroidogenesis inhibitor,
aminoglutethamide was added. This inhibits enzymes involved in the early, common
steps in steroidogenesis. Where progesterone was added to culture medium,
Chapter 4 Progesterone and VEGF expression 159
obviously the progesterone assay is measuring what has been added as well as that














Figure 4.9 Graph to illustrate the effect of different treatments on progesterone
secretion (nmol/1) from human luteinised granulosa cells in vitro. All treatments were
applied to cells for 24 hours. Significant differences as determined by 1-way
ANOVA (P<0.05) are shown by connecting bars. Values are means ± SEM (n=8 cell
cultures from individual patients per treatment).
There were no significant differences with regard to VEGF expression as
determined by 1-way ANOVA (Figure 4.10) however, there was a tendency to
higher expression with hCG treatment. This preliminary data provides valuable
information eluding to the absence of a role for progesterone in upregulating luteal
VEGF in human pregnancy. Treatment with progesterone failed to induce an
upregulation of VEGF nor did inhibition of steriodogenesis by aminoglutethamide
treatment cause a down regulation of VEGF expression, indicating that increased
VEGF expression in the human CL of pregnancy is not a progesterone mediated
effect. These data will be further examined in the discussion.
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Figure 4.10 Graph to illustrate the effect of different treatments on relative VEGF
expression normalised to G6PDH expression in human luteinised granulosa cells in
vitro. All treatments were applied to cells for 24 hours. Values are means ± SEM
(n=8 cell cultures from individual patients per treatment)
4.3.5 The effect of duration of hCG treatment on luteal
steroidogenic cells in vitro
4.3.5.1 The effect of duration of hCG treatment on progesterone
As illustrated above, these data do not yet support the hypothesis that
progesterone has a direct effect on VEGF expression in luteinised granulosa cells. If
progesterone were having an effect, it would be expected that the increase in VEGF
would follow the increase in progesterone induced by hCG treatment.
Figure 4.11 and 4.12 depict responses of cells to treatment with lOng/ml
hCG for 12 and 24 hours in terms of progesterone secretion and VEGF expression,
respectively. It would appear that the rise in progesterone observed after hCG
treatment occurs after 24h, whereas the rise in VEGF expression occurs earlier and is
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detectable at 12 hours after treatment. Therefore, hCG treatment appears to induce a




































Figure 4.11 Time course data illustrating the effect of varying the duration of hCG
treatment on progesterone secretion (nmol/1) from luteinised human granulosa cells
in vitro. All cells received lOng/ml hCG. Values are means ± SEM (n=5 cell cultures
from individual patients per treatment).
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4.3.5.2 The effect of duration of hCG treatment on VEGF expression
12h 24h 24C
Treatment duration
Figure 4.12 Time course data illustrating the effect of varying the duration of hCG
treatment on relative VEGF mRNA expression in luteinised human granulosa cells in
vitro. All cells received lOng/ml hCG. Values are means ± SEM (n=5 cell cultures
from individual patients per treatment).
4.4 Discussion
Luteal rescue and maintenance of the corpus luteum is of profound
importance for the success of early pregnancy. Until such time as the placenta takes
over progesterone production, the corpus luteum is the sole provider of progesterone,
without which pregnancy is abolished.
An earlier study conducted in women treated with hCG to induce
pharmacological rescue of the corpus luteum has demonstrated increased luteal
angiogenesis accompanied by an upregulation of VEGF mRNA as demonstrated by
in situ hybridisation, associated with luteal rescue (Wulff, et al., 2001). I utilised the
marmoset as an animal model where physiological early pregnancy could be studied
as opposed to pharmacological rescue of the CL. It was surprising that a similar
increase in angiogenesis did not occur in luteal rescue as in women, documented in
Chapter 3. It was concluded that in the marmoset, maintenance of the already
established late luteal vasculature is all that is required for establishment of early
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pregnancy without the necessity for increased angiogenesis as observed in the human
(Rowe, et ah, 2002).
There does not appear to be an upregulation in VEGF mRNA during early
pregnancy in the marmoset (Rowe, et al., 2002), however, like the human, the
marmoset corpus luteum is "rescued" by a chorionic gonadotrophin molecule
secreted by the trophoblast. This CG acts through LH receptors on the surface of the
steroidogenic cells. If CG were directly responsible for increased VEGF expression,
it is surprising that VEGF is not upregulated in the marmoset. One clear difference
however, between early pregnancy in the marmoset and human is the effect ofCG on
progesterone. Progesterone levels in the marmoset in early pregnancy are maintained
without further increase, at levels already attained in the late luteal phase. In the
human, progesterone levels rise in early pregnancy compared to peak mid-luteal
phase levels. This disparity between species brought forward the hypothesis that the
observed upregulation of VEGF mRNA expression in the human could be a
progesterone mediated effect.
Not only do marmosets not display increased levels of progesterone in luteal
rescue, immunocytochemistry revealed that the marmoset CL does not have
progesterone receptors in contrast to the human CL. Therefore, it could be that the
increase in angiogenesis observed in the human CL is attributed to its ability to
detect this rise in progesterone in response to early pregnancy. The marmoset, not
having progesterone receptors in the CL cannot perceive a progesterone stimulus and
so therefore does not display increased angiogenesis at this time. This may also
explain why marmosets do not have elevated levels of plasma progesterone in early
pregnancy compared to the mid luteal phase, as the corpus luteum is unable to
respond to this stimulus anyway.
In order to answer the question as to whether or not increased VEGF
expression in human CL is progesterone mediated, an in vitro luteal steroidogenic
cell system was utilised. This system allows the precise addition or removal of
various stimuli in order to investigate this hypothesis.
I was able to demonstrate that human luteal steroidogenic cells in culture
respond to hCG by increased synthesis and secretion of progesterone accompanied
by upregulation of VEGF expression. If a steroidogenesis inhibitor is added together
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with hCG, progesterone secretion is reduced but the level of VEGF expression
remains at levels similar to those observed with hCG treatment alone. Also, if
exogenous progesterone is added to the system, no upregulation in VEGF expression
was observed.
Although many of these results were trends rather than specific differences,
this preliminary experiment suggests that the increase in VEGF mRNA observed in
CL ofwomen treated with hCG, is not a progesterone mediated effect as this increase
is not blocked when progesterone synthesis is inhibited, nor is it enhanced by
addition of exogenous progesterone to the system. Furthermore, time course
experiments revealed that the increase in VEGF expression apparently precedes the
increase in progesterone. Therefore, increased VEGF at this time cannot be a
sequential effect of increased progesterone.
While progesterone and VEGF expression both increased with increasing
doses of hCG, the levels reached were not as markedly different from control levels
as anticipated. It could be that the cells should be left longer in culture before
application of treatments. Comparing this system to the physiological situation, cells
were collected upon aspiration of follicles, so in real time this represents the day of
ovulation. Cells were then cultured for 24 hours before treatments were started so
therefore cells were treated in the early luteal phase. Luteal rescue would not occur
until the late luteal phase and so it may be that the cells should be left in culture for
longer before addition of treatments in order that they become fully acclimatised and
responsive to hCG at a more physiological time point. In the macaque, the rescue of
the corpus luteum in early pregnancy by CG is transient, despite a continued rise in
circulating CG. Therefore, age of the primate corpus luteum may be an important
factor in determining the nature of the luteal response to CG (Wilks and Noble,
1983). CG administration to macaques in the mid-luteal phase has been demonstrated
to cause a transient stimulation of luteal progesterone production similar to that
observed in early pregnancy. CG administration in the early luteal phase resulted in
persistent, rather than transient stimulation of luteal progesterone production.
Therefore in the macaque, the mechanisms involved in the transitory response of the
primate CL to CG during pregnancy appear to be inoperative during the early luteal
phase of the menstrual cycle (Ottobre and Stouffer, 1984). This has also been
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suggested in the marmoset where the CL is thought to gain responsiveness to CG
between 6 and 14 days after ovulation (Webley et al., 1989). However, other in vitro
experiments on human granulosa cells have reported responsiveness of granulosa
cells to hCG in terms of upregulation of VEGF expression in the equivalent time
period as the early luteal phase. This phenomenon was absent from control cells, not
treated with hCG, suggesting that these cells are responsive to hCG at this time
(Neulen, et al., 1998). In the current experiment, divergent responses in progesterone
secretion and VEGF expression were observed between cells treated with hCG and
control cells, suggesting that in these circumstances, the cells were responsive to
hCG. Whether the response would be more marked, were the cells cultured for
longer before the onset of treatment remains to be elucidated.
If the increase in VEGF expression observed in hCG rescued human CL is not
a progesterone mediated effect, then what other factors could be involved to cause
this disparity between the marmoset and human? Plasma progesterone levels in the
marmoset are extremely high compared to those in women. As such it is possible that
progesterone receptors in the marmoset corpus luteum are down regulated by
hyperstimulation and this is why I was unable to detect them by
immunocytochemistry. It may also be that progesterone can exert effects in the
marmoset CL without acting at classic nuclear progesterone receptors. In rat, for
example, progesterone receptors are not present in the corpus luteum of pregnancy
despite being present in the endometrium and theca and granulosa cells of growing
follicles as observed here. This group concluded that progesterone receptor is not
required for progesterone action in the rat corpus luteum ofpregnancy (Telleria et al.,
1999).
It is also possible that hCG may not be the only important signal maintaining
CL function at this time. This experiment has demonstrated that an upregulation in
progesterone alone does not cause increased VEGF expression, therefore, in human it
could be that a rise in progesterone in luteal rescue only when accompanied by
upregulation of other local factors contributes to increased VEGF expression and
angiogenesis at this time. The system that I have used here isolates luteal
steroidogenic cells from the surrounding corpus luteum. It may be that endothelial
cells, fibroblasts or immune cells, for example contribute to increased angiogenesis.
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Other factors known to stimulate progesterone production by the CL in experimental
studies include prostaglandins (Hamberger et ah, 1991). Also the human CL
increases production of substances other than progesterone during very early
pregnancy, including, oestrogen, inhibin and relaxin, however these hormones do not
all increase at the same time (Sunder and Lenton, 2000). It is probably hCG which is
the first of several signals to the CL which causes up regulation of many hormones
and growth factors for example VEGF. Also in the study by Wulff et al, hCG was
the only signal introduced to the system to induce pharmacological rescue of the
corpus luteum. While this probably is the first of several stimuli to be received by the
CL in physiological pregnancy, without the presence of a trophoblast and resultant
uterine reactions, it is impossible to determine the exact mechanisms occurring in the
CL in physiological pregnancy as opposed to pharmacological rescue.
Luteal progesterone production is dependent on luteinizing hormone (LH)
from the pituitary gland, despite continuing LH secretion, the human corpus luteum
undergoes functional luteolysis unless it is "rescued" by hCG. LH and hCG act
through a common receptor which is not down regulated during the maternal
recognition of pregnancy in human (Duncan, et al., 1996). In women there is an
increase in progesterone production by hCG stimulation, therefore despite LH and
hCG acting at the same receptor, differential effects occur in response to each. It
would appear that LH maintains the CL during its functional luteal lifespan but in
order that the corpus luteum is maintained, beyond the normal time of luteolysis, an
hCG stimulus is necessary evoking a divergent effect and increased progesterone
synthesis and secretion. In the marmoset however, the corpus luteum of pregnancy
did not appear to differ from that in the late luteal phase of non-pregnant cycles. It
seems that the marmoset prepares for pregnancy every cycle. The corpus luteum is
equipped to produce adequate levels of progesterone to maintain early pregnancy
throughout the luteal phase so there is no need for an upregulation of progesterone
synthesis nor angiogenesis upon detection of a CG stimulus. It may be that marmoset
LH acts more like hCG and so the marmoset enters a "conception" luteal phase every
cycle regardless of whether or not a blastocyst is present until such time as it
undergoes structural and functional regression probably as a consequence of down
regulation of LH receptors (Duncan, et al., 1998). One very interesting observation is
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the nature of the marmoset LHR, in that it lacks exon 10 (Zhang et al., 1997). Recent
data shows that the human LH receptor lacking exon 10 responds to hCG but not LH
(Muller et al., 2003). It is possible therefore that marmoset LH is more like CG in its
action. It is also of interest that normally fertile humans only have 22% chance of
conception per cycle, while marmosets have greater than 80%.
It would appear that this is a very complex system which requires a great deal
more investigation in order that the exact mechanisms by which increased
angiogenesis occur in hCG rescue of the human corpus luteum occur. This
preliminary experiment suggests that increased VEGF expression in luteal rescue is
not a progesterone mediated effect.
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5 Cellular and morphological changes associated
with early pregnancy in the marmoset
5.1 Introduction
Angiogenesis is a fundamental process of generating new blood vessels. In
the female reproductive tract, angiogenesis has been suggested to be involved in such
disorders as luteal phase defects, endometriosis, pregnancy loss, pre-eclampsia and
cancer (Gordon et ah, 1995). Embryo implantation requires a viable blastocyst and
receptive stage endometrium. Angiogenesis in the human uterus is of paramount
importance to support the reconstruction of endometrium after menstruation and to
provide a vascularised, receptive endometrium for implantation and placentation
three weeks later (Torry et al., 1996). This part of the project aims to describe the
cellular and morphological events occurring in the marmoset endometrium
throughout the cycle and in early pregnancy and to address whether there is increased
angiogenesis associated therein.
Implantation in the marmoset occurs at day 12 after ovulation (Enders and
Lopata, 1999), yet the maternal vasculature is not invaded until much later, at around
day 60 (Smith, et al., 1987). The newly implanted blastocyst must therefore receive
the nutrients and oxygen that it requires to meet its increasing metabolic demands by
diffusion. In order that this transfer be efficient, it follows that a well developed
uterine vasculature is of critical importance. The endometrium is controlled by
ovarian steroids, under oestrogen dominance in the proliferative phase and
progesterone in the secretory phase. This study describes the proliferative events
occurring in the marmoset endometrium in response to ovarian steroids in vivo and
begins to dissect the pre-implantation events occurring and whether they contribute
to successful establishment of pregnancy. I have previously documented in chapter
3, no increase in angiogenesis in the marmoset corpus luteum in early pregnancy
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compared to structurally intact non-pregnant controls (Rowe, et al., 2002), where the
hormone milieu is the same except for the presence of chorionic gonadotrophin in the
systemic circulation of pregnant animals. The ovarian and uterine systems are so
intimately linked the question of "will there be any differences in angiogenesis in the
endometrium?" begs to be answered.
Animals from the mid-proliferative, late proliferative, early luteal, mid luteal
and late luteal stages were studied for morphological comparisons. Animals from the
mid-luteal and late-luteal stages were compared to pregnant animals at day 14, 21
and 28 post ovulation. Qualitative studies were conducted on all groups but
morphometric analyses of angiogenesis were only performed on non-pregnant
animals from the mid (day14) and late (day 21) secretory phase and on all pregnant
animals. The early implantation site and foetal maternal interface will be described
but only briefly. The marmoset implantation site at the stages of pregnancy studied
here have been previously described by others using light (Moore, et al., 1985) and
electron microscopy (Smith, et al., 1987). This experiment aims to compliment these
observations and to link morphological observations with quantitative analysis of
angiogenic events occurring within the endometrium at this time.
5.2 Specific methods
5.2.1 Details of animals used for the experiment
Experiment Groups Number of animals
Angiogenesis in the
endometrium
Mid-luteal Day 14 5




Pregnant (Day 28) 5
Table 5.1 Details of animals used for the experiments
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5.2.2 Dual immunostaining of CD31 and BrdU by Confocal
microscopy
This is a similar method to that employed in all other immunocytochemical
techniques described previously except that a fluorescent detection system is
employed and 0.05M TBS /1% tween is used for all washes and to make the normal
serum block. Slides were dewaxed and rehydrated before undergoing antigen
retrieval by pressure cooking in 0.01 M citrate buffer as described in Chapter 2. This
was followed by a standard peroxidase block and avidin/biotin block in NRS diluted
in TBS/tween, (Chapter 2). Two primary antibodies, Anti-BrdU (sheep) and CD31
(mouse) were used, see Table 2.1, diluted together in normal rabbit serum at 1:300
and 1:20 respectively before application to slides overnight in a sequenza at 4°C.
After 3, 5 minute TBS/Tween washes, biotinylated rabbit anti-sheep was
added (1:500) with rabbit anti-mouse peroxidase (1:500) in normal rabbit serum
block for lh at room temperature. Slides then received 3 TBS/tween washes followed
by 2 0.01MPBS/1% tween washes and a final wash with PBS alone. In order to
detect the CD31 antibody, a TSA-plus cyanine system was used (Perkin Elmer Life
Sciences), diluted 1:50 in supplied buffer. This was applied for 10 minutes at room
temperature before slides received 2 PBS/tween washes followed by a PBS wash.
Slides were then incubated with Streptavidin Alexafluor 488, diluted 1:200 with PBS
for 2-3h at room temp before being washed with PBS overnight.
Finally, propidium iodide was added (lOpg/ml in PBS/tween) for 20 minutes
at room temperature before slides were washed in PBS/tween for at least 2 hours.
Slides were mounted straight from PBS/tween in permafluor aqueous mounting
medium (Beckman Coulter, Luton, Beds, UK) and examined under a confocal
microscope (Carl Zeiss laser scanning microscope LSM510, Axiovert 100M, version
3.2).
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5.2.3 Quantification of dual immunostaining
5.2.3.1 Volume fraction measurements
In terms of quantitative analysis of proliferation, a grid system was devised
according to Hastings et al, (Hastings, et ah, 2003). This allows for the accurate
volume fraction analysis of each of these different compartments across a uterine
section and subsequent proliferation indices to be calculated. The uterus is an organ
subject to oedematous changes and therefore analyses of immunocytochemical
staining in the same way as employed for the CL were not appropriate. The methods
employed take into account any volume changes and so therefore correct for this
phenomenon and allow comparison between groups where changes in oedema may
not occur to the same degree.
Volume fraction analyses were performed in three directions, from luminal
epithelium to myometrium, each perpendicular to the luminal epithelium. The first,
at the fundic end of the uterus. The second and third on the right and left hand side of
the cross section respectively (See Figure 5.2) In each direction, every field of view
was analysed, ensuring no overlap occurred between each. This gave rise to between
30 and 40 grids per animal, an example of which is given in Figure 5.1. The test
grid, superimposed on the sections, consisted of 588 points. The number of test
points falling on glands (including lumen), proliferating glandular epithelium, uterine
lumen, stroma, proliferating stromal cells, myometrium, luminal epithelium,
proliferating luminal epithelial cells, endothelial cells and proliferating endothelial
cells (characterised by colocalised BrdU and CD31 immunostaining), were counted.
The volume fraction occupied by each component was then calculated by expressing
the number of points hitting that component as a percentage of the total number of
test points applied. If, for example, the volume fraction of proliferating endothelial
cells was required, it was expressed as volume fraction of proliferating endothelial
cells as a percentage of volume fraction of total endothelial cells.
Analysis of randomly selected sections was conducted by two independent
scorers. To validate this method the two data sets gained from each observer were
compared using a T-test. No significant differences in results were seen signifying
that this technique was repeatable and accurate.
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Figure 5.1 Example of the grid system used to obtain volume fraction data. The grid
consists of 588 points (21 x 28). This grid size was chosen as it allows differentiation
of individual cells with no cell being counted by more than one point. At each point
on the grid, the cell type was recorded and expressed as a volume fraction of the total
588 points. The number of proliferating cells were expressed as a volume fraction of
the total volume fraction of that cell type. For example the number of points
overlaying proliferating endothelial cells was divided by the total volume fraction of
endothelial cells to gain a volume fraction of proliferating endothelial cells.
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Figure 5.2 Schematic illustrating grid placement. Volume fraction analyses were
performed in three directions, from luminal epithelium to myometrium, each
perpendicular to the luminal epithelium. The first, at the fundal end of the uterus (1).
The second and third on the right and left hand side of the cross section respectively,
(2) and (3). In each direction, every field of view was analysed at x40 objective
magnification, ensuring no overlap occurred between each. This gave rise to between
30 and 40 grids per animal.
5.3 Results
5.3.1 Gross morphology and patterns of cell proliferation in
marmoset endometrium throughout the cycle
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Figures 5.3 - 5.7 document uterine morphology and the patterns of cell
proliferation throughout the ovulatory cycle of non-pregnant marmoset endometrium
Figure 5.3A and B are photomicrographs of H & E stained sections of full thickness
endometrium from the mid-proliferative phase highlighting the luminal epithelium
(LE), glandular epithelium (GE) and stroma (S). (C and D) depict BrdU
incorporation into proliferating cells. In the mid-proliferative phase, the luminal
epithelium and glandular epithelium of the functionalis are intensely proliferating,
while glandular epithelium of the basalis region does not appear to be undergoing
mitosis. No positively stained stromal cells were detected in the endometrium at this
stage.
By the late proliferative phase, glandular epithelial proliferation has
progressed throughout the full thickness endometrium and BrdU staining remains
high in the luminal epithelium (Figure 5.4C and D). Low levels of BrdU
immunostaining were present in the stroma at this stage.
Figure 5.5 documents uterine morphology (A and B) and BrdU incorporation
(C and D) in the early secretory phase. At this stage of the cycle, there still exists a
high level of cellular proliferation in the luminal epithelium and glandular
epithelium. Stromal proliferation is apparent throughout the full thickness
endometrium, particularly in the functionalis region. By the mid-secretory phase, no
luminal epithelial or glandular epithelial proliferation was detectable in the
functionalis (Figure 5.6 D and F) however, glandular proliferation is maintained in
the basalis (Figure 5.6B). Also note accumulation of large maternal vessels (MV)
beneath the luminal epithelial surface (A).
In the late secretory phase, (Figure 5.7), no glandular nor luminal epithelial
proliferation was detectable in any zone of the endometrium. Stromal proliferation
remained high in the functionalis and the large maternal vessels (MV) first observed
in the mid-secretory phase are still apparent in the late luteal phase (B).
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Figure 5.3 Uterine morphology in the mid-proliferative phase. (A) and (B) are H &
E stained sections highlighting the luminal epithelium (LE), glandular epithelium
(GE) and stromal (S) compartments of the uterus. (C) and (D) illustrate cell
proliferation by immunocytochemical detection of BrdU. Note high level of
glandular proliferation and absence of staining in the stroma.
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Late Proliferative
Figure 5.4 Uterine morphology in the late-proliferative phase. (A) and (B) are H & E
stained sections highlighting the luminal epithelium (LE), glandular epithelium (GE)
and stromal (S) compartments of the uterus. (C) and (D) illustrate cell proliferation
by immunocytochemical detection of BrdU. Note high level of glandular
proliferation and few immunopositive nuclei in the stroma.
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Early secretory
Figure 5.5 Uterine morphology in the early-secretory phase. (A) and (B) are H & E
stained sections highlighting the luminal epithelium (LE), glandular epithelium (GE)
and stromal (S) compartments of the uterus. (C) and (D) illustrate cell proliferation
by immunocytochemical detection of BrdU. Note high level of glandular and stromal
proliferation.
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Figure 5.6 Uterine morphology in the mid-secretory phase. (A, C, E ) are H & E
stained sections. (B) illustrates cell proliferation across the entire endometrial section
by immunocytochemical detection of BrdU. (D and F) illustrate BrdU incorporation
in the functionalis and basalis layer, respectively. Note presence of glandular BrdU
in the basalis (F), and absence of glandular proliferation in the functionalis (D). The
large maternal vessels appearing just beneath the luminal epithelium have been
highlighted (MV).
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Figure 5.7 Uterine morphology in the late-secretory phase. (A) and (B) are H & E
stained sections highlighting the luminal epithelium (LE), glandular epithelium (GE),
stroma (S) and large capillaries near the lumen of the uterus (Cap). (C, D, E and F)
illustrate cell proliferation by immunocytochemical detection of BrdU. Note absence
of proliferation in the glandular epithelium, and high level of stromal proliferation
particularly around the luminal epithelium.
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5.3.2 Description of the foetal-maternal interface
Figure 5.8 illustrates cytokeratin immunocytochemistry at day 28 of
pregnancy in order to distinguish the foetal maternal interface. Cytokeratin is a
trophoblast marker. It was used to distinguish foetal and maternal tissues. Note the
superficial attachment of the trophoblast to the surface epithelium of the
endometrium without invasion of luminal epithelium. Maternal vessels (MV)
depicted in (D) are not invaded by trophoblast at this stage. A diagrammatic
representation of the marmoset implantation site is shown in Figure 5.9, depicting
the main cell types and structures present at the implantation site. Foetal vessels have
been included for completeness, although the trophoblast remains avascular during
the stages of pregnancy studied for the purposes of this thesis and does not become





Chapter 5 Cellular and morphological changes associated with 182
early pregnancy in the marmoset
Figure 5.8 Cytokeratin immunocytochemistry for differentiation of trophoblast from
maternal tissue in early pregnancy. (A) Note high level of immunostaining in the
trophoblast and foetal membranes (FM) with absence of staining in the maternal
decidual endometrium (DE). (B and C) are negative and positive controls
respectively. (D) H & E stained section to illustrate uterine morphology at this time.
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5.3.3 Gross morphology and patterns of cell proliferation at the
time of implantation and in early pregnancy in marmoset
endometrium
Figures 5.10 - 5.12 illustrate uterine morphology and cell proliferation
during early pregnany. Figure 5.10 depicts morphology of the marmoset
implantation site. Note the superficial attachment of the blastocyst (Bl) to the uterine
epithelium (LE) best shown in (Figure 5.10C). The luminal epithelium appears to
remain intact with minimal cellular damage by the newly implanted conceptus (D).
Also highlighted in (D) are the large, maternal vessels immediately beneath the
luminal surface. These appear larger than those in secretory phase non-pregnant
endometium, particularly those immediately beneath the implantation site, best
depicted in (A and B). The pattern of BrdU incorporation is illustrated in (E and F).
No glandular epithelial proliferation was observed in any region of the endometrium.
Intense stromal proliferation was apparent in the functionalis, particularly
immediately surrounding the glands of this region. The inner cell mass of the
conceptus is also intensely proliferating at this time (F).
Figure 5.11 depicts the marmoset implantation site one week later at day 21.
The blastocyst remains in superficial attachment to the endometrium with minimal
invasion of luminal epithelium (D). Decidualisation of stromal cells is occurring,
beginning in the functionalis around the entire luminal surface of the endometrium
irrespective of the implantation site and progressing to the basalis (A and E). Stromal
proliferation in the functionalis is very intense at this time particularly notable in
decidua (F).
By week 4 of pregnancy (Figure 5.12), the stroma has become decidualised
to a greater depth towards the basalis. While the trophoblast still remains in
superficial attachment to the surface endometrium, penetration of syncytial
trophoblast beneath the luminal epithelium is evident (D). Large maternal vessels
(MV) rest beneath the luminal epithelium around the entire uterine lumen and there
appears to be no penetration of these vessels by invading trophoblast. They clearly
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retain a continuous endothelium which is undisrupted. Note the high level of
glandular epithelial proliferation in the basalis region at this stage of pregnancy (E),
and the intensity of proliferation of decidualised stromal cells throughout the entire
endometrium, most intensely in the functionalis (F).
Figure 5.13 illustrates confocal microscopy images of sections dual stained
with CD31 (blue) and BrdU (green). This was done to determine whether or not the
intensely proliferating decidual stromal cells depicted in Figure 5.12F are
endothelial cells. A positive control from the marmoset corpus luteum is included
(C). This illustrates a dual stained proliferating endothelial cell which appears
yellow. In (A and B) all BrdU stained cells colocalise with CD31 giving rise to a
yellow cell. However, in (D), the BrdU and CD31 do not colocalise and retain their
individual green and blue colours respectively, therefore, these are not co-localising
and so the proliferating decidual stromal cells in early pregnancy in the marmoset are
clearly not endothelial cells. In (A), the foetal membranes are immunopositive for
CD31 yet are avascular throughout pregnancy. It may be that the antibody is cross
reacting here or that these cells may be endothelial precursors for later development
into endothelial cells.
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Figure 5.10 Uterine morphology at 2 weeks of pregnancy. (A, B, C and D) are H &
E stained sections highlighting the luminal epithelium (LE), blastocyst (Bl) foetal
membranes (FM) and large maternal vessels (MV). (E and F) illustrate
immunocytochemical detection of BrdU. Note high level of proliferation in
blastocyst and stroma nearest the luminal epithelium, while no BrdU was detected in
the glandular epithelium.
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Pregnant, Day 21
Figure 5.11 Uterine morphology at 3 weeks of pregnancy. (A, B, C and D) are H &
E stained sections highlighting the luminal epithelium (LE), foetal membranes (FM)
and large maternal vessels (MV). (E and F) illustrate immunocytochemical detection
of BrdU. Note high level of proliferation in decidualised stroma nearest the luminal
epithelium (F), while little BrdU was detected in the glandular epithelium. Also note
syncytial trophoblast invasion of the uterine lumen at this stage (ST), (D) Decidua.
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Figure 5.12 Uterine morphology at 4 weeks of pregnancy. (A, B, C and D) are H &
E stained sections highlighting the luminal epithelium (LE), foetal membranes (FM),
blastocyst (Bl), trophoblast (T), endothelial cells (EC) and large maternal vessels
(MV). (E and F) illustrate immunocytochemical detection of BrdU. Note high level
of proliferation in decidualised stroma nearest the luminal epithelium, and BrdU
immunostaining in the glandular epithelium.
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Figure 5.13 Confocal microscopy illustrating dual staining for CD31 (blue) and
BrdU (green). (A) foetal membranes (FM) and upper zone endometrum at day 14 of
pregnancy, (B) Non-pregnant late secretory phase endometrium at day 21. (C)
Positive control from marmoset corpus luteum and (D) decidualised upper zone
endometrium from day 28 of pregnancy. Where endothelial cells (blue) are
colocalising with BrdU (green), a resulting yellow colour is seen as marked in (C).
This depicts a proliferating endothelial cell.
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5.3.4 Uterine weight
Figure 5.14 A and B illustrate mean uterine weights before tissue fixation. If
precise uterine weights are plotted against stage of the cycle as in (A), there is a
significant increase in uterine weight at day 28 of pregnancy compared to late luteal
controls. However, this does not take into account animal body weight. If uterine
weight is expressed as a relative proportion of body weight, it can be seen that uteri
at pregnancy day 28 are heavier than both groups of non-pregnant controls.
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Figure 5.14 Graphs to show mean uterine weight before fixation from marmosets in
the different study groups. (A) Uterine weight without correction for body weight.
(B) Relative uterine weight as a percentage of body weight. Significant differences
(P<0.05) as determined by 1 way-ANOVA are denoted by adjoining lines. Values
are means ± SEM. (n=5 per group)
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5.3.5 Volume fraction analysis
5.3.5.1 Cellular compartment analysis
Figure 5.15 (A and B) depict the differences in volume fraction occupied by
glands (including lumen), luminal epithelium, endothelial cells and stroma
throughout the stages of the cycle and early pregnancy studied. These figures
illustrate total volume fraction across full thickness endometrium. There is no
significant difference in volume fraction of endothelial cells between the stages
studied here, nor does the volume fraction of stromal cells change between groups.
Volume fraction of glands decreases as pregnancy progresses. At day 28 of
pregnancy, there is a significantly lower volume fraction of glands compared to all
other stages. The volume fraction of luminal epithelium is significantly reduced in
the late luteal phase compared to the other study groups.
Figure 5.16 A and B illustrate the differences in volume fraction occupied by
the different cellular compartments within the basalis and functionalis regions of the
endometrium. The basalis was definded as the region where glands were long and
thin in appearance on a cross section of the endometrium. The functionalis was
defined as the region where glands were more rounded. This was an arbitrary
assignment by eye. Similar trends are observed as in Figure 5.15 A and B. It is
apparent that it is the volume fraction of glands in the functionalis that decreases as
pregnancy progresses, because volume fraction of glands in the basalis are unaltered
between the stages studied here. The statistical tests used was a 1-way ANOVA.
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Figure 5.15 Scatter (A) and Mean (B) volume fraction of cellular compartments of
the marmoset uterus. Volume fractions were measured using a test grid of 588 points
and are represented as a percentage of the total volume. Significant differences
(P<0.05) as determined by 1-way ANOVA are denoted by different letters and/or
bars. Values are means ± SEM (n=5 in all groups).
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Figure 5.16 Scatter (A) and Mean (B) volume fraction of cellular compartments of
the marmoset uterus. The endometrium has been subdivided into functionalis (upper)
and basalis (lower) regions. Volume fractions were measured using a test grid of 588
points. Volume fraction is represented as a percentage of the total volume.
Significant differences (P<0.05) as determined by 1-way ANOVA between groups
are denoted by connecting lines. Values are means ± SEM (n=5 in all groups).
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Luminal epithelial proliferation
Figure 5.17 illustrates luminal epithelial proliferation as a percentage of total
luminal epithelium. There is a general increase in luminal epithelial proliferation as
pregnancy progresses. Day 28 pregnant animals have significantly higher luminal
epithelial proliferation compared to non-pregnant animals and pregnant animals at
day 14 as determined by a 1-way ANOVA.
Figure 5.17 Mean volume fraction of proliferating luminal epithelium as a
percentage of total luminal epithelium. Values are means ± SEM. (n=5 in each
group). Significant differences (P<0.05) as determined by 1-way ANOVA are
represented by adjoining bars.
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Glandular epithelial proliferation
Figure 5.18 and 5.19 illlustrate mean volume fraction of proliferating
glandular epithelial cells as a percentage of total glandular epithelium. There is
significantly higher glandular epithelial proliferation in the functionalis of day 21 and
day 28 pregnant animals compared to the functionalis of other study groups. This
level of proliferation in the functionalis is significantly higher than that recorded in
the basalis region of these uteri.
In the basalis region of the mid luteal phase (day 14) uteri there is
significantly higher glandular epithelial proliferation compared to the functionalis.
This is also significantly higher than that recorded in the basalis from all other

















Figure 5.18 Mean volume fraction of proliferating glandular epithelium as a
percentage of total glandular epithelium. This graph illustrates differences in
glandular proliferation between groups within the functionalis layer and similarly
within the basalis. It does not denote differences between the functionalis and
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basalis. Significant differences (P<0.05) as determined by 1-way ANOVA are
denoted by adjoining bars. Values are means ± SEM (n=5 in each group).
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Figure 5.19 Mean volume fraction of proliferating glandular epithelium as a
percentage of total glandular epithelium. This graph illustrates differences in
glandular proliferation between the functionalis and basalis layer within each group.
It does not denote differences between groups. Significant differences (P<0.05) as
determined by 1-way ANOVA are denoted by adjoining bars. Values are means ±
SEM (n=5 in each group).
Endothelial cell proliferation
Figures 5.20 and 5.21 depict differences in mean volume fraction of
endothelial cell proliferation as a percentage of total endothelial cells. There is a
significant increase in endothelial cell proliferation in the functionalis region of the
endometrium at day 21 of pregnancy, compared to late secretory non-pregnant
endometrium at day 21. There is no difference in the level of endothelial cell
proliferation in the basalis region between the stages studied here as determined by
1-way ANOVA.
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Figure 5.20 Mean volume fraction of proliferating endothelial cells as a percentage
of total endothelial cells. This graph illustrates differences in endothelial proliferation
between groups within the functionalis layer and similarly within the basalis. It does
not denote differences between the functionalis and basalis. Values are means ± SEM
(n=5 in each group). Significant differences as determined by 1-way ANOVA are
denoted by connecting bars. For this graph, animals from the early luteal phase were
included to illustrate declining endothelial cell proliferation as the luteal phase
progresses.
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Figure 5.21 Mean volume fraction of proliferating endothelial cells as a percentage
of total endothelial cells. This graph illustrates differences in endothelial proliferation
between the functionalis and basalis layer within each group. It does not denote
differences between groups. Values are means ± SEM. Significant differences
(P<0.05) as determined by 1-way ANOVA are denoted by connecting bars. (n=5 in
each group)
5.4 Discussion
Early miscarriage within the first few weeks after conception is a common
phenomenon in women. Genetic and congenital abnormalities may account for some
early pregnancy loss, but it is also possible that failure of the conceptus and
endometrium to establish an effective implantation may be involved (Smith, et al.,
1987). Marmoset implantation occurs at day 12 after ovulation (Enders, 1993) and in
many ways displays a placentation similar to that in the human in that both develop a
true hemochorial placenta. In human, the blastocyst implants superficially giving rise
to an eccentric, discoid placenta, while the marmoset blastocyst implants
superficially giving rise to a centric placenta (Smith, et ah, 1987).
In women, baboon and macaque for example, subepithelial maternal vessels
are penetrated early on in the process of implantation, at day 12, 10 and 11 of
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gestation, respectively (Enders, 1993). The marmoset is at the other extreme, where
maternal vessels are not penetrated by trophoblast until 45 to 60 days of gestation
(Smith and Moore, 1990). It is therefore of paramount importance that the
mechanisms required to meet the growing metabolic demands of the newly
implanted blastocyst be in place throughout the early implantation stages. Increased
angiogenesis at this time may be an important mechanism involved in ensuring that
an adequate vasculature is available to support the conceptus. Nutrients and oxygen
from the maternal circulation will be supplied to the trophoblast by diffusion, and so
a well developed maternal vascular system is of paramount importance. A great deal
of uterine remodelling occurs during early pregnancy. In ewes, vascularity of
endometrial tissues, was elevated on Days 24 and 30 after mating. In addition,
dramatic changes in uterine architecture (increased lumenal diameter and decreased
endometrial thickness) and in uterine microvascular development (increased
abundance of large microvessels and development of a subepithelial capillary plexus)
were observed by Day 24 after mating (Reynolds and Redmer, 1992). In pigs, blood
flow dramatically increases to the uterine vascular bed in early pregnancy (Ford, et
al., 1982). Characterization of the patterns of uterine growth and microvascular
development will enable us to further define the role of previously reported uterine
and conceptus-derived growth and angiogenic factors during early pregnancy
(Reynolds and Redmer, 1992). Marmosets have a very high fertility rate compared to
most other primates, and as such provide an excellent model for early pregnancy
where the angiogenic events occurring therein can be addressed. This has allowed
elucidation and speculation as to whether early embryo loss could be attributed to
not only a poorly established implantation but also to an inadequately developed
endometrial vasculature, by looking at successful implantation in a highly fecund
species. I have examined the cellular and morphological events occurring in
marmoset implantation at days 14, 21 and 28 of gestation and the angiogenic events
associated therein.
Development of a receptive endometrium and its subsequent transformation
into the decidua is a key aspect of mammalian implantation (Smith, 2000). The
human endometrium undergoes angiogenesis to develop new capillaries, which then
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undergo maturation and remodelling during each menstrual cycle. Abnormal vessel
development may not only cause implantation failure but also lead to dysfunctional
bleeding, endometriosis and menorrhagia (Albrecht and Pepe, 2003). The fate of the
endometrium is cyclically dependent on ovarian steroids. Increased vascular
permeability and angiogenesis are essential to successful implantation and
placentation and several studies have provided evidence for the potential role for
oestrogen and progesterone in these processes (Chakraborty et al., 1995, Haider et
al., 2000, Hyder and Stancel, 1999). However, there appears to be conflicting
evidence as to whether these hormones are pro-or anti-angiogenic. Although I will
not detail mechanisms or sites of action of the steroid hormones in the marmoset
endometrium, I have documented the cellular and proliferative changes throughout
the cycle that I believe occur as a direct consequence of the hormone milieu at that
time.
In the proliferative phase, under oestrogen dominance, a high level of luminal
and glandular epithelial proliferation was observed, consistent with findings in the
mouse (Martin and Finn, 1968). This group also demonstrated that progesterone
inhibits oestrogen-mediated epithelial proliferation consistent with my observations
where by the mid-secretory phase no epithelial proliferation remains in the
functionalis region. However, in combination with oestrogen, progesterone has been
reported to induce stromal cell proliferation (Martin and Finn, 1968). Under
oestrogen dominance in the proliferative phase, very little stromal or endothelial
proliferation was observed, thus it would appear that oestrogen may inhibit
angiogenesis in the marmoset. In the secretory phase and in early pregnancy, I
observed profound stromal and endothelial cell proliferation, probably directly
attributed to progesterone being introduced to the system after ovulation. Not only
does oestrogen not promote angiogenesis, in mouse, it has been shown to profoundly
inhibit angiogenesis, but promoted uterine vascular permeability, whereas
progesterone stimulates angiogenesis with little effect on permeability (Ma et al.,
2001). This finding is somewhat inconsistent. Other groups have reported oestrogen
to act as an inducer of rapid proliferation of endothelial cells, preceeding endometrial
tissue remodelling in mouse (Hastings, et al., 2003, Heryanto and Rogers, 2002,
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Heryanto et al., 2003), raising the possibility that the ultimate mass of a tissue may
be regulated in part by endothelial cell growth (Folkman, 1998). Progesterone has
also been documented as an inhibitor of endothelial cell proliferation, in mouse,
unless acting together with high dose oestrogen (Heryanto and Rogers, 2002).
Several immunohistochemical studies on endothelial cell proliferation
indicate that classical sprouting angiogenesis does not occur in human endometrium,
reviewed by (Gargett and Rogers, 2001). Most studies have failed to demonstrate
oestrogen or progesterone receptors in human endometrial endothelium. However,
oestrogen and progesterone receptors have been detected in human endometrial cells
in vitro by immunocytochemistry and RT-PCR (Iruela-Arispe et al., 1999). ERp,
specifically has also been reported in endothelial cells of macaque and women by
immunocytochemistry (Critchley, et al., 2001).
Endothelial cell proliferation does vary widely throughout the menstrual
cycle, but thought to show no relationship to the stage of the cycle, reviewed by
(Gargett and Rogers, 2001). Early work using anti-proliferating cell nuclear antigen
to identify proliferating cells and anti-CD34 to localize endothelial cells in human
endometrium, demonstrated that proliferative activity of endothelial cells reached a
peak in the mid to late proliferative phase of the cycle increasing again in the
secretory phase (Goodger and Rogers, 1994). This is consistent with a more recent
study in macaque endometrium, where a dramatic oestrogen dependent peak in
endothelial cell proliferation during the mid-proliferative phase occurred (Nayak and
Brenner, 2002). I did not perform quantitative analyses on proliferative phase
sections, so I am unable to comment on whether a similar phenomenon exists in the
marmoset. Stromal cell proliferation is apparent in the secretory phase and appears to
increase as the secretory phase progresses.
Profound differences in endothelial cell proliferation were found between the
superficial functionalis and basalis layers, where the functionalis always displayed
more intense angiogenesis than the basalis, consistent with reports in women where
proliferative activity was seen to remain fairly constant in the basalis throughout the
cycle, but changing in the functionalis (Rogers, 1998).
Chapter 5 Cellular and morphological changes associated with 204
early pregnancy in the marmoset
In the face of the conflicting literature, from these results it would seem that
in the marmoset in the proliferative phase, oestrogen acts to inhibit endothelial cell
proliferation. This is concluded from the low level of BrdU incorporation observed in
endometrial sections from the proliferative phase. However, this was not examined
quantitatively. Oestrogen would appear to be promoting luminal and glandular
epithelial proliferation at this time. Progesterone would appear to inhibit epithelial
proliferation while stimulating endothelial proliferation.
Not surprisingly, the endometrium is a rich source of angiogenic growth
factors. VEGF is thought to be regulated by progesterone and oestrogen, and
contains progesterone and oestrogen response elements (Hyder and Stancel, 1999,
Hyder and Stancel, 2000). VEGF expression and endothelial cell proliferation have
been demonstrated to peak in the mid-proliferative phase in rhesus macaque
endometrium, coinciding with a peak in oestrogen (Nayak and Brenner, 2002). This
is a synchronised model system where animals were ovariectomised and then
hormones replaced. This does not appear to be the case in human, where no
correlation between VEGF production and endothelial cell proliferation was
observed throughout the cycle (Gargett et al., 1999), however, this was not such an
easy system to control as it was in the natural cycle rather than after ovariectomy and
hormone replacement.
Expression of VEGF and its role in promoting vascular permeability and
angiogenesis during early pregnancy and placentation have been frequently
documented. I have described the specific localisation ofVEGF, its receptors and the
angiopoietins in marmoset endometrium during the peri-implantation period and in
early pregnancy in Chapter 6 (Rowe et ah, 2003). Increased expression of VEGF in
stroma of the functionalis particularly adjacent to the implantation site during the
peri-implantation period was observed, and continuing to increase up to day 28 of
pregnancy. I also documented increased endothelial expression of KDR and Fit
mRNA immediately surrounding the glands of the functionalis, once again most
profoundly adjacent to the implantation site.
A significant increase in endothelial cell proliferation was observed in the
functionalis layer of the endometrium in all pregnant groups compared to late luteal
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non-pregnant controls. It is surprising that no significant differences in endothelial
cell proliferation were observed between day 14 pregnant animals and non-pregnant
marmosets. This is where the system becomes divergent in a fertile versus a non-
fertile cycle, in that it is from this point onwards that the blastocyst is present in the
pregnant uterus, chorionic gonadotrophin present in the system and where changes in
angiogenesis may be expected to occur. It could be that it takes time for the
endometrium to adapt to the newly implanted blastocyst before an upregulation in
angiogenesis is observed. In a non-pregnant cycle, after functional regression of the
CL, levels of VEGF decline (Rowe, et al., 2002). A similar phenomenon could be
occurring here. It would appear that a divergence in endometrial angiogenesis occurs
at the point at which the corpus luteum is either maintained or regresses. In a non¬
pregnant cycle, the corpus luteum undergoes functional luteal regression at around
day 21, thus progesterone levels decline unlike in luteal rescue where they are
maintained. Therefore it could be the continued perception of progesterone in the
system at day 21 of pregnancy in the marmoset that induces this significant increase
in angiogenesis, compared to late-secretory non-pregnant controls.
In the stages of pregnancy studied here, the trophoblast remains in relatively
superficial attachment to the uterus with no development of its own vasculature.
Maternal vessels are not invaded until much later in pregnancy (day 60) (Enders,
1993) and so foetal metabolic demands must be met by an alternative mechanism.
This would appear to be by increased angiogenesis in the functionalis layer mediated
by an increase in VEGF and its receptor mRNA. VEGF is also a potent permeability
factor and no doubt has a role in inducing fenestration of maternal vessels to aid the
diffusion process.
However, in the marmoset, unlike in the human, serum progesterone levels
are not further increased in response to chorionic gonadotrophin, compared to late
secretory phase levels, rather they are maintained at the level reached in the secretory
phase (Rowe, et al., 2002). Therefore, if increased VEGF and consequently increased
angiogenesis were purely attributable to progesterone alone, then this observed
increase only evident in pregnant animals, would surely be apparent in the secretory
phase regardless of conception? This is not the case and so increased angiogenesis at
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this time is clearly not solely dependent on the stimulatory effect of progesterone on
endothelial cells. Local factors possibly produced within the trophoblast itself and
hypoxia are possible factors which could give rise to increased VEGF and increased
angiogenesis in the functionalis. I observed increased VEGF mRNA throughout the
whole of the functionalis layer but the most intense expression was observed
immediately below the luminal epithelium adjacent to the implantation site providing
evidence for focal upregulation in pregnancy (Rowe, et al., 2003).
In rats, embryo implantation is associated with increased endothelial cell
proliferation (Macpherson and Rogers, 1993). They demonstrated that endothelial
cell proliferation was increased from day 3 of pregnancy and increased throughout
the entire endometrium up to day 5 of pregnancy. They implicated VEGF as being
the main promoter of this observed increase in endothelial proliferation but found
that although it appeared to be responsible for increased endometrial vascular
permeability at implantation, it was not soley responsible for regulating endothelial
cell proliferation at the site of implantation. Therefore other mechanisms may be
involved in promoting this increase. Angiogenesis can be driven by multiple
mechanisms with some considerable degree of redundancy between them.
This experiment also illustrated increased glandular and luminal epithelial
proliferation as pregnancy progressed from the time of implantation. This could be
due to the increased requirement for glandular secretions into the uterine lumen
during early pregnancy. Also, the luminal epithelium is being invaded during the
process of implantation and so may be undergoing rapid proliferation to replace
damaged cells as a result of the epithelial reaction.
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6 Molecular regulation of angiogenesis in
implantation and early pregnancy
6.1 Introduction
During the last few years, considerable progress has been made in
understanding the molecular regulation of angiogenesis in the female reproductive
tract. In particular, the role of vascular endothelial growth factor (VEGF) during
follicular and luteal development in the marmoset model has been established by
specific inhibition of this angiogenic factor in vivo (Fraser and Lunn, 2001). Since
inhibitors of angiogenic factors are likely to be used clinically, it is important that
their role during implantation and early pregnancy be elucidated. As a first step
towards this goal, this experimental chapter aims to build on our knowledge of the
regulation of angiogenesis in the reproductive tract of the female marmoset by
investigating the expression patterns of angiogenic factors during this period.
Successful pregnancy is dependent on implantation of the blastocyst into the
endometrium. Angiogenesis may have a key role in the implantation process,
however, the mechanisms by which localised changes in vascular permeability and
angiogenesis occur at the implantation site have yet to be elucidated.
VEGF and its receptors, Fit and KDR have been implicated as key players in
vascular remodelling and placentation on the basis that their mRNA and proteins
have been localised in endometrium of several species. These include human
(Ahmed et al., 1995, Clark et al., 1996, Clark et al., 1998, Cooper et al., 1995, Geva
et al., 2002, Goldman-Wohl et al., 2000, Helske et al., 2001, Sugino et al., 2002),
sheep (Bogie et al., 2001), pig (Winther et al., 1999), marmoset (Wulff et al., 2002)
mouse (Chakraborty, et al., 1995, Haider, et al., 2000), golden hamster (Yi et al.,
1999) rat (Rabbani and Rogers, 2001), rabbit (Das et al., 1997) and rhesus monkey
(Dhawan et al., 2000) during the first trimester of pregnancy. In vivo manipulation
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experiments are limited to the rodent to date but have provided further evidence for
the importance of VEGF in early pregnancy. In the mouse, inhibition of VEGF
prevented estrogen-induced uterine oedema and implantation (Rockwell, et ah, 2002)
and in the rat, the number of implantation sites were reduced after administration of a
VEGF blocking antibody (Rabbani and Rogers, 2001).
Angiopoietins also appear to have a major role in regulation of blood vessel
growth, maturation and regression, but their importance at the time of implantation
has yet to be studied. However their presence in placenta in later stages of pregnancy
has been documented in human (Dunk et al., 2000, Goldman-Wohl, et al., 2000) and
marmoset (Wulff, et al., 2002).
This experimental chapter aims to describe the localisation of mRNA for
angiogenic factors and their receptors. In the marmoset, implantation occurs at day
11 after ovulation. This study was conducted on tissue collected at the peri-
implantation period (2 weeks post ovulation), and 3 and 4 weeks of gestation.
Angiogenic processes occurring at this early stage of pregnancy are still poorly
understood in the human and with accumulating knowledge on effects of
manipulation of angiogenesis in the marmoset, this species represents a potentially
valuable model in which to study these events.
6.2 Methods
6.2.1 Details of animals used in the experiment
Study Groups Number of animals
Gene expression in the
.endometrium
Late luteal (Day 21) 5 (all animals had
structurally intact CL)
Pregnant (Day14) 5
Pregnant (Day 21) 5
Pregnant (Day 28) 5
Table 6.1. Details of animals used for the experiments
6.2.2 In situ hybridisation
Localisation of mRNA for VEGF, Fit, KDR, Ang-1, Ang-2 and Tie-2 was
performed by in situ hybridisation as described in Chapter 2. H & E stained uterine
sections were also photographed to confirm tissue morphology. In order to determine
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whether or not endothelial cells expressed these angiogenic factors, CD31
immunocytochemistry was performed on serially cut sections to those used for the in
situ hybridisation. It was not possible to co-localise CD31 surface antigen and
mRNA for an angiogenic factor on the same slide as the stains used to detect CD31
interfered with dark field microscopy.
6.2.3 Quantification of In situ hybridisation
Uterine sections were scored and means calculated according to the grain
density in the various different uterine compartments namely, luminal epithelium,
upper zone stroma, (area beneath the luminal epithelium) upper zone glands, lower
zone glands (area adjacent to myometrium), lower zone stroma and endothelial cells.
Scoring was carried out by two independent observers, myself and Dr. H. Fraser,
with the following classification: - (0) No detectable specific signal above
background levels, + (1) detectable but low grain density clearly above background
levels, ++ (2) Moderate grain density, +++ (3) high grain density without grain
coalescence and ++++ (4) grain coalescence. Scoring of uteri was blind and random
by each observer. For each compartment within a section, an overall score was
assigned, resulting in the whole uterus being classified according to grain density. It
should be noted that individual grain counts were not performed. Unlike the corpus
luteum, the endometrium is not a uniform tissue. It is extremely heterogeneous with
many different cellular compartments. As such, it was impossible to accurately count
grains from a given field of view because inevitably each field of view contained
different uterine compartments and thus could not be compared accurately to another
equally sized area.
Significant differences between groups (P<0.05) within a particular uterine
compartment were determined using a Kruskal-Wallis non-parametric test followed
by Dunn's multiple comparisons test.
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6.3 Results
6.3.1 Vascular Endothelial Growth Factor
Photomicrographs of each in situ hybridisation are presented in this section
(Figures 6.1-6.5) to illustrate the cellular localisation of each of the different
angiogenic factors. Also, a table is included to summarise the scores assigned to each
section in terms ofmean grain density (Table 6.1).
VEGF mRNA was localised to the glandular epithelium in the late secretory
phase non-pregnant endometrium. Highest grain density was observed in the luminal
epithelium and glands of the upper zones. Grain density was much reduced in the
mid-zone glands, while grains were completely absent from the lower zone (Figure
6.1A and B). Exact cellular localisation of VEGF mRNA to glandular epithelium
was confirmed at high power magnification (Figure 6.1J).
In early pregnant endometrium, 2 weeks post ovulation, a similar localisation
was observed to that seen in the non-pregnant animals (Figure 6.1C-E). However, a
low level of stromal VEGF mRNA expression was apparent just beneath the luminal
epithelium (Figure 6.1C and D). At this very early stage of pregnancy, 3 days after
implantation, no VEGF mRNA expression was observed in the blastocyst or foetal
membranes (Figure 6.1C and D). By 3 weeks of pregnancy (day 21), VEGF mRNA
levels remained high in the glandular epithelium and also appeared at a lower level in
the lower zone glands (Figure 6.1H and K). At 3 weeks of pregnancy, VEGF
expression was relatively high in luminal epithelium and in decidua where
expression was punctate (Figure 6. IF, G and I). Also, by this stage of pregnancy the
blastocyst and foetal membranes were expressing VEGF mRNA. Four week
pregnant animals (day 28) had similar VEGF mRNA localisation to those animals at
3 weeks hence a representative figure at 4 weeks is shown. In all sense slides, no
specific signal was detected above a low background (Figure 6.1H insert).
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Figure 6.1 In each figure, a representative scale bar is. (A-K) In situ hybridisation of
VEGF mRNA in the marmoset endometrium. Dark field (A,C and F) and
corresponding light field images (B, D and G respectively). (A and B) Non-pregnant
late secretory phase endometrium. Note high expression in upper zone glands (UZ)
and luminal epithelium, declining in the mid-zone (MZ) and absent in the lower zone
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(LZ). (C, D, E) Pregnant marmoset endometrium at day 14 after ovulation. (C) Note
high expression in luminal epithelium (LE) and upper zone (UZ) glands and absence
of expression in the blastocyst (B) and foetal membranes (FM). A lower level of
VEGF expression can be seen in the upper zone stroma (UZS). Insert in (C) is a
higher power image of the luminal epithelium. Insert in (D) is a higher power bright
field image of the upper zone stroma. (E) CD31 staining for endothelial cells (EC) to
emphasise non-endothelial localisation of stromal VEGF. (F, G, H) Typical VEGF
expression at day 21 and day 28. (F) Dark field image of marmoset early
implantation site. Note high punctate expression in the decidualised endometrium
(DE) and appearance of expression in the foetal membranes (FM). (G)
Corresponding light field image. (H) Dark field image of lower zone endometrium
where there is a low level of glandular VEGF expression. (I) is a higher power
bright field image of the luminal epithelium (LE) of 3 week pregnant animals and
also illustrates the hybridisation observed in decidualised stroma (DE). (J) is a high
power image of the upper zone glands in the late secretory non-pregnant
endometrium to confirm cellular localisation. (K) highlights glandular expression of
VEGF in the lower zones at this time. Insert in (H) is a representative sense
photograph.
6.3.2 KDR and Fit (VEGFR-1 and VEGFR-2)
Figure 6.2 shows VEGFR-2 mRNA localisation. It should be noted that
VEGFR-1 mRNA expression was consistently lower than that of VEGFR-2, but was
found in the same cellular locations, thus mainly photographs of VEGFR-2 mRNA
are represented here (Figure 6.2 A-L), however representative images are included
of VEGFR-1 hybridisation at 2 weeks of pregnancy (Figure 6.2M and N). Each
• receptor localisation and grain density were scored separately and detailed in Table
6.2. In the late secretory non-pregnant endometrium, VEGFR-2 mRNA was found
exclusively in endothelial cells surrounding the upper zone glands beneath the
luminal epithelium (Figure 6.2A, B and J). This was confirmed by comparison to
CD31 immunocytochemistry to identify endothelial cells in sequential sections
(Figure 6.2C). In 2 week pregnant endometrium, VEGFR-2 mRNA was localised to
the upper zone endothelium as in non-pregnant endometrium. Grains were absent
from the blastocyst and foetal membranes (Figure 6.2D and E). At 3 and 4 weeks of
pregnancy, VEGFR-2 mRNA expression remained in endothelial cells of the upper
zone with highest grain density being seen around large maternal vessels beneath the
luminal epithelium (Figure 6.2G, H and K), again confirmed by comparison to
CD31 localisation (Figure 6.21). VEGFR-2 mRNA was also observed to a lesser
extent throughout the stromal compartment again localised to endothelial cells
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(Figure 6.2L). In all sense slides, no specific signal was detected above a low
background. This is shown in (O), a xlOO magnification bright field image of the
corresponding sense slide to (K).
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Figure 6.2 In situ hybridisation of VEGF receptor R2 (A-L) and R1 (M,N) mRNA
in marmoset endometrium. (A-C) Non-pregnant late secretory phase endometrium.
(A) Dark field and (B) light field images of VEGF R2 expression in upper zone
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endometrium. Note endothelial localisation immediately surrounding glands as
demonstrated by CD31 immunocytochemistry (C) and high power bright field image
(J). Also note punctate expression throughout the stroma in all stages studied
illustrated by a representative high power bright field image (L). (D-F) Pregnant
marmoset endometrium at day 14 after ovulation. (D) Dark field and (E)
corresponding light field images showing localisation to large and small luminal
blood vessels surrounding the upper most glands as indicated by CD31
immunocytochemistry for endothelial cells (F). Note absence of grains in blastocyst
and foetal membranes (FM). (G) Dark field and (H) light field images of VEGF R2
expression. Note localisation in upper zone to luminal maternal vessels as
demonstrated by CD31 immunocytochemistry (I), and high power bright field image
(K). Also note absence of localisation to foetal membranes. (K) and punctate
expression throughout the stroma of lower zones (L). A high power bright field sense
image is given (O).
6.3.3 Angiopoietin-1
Ang-1 mRNA was localised to upper zone stroma and to a lesser extent the
glandular epithelium of the upper zone in late secretory non-pregnant endometrium.
In pregnant endometrium at day 14, Ang-1 mRNA is present at a high level in the
lower zone glands (Figure 6.3D, E and O) but completely absent from adjacent
compartments, the myometrium and mid-zone endometrium (see insert Figure
6.3D). In the upper zone, Ang-1 mRNA was expressed at a low level in the glandular
epithelium but much more intensely in stroma (Figure 6.3P). Grains were absent
from blastocyst and foetal membranes (Figure 6.3F and G). At three weeks of
pregnancy, upper and lower zone glandular epithelial expression of Ang-1 mRNA
was retained (Figure 6.3H and J). Grain density greatly increased in the stroma at
this stage (Figure 6.3H and I). By Day 28, clear, punctate Ang-1 mRNA localisation
was observed throughout the decidualised stroma (Figure 6.3K, L and N). In all
sense slides, no specific signal was detected above a low background.
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Figure 6.3 (A-P) In situ hybridisation of Ang-1 mRNA in marmoset endometrium.
(A) dark field and (B) corresponding light field images of non-pregnant late
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secretory phase endometrium. Note Ang-1 expression in stroma and a low level in
glands of the upper zone endometrium. (C) Haematoxylin and eosin stained section
of upper zone and luminal epithelium. (D-G) Day 14, pregnant marmoset
endometrium. (D) Dark field and (E) corresponding light field images of Ang-1
expression at a high level in the glandular epithelium of the lower zone. Insert in (D)
is a lower power image to demonstrate absence of grains in myometrium and mid-
zone endometrium. (O) is a high power image to confirm cellular localisation to
glands of the lower zone. (E) corresponding light field image of (D). (F) Dark field
and (G) corresponding light field images of Ang-1 mRNA localisation in the upper
zone. Note low glandular localisation together with stromal expression. Ang-1 is
absent from the foetal membranes (FM) and blastocyst (B). (H-J) Ang-1 expression
at day 21 (H) Dark field and (I) light field images of Ang-1 expression in the upper
zone. Note expression in glandular epithelium and to a greater extent in stroma. This
is also highlighted in (P), high power (xlOO) bright field image. (J) Dark field image
of lower zone endometrium. Note glandular epithelial localisation of Ang-1. (K-M)
Ang-1 expression at day 28 of pregnancy. (K) Dark field and (L) corresponding light
field images of decidualised endometrium and luminal epithelium (LE). Note
punctate expression of Ang-1 mRNA throughout decidualised stroma, not in
endothelial cells, further illustrated in (N), a higher power bright field image. (M)
Flaematoxylin and eosin stained section to demonstrate decidual morphology.
6.3.4 Angiopoietin-2
Ang-2 mRNA was only detected in 4 week pregnant animals where it was
localised exclusively in endothelial cells of maternal vessels (Figure 6.4). In all
sense slides, no specific signal was detected above a low background.
Angiopoietin-2
Figure 6.4 (A-C) In situ hybridisation of Ang-2 mRNA in pregnant endometrium at
day 28. (A) Dark field and (B) light field images of upper zone endometrium. Note
Ang-2 expression in endothelial cells of large maternal vessels (MV), as
demonstrated by CD31 immunocytochemistry in (C) and higher power image in (B).
Ang-2 was absent from all other stages studied.
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6.3.5 Tie-2
In non-pregnant late secretory endometrium Tie-2 mRNA was expressed
predominantly in endothelial cells throughout the stroma of all zones (Figure 6.5A,B
and L). At two weeks of pregnancy (day 14), the generalised stromal expression
pattern seen in the non-pregnant animals is much reduced but still present at a low
level. (Figure 6.5D and E). High grain density was observed in endothelium
immediately surrounding the upper zone glands at this time (Figure 6.5D, E and J).
By 3 and 4 weeks of pregnancy, luminal epithelial Tie-2 mRNA expression is lost
but expression remains in upper zone decidualised stroma. (Figure 6.5G). By
comparison to CD31 immunocytochemistry (Figure 6.51) and high power
haematoxylin and eosin stained sections (Insert Figure 6.5H), Tie-2 appeared to be
expressed in blood vessels throughout the decidua. In sense slides, no specific signal
was detected above a low background.
50um







'• % '• ■>. h.-'V".'
* / |
, /' v2->-V-














Figure 6.5 (A-L) In situ hybridisation of Tie-2 mRNA in marmoset endometrium.
(A-C) Non-pregnant late secretory phase endometrium. (A) Dark field and (B) light
field images of Tie 2 expression in stroma throughout all zones of the non-pregnant
endometrium. Note expression localised to endothelial cells as demonstrated by
CD31 immunocytochemistry (C) and (L). The insert in (L) illustrates CD31
immunocytochemistry, counterstained with haemoyoxylin. (D-F) Pregnant marmoset
endometrium at day 14 after ovulation. (D) Dark field and (E) corresponding light
field images of upper zone endometrium. Note localisation to endothelial cells
immediately surrounding upper zone glands as demonstrated by (F) CD31
immunocytochemistr. (K) illustrates CD31 immunocytochemistry counterstained
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with haemotoxylin. (G-I) Typical Tie-2 expression at day 21 and day 28 of
pregnancy. (G) Dark field and (H) light field images of upper zone decidualised
endometrium. Note punctate expression of Tie-2 probably localised to endothelial
cells as demonstrated by (I) CD31 immunocytochemistry. Insert shows a
haematoxylin and eosin stained section. Note vessels similar to areas of grain
localisation in (G).
Chapter 6 Molecular regulation of angiogenesis in implantation 222
and early pregnancy
Table 6.2 Quantification of in situ hybridisation using relative grain density within different uterine
compartments throughout the stages studied for VEGF, VEGF R1 and R2, Ang-1, Ang-2 and Tie-2.
This scoring was based on an overall impression of the region by two independent observers. Data
was combined before statistical tests were applied. Values given are mean scores.
Significant differences (P<0.05) are marked with different letters. Where no differences occurred, no
letters are given. (n=5 per group).
VEGF le uzge uzs lzge lzs
LS +++a +++
P,D14 +++ab ++ +
P,D21 +ab ++ ++ +
P,D28 -b + ++ ++
R2 (Rl) LE UZGE UZS Endo LZGE LZS
LS - +++ (+)
P,D14 - - - ++(+)-
P,D21 - - - ++(+)-
P,D28 - - - ++(+)-
Ang-1 LE UZGE UZS LZGE LZS
LS + +
P,D14 - + ++ +++
P,D21 - + +++ ++
P,D28 - + ++ +




P,D28 - - - +++b
Tie-2 LE UZGE UZS Endo LZGE LZS
LS + +++ - +
P,D14 - - + ++
P,D21 - - + ++ +
P,D28 - - + ++ +
Row Headings (LE) Luminal Epithelium, (UZGE and LZGE) Upper and Lower Zone Glandular
Epithelium, respectively, (UZS and LZS) Upper and Lower zone stroma, respectively, (UZEndo)
Upper Zone Endothelium.
Column Headings Stage of cycle of endometrium (LS) Late Secretory non-pregnant, (P,D14) 2
weeks, (P,D21) 3 weeks and (P,28) 4 weeks of pregnancy. NOTE scores for VEGF Rl are given in
brackets next to values for VEGF R2.
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Figure 6.6 (A-F) Diagrammatic representations of angiogenic factor expression in
the marmoset endometrium. Yellow represents VEGF, blue is VEGF receptors R1
and R2, orange is VEGF + R1R2 localised to the same areas. Green is Tie-2, Lilac
represents Ang-1, pink is Ang-1 and Tie-2 in the same location and red is Ang-2. (A
and B) Late secretory non-pregnant endometrium. (C and D) Pregnant endometrium,
14 days after ovulation. (E and F) Pregnant endometrium at 3 (21 days) and 4 (28
days) weeks of pregnancy. (LV) Luminal vessels, (UZS) Upper zone stroma, (UZG)
Upper zone glands, (LE) Luminal epithelium, (LZS) Lower zone stroma and (LZG)
Lower zone glands
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6.4 Discussion
This experimental chapter has described the spatial and temporal expression
patterns of mRNAs for VEGF-A, angiopoietins and their receptors in the marmoset
uterus during the peri-implantation period, allowing us to begin to construct a
working hypothesis as to their potential role in oxygen and nutrient exchange and
maternal vascular remodelling. Figure 6.6 is a summary diagram of the exprerssion
patterns detailed in the results sections and explained below as a system of
angiogenesis highlighting the interplay between the different angiogenic factors.
Implantation occurs on day 11 after ovulation in the marmoset, three days
later than in the human, and the blastocyst remains in loose attachment to the surface
epithelium without epithelial fusion. Penetration of trophoblast into maternal vessels
occurs quite late, days 45 to 60 of gestation in this species, compared to about day 12
in the human (Enders, 1993). Therefore, foetal demand for nutrients and oxygen
during early pregnancy must be met by diffusion across the foeto-maternal interface,
a process likely to be critically dependent on vascular permeability. Increased
permeability is generally thought to accompany tissue growth and remodelling
(Dvorak et al., 1999, Dvorak, 2000, Rabbani and Rogers, 2001). VEGF is a vascular
permeability factor as well as a mitogen for endothelial cells (Keck, et al., 1989).
Permeability and uterine oedema mediated by VEGF have been shown to be critical
for successful implantation in the rodent where inhibition of VEGF prevented
implantation (Rabbani and Rogers, 2001, Rockwell, et al., 2002). VEGF mRNA
localisation to upper zone endometrium of all groups, increasing during the first few
weeks of pregnancy as found here implies a role for VEGF as a permeability factor at
this time.
The presence of VEGF mRNA in upper zone glandular epithelium and
luminal epithelium of non-pregnant late secretory endometrium, with both VEGF R1
and VEGF R2 mRNA in endothelial cells of blood vessels immediately surrounding
these glands suggests a local action of VEGF. This is also observed in 2 and 3 week
pregnant endometrium where it may be involved in promoting fenestration of these
vessels facilitating oxygen transfer to the avascular foetus. Although I observed
Chapter 6 Molecular regulation of angiogenesis in implantation 225
and early pregnancy
foetal membranes positive for CD31, they had no capillary formation. At 4 weeks of
pregnancy, upregulation of stromal VEGF mRNA was observed. It is likely that the
permeability role of VEGF is declining at this point, as glandular secretions are
reduced and maternal sinusoids, although not yet invaded by trophoblast, have much
more intimate contact with the more closely attached blastocyst thus facilitating
diffusion. I also observed very strong expression of VEGFR-2 mRNA in endothelial
cells of large maternal vessels immediately beneath the luminal epithelium where
foetal VEGF could be acting to promote vessel migration in order that foetal
metabolic demands can be adequately met. The pattern of mRNA localisation of
VEGF and its receptors observed here is consistent with findings in human, where
foetal VEGF expression in tripronuclear zygotes has been implicated to induce
neoangiogenesis at the implantation site (Krussel et al., 2000). VEGF expression has
been documented in human placenta and other species in later stages of placentation
where it is reported to be expressed in maternal decidua, but unlike my findings, its
receptor VEGFR-1 appeared to be expressed in invading syncytial trophoblast
(Ahmed, et al., 1995, Clark, et al., 1996, Cooper, et al., 1995). It may be that foetal
VEGF receptors are only present at later stages in the marmoset when a more
intimate interplay between maternal and foetal tissues occurs (Wulff et al., 2002).
Soluble fit is produced by human trophoblast in pregnancy and is detectable in serum
of pregnant women (Banks et al., 1998). It is possible that this also occurs in the
marmoset, however no hybridisation of VEGFR-1 probe to trophoblast was observed
in this study despite our probe detecting both the soluble and full length receptor. No
serum analyses were conducted.
The roles of the angiopoietins and their receptor Tie-2 in early pregnancy are
just beginning to be explored. In general, Ang-1 acts on its receptor Tie-2 to promote
stabilisation of the endothelial cell-vascular smooth muscle structure (Suri et al.,
1996), while Ang-2 acts as an antagonist by binding to the Tie-2 receptor without
transmitting a signal (Lobov et al., 2002, Maisonpierre, et al., 1997). In the
marmoset uterus, Ang-1 mRNA was the most abundantly expressed angiopoietin,
localised to upper zone glands and stroma while Tie-2 mRNA was expressed in
endothelial cells. In menstruating species following an infertile cycle, menstruation
and shedding of the upper zones of the endometrium occur. The lower zone and
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myometrium are comparatively more stable compartments from which a new
vascular and new upper zone endometrium is supplied (Smith, 2001). Although the
marmoset does not menstruate, in infertile cycles a degree of vascular remodelling
may occur in the upper zones while the lower zones remain more stable, implicating
a role for Ang-1 in this region as observed here. However, fertility rate is extremely
high in marmosets (Rowe, et al., 2002), consequently this species may retain a stable
upper zone endometrium without remodelling in response to progesterone
withdrawal, associated with basal levels of expression of Ang-1 and Tie-2 in
preparation for pregnancy. In fertile cycles, the endometrium is preparing to receive
an implanting blastocyst and thus would require a stable maternal vasculature. Ang-1
mRNA may be expressed in the lower zones to maintain core vessel stability.
During the peri-implantation period, stromal Ang-1 and Tie-2 mRNA
expression in the upper zones was greatly increased compared to non-pregnant
endometrium, particularly adjacent to the implantation site. As gestation progressed
into the third and fourth week, Ang-1 and Tie-2 mRNA expression in upper zone
stroma and decidua was further increased. This corresponds with a continued
requirement for a stable vasculature at the maternal-foetal interface and eventual
placentation and development of a hemochorial placenta. This role appears to extend
to later pregnancy in the marmoset, where Ang-1 mRNA is exclusively localised to
syncytial trophoblast (Wulff, et al., 2002), suggesting that once the foetal
vasculature begins to develop, there exists a need for stabilisation of newly formed
foetal vessels.
The only site of Ang-2 mRNA localisation was in large maternal vessels
immediately beneath the luminal epithelium of 4 week pregnant animals where it
was co-localised with Tie-2 mRNA. This is similar to the situation observed in later
stages of placentation in the marmoset (Wulff, et al., 2002). The presence of VEGF
mRNA in the decidualised upper zone endometrium with its receptors in endothelial
cells of this same region, including large maternal vessels, suggests a similar
paracrine modulation of Ang-2 and VEGF. Ang-2, when expressed in conjunction
with VEGF, is generally thought to be pro-angiogenic, promoting destabilisation of
vessels and breakdown of basal lamina to allow migration of endothelial cells and
subsequent angiogenesis. My findings suggest that at 4 weeks of pregnancy, VEGF
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and Ang-2 could be working synergistically to promote migration of these vessels
and establishment of an efficient interface for nutrient and oxygen exchange between
the foetal and maternal circulation.
No angiopoietin or Tie-2 mRNA was detected in blastocyst or foetal
membranes. Their presence in first trimester placenta has been reported in the
human; Tie-2 has also been localised to trophoblast cells as well as endothelial cells
(Dunk, et al., 2000). Tie-2 mRNA in trophoblast has been observed in later stages of
pregnancy in the marmoset in our laboratory (Wulff, et al., 2002).
Ang-2 is expressed by uterine natural killer cells in human endometrium,
particularly those situated beneath the luminal epithelium and around vascular
smooth muscle cells (Smith, 2001). I found no evidence for this phenomenon in the
marmoset where Ang-2 mRNA was found exclusively in endothelial cells of luminal
maternal vessels as confirmed by CD31 immunocytochemistry.
In conclusion, this experimental chapter has described the molecular
regulation of angiogenesis associated with implantation and vascular remodelling
during the peri-implantation period in the marmoset. It provides evidence that
VEGF/R1R2 and Ang-l,Ang-2/Tie-2 interactions may be involved in the
preparation of endometrium for implantation, remodelling of the maternal
vasculature during the peri-implantation period and trophoblast invasion.
















Figure 6.7 Flow diagram to illustrate putative roles of the angiogenic factors during
implantation and early pregnancy
Figure 6.7 summarises the suggested roles for the angiogenic factors during
the implantation process. From the in situ photographs it can be seen that with all
probes, there appears to be an area of intense hybridisation immediately adjacent to
the implantation site itself. This has caused a few apparent discrepancies between
what is represented in Table 6.1 and what is presented as photographs. For the
quantification, the uterus was compartmentalised into upper and lower zones, then
further divided into cellular compartments. Therefore in terms of quantification, this
area of intense hybridisation was not categorised separately, rather as part of the
upper zone. This is apparent, for example with Tie-2 expression in the upper zone
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endothelium. I refer to an increase in Tie-2 expression as pregnancy progresses. This
however, does not appear to be the case in Table 6.2 where the highest intensity of
hybridisation was recorded in the non-pregnant late secretory phase. It is only in this
isolated region of endometrium, immediately beneath the implantation site where
Tie-2 expression increases as pregnancy progresses, as represented by the
photographs.
I have proposed putative roles for the angiogenic factors studied here during
this time point. I believe that VEGF is acting not only as an angiogenic mitogen to
promote proliferation and migration of endothelial cells but also as a permeability
factor. This would give rise to a well developed vasculature in the upper zone as
pregnancy progresses and induce vessel fenestration; both greatly enhancing the
diffusion process across the foetal-maternal interface to meet the growing metabolic
demands of the newly implanted blastocyst.
I suggest that angiopoietin-1 is acting to stabilise these newly formed
capillaries in order that placentation be successful with a well established maternal
vasculature. Angiopoietin-2 was found to be highly expressed in upper zone large
maternal vessels. Also at this cellular location, its receptor Tie-2 was found together
with VEGF receptors K.DR and Fit. Angiopoietin-2 is reported to have a
destabilising role and involvement in vessel degradation. This could be true if
maternal vessels were being invaded by syncytial trophoblast, however, in the
marmoset this does not occur until later in pregnancy. I suggest that a complex
synergism between VEGF and Angiopoietin-2 is in place by day 28 of pregnancy in
order that the endothelial cells of these large vessels can proliferate and migrate to
further increase the capillary density in this region, in preparation for true
hemochorial placentation.
This experiment complements earlier work performed by our laboratory
group documenting the molecular angiogenic events occurring from week 7 of
pregnancy to term, and provides a comprehensive picture of implantation and
placentation in this primate. Having proposed putative roles for these angiogenic
regulators in this process, there exists potential for in vivo studies using specific
antagonists to determine their physiological function.
Chapter 7 General Discussion 230
Chapter 7
General Discussion
Chapter 7 General Discussion 231
7 General Discussion
This thesis has illustrated the results of a series of investigations into the role of
angiogenesis in the female reproductive tract in early pregnancy of the primate using
the marmoset as an in vivo model.
The results from each experiment have been discussed in detail at the end of
each chapter, and thus this general discussion provides an opportunity to dissect and
summarise the main findings of the thesis, to discuss the appropriateness of the
marmoset model and the clinical implications of this research.
The results presented in this thesis provide a comprehensive understanding of
the role of angiogenesis in the corpus luteum and endometrium of early pregnancy,
and allow for the opportunity to discuss possible future approaches to further
investigate this complex process.
7.1 The findings of the thesis
The importance of angiogenesis in early pregnancy is a phenomenon that has
been widely studied using pharmacological rescue of the corpus luteum, ie. treatment
of women and experimental animals with hCG to mimic early pregnancy. While this
gives valuable insight into the processes involved in rescue of the corpus luteum and
preparation of the endometrium for early pregnancy, it is an isolated system where
no conception has occurred and subsequently there is no implantation event. This is
relevant because while hCG is recognised as being the primary stimulus for the
maternal recognition of pregnancy, there may be other factors or indeed physical
stimulation of an implantation event that trigger other mechanisms which would be
lost in this model system. The marmoset allows us to overcome this problem as it is a
highly fecund species and as such provides a primate model in which to study
physiological pregnancy.
Angiogenesis has been shown to be intense during the first few days of the
lifespan of the corpus luteum (CL) in a large number of species studied, including
women (Christenson and Stouffer, 1996, Dickson and Fraser, 2000, Rodger, et al.,
1997, Zheng, et ah, 1994) and is stimulated principally by LH-driven vascular
endothelial cell growth factor (VEGF) (Dickson, et ah, 2001, Fraser, et ah, 2000).
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The rationale behind the initial hypothesis was to use the marmoset as a
model for in vivo luteal angiogenesis in early pregnancy and to determine whether or
not the same cellular and molecular events were taking place as had been reported in
the human after hCG rescue of the corpus luteum. When pharmacological 'rescue' of
the CL by hCG was carried out in women, a second wave of angiogenesis,
accompanied by vascular stabilisation by pericytes was associated with luteal rescue
(Wulff, et ah, 2001). It was also found that mRNA for VEGF increased in the CL
after hCG rescue (Wulff, et ah, 2000). These findings suggested that luteal
angiogenesis could be a component of luteal rescue which is important for
prolonging the lifespan of the corpus luteum and the establishment of early
pregnancy. Since failure of the CL due to a malfunction of the vasculature could
possibly lead to miscarriage or infertility, it was considered important to establish a
non-human primate model of early pregnancy in which this issue could be addressed
experimentally.
The finding that the marmoset does not appear to undergo further
angiogenesis during luteal rescue, gave rise to the second experiment presented in
this thesis, whereby the effect of progesterone on VEGF expression in vitro was
examined in human luteinised granulosa cells. This was done to determine whether
or not the increase in VEGF expression observed in the human CL in vivo was a
progesterone mediated effect.
The endometrium is cyclically dependent on ovarian steroids and as such was
considered an ideal target tissue within which to explore possible angiogenic events
that may be occurring throughout the non-pregnant cycle, during the peri-
implantation period and in early pregnancy. The time points of early pregnancy
studied here provide novel insights into the angiogenic process and its involvement
during the peri-implantation period in a primate model.
A number of important findings have been described 1) I have demonstrated
that by the late luteal phase in the marmoset, the corpus luteum has already
established a mature vascular system and the molecular capacity to synthesize VEGF
and its receptors which are not further enhanced in early pregnancy. A pregnancy
induced spurt of angiogenesis does not take place, rather a maintenance of the
existing vasculature is all that is required for establishment of pregnancy. Therefore,
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it has to be concluded that the changing morphological and cellular events thought to
be associated with early pregnancy in the human after hCG rescue do not occur in the
marmoset. 2) From in vitro studies using human luteinised granulosa cells, it would
appear that increased VEGF expression in luteal rescue is not a progesterone
mediated effect. However, this is a complex system which requires further
investigation in order that the exact mechanisms by which increased angiogenesis
occurs in hCG rescue of the human corpus luteum are understood. 3) There exists an
increase in angiogenesis associated with early pregnancy in the marmoset
endometrium compared to late-secretory non-pregnant controls, and 4) I have
described the molecular regulation of angiogenesis associated with implantation and
vascular remodelling during the peri-implantation period in the marmoset. These data
provide evidence that VEGF/R1R2 and Ang-l,Ang-2/Tie-2 interactions may be
involved in the preparation of endometrium for implantation, remodelling of the
maternal vasculature during the peri-implantation period and trophoblast invasion.
These results provide valuable insights into the importance of angiogenesis
during early pregnancy in the marmoset female reproductive tract. Dissection of
these systems will allow the exact roles of the angiogenic factors at this time to be
elucidated by various manipulations including antagonist treatment.
The techniques employed in this thesis in order to assess the angiogenic
process during early pregnancy are robust and reproducible. Incorporation of BrdU
into proliferating cells during the S phase of the cycle has served as the basis for
measuring vessel proliferation, the first step in the angiogenic process. In the corpus
luteum, this method proved to be very accurate. The mannoset corpus luteum is a
relatively homogeneous gland, where vascularisation is distributed evenly over the
gland by the late luteal phase. As such, using image analysis to quantify
proliferation, throughout the whole cross section of the CL allowed for the
generation of extremely accurate results. This is true of all immunohistochemical
techniques employed for the purposes of this thesis in the CL, equally true for in situ
hybridisation, where, expression of VEGF, Fit and KDR is fairly consistent
throughout the CL cross section. At this point I would like to comment on the fact
that I was unable to localise the angiopoietins and Tie-2 in the marmoset CL by in
situ hybridisation. I established that the human riboprobes used, do cross react in the
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marmoset as demonstrated in Chapter 6 in the endometrium. I conclude therefore that
the angiopoietins and their receptor Tie-2 mRNA are too low to be detected by in situ
hybridisation in the marmoset CL. This is surprising however, because angiopoietin-
1 is thought to have a role in vessel stabilisation and pericyte recruitment, so, having
localised pericytes in the marmoset CL at this time, the mechanism by which these
cells are recruited by the newly formed capillaries remains to be elucidated.
Another limitation of this experimental model was the difficulty in accurately
assessing the processes involved in luteal regression. Those CL which had undergone
structural regression by day 21 had extremely disrupted CL, with no clear
morphology to the degree that steroidogenic cells could no longer be distinguished.
As such, the methods employed to assess angiogenesis in the other experimental
groups could not be used as these rely on the integrity of the tissue under analysis.
Therefore it was impossible to determine the angiogenic response at this stage. I did
observe that VEGF expression was completely obliterated at this time. VEGF could
act as a survival factor for endothelial cells, so that its absence would cause vascular
regression and consequently result in a hypoxic environment. However, it is difficult
to make accurate conclusions about this, as it could be that due to the poor structural
integrity of the tissue, that RNA degradation had occurred to such an extent that the
riboprobes were unable to detect VEGF in these cells rather than it actually being
"switched off. We have no evidence for a decline in VEGF prior to luteolysis.
Luteolysis in primates and the trigger for this remains unclear. The length of
the luteal phase in marmosets is 21 days theoretically although I found this length to
be variable, where some animals had undergone structural and functional regression
by day 21, others still had intact and functionally active corpora lutea as late as day
25. As such, looking at triggers for luteolysis in this species is very difficult. It would
appear that in the marmoset, the corpus luteum remains functionally and structurally
active until such time as it undergoes luteolysis which seems to be a very rapidly
triggered event.
In the endometrium, quantification of angiogenesis, both by
immunocytochemistry and by in situ hybridisation proved more challenging. Unlike
the CL, the uterus is not homogeneous. It is compartmentalised and not surprisingly
these compartments showed varying levels of proliferation and expression of
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angiogenic factors. In order that these problems could be overcome, the endometrium
was separated into the various different compartments, namely, luminal epithelium,
glandular epithelium, stroma and endothelium. In terms of quantitative analysis of
proliferation, a grid system was devised according to Hastings et al, (Hastings, et al.,
2003). This allows for the accurate volume fraction analysis of each of these
different compartments across a uterine section and subsequent proliferation indices
to be calculated. The uterus is an organ subject to oedematous changes and therefore
analyses of immunocytochemical staining in the same way as employed for the CL
were not appropriate. The methods employed take into account any volume changes
and so therefore correct for this phenomenon and allow comparison between groups
where changes in oedema may not occur to the same degree.
In situ hybridisation was employed to localise and semi-quantify mRNAs for
the angiogenic growth factors, but posed a higher degree of complexity. The level of
proliferation of endothelial cells varied between endometrial compartments and
between stages, and so therefore it was expected that the angiogenic factor
distribution, presumably responsible for this would also vary. To address this issue,
once again the endometrium was subdivided into cellular compartments and a
scoring system employed. Grain counts per unit area, as used in the CL, would not
have been an appropriate method of quantification here, due to this degree of
variability.
Using the marmoset as a model for early pregnancy and taking into account
the variability between cellular compartments and variations throughout the cycle,
allows this important process and the angiogenic events associated therein to be
elucidated. It was surprising that I did not observe an increase in angiogenesis in the
CL associated with early pregnancy as had been reported in women. However,
earlier experiments in hCG treated rhesus macaques had reported similar findings to
the marmoset, where no increase in angiogenesis was associated with hCG rescue
(Christenson and Stouffer, 1996). In the human corpus luteum, endothelial cell
proliferation mirrors that of the marmoset in the early, mid- and late luteal phase,
where maximal proliferation occurs in the early luteal phase and declines
significantly in the mid- and late luteal phase (Gaytan, et al., 1998, Rodger, et al.,
1997). This is also true in the rhesus monkey, (Christenson and Stouffer, 1996),
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sheep (Jablonka-Shariff, et al., 1993, Jablonka-Shariff, et al., 1997) and in cattle
(Zheng, et al., 1994).
The rescue of the corpus luteum of pregnancy allows it to persist functionally
and structurally for longer than in the non-pregnant cycle. Presumably, this survival
requires a stable vasculature, with recruitment of pericytes and prolonged endothelial
cell survival, in addition to prolongation of the lifespan of the luteal cells. Since
endothelial cell proliferation did not increase after administration of hCG in the
rhesus monkey (Christenson and Stouffer, 1996), it was suggested that early
pregnancy may be associated with an increase in vessel stability, and there is
evidence from our group for hCG-induced increase in pericyte number in the human
CL (Wulff, et al., 2001). However, no evidence for this was found here.
It is well established that progesterone levels are maintained due to the
continued responsiveness of luteal cells to gonadotrophins via CG in pregnancy
(Stouffer, et al., 1978). It would appear that in the marmoset, despite the absence of
CG, the late luteal CL of a non-pregnant cycle is maintained until it undergoes a
rapid regression and thus decline in progesterone production. Luteal regression in the
marmoset must therefore be a very rapidly triggered event, for up until that point the
CL of a non-fertile cycle retains its morphology and functional capacity to the same
extent as in a pregnant cycle.
Having established this disparity between the marmoset and human, I
addressed the issue of what could be responsible for the upregulation of VEGF seen
in the human CL. Cell culture studies using luteinised granulosa cells, have revealed
that hCG treatment leads to increased VEGF mRNA levels (Neulen, et al., 1998).
This reported up-regulation of VEGF by hCG rescue supports the view that in the
human, pregnancy is associated with further angiogensis. The marmoset and human
vary in terms of their progesterone profiles in early pregnancy. In the human, after
hCG rescue, progesterone levels increase unlike in the marmoset where levels
attained in the late luteal phase are maintained without further increase. This in itself
provides compelling evidence for the disparity observed in the angiogenic response
of these two species. The CL of pregnancy in the marmoset appears fuctionally and
structurally the same as the structurally intact non-pregnant CL, as such, no
upregulation of progesterone synthesis occurs. The second disparity is that marmoset
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CL do not express progesterone receptors unlike the human. Therefore I proposed
that progesterone produced by the human CL can be detected by its steroidogenic
cells and that this stimulation causes a positive feedback response to further
upregulate angiogenesis and progesterone synthesis. Marmosets, not having luteal
progesterone receptors, could not undergo this phenomenon and therefore
progesterone remains at levels attained in the late luteal phase.
A cell culture system was used to address the importance of progesterone in
luteal rescue in the marmoset. Inhibition of steroidogenesis in these cells did not
abolish VEGF upregulation upon hCG treatment. Nor did treatment with exogenous
progesterone augment this effect. This leaves a very interesting question that remains
to be answered. Clearly establishment and maintenance of pregnancy in the
marmoset is a very efficient system, with fertility rates greater than 70% in our
colony. How does this species establish early pregnancy without any apparent
functional or structural changes in the CL at this time?
Angiogenic events occurring in the marmoset endometrium have not been
addressed to date. The endometrium is very dynamic tissue undergoing profound
cyclic changes in response to ovarian steroids. Also, angiogenic changes occurring
during implantation and early pregnancy have not yet been elucidated. Marmoset
implantation and placentation are much more superficial processes than in other
primates. Maternal vessels are not invaded until around day 60 of gestation, as such
the metabolic demands of the trophoblast must be met by diffusion. Consequently, a
large degree of tissue remodelling would be expected as implantation is established
but also, a degree of vascular remodelling in order that the nutrient and oxygen
requirements of the newly implanting foetus be met.
VEGF and its receptors, Fit and KDR have been implicated as key players in
vascular remodelling and placentation on the basis that their mRNA and proteins
have been localised in endometrium of several species. These include human
(Ahmed, et al., 1995, Clark, et ah, 1996, Clark, et ah, 1998, Cooper, et ah, 1995,
Geva, et ah, 2002, Goldman-Wohl, et ah, 2000, Helske, et ah, 2001, Sugino, et ah,
2002), sheep (Bogie, et ah, 2001), pig (Winther, et ah, 1999), marmoset (Wulff, et
ah, 2002) mouse (Chakraborty, et ah, 1995, Haider, et ah, 2000), golden hamster (Yi,
et ah, 1999) rat (Rabbani and Rogers, 2001), rabbit (Das, et ah, 1997) and rhesus
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monkey (Ghosh et ah, 2000) during the first trimester of pregnancy. In vivo
manipulation experiments are limited to the rodent to date but have provided further
evidence for the importance ofVEGF in early pregnancy. In the mouse, inhibition of
VEGF prevented estrogen-induced uterine oedema and implantation (Rockwell, et
ah, 2002) and in the rat, the number of implantation sites were reduced after
administration of a VEGF blocking antibody (Rabbani and Rogers, 2001).
Angiopoietins also appear to have a major role in regulation of blood vessel
growth, maturation and regression, but their importance at the time of implantation
has yet to be studied. However their presence in placenta in later stages of pregnancy
has been documented in human (Dunk, et ah, 2000, Goldman-Wohl, et al., 2000) and
marmoset (Wulff, et al., 2002). Having established that there is an increase in
angiogensis in the fiinctionalis of early pregnancy in the marmoset, compared to late-
secretory non-pregnant controls, I wanted to determine putative molecular regulation
of this event by describing the localisation ofmRNA for angiogenic factors and their
receptors. Angiogenic processes occurring at this early stage of pregnancy are still
poorly understood in the human and with accumulating knowledge on effects of
manipulation of angiogenesis in the marmoset, this species represents a potentially
valuable model in which to study these events.
Not surprisingly, the endometrium is a rich source of angiogenic growth
factors. VEGF expression and endothelial cell proliferation have been demonstrated
to peak in the mid-proliferative phase in rhesus macaque endometrium, coninciding
with a peak in oestrogen (Nayak and Brenner, 2002). Expression of VEGF and its
role in promoting vascular permeability and angiogenesis during early pregnancy and
placentation have been frequently documented. I have described the specific
localisation of VEGF, its receptors and the angiopoietins in marmoset endometrium
during the peri-implantation period and in early pregnancy in Chapter 6 (Rowe, et
al., 2003)
Having described the distribution of VEGF, the angiopoietins and their
receptors in the endometrium during the peri-implantation period and their
upregulation in early pregnancy, it is clear that these factors must play a critical role
in establishment of early pregnancy in this species. In order that their exact role be
elucidated, antagonist experiments should be carried out to determine whether or not
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they are critical for the establishment of early pregnancy. To date, most antagonist
studies are limited to the rodent (Rabbani and Rogers, 2001, Rockwell, et ah, 2002).
However, we have treated marmosets with a VEGF antibody to examine the effects
on progesterone secretion by the CL and establishment of pregnancy. While the
antibody significantly suppressed progesterone secretion during the treatment period,
it failed to significantly reduce pregnancy rate. The results were somewhat
inconclusive, where in control animals, 5 of 6 became pregnant, while in treated
animals, 5 of 10 became pregnant. Therefore, it appears that this treatment did
prevent pregnancy in some animals and perhaps with a larger study group this may
have been significant (Rowe, et al., 2002). It may also be that this antibody was not
potent enough and that more potent VEGF inhibitors, such as VEGF traps, would
prevent pregnancy in this species.
It is of great interest that despite significantly reduced levels of progesterone
during the treatment period in this study, pregnancy could still be established. It
would appear that the CL was able to recover and resume normal progesterone
synthesis after cessation of treatment. This evokes questions about how important the
normal quota of progesterone is in establishment of early pregnancy in the marmoset.
It may be that in a normal cycle, levels of progesterone synthesised and secreted are
well in excess of requirement for establishment of pregnancy, and that despite
significant reduction in this level, enough progesterone remained in the system in
order that pregnancy be established. In human, it is well known that treatment with
progesterone antagonists can prevent implantation as well as terminating early and
established pregnancy. The marmoset is a highly efficient reproductive species. It
would appear from my results that the corpus luteum of every cycle resembles that of
a pregnant cycle whereby adequate levels of progesterone and vascular development
are established regardless of whether or not a conception event has occurred. The
endometrium, does respond differently in a fertile cycle, after implantation where
there is an upregulation of angiogenesis. It is at this point that the maternal
recognition of pregnancy would be perceived. It would be feasible to assume that
should no implantation event occur, thus no maternal recognition of pregnancy, that
the corpus luteum would regress. The situation observed here, does not appear to be
as simple as this. The CG stimulus "rescues" the CL, yet evokes no cellular or
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morphological changes in terms of angiogenesis. Therefore it is as if the CL
undergoes this response regardless of a conception event occurring as described
before. "Rescue" of the CL cannot purely be a consequence of CG alone because
timing of luteolysis is so variable. If it were, regression would be expected to occur
at a set time in all animals should a CG stimulus not be detected. It may be that
marmoset LH receptors undergo a refractory period when they are no longer
sensitive to LH and that timing of this varies between animals. I propose that
marmoset LH is not as dissimilar to CG as in other species and because they act
through the same receptor on luteal steroidogenic cells, it could be that the marmoset
detects the LH and hCG stimulus as the same thing and consequently prepares for
early pregnancy in every cycle. It has been suggested that luteinizing
hormone/chorionic gonadotropin bioactivity in the marmoset is due to a chorionic
gonadotropin molecule with a structure intermediate between human chorionic
gonadotropin and human luteinizing hormone (Simula et al., 1995).
Implantation in the marmoset occurs at day 12 after ovulation, in the mid-
luteal phase. In a pregnant cycle, the blastocyst implants and angiogenesis in the
endometrium is upregulated. The trigger for this upregulation is unclear. No
angiogenic factors were detectable in the blastocyst until day 28, yet increased
VEGF, angiopoietins and their receptors in the functionalis immediately surrounding
the implantation site occur at the time of implantation, or by day 14 to use my time
points. Therefore it is not the blastocyst per se that is stimulating an upregulation of
these factors. It could be oestrogen. This is well known to cause uterine oedema by
increased fenestration of vessels, possibly as a consequence ofVEGF upregulation. It
could also be a consequence of a hypoxic environment caused by the demands of the
newly implanting blastocyst. It could also be a direct effect of CG produced by the
invading trophoblast and acting locally on the endometrium, however, I am not
aware of LH receptor expression in the marmoset uterus. It is not likely to be a direct
effect of progesterone because levels of progesterone do not differ between pregnant
and non-pregnant cycles. However, I have not looked at progesterone receptors at
this time. It may well be that progesterone receptors are upregulated in marmoset
endometrium in early pregnancy.
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7.2 The marmoset as a model for early pregnancy
The studies in this thesis used the marmoset as a model for early pregnancy and
to study the role of angiogenesis at this time in the CL and endometrium. As a model
for the human, the marmoset presents some differences. It is not a mono-ovulatory
species, it has a luteal phase length of approximately 21 days, as opposed to 14 days
in the human, and the structure of its corpus luteum differs to that of the human. It
displays subtly different implantation and placentation and does not menstruate.
However, it has allowed for the first time, the study of physiological pregnancy as
opposed to pharmacological pregnancy, by hCG treatment, in a primate model. Such
invasive investigations of endometrial angiogenesis and structure of the early
implantation site could not be carried out in higher primates. Its high fecundity,
greater that 70% fertility rate, offers a considerable advantage over other commonly
studied non-human primates, where fertility rate is in the region of 30%. The
marmoset has an ovulatory cycle more analogous to the human than any rodent
species, and so is an appropriate animal model.
The next step in our understanding of the role of angiogenesis in pregnancy
would be to target it using specific antagonists, for which the marmoset should
provide an invaluable model system.
7.3 Clinical implications of the thesis findings
The major function of the corpus luteum is progesterone production, resulting
in provision of a receptive endometrium and quiescent myometrium for
establishment and maintenance of early pregnancy. Since failure of the CL due to a
malfunction of the vasculature could possibly lead to miscarriage or infertility, it was
considered important to establish a non-human primate model of early pregnancy in
which this issue could be addressed. We have demonstrated that the marmoset can
become pregnant in the face of reduced progesterone synthesis, therefore further
research is necessary to investigate the required level of progesterone suppression to
prevent pregnancy. If progesterone levels could be suppressed to a level at which
pregnancy could not be established, this could provide a model for post-ovulatory
fertility control.
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The demonstration that there is an upregulation of angiogenesis in the
marmoset endometrium associated with early pregnancy provides the first step in our
understanding of the role of angiogenesis in primate implantation. Targeting specific
angiogenic factors could result in failure of implantation to occur, evoking
possibilities for post-ovulatory or post-coital fertility control. It may be that if
ongoing angiogenesis is targeted and inhibited during a specific window after
implantation in the primate that an abortive agent could be developed.
Angiogenesis research in early pregnancy not only has implications in
contraceptive development, it is also of relevance in understanding infertility. It may
be that women suffering recurrent miscarriage may have inadequate luteal
progesterone production, but also could have defects in the ability to establish an
adequate endometrial vasculature in order to allow provision of nutrients and oxygen
to the newly implanted foetus. This gives rise to opportunities for administration of
pro-angiogenic agents to enhance this process. Pre-eclampsia is also a common
illness associated with early pregnancy which has angiogenic implications.
Tumour growth is dependent on stimulation of new blood vessel growth from
the pre-existing vasculature (Folkman and Klagsbrun, 1987), and therefore has been
long proposed as a therapeutic target. Using the marmoset CL and endometrium as
models for angiogenesis could result in development of new anti-angiogenic
therapies not just for use in reproductive pathologies but for use in cancer treatment.
These factors are also likely to have a role in other angiogenic pathologies such as
rheumatoid arthritis, psoriasis and retinal neovascularisation in which uncontrolled
angiogenesis occur. Pro- angiogenic factors are also likely to have great clinical
importance in treating diseases where inadequate vascularisation is symptomatic, for
example, in limb and heart ischaemia.
7.4 Future speculation
This thesis has provided a basis for studying angiogenesis in early pregnancy
in the marmoset. Next steps into further dissecting this tightly regulated process
include understanding the intricate development and progression of the vasculature
in the embryo throughout the early stages of pregnancy. This thesis has focussed
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predominantly on maternal tissues, but the capacity for investigating the relationship
between the endometrium and foetus is unending.
Chapter 3 has described the angiogenic events associated with early
pregnancy in the marmoset corpus luteum. In order to further understand this process
other techniques could be employed such as Doppler imaging and perfusion fixing of
tissue. This would allow for a more accurate determination of capillary volume
without the effect of fixation after tissues are removed from the body. The process of
exsanguination can cause small capillaries to collapse and therefore may interfere
with the accuracy of the techniques employed in this thesis to examine capillary
density. However, it was assumed that any degree of collapse would be occurring in
all groups studied and therefore they were comparable.
Chapter 4 has allowed for the basic understanding into the role of
progesterone in early pregnancy in rescue of the marmoset corpus luteum. It would
be useful to look at different culture timings whereby the cell environment, length of
culture time and hormone milieu more accurately represent the in vivo situation.
Chapter 5 has described the morphological and vascular status of the
endometrium throughout the stages of pregnancy studied. This has provided a
valuable insight into this field, but leaves much scope for future experiments. For
example, it would be useful to look at the gene expression of ER and PR in the stages
studies and to compare this with systemic levels of oestrogen and progesterone. I
would also suggest that different groups of animals be studied with smaller windows
in development between each.
Finally Chapter 6 has enabled for the first time the angiogenic factors to be
localised and characterised in the marmoset uterus during early pregnancy. The real
future benefit of this work will be to determine how critical these factors are in
maintenance of early pregnancy. I feel that the most exciting future work arising
from this thesis will be to look at potential antagonists to be administered during
early pregnancy and to investigate the effect on the CL, uterus and embryo.
Chapter 7 General Discussion 244
7.5 Conclusions
This thesis has provided powerful insights into the role of angiogenesis in
early pregnancy in the primate. Using the marmoset as a model, studies reported in
this thesis provide comprehensive evidence that the marmoset corpus luteum and
maternal recognition of pregnancy differ somewhat to that of the human, and that
angiogenesis is an important process in establishment of early pregnancy,
particularly in the endometrium. Having established putative roles for angiogenic
factors at the time of implantation, the potential to inhibit angiogenesis in the female
reproductive tract should have important implications for clinical practice, be it in
fertility control or pathology. This research provides a basis for our understanding of
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ABSTRACT
This study investigated vascular and molecular changes in the
corpus luteum (CL) of early pregnancy in the marmoset Ovaries
were studied on Days 21 (n = 6) and 28 (n = 6) of pregnancy
and compared with corpora lutea from Day 21 (late luteal) of
the nonconception cycle (n = 8). Endothelial cell proliferation
was measured by immunocytochemical detection of incorporat¬
ed bromodeoxyuridine. Endothelial cell and pericyte area were
assessed by quantitative immunocytochemistry for CD31 and a-
smooth muscle actin, respectively. Vascular endothelial growth
factor (VEGF) and its receptors, kinase insert domain-containing
region (KDR) and fins-like tyrosine kinase (Fit) mRNA, were lo¬
calized and quantified in in situ hybridization. In addition, the
effects of immunoneutralization of VEGF on establishment and
maintenance of pregnancy were investigated by administering a
VEGF neutralizing antibody on Days 0-10 of the luteal phase
during potentially fertile cycles (n = 10) and compared with
fertile controls (n = 6). No differences in the cellular or mor¬
phological parameters were found between pregnant and struc¬
turally intact nonpregnant corpora lutea. No major differences
were found in expression of VEGF, Fit, or KDR in these CL. VEGF
immunoneutralization markedly suppressed plasma progester¬
one secretion during treatment, but pregnancy rate was not sig¬
nificantly reduced. Thus, a role for VEGF in early pregnancy in
the marmoset remains to be established. These results show that,
by the late luteal phase in the marmoset, the corpus luteum has
established a mature vascular system and the molecular capacity
to synthesize VEGF and its receptors. A pregnancy-induced spurt
of angiogenesis or gene expression does not appear to take
place; rather, maintenance of the existing vasculature is all that
is required for the establishment of pregnancy.
corpus luteum, corpus luteum function, ovary, ovulation, proges¬
terone
INTRODUCTION
Angiogenesis, the formation of new blood vessels via
endothelial replication, has been shown to be intense during
the first few days of the lifespan of the corpus luteum (CL)
in a large number of species studied, including women [1-
4], and is principally dependent on vascular endothelial cell
growth factor (VEGF) [5, 6].
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In the corpus luteum of early pregnancy, the changes in
angiogenesis and the role of the luteal vasculature in the
maintenance of progesterone secretion remain to be eluci¬
dated. When pharmacologic "rescue" of the CL by human
chorionic gonadotrophin (hCG) treatment in vivo was car¬
ried out in rhesus monkeys, no stimulation of angiogenesis,
as monitored by Ki-67 incorporation, was observed despite
maintaining plasma progesterone concentrations [3]. In ap¬
parent contrast, in women similarly treated with hCG, a
second wave of angiogenesis, accompanied by vascular sta¬
bilization by pericytes and increased VEGF expression, was
associated with luteal rescue [7, 8]. These findings suggest
that luteal angiogenesis could be a component of luteal res¬
cue, which is important for prolonging the lifespan of the
corpus luteum.
Because failure of the CL due to a malfunction of the
vasculature might lead to miscarriage or infertility, it was
considered important to establish a nonhuman primate
model of early pregnancy in which this issue could be ad¬
dressed. The marmoset monkey offers several potential ad¬
vantages for such studies. First, it has an exceptionally high
rate of fertility (>70%) when compared with other pri¬
mates, so physiological pregnancy, rather than pharmaco¬
logic hCG rescue, may be studied [9]. Second, we have a
detailed description of the cellular and molecular regulation
of angiogenesis during the normal cycle [4]. Angiogenesis
was therefore determined by comparing bromodeoxyuri¬
dine (BrdU) incorporation into corpora lutea of the late lu¬
teal phase versus early pregnancy. Vascular stability was
monitored by determining pericyte area. Localization of ex¬
pression of VEGF mRNA and its receptors, KDR and Fit,
was determined and changes associated with pregnancy
quantified using in situ hybridization. Finally, the effect of
neutralization of VEGF on luteal function and pregnancy
rate in mated marmosets was studied.
MATERIALS AND METHODS
Angiogenesis and Pericyte Accumulation in the Corpus
Luteum of Early Pregnancy
Experiments were earned out under the Animals (Scientific Proce¬
dures) Act (1986) and approved by the Ethical Review Committee. Blood
samples were collected from adult female marmosets three times per week
and assayed for presence of ovulatory rises in plasma progesterone [10].
During the mid to late luteal phase of the second recorded cycle, prosta¬
glandin (PG) analogue, 1 |j.g PGFj,, (cloprostenol, Planate, Coopers Ani¬
mal Health Ltd., Crewe, UK) i.m., was administered to induce luteolysis
so that timing of the subsequent ovulation could be identified accurately.
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At the time of PG administration, a fertile male was introduced. Marmo¬
sets were humanely killed on Day 21 or 28 postovulation after receiving
BrdU as described previously [5J. Of 17 animals mated, 12 were confirmed
pregnant by the presence of a trophoblast in serial sections of the uterus
and plasma levels ofCG of >20 ng/ml. CG was measured using the assay
described by Saltzman et al. [11] and had a detection limit of 12 ng/ml.
According to these criteria, six animals on Day 21 and six on Day 28
were pregnant. The nonpregnant animals were studied on Day 21 together
with three additional animals, recruited by carrying out the above proce¬
dure in the absence of a male. Day 21 is the mean time of luteolysis in
the marmoset, but this is variable. Of the eight nonpregnant animals, three
had structurally regressed CL and the remainder had structurally intact
CL. Uteri were fixed in 4% paraformaldehyde (PFA). Ovaries were bi¬
sected and fixed, one half of each ovary in 4% paraformaldehyde and the
other in 4% neutral buffered formalin (NBF). Experiments were initially
earned out on both NBF- and PFA-fixed tissue, but on analysis, no sig¬
nificant difference was found between the two fixatives; thus, only results
from NBF-fixed tissues are presented here.
Immunocytochemistry
Cellular responses were studied by 1) measuring cell size in sections
stained with hematoxylin and eosin, 2) quantifying the number of mitotic
cells stained for BrdU, 3) examining the establishment of the microvas¬
cular network using CD31 staining to identify endothelial cells, 4) study¬
ing the recruitment of pericytes using immunocytochemical staining of
smooth muscle a-actin, and 5) dual labeling to record the incidence of
colocalization of BrdU and CD3I.
Tissue sections (5 gm) were cut onto Super-frost plus slides (Sigma,
Poole, Dorset, UK) for immunocytochemistry. Sections were dewaxed in
xylene, rehydrated in descending concentrations of ethanol, and washed
in distilled water. Antigen retrieval was performed by boiling sections in
a Tefal Clypso pressure cooker (Tefal, Essex, UK) in 0.01 M citrate buffer,
pH 6, for 6 min at high pressure setting 2. Slides were then left for 20
min in hot buffer and washed in Tris buffered saline (TBS; 0.05 mol/L
Tris, pH 7.4, NaCl2 9 g/L). To reduce nonspecific binding, sections were
blocked in normal rabbit serum (diluted 1:5 in TBS) for 30 min. The
primary antibodies used were CD31 (monoclonal; Dako, Denmark; diluted
1:20 in TBS). BrdU (monoclonal; Boehringer, Mannheim, Germany; di¬
luted 1:30 in TBS), and a-smooth muscle actin (monoclonal; Dako, Den¬
mark: diluted 1:20 in TBS). Incubation was carried out overnight at 4°C.
Slides were then washed three times in TBS. Incubation with the second¬
ary antibody (rabbit anti-mouse Ig; Dako, 1:60 diluted in TBS) was for
40 min at room temperature. This was followed by two TBS washes and
incubation of the APAAP complex (Dako; 1:100 dilution in normal rabbit
serum and TBS) for 40 min at room temperature. Visualization was per¬
formed using nitroblue tetrazolium (NBT) solution containing 45 pi NBT
substrate (Boehringer Mannheim), 10 ml NBT buffer, 35 p.1 Xphosphate
(Boehringer Mannheim), and 10 p.1 levamisole (Sigma). Sections for BrdU
were counterstained with hematoxylin (Richard-Allan, Richland, Ml),
whereas sections for CD31 and smooth muscle actin were not counter-
stained so that quantitative image analysis could be performed. For dual
labeling, slides were incubated first with C'D31 and visualized with fast
red (Sigma), followed by incubation with BrdU and visualized with NBT
as described above. Fast red solution contained 1 mg fast red/ml buffer
(20 mg naphthol AS-MX phosphate, 2 ml dimethyl formamide, 98 ml 0.1
M Tris, pH 8.2; Sigma).
Localization of VEGF, Fit, and KDR mRNA
in the Corpus Luteum
To investigate possible changes in expression patterns of the mRNA
for angiogenic factors and their receptors in the corpus luteum of preg¬
nancy, in situ hybridization was performed as described previously using
complementary RNA probes for human VEGF A, Fit, and KDR [8J. Sense
and antisense probes were prepared using an RNA transcription kit (Am-
bion, Austin, TX) and labeled with 35S uridine 5'-triphosphate (NEN,
Boston, MA). Deparaffinized sections were treated with 0.1 N HC1 for 20
min and then digested in proteinase K (5 pg/ml; Sigma) for 30 min at
37°C. After prehybridization for 2 h at 55°C, subsequent hybridization was
performed in a moist chamber overnight at 55 U. High stringency posthy-
bridization washings and ribonuclease A treatment were used to remove
excess probe. Slides were then dehydrated, dried, and dipped in llford G5
liquid emulsion (H.A. West, Edinburgh, UK). Exposure times for VEGF,
Fit, and KDR were 5, 9 and 9 wk, respectively. Slides were subsequently
developed (Kodak D19 developer, Kodak, Rochester, NY) and fixed (Ko¬
dak GBS, Kodak). All slides were counterstained with hematoxylin, de¬
hydrated, and mounted.
Quantification
Quantification of lutein cell area. Hematoxylin and eosin-stained sec¬
tions were examined under a 40X objective lens, images captured, and
lutein cells identified according to morphologic appearance. Cell perimeter
was accurately determined and cross-sectional area measured. Ten lutein
cells from each of 10 fields were randomly selected from ovarian cross-
sections from each animal.
Quantification of BrdU staining. Sections were examined using a 20X
objective lens. Image Pro-Plus was used to measure the number of dark-
stained nuclei only (those with incorporated BrdU) and the number of total
cells per field (dark- and light-stained nuclei). These parameters were mea¬
sured across the whole cross-section of the CL. To obtain a proliferation
index, the number of BrdU-positive cells was expressed as a percentage
of total cell nuclei per field of view. Mean values per animal were re¬
corded.
Quantification of CD31 and smooth muscle a-actin. Sections were
examined using a 20X objective lens and the area of CD31 and smooth
muscle a-actin staining recorded across the whole corpus luteum. Because
immunostaining was localized either to the cytoplasm or plasma mem¬
brane, visualization of individual cells was difficult; thus, it was not pos¬
sible to measure absolute numbers of endothelial cells or pericytes. The
image analysis system was therefore set to measure the area of staining
within a given field of view. Mean values were calculated per animal.
Quantification of dual labeling (BrdU and CD31). Dual labeling for
BrdU and CD31 enabled the percentage of proliferating cells that were
endothelial to be determined. Total incidences of dual staining were re¬
corded and expressed as a percentage of total number ofproliferating cells
throughout the CL. Three animals from each group were assessed and a
mean percentage calculated.
Quantification of VEGF, Fit, and KDR in situ. Quantification of VEGF,
Fit, and KDR mRNA was carried out using an image-analysis macro de¬
signed to distinguish silver grains in dark field at 20X objective magni¬
fication against the black background of the tissue. Both grain area per
field of view (gm2), giving a relative estimate of number of cells per field
(3.2 X 105 pm2) and grain density/pm2. representative of amount of ex¬
pression per cell, were recorded.
Effects of Immunoneutralization of VEGF
on Establishment of Pregnancy
In a second experiment, we sought to investigate the role of luteal
VEGF in the establishment and maintenance of early pregnancy by inhib¬
iting its action with a neutralizing antibody in vivo. The experiment was
designed so that effects could be monitored by measuring plasma proges¬
terone concentrations during the first third of pregnancy and by recording
number of live births. Females used in this experiment had all previously
given birth to live young on at least two occasions. Each female had been
continually housed with the same male for over a year in stable family
groups consisting of the dominant female and male together with their
offspring. In these conditions, the marmoset is a highly fecund species,
commonly ovulating within 2 wk postpartum and becoming pregnant dur¬
ing the first postpartum cycle [9]. This was confirmed in the animals stud¬
ied; in the pregnancy prior to treatment, 13 out of 16 (81%) had had an
interbirth interval of 150-164 days (normal gestation length being 144
days). These animals therefore represented a potentially highly efficient
group in which to study the effect of anti-VEGF treatment on incidence
of pregnancy. Animals in which vaginal lavage had shown the presence
of sperm on Day 7 or 9 postpartum were treated starting at Day 10 post¬
partum, i.e., around the time of anticipated ovulation. Ten marmosets re¬
ceived VEGF antibody in the regime described previously [5], i.e., 2 mg
i.v. on Day 10, followed by 1 mg on Days 11, 12, 13, 15, 17, and 19,
while six controls received the same dose ofmouse gamma globulin (Sig¬
ma). Blood samples were collected daily from 2 days prior to onset of
treatment (Day 0) to treatment Day 10, then three times per week until
Day 40, and plasma assayed for progesterone concentration. This treatment
had previously been shown to inhibit the development of the luteal mi¬
crovascular tree and suppress plasma progesterone in normal cycles [5].
In the current study, suppression of progesterone was taken as an index
of effectiveness of inhibition of luteal angiogenesis by VEGF antibody.
Thus, the end point of the study was whether pregnancy rate was affected.
The day of delivery, total number of offspring, and surviving offspring
were recorded for each animal.
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FIG. 1. Plasma progesterone concentra- 400 -
tions from ovulation to Day 21 in non¬
pregnant and pregnant animals. Values are 350 -
means ± SEM (n = 6, Days 21 and 28 of ^
pregnancy; n = 5, Day 21 structurally in- O 300-
tact; and n = 3 in Day 21 regressed). In ^
the five nonpregnant animals with structur- '—' 250 -
ally intact CL, elevated progesterone levels jjj
continued up to Day 21 despite anticipat- 2 200-
ed luteal regression. Progesterone levels iU
from three nonpregnant animals with <8 150 -
structurally regressed CL, however, had g5















Separate one-way analysis of variance (ANOVA) tests were conducted
for each set of data and a Bonferroni post hoc test performed. P < 0.05
was taken as the level of significance for each test. Tests were performed
using SPSS 10 for Macintosh. For determining differences in plasma pro¬
gesterone between groups, repeated ANOVAs were used to compare study
groups on each day of blood sampling.
To compare the number of successful pregnancies after anti-VEGF or
mouse gamma globulin treatment, the Fisher exact test was used.
RESULTS
Plasma Progesterone and CG during Early Pregnancy
Pregnancy was confirmed by the presence of a tropho-
blast and CG levels greater than 20 ng/ml, while nonpreg¬
nant animals had a uterus compatible with an infertile cycle
and nondetectable levels of CG. Plasma progesterone pro¬
files of pregnant and nonpregnant marmosets from ovula¬
tion (Day 0) to Day 21 are shown in Figure 1. The late
luteal nonpregnant animals were subdivided into two
groups according to whether functional and structural re¬
gression had taken place by Day 21. In five animals, plasma
progesterone levels were maintained and CL were structur¬
ally intact despite being anticipated to shortly undergo
functional and structural regression. The nonregressed state
of the CL was not dependent on a male being present, as
one of this group included an animal that was housed in
the absence of a male and we have commonly observed
this phenomenon in other females in our colony. Three of
the late luteal control animals had undergone functional and
structural regression accompanied by low progesterone lev¬
els by Day 21. In these animals, there was a significant
> decline in plasma progesterone compared with both the
pregnant and control animals.
Following the initial rise in progesterone indicative of
i ovulation, progesterone levels remained elevated (>150
nmol/L) in all four groups until Day 10-11 postovulation,
which corresponds to the time of implantation in marmosets
» [12]. After Day 14, the regressed late luteal control animals
showed declining progesterone for the remainder of the re¬
corded cycle, whereas a continued elevation of progester¬
one was observed in both groups of pregnant animals and
the structurally intact control animals. Progesterone re¬
mained elevated between Days 21 and 28 in the Day 28
pregnant marmosets (data not shown). Statistical analysis
revealed that progesterone levels in the regressed control
group were significantly different from the structurally in¬
tact controls and both groups of pregnant animals (P <
0.05) from Day 19.
Lutein Cell Area
Cross-sectional area of individual lutein cells was not
significantly different (P > 0.05) between structurally intact
nonpregnant CL and the pregnant animals at Days 21 and
28 postovulation (492 ± 26, 530 ± 21, and 584 ± 34,
respectively), while those in the regressed CL showed var¬
iable degrees of involution and degenerative change, which
precluded meaningful measurements (Fig. 2).
BrdU Immunostaining
BrdU immunostaining indicating proliferating cells was
readily detected in all corpora lutea. Previously published
data [4] from the early, mid and late luteal phase are in¬
cluded in the graph to show the changes in endothelial cell
proliferation throughout the luteal phase of the cycle (Fig.
3, A and B). An intense burst of angiogenesis with high
endothelial cell proliferation is observed in the early luteal
phase, decreasing in the mid luteal phase, and further still
toward the end of the luteal phase. No significant difference
(P > 0.05) was observed between structurally intact late
luteal and pregnant CL. 1 lowever, significantly higher (P <
0.05) proliferation indices were observed in regressed CL.
The insert (Fig. 3a) illustrates the colocalization of CD31
and BrdU immunostaining, i.e., proliferating endothelial
cells. Quantification of intact CL showed that more than
90% of proliferating cells were endothelial cells. In struc¬
turally regressed CL, it was not possible to determine
whether or not these cells were endothelial due to the dif¬
fuse nature of the CD31 staining.
CD31 Immunostaining
Measurement of CD31 was used to quantify endothelial
cell area. There was no significant difference between
groups (P > 0.05) (Fig. 3, C and D). By the late luteal
phase, the microvascular tree of the corpus luteum is ex¬
tensive, and from the photomicrograph, it can be seen that
every lutein cell is in contact with at least one endothelial
cell. Structurally regressed CL were not included in the
quantitative analysis because of poor structural integrity,
leading to diffuse staining.
Pericyte Immunostaining
Immunostaining for a-smooth muscle act in was evident
in all stages, predominantly in large luminal vessels but
also to a lesser extent in smaller vessels and capillaries (Fig.
3, E and F). No significant difference in endothelium cov-
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FIG. 2. Hematoxylin and eosin-stained
sections from structurally intact late luteal
CL (n = 5) (A), structurally regressed CL (n
= 3) (B), Day 21 pregnant CL (n = 6) (C),
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FIG. 3. A) Cell proliferation in the mar¬
moset corpus luteum (X40 objective). In¬
sert (a) shows colocalization of CD31 and
BrdU (X20 objective). B) Mean prolifera¬
tion index in corpora lutea of animals
from the different study groups, structurally
intact late luteal (SILL), structurally re¬
gressed late luteal (SKLL), Day 21 and Day
28 pregnant animals (P,D21 and P,D28, re¬
spectively). Previously published data from
the early, mid, and late luteal phase are
included in this graph. C) Immunocyto-
chemical localization of endothelial cell
marker CD31 (X40 objective). D) Mean
endothelial cell area in corpora lutea of
animals from the different study groups. E)
Immunocytochemical localization of
smooth muscle a-actin marker (X40 ob¬
jective). F) Mean pericyte area in corpora
lutea of animals from the different study
groups. Bar = 100 pm in a, 50 pm in A,
C, and E. Values are means ± SEM. In all
photographs and graphs, n = 5 for struc¬
turally intact CL, n = 6 for Day 21 preg¬
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FIG. 4. Representative photomicrographs
showing localization of VEGF mRNA to lu¬
tein cells by in situ hybridization in the CL
(A, dark field; B, higher power light field).
Structurally intact and pregnant CL were
similar. Bars = 50 jim in A and 25 jj.m in
B. C) Mean grain density/jcm2 and mean
grain area (|xm') in nonpregnant and preg¬
nant CL. No significant difference was
seen between these groups. Values are
means ± SEM.
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erage by pericytes (P > 0.05) was seen between study
groups. Again, structurally regressed CL were not quanti¬
fied because of diffuse staining.
Vascular Endothelial Growth Factor
Intense hybridization to VEGF mRNA was localized to
lutein cells, with absence of hybridization to endothelial
cells. Distinct, punctate hybridization in lutein cells was
clearly seen in structurally intact control and pregnant CL
(Fig. 4, A and B). There was no significant difference (P
> 0.05) in either mean grain area or mean grain density
between the groups (Fig. 4C). In the structurally regressed
CL, most of the lutein cells were devoid of punctate VEGF
expression and there was a marked reduction in grain area
and density (Fig. 5, A and B).
Kinase Insert Domain-Containing Region and Fit
Hybridization to KDR mRNA was localized to endothe¬
lial cells (Fig. 6, A and B). No significant difference in
grain area or density was observed between groups (P >
0.05) as illustrated by Figure 6E. Structurally intact and
regressed nonpregnant CL were analyzed independently
but, in contrast with VEGF, KDR expression was main¬
tained in the regressed CL. Because grain area and density
were the same in each group, the results were combined.
Hybridization to Fit mRNA was localized to endothelial
cells (Fig. 6, D and E). A significantly lower mean grain
area was observed in Day 28 pregnant corpora lutea than
in Day 21 luteal animals (P < 0.05), as illustrated by Figure
6F. However, no significant difference in grain area was
seen between late luteal and pregnant Day 21 animals nor
was there any observable difference in grain density be¬
tween groups. As above, late luteal regressed and intact
controls were combined because there was no difference in
Fit expression between them.
Effects of Immunoneutralization of VEGF on Progesterone
and Pregnancy Rate
Plasma progesterone profiles for pregnant control and
anti-VEGF-treated marmosets from the time of postpartum
ovulation are shown in Figure 7. In control marmosets, pro¬
gesterone rises indicative of ovulation and establishment of
early pregnancy were observed in five of the six animals
(83%), with ovulation occurring, as expected, on Days 8-
11 postpartum. In the treated animals, all 10 ovulated 9-
11 days postpartum, as indicated by a rise in plasma pro¬
gesterone, but during the treatment period, this level was
significantly lower than in control animals (P < 0.05). In
five marmosets in this group, the posttreatment period was
associated with a variable degree of apparent partial recov¬
ery of progesterone, which was followed by functional lu-
teolysis around Day 20—25 postovulation. These animals
were classified as the delayed-pregnancy group (because
they did not become pregnant during the treatment cycle
but conception occurred during the subsequent cycle). In
the remaining five treated animals, a more robust recovery
of plasma progesterone was evident, followed by a sus¬
tained rise, reaching the same levels as attained in the preg¬
nant control animals by Day 20-25. Because gestational
length subsequently confirmed that these animals had be¬
come pregnant within the treatment cycle, they were thus
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FIG. 5. Depiction of VEGF mRNA locali¬
zation by in situ hybridization in structur¬
ally regressed nonpregnant CL (A, dark
field; B, light field). Note low level of cel¬
lular localization. Bars = 50 pm in A and
25 pm in B
classified as having no delayed pregnancy. A Fisher exact
test to compare number of pregnancies achieved between
the 6 control and 10 treated animals revealed no significant
difference (P > 0.05). Plasma progesterone in the delayed
pregnancy group continued to be significantly lower than
controls until Day 27, when levels began to rise again, in¬
dicating ovulation, and all these animals became pregnant
in the subsequent cycle.
Interbirth interval was recorded for all animals. Using
the Student f-test, the 1-mo delay in conception observed
in 50% of treated animals (188 days ± 1.5 SEM) was sig¬
nificantly different from the interbirth interval seen in con¬
trols (157 days ± 0.89 SEM) (P < 0.05). In the treated
group in which pregnancy was not delayed, the interbirth
interval was not significantly different from controls (159
days ±1.8 SEM). The number of offspring was also com¬
pared for each group. The delayed pregnancy group had a
significantly higher number of live births than the control
group (P < 0.05) (Fig. 8). No abnormalities were observed
in any of the offspring.
DISCUSSION
This study has described the cellular and morphological
changes in the corpus luteum associated with early preg¬






(n = 8) (n = 6) (n = 8)
FIG. 6. KDR mRNA localization (A, dark
field; B, light field). Dark field shows over¬
all grain distribution (bar = 50 (imi. Light
field shows cellular localization to endo¬
thelial cells (bar = 25 pm). E) Mean grain
density/pm2 and mean grain area (pm2) for
KDR in nonpregnant and pregnant CL. De¬
piction of Fit mRNA localization to endo¬
thelial cells (C, dark field; D, light field);
mean grain density/pm2 and mean grain
area lpm-'| for Fit in nonpregnant and
pregnant CL (F). Values are means ± SEM.
Grain density Grain area
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FIG. 7. Plasma progesterone concentra¬
tions in control (n = 5, ■—■) and marmo¬
sets treated with anti-VEGF on Days 0-10
of the luteal phase (n = 10). Values are
means ± SEM. Progesterone was signifi¬
cantly suppressed by treatment. After treat¬
ment, a degree of recovery in progester¬
one occurred. Five of the 10 treated ani¬
mals became pregnant during the treat¬
ment cycle (o - - - o). In the remaining
five animals (A—A), no recovery of pro¬
gesterone was observed; thus, luteal devel¬
opment was blocked and they did not






















ductive research. Neither luteal cell area, endothelial cell
area, pericyte area, or endothelial cell proliferation differed
in early pregnancy from the late luteal structurally intact
CL of the nonpregnant cycle. In addition, levels of VEGF,
KDR, and Fit mRNA were largely unaltered. Thus, a fur¬
ther burst of angiogenesis does not occur in early pregnancy
in the marmoset. It would appear that the late, preregressed
luteal vasculature is equipped with the molecular and cel¬
lular components to perform the functions of the vascula¬
ture of the CL of early pregnancy.
In the human corpus luteum, the pattern of endothelial
cell proliferation is similar to that of the marmoset in the
early, mid, and late luteal phase, with maximal proliferation
occurring in the early luteal phase and declining in the mid
and late luteal phase [2, 13]. This is also true in the rhesus
monkey [3], sheep [14, 15], and cattle [1]. During phar¬
macologically induced luteal rescue in women by hCG, an
increase in endothelial cell proliferation was observed [7],
accompanied by an increase in VEGF expression [7, 8]. In
addition, when changes in luteal cell volume were taken
into account, an increase in endothelial cell and pericyte
area on luteal sections was found [7]. Taken together, these
findings suggest that, in the human CL, hCG treatment re¬
sults in increased angiogenesis accompanied by vessel sta¬
bilization [7], This appears to mirror the situation observed
in rats, where endothelial cell proliferation is also seen to
increase in early pregnancy [16, 17]. In contrast, the ap-
3.0
Control Treated no Treated delayed
delayed pregnancy pregnancy
FIG. 8. Number of live births from the different study groups. Significant
differences are represented by different letters.
parent absence of an increase in endothelial cell prolifera¬
tion in early pregnancy in the marmoset is similar to find¬
ings in the sheep [14] and, after hCG-induced rescue of the
CL, in the rhesus monkey [3],
The rescue of the corpus luteum of pregnancy allows it
to persist functionally and structurally for longer than in the
nonpregnant cycle. Presumably, this survival requires a sta¬
ble vasculature, with increased recruitment of pericytes and
prolonged endothelial cell survival in addition to prolon¬
gation of the lifespan of the luteal cells. Because endothe¬
lial cell proliferation did not increase after administration
of hCG in the rhesus monkey [3], it was suggested that
early pregnancy may be associated with an increase in ves¬
sel stability, and there is recent evidence for an hCG-in-
duced increase in pericyte number in the human CL [7],
However, we found no evidence for this in the marmoset.
The increase in pericyte and endothelial cell area after
hCG in the human was dependent on taking account of the
increase in lutein cell volume after hCG administration [7].
However, in the pregnant marmoset, no such increase in
lutein cell volume was observed. This is consistent with the
findings of Webley et al. [18], who reported that size dis¬
tribution of luteal cells from pregnant and nonpregnant
marmosets revealed an increase in mean cell diameter from
luteal Day 6 to 14 in both pregnant and nonpregnant ani¬
mals but no further increase on Day 20 [18].
While in the structurally regressed CL, VEGF mRNA
expression was markedly reduced, there was no apparent
difference in VEGF expression between structurally intact
late luteal controls and pregnant corpora lutea in the mar¬
moset. VEGF expression is maintained in the CL of preg¬
nancy in a number of species, implying a role in either
angiogenesis or endothelial cell survival [8, 19, 20], A sig¬
nificant increase in VEGF expression, compared with the
late luteal phase, was found in hCG rescued human CL
using the same method as in the present study [7]. Cell
culture studies using human luteinized granulosa cells have
also revealed that hCG treatment leads to increased VEGF
mRNA levels [21], This reported up-regulation of VEGF
by hCG rescue supports the view that, in the human, preg¬
nancy is associated with further angiogenesis. The absence
of up-regulation of VEGF mRNA during early pregnancy
in the marmoset is similar to observations in the early preg¬
nant CL of the cow [20]. It is also of interest that there is
no evidence for a decline in VEGF mRNA preceding an-
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ticipated luteolysis; rather, the decrease of VEGF mRNA
was only observed at the time of structural regression.
Levels of KDR mRNA also did not change in the preg¬
nant animals. Fit mRNA was unchanged in the Day 21
pregnant group but significantly decreased in the Day 28
animals compared with the nonpregnant controls. This
could be explained by the fact that Fit expression is asso¬
ciated with proliferating endothelial cells, of which there
are more in the earlier luteal phases of the cycle. Therefore,
by 28 days postovulation, the endothelial cells from these
earlier phases may have passed the stage of maximal Fit
expression. In the human CL, RT-PCR demonstrated that
there was no increase in KDR or Fit mRNA levels in the
CL of pregnancy compared with the nonpregnant cycle
[22], Thus, luteal rescue is not associated with an increase
in VEGF receptors. These results lead us to propose that
the structurally intact late luteal CL of the marmoset retains
its molecular integrity and is similar to the rescued CL with
regard to VEGF mRNA and its receptors until such time
as it does undergo structural regression.
In view of these results, it was considered that a period
of intense angiogenesis may be occurring earlier than Day
21, e.g., at around Day 14 of early pregnancy, soon after
implantation of the blastocyst on Day 11. However, a pilot
study, examining endothelial cell proliferation in the CL
from animals at Day 14 of pregnancy, failed to demonstrate
increased angiogenesis at this time (unpublished data).
While we have focused on VEGF and its receptors in
this study, it is possible that other angiogenic factors may
be involved in regulation of the vasculature of early preg¬
nancy. Because the angiopoietins are thought to participate
in stabilization of blood vessels, we examined mRNA lev¬
els for Angiopoietin-1 and -2 and their receptor, Tie-2, as
described for the human CL [7]. However, low expression
of the angiopoietins was observed and, as with VEGF, there
was no difference between rescued and regressing CL (un¬
published data).
The length of the luteal phase in the nonpregnant mar¬
mosets varied. This was advantageous here because it al¬
lowed for the study of both structurally intact nonpregnant
and structurally regressed CL, but the cause of this varia¬
tion is unclear. Some animals have functionally and struc¬
turally regressed CL by Day 21, whereas other nonpregnant
animals are still functionally and structurally active al¬
though anticipated to shortly undergo regression. Recent
estimations from our colony have shown luteal length to
vary between 16 and 24 days (unpublished data), which is
consistent with previous reports on variability in luteal
phase length [23-25]. It is well established that progester¬
one levels are maintained due to the continued responsive¬
ness of luteal cells to gonadotropins via CG in pregnancy
[26]. It would appear that, in the marmoset, despite the
absence of CG, the late luteal CL of a nonpregnant cycle
is maintained until it undergoes a rapid regression and thus
decline in progesterone production. Luteal regression in the
marmoset must therefore be a rapidly triggered event be¬
cause, until that point, the CL of a nonfertile cycle retains
its morphology and functional capacity to the same extent
as in a pregnant cycle. As reported previously, increased
BrdU incorporation was observed in the structurally re¬
gressed CL. It was not possible to determine whether or
not these cells were endothelial due to the diffuse nature
of the CD31 staining in these animals. It may be that these
cells are fibroblasts, but this remains to be elucidated [27].
In view of the fact that the period of intense luteal an¬
giogenesis in the fertile cycle of the marmoset is restricted
to the early luteal phase, the effects of inhibiting VEGF
during this period were examined in animals in stable fam¬
ily groups containing a fertile male. A previous study in
marmosets not exposed to pregnancy had shown that such
treatment inhibited angiogenesis, prevented formation of
the microvascular tree, and suppressed plasma progesterone
by more than 60% [5], The present results confirmed that
the anti-VEGF treatment suppressed plasma progesterone
in all animals. However, after cessation of treatment, a de¬
gree of recovery of progesterone secretion was observed.
While in 5 of the 10 treated marmosets, luteal regression
subsequently occurred, in the remainder, the corpus luteum
function recovered and these animals went on to deliver
offspring after a similar gestation period to the controls.
The fact that pregnancy was successfully established in the
face of a marked reduction in plasma progesterone concen¬
trations suggests that, in the marmoset, the normal quota of
luteal progesterone is in excess of requirement. Further¬
more, the rise in plasma progesterone posttreatment in half
of the animals implies that angiogenesis is capable of rein¬
itiation after cessation of VEGF inhibition. It is of particular
interest that, despite systemic administration of the anti¬
body to VEGF, implantation must having taken place dur¬
ing the treatment cycle, gestation length was normal, and
no abnormalities were observed in the offspring. Because
VEGF is likely to be involved in implantation, it may be
that the large molecular weight of the antibody prevented
access to the fetal-placental unit.
Where delayed pregnancy occurred, the resulting num¬
ber of live births in the subsequent cycle was significantly
higher than in controls. This may be the result of an over¬
compensation in VEGF production during the treatment pe¬
riod, resulting in the development of more antral follicles
and thus higher numbers of offspring per animal in the
following cycle.
This study has demonstrated that, by the late luteal phase
in the marmoset, the corpus luteum has already established
a mature vascular system and the molecular capacity to
synthesize VEGF and its receptors, which are not further
enhanced in early pregnancy. A pregnancy-induced spurt of
angiogenesis does not take place; rather, a maintenance of
the existing vasculature is all that is required for establish¬
ment of pregnancy in the marmoset. Therefore, it has to be
concluded that the changing morphological and cellular
events thought to be associated with early pregnancy in the
human after hCG rescue do not occur in the marmoset.
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Implantation of a blastocyst into a receptive endometrium
is a prerequisite for successful pregnancy. Angiogenesis is a
key event in this process but the mechanisms by which
localized changes in vascular permeability and angiogen¬
esis occur have yet to be elucidated. Vascular endothelial
growth factor (VEGF) and its receptors VEGFR-1 and
VEGFR-2 have been implicated as key players in vascular
remodelling and placentation. Angiopoietins also appear to
have a significant role in regulation of blood vessel growth,
maturation and regression. The aim of this study was to de¬
scribe the molecular regulation of angiogenesis in the first
month of pregnancy in marmosets and to address the pu¬
tative physiological roles for these factors. Uteri were stud¬
ied at weeks 2, 3 and 4 of pregnancy and compared with
late secretory non-pregnant endometrium. Implantation in
marmosets occurs at day 11 of pregnancy; hence, these
time points were chosen so that the peri-implantation
period and very early pregnancy could be studied. mRNAs
for VEGF, VEGFR-1 and VEGFR-2, angiopoietin 1, angio-
poietin 2 and their receptor Tie-2 were localized and
quantified by in situ hybridization. Endothelial cells were
identified by CD31 immunocytochemistry. VEGF mRNA
was present in all compartments except endothelial
cells, and its expression generally increased throughout
pregnancy except in upper zone glandular epithelium
and luminal epithelium, where a decrease in expression
was observed. VEGF receptor mRNAs were found in
endothelial cells of the upper zones immediately sur¬
rounding glandular epithelium. Angiopoietin 1 mRNA was
localized to glandular epithelium of the upper and lower
zones throughout pregnancy, and increased in stroma
at week 4. Expression of angiopoietin 2 mRNA was
localized exclusively to endothelial cells of large luminal
vessels and was higher in endometrium from marmosets
at week 4 of pregnancy than in endometrium from all
other stages. These data provide comprehensive evidence
that VEGFR-1 and -2, and angiopoietin 1, angiopoietin
2 and Tie-2 interactions may be involved in the pre¬
paration of endometrium for implantation, remodelling
of the maternal vasculature and trophoblast invasion
during the peri-implantation period in this primate species.
i Introduction
During the last few years, considerable progress has
been made in understanding the molecular regulation
of angiogenesis in the female reproductive tract. In
particular, the role of vascular endothelial growth factor
» (VEGF) during follicular and luteaj development in the
marmoset (Callithrix jacchus) model has been esta¬
blished by specific inhibition of this angiogenic factor
in vivo (Fraser and Lunn, 2001). As inhibitors of angio¬
genic factors are likely to be used clinically, it is important
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that their role during implantation and early pregnancy is
elucidated. The aim of the present study was to build on
our knowledge of the regulation of angiogenesis in the
reproductive tract of female marmosets by investigating
the patterns of expression of angiogenic factors during
this period.
Successful pregnancy is dependent on implantation of
the blastocyst into the endometrium. Angiogenesis may
have a key role in implantation; however, the mecha¬
nisms by which localized changes in vascular permeab¬
ility and angiogenesis occur at the site of implantation
have yet to be elucidated.
VEGF and its receptors, fms-like tyrosine kinase (Fit
or VEGFR-1) and kinase insert domain-containing region
© 2003 Society for Reproduction and Fertility
1470-1626/2003
228 A. J. Rowe et al.
(KDR or VEGFR-2) have been implicated as key players
in vascular remodelling and placentation in women
(Ahmed et al., 1995; Cooper et al., 1995; Clark et al.,
1996, 1998; Coldman-Wohl et al., 2000; Helske et al.,
2001; Geva et al., 2002; Sugino et al., 2002), sheep
(Bogie et al., 2001), pigs (Winther et al., 1999) and
marmosets (Wulff et al., 2002) at later stages of preg¬
nancy. VEGF has been localized in endometrium of mice
(Chakraborty et al., 1995; Haider et al., 2000), golden
hamsters (Yi et al., 1999), rats (Rabbani and Rogers,
2001), rabbits (Das eta!., 1997) and Rhesus monkeys
(Ghosh et al., 2000) at this time. In mice, inhibition
of VEGF prevents oestrogen-induced uterine oedema
and implantation (Rockwell et al., 2002), and in rats,
the number of implantation sites was reduced after
administration of a VEGF blocking antibody (Rabbani
and Rogers, 2001).
Angiopoietins also appear to have a major role in regu¬
lation of blood vessel growth, maturation and regression,
but their importance at the time of implantation has yet to
be studied. However, their presence in placenta in later
stages of pregnancy has been documented in women
(Dunk et al., 2000) and marmosets (Wulff et al., 2002).
The aim of the present study was to describe the
localization of mRNA for angiogenic factors and their re¬
ceptors. Implantation occurs at day 11 after ovulation in
marmosets. This study was conducted on tissue collected
at the peri-implantation period (week 2 after ovulation) to
week 4 of gestation. Angiogenic processes occurring at
this early stage of pregnancy are still poorly understood
in women and with accumulating knowledge on the
effects of manipulation of angiogenesis in marmosets,
this species represents a potentially valuable model in
which to study these events.
Materials and Methods
Angiogenesis in marmoset endometrium
Experiments were carried out under the Animals
(Scientific Procedures) Act (1986) and were approved by
the local Ethical Review Committee. The tissues studied
were collected from marmosets which were the subject
of a previous report describing the changes in expres¬
sion of angiogenic factors associated with early preg¬
nancy in the corpus luteum (Rowe et al., 2002). Blood
samples were collected from adult female marmosets
three times a week and were assayed for ovulatory
increases in plasma progesterone concentration (Wulff
et al., 2001). During the mid- to late luteal phase of
the second recorded cycle, prostaglandin analogue, 1 p.g
PGF2c[ (cloprostenol; Planate, Coopers Animal Health
Ltd, Crewe), was administered i.m. to induce luteolysis
so that timing of the subsequent ovulation could be iden¬
tified accurately. A fertile male was introduced at the time
of prostaglandin administration. In anticipation of ovula¬
tion occurring 10 days after prostaglandin administration,
vaginal lavages were collected on days 7 and 9 of the fol¬
licular phase and examined for the presence of sper¬
matozoa. Marmosets were killed humanely at week 2
(n= 4), 3 (n—6) or 4 (n—6) after ovulation. A further
six non-pregnant late secretory phase animals were also
studied (Rowe etal., 2002). Uteri were fixed in 4% (w/v)
paraformaldehyde (Sigma, Poole).
Pregnancy was confirmed by examining serial sections
of the uterus for the presence of a trophoblast and determ-
ining plasma concentrations of chorionic gonadotrophin.
Chorionic gonadotrophin was measured according to the
method of Saltzman et al. (1998). The detection limit for
the assay was 12 ng ml-1. All non-pregnant animals had
concentrations of CG which were below the detection
limit of the assay.
Haematoxylin-eosin staining
Tissue sections (5 jo-m thickness) were cut on to
Super-frost plus slides (Sigma). Sections were dewaxed
in xylene, rehydrated in decreasing concentrations of
ethanol, and washed in distilled water before undergoing
haematoxylin-eosin staining. The slides were dehydrated
and mounted in pertex.
Localization of blood vessels by CD31
immunocytochemistry
Immunocytochemistry was performed to confirm
suggested endothelial cell localization of VEGFR-1,
VEGFR-2 and Tie-2 mRNA. Tissue sections (5 |xm thick¬
ness) were cut on to Super-frost plus slides for immun¬
ocytochemistry. The sections were dewaxed in xylene,
rehydrated in decreasing concentrations of ethanol and
washed in distilled water. Antigen retrieval was per¬
formed by boiling sections in a Tefal Clypso pressure
cooker in 0.01 mol citrate buffer l~', pH 6, for 6 min at
high pressure setting 2. The slides were then left for 20
min in hot buffer and washed in Tris-buffered saline (TBS:
0.05 mol Tris I"1, pH 7.4, 9 g NaCI I"1). The sections
were blocked in normal rabbit serum (diluted 1:5 in
TBS) for 30 min to reduce non-specific binding. The
primary antibody CD31 (monoclonal mouse anti-human
endothelial cell CD31, Clone JC/70A, no. M0823; Dako,
Glostrup) diluted 1:20 in TBS was used. Incubation was
performed overnight at 4°C. The slides were washed
three times in TBS. Incubation with the secondary
antibody (rabbit anti-mouse Ig; Dako, 1:60 diluted in
TBS) was performed for 40 min at room temperature
(22°C). This was followed by two TBS washes and
incubation of the APAAP complex (Dako; 1:100 dilution
in normal rabbit serum and TBS) for 40 min at room
temperature. Visualization was performed using ni-
troblue tetrazolium (NBT) solution containing 45 p,l NBT
substrate (Boehringer Mannheim, Mannheim), 10 ml
NBT buffer, 35 (xl Xphosphate (Boehringer Mannheim)
and 10 |xl levamisole (Sigma).
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Localization of VEGF, VEGFR-1 VEGFR-2,
angiopoietin I, angiopoietin 2 and Tie-2 mRNA
in the endometrium
In situ hybridization was performed as described
previously using complementary RNA probes for human
VEGF, VEGFR-1, VEGFR-2, angiopoietin 1, angiopoietin 2
and Tie-2 (Wulff et ah, 2000). The hVEGFR-1 probe was
a 641 bp PCR fragment that hybridizes to base pairs 22-
663 of the Fit mRNA. This comprises the region of the
encoding extracellular domain of the Fit protein. Thus,
the probe recognizes mRNA for both full-length and
soluble Fit. Sense and anti-sense probes were prepared
using an RNA transcription kit (Ambion, Austin, TX)
and labelled with 35[S] uridine 5[^-triphosphate (NEN,
Boston, MA). Deparaffinized sections were treated with
0.1 mol HCI I-1 for 20 min and digested in proteinase
K (5 p.g ml-1; Sigma) for 30 min at 37°C. After pre-
hybridization for 2 h at 55°C, subsequent hybridization
was performed in a moist chamber overnight at 55°C.
High stringency post-hybridization washings and ribo-
nuclease A treatment were used to remove excess probe.
The slides were dehydrated, dried and dipped in llford G5
liquid emulsion (H. A. West, Edinburgh) and exposed
for 12 weeks. The slides were subsequently developed
(Kodak D19 developer; Kodak, Rochester, NY) and fixed
(Kodak GBS, Kodak). All slides were counterstained with
haematoxylin, dehydrated and mounted.
Quantification of in situ hybridization
Uterine sections were scored and means were calcu¬
lated according to the grain density in the various differ¬
ent uterine compartments: namely, luminal epithelium,
upper zone stroma (area beneath the luminal epithe¬
lium), upper zone glands, lower zone glands (area adja¬
cent to myometrium), lower zone stroma and endothelial
cells. Scoring was performed by two independent observ¬
ers with the following classification: —: no detectable
specific signal above background levels; + (1): detectable
but low grain density clearly above background levels;
++ (2): moderate grain density; +++ (3): high grain density
without grain coalescence; and ++++ (4): grain coales¬
cence. Scoring of uteri was blind and random by each ob¬
server. An overall score was assigned for each compart¬
ment within a section. Significant differences between
groups (P<0.05) were determined using a Kruskal-Wallis
non-parametric test followed by Dunn's multiple com¬
parisons test. Representative photographs illustrate the
localization of mRNAs. In general, these reflect the
quantitative scoring but also show focal changes within
a compartment not distinguished by the scoring.
Results
Vascular endothelial growth factor (VEGF)
VEGF mRNA was localized to the glandular epithe¬
lium in the late secretory phase non-pregnant endomet¬
rium. Highest grain density was observed in the luminal
epithelium and glands of the upper zones. Grain density
was much reduced in the mid-zone glands, whereas
grains were completely absent from the lower zone
(Fig. 1 a,b). Exact cellular localization of VEGF mRNA to
glandular epithelium was confirmed under high power
images (Fig. 1 j).
In early pregnant endometrium, at 2 weeks after
ovulation, a similar localization was observed to that
in the non-pregnant animals (Fig. 1c-e). However, low
expression of stromal VEGF mRNA was apparent just
beneath the luminal epithelium (Fig. 1c,d). At this very
early stage of pregnancy, 3 days after implantation,
no expression of VEGF mRNA was observed in the
blastocyst or fetal membranes (Fig. 1c,d). By week 3 of
pregnancy (day 21), expression of VEGF mRNA remained
high in the glandular epithelium. Lower expression was
also observed in the lower zone glands (Fig. 1h,k). In
decidua, VEGF expression was relatively high and
punctate (Fig. 1f,g,i). In addition, by this stage of
pregnancy the blastocyst and fetal membranes were
expressing VEGF mRNA. Animals atweek 4 of pregnancy
(day 28) had similar VEGF mRNA localization to animals
at week 3; hence, a representative figure at 3 weeks is
shown (Fig. 1 f (dark field) and Fig. 1g (bright field). In all
sense slides, no specific signal was detected above a low
background (Fig. 1 h insert).
KDR and Fit (VEGFR-1 and VEGFR-2)
VEGFR-2 mRNA localization is shown (Fig. 2). It
should be noted that expression of VEGFR-1 mRNA was
consistently lower than that of VEGFR-2, but it was found
in the same cellular locations; thus, mainly photographs
of VEGFR-2 mRNA are shown (Fig. 2a—I). However, re¬
presentative images are included of VEGFR-1 hybridiza¬
tion at week 2 of pregnancy (Fig. 2m,n). Each receptor
localization and grain density was scored separately
(Table 1). In the late secretory non-pregnant endome¬
trium, VEGFR-2 mRNA was found exclusively in endo¬
thelial cells surrounding the upper zone glands beneath
the luminal epithelium (Fig. 2a,b,j). This observation
was confirmed by comparison with CD31 immunocyto-
chemistry to identify endothelial cells in sequential
sections (Fig. 2c). In endometrium from week 2 of
pregnancy, VEGFR-2 mRNA was localized to the upper
zone endothelium as in non-pregnant endometrium.
Grains were absent from the blastocyst and fetal mem¬
branes (Fig. 2d,e). At weeks 3 and 4 of pregnancy,
expression of VEGFR-2 mRNA remained in endothelial
cells of the upper zone with highest grain density
observed around large maternal vessels beneath the
luminal epithelium (Fig. 2g,h,k), which was again con¬
firmed by comparison with CD31 localization (Fig. 2i).
VEGFR-2 mRNA was also observed to a lesser extent
throughout the stromal compartment, again localized to
endothelial cells (Fig. 2l). In all sense slides, no specific
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Fig. 1. (a-k) In situ hybridization of vascular endothelial growth factor (VEGF) mRNA in marmoset (Callithrix jac-
chus) endometrium. (a,c,f) Dark-field and (b,d,g) corresponding light-field images. (a,b) Non-pregnant late secretory
phase endometrium. Note high expression in upper zone glands (UZ) and luminal epithelium (LE), which decreases
in the mid-zone (MZ) and is absent in the lower zone (LZ). (c,d,e) Endometrium from pregnant marmoset at day 14
after ovulation. (c,d) Note high expression in luminal epithelium (LE) and upper zone (UZ) glands, and absence of
expression in the blastocyst (B) and fetal membranes (FM). Lower VEGF expression can be seen in the upper zone
stroma (UZS) in (c). Insert in (c) is a higher power image of the luminal epithelium (x40). Insert in (d) is a higher
power bright-field image of the upper zone stroma (x 100). (e) CD31 staining for endothelial cells (EC) to emphasize
non-endothelial localization of stromal VEGF. (f-h) Typical VEGF expression at day 21 and day 28. (f) Dark-field
image of marmoset early implantation site. Note high punctate expression in the decidualized endometrium (DE)
and appearance of expression in the fetal membranes (FM). (g) Corresponding light-field image to (f). (h) Dark-field
image of lower zone (LZ) endometrium where there is low glandular VEGF expression. Insert in (h) is a representa¬
tive sense photograph, (i) Higher power (x 100) bright-field image of the luminal epithelium (LE) of an animal at week 3
of pregnancy; this image also illustrates the hybridization observed in decidualized stroma (DE). (j) High power (x 100)
image of the upper zone glands (UZG) in late secretory non-pregnant endometrium to confirm cellular localization,
(k) High power (x 100) image to highlight expression of VEGF in the lower zone glands (LZG) at this time. G: gland;
S: stroma. Scale bars represent (a,b,f,g) 100, (c,d inserts) 50 and (i-k) 25 tern.
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Fig. 2 In situ hybridization of vascular endothelial growth factor receptor (VEGFR) (a-l) -2 and (m,n) -1 mRNA in mar¬
moset (Callithrix jacchus) endometrium, (a-c) Non-pregnant late secretory phase endometrium, (a) Dark-field and
(b) light-field images of VEGFR-2 expression in upper zone endometrium. Note endothelial localization immediately sur¬
rounding glands as demonstrated by (c) CD31 immunocytochemistry and (j) high power (x 100) bright-field image. Also
note punctate expression in endothelial cells throughout the stroma in all stages studied illustrated by a representative
high power bright-field image (I), (d-f) Pregnant marmoset endometrium at day 14 after ovulation, (d) Dark-field and
(e) corresponding light-field images showing localization to large and small luminal blood vessels surrounding the
uppermost glands as indicated by CD31 immunocytochemistry for endothelial cells (f). Note absence of grains in
blastocyst and fetal membranes (FM). (g) Dark-field and (h) light-field images of VEGFR-2 expression at 3-4 weeks. Note
localization in upper zone to luminal maternal vessels (MV) as demonstrated by CD31 immunocytochemistry (i), and
high power bright-field image (k). In addition, note absence of localization to fetal membranes (g) and punctate through¬
out the stroma of lower zones (I), (o) A high power (x 100) bright-field sense image. Scale bars represent (b) 100, (f,i) 50
and (j—l,o) 25 jcm.
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Table 1. Quantification of in situ hybridization using relative grain density within uterine compartments of marmosets (Callithrix
jacchus) throughout the stages of pregnancy studied for vascular endothelial growth factor (VEGF), VEGFR-1 and -2, angiopoietin 1,
angiopoietin 2 and Tie-2
Upper zone Lower zone
Stage of cycle Luminal glandular Upper zone Upper zone glandular Lower zone
of endometrium epithelium epithelium stroma endothelium epithelium stroma
VEGF
Late secretory, non-pregnant +++a +++ - na - -
Week 2 of pregnancy +++ab ++ + na - -
Week 3 of pregnancy _l_ab ++ ++ na + -
Week 4 of pregnancy _b + ++ na ++ -
VEGFR-2 (-1)
Late secretory, non-pregnant - - - +++ (+) - -
Week 2 of pregnancy - - - ++ (+) - -
Week 3 of pregnancy - - - ++ (+) - -
Week 4 of pregnancy - - - ++ (+) - -
Angiopoietin 1
Late secretory, non-pregnant - + + na - -
Week 2 of pregnancy - + ++ na +++ -
Week 3 of pregnancy - + +++ na ++ -
Week 4 of pregnancy - + +++ na + -
Angiopoietin 2
Late secretory, non-pregnant - - - _a - -
Week 2 of pregnancy - - - _a - -
Week 3 of pregnancy - - - _a - -
Week 4 of pregnancy - - - +++b - -
Tie-2
Late secretory, non-pregnant - - + +++ - +
Week 2 of pregnancy - - + ++ - -
Week 3 of pregnancy - - + ++ - +
Week 4 of pregnancy - - + ++ - +
Analysis was performed by two independent observers. A Kruskal-Wallis test followed by a Dunn's multiple comparison test was used to
determine significant differences within a particular uterine compartment between groups.
Values given are mean scores, na: not assessed.
abDifferent letters denote significant differences (P < 0.05). No statistical comparisons were made between uterine compartments within
the same stage of the cycle.
signal was detected above a low background. This is
shown in (Fig. 2o), a x 100 magnification bright-field
image of the corresponding sense slide to Fig. 2k.
Angiopoietin 7
Angiopoietin 1 mRNA was localized to upper zone
stroma and, to a lesser extent, the glandular epithelium
of the upper zone in late secretory non-pregnant
endometrium. In pregnant endometrium at day 14, there
was high expression of angiopoietin 1 mRNA in the lower
zone glands (Fig. 3d,e,o) but it was completely absent
from adjacent compartments, the myometrium and mid-
zone endometrium (see insert Fig. 3d). In the upper
zone, expression of angiopoietin 1 mRNA was low in the
glandular epithelium but much more intense in stroma
(Fig. 3p). Grains were absent from blastocyst and fetal
membranes (Fig. 3f,g). At week 3 of pregnancy, upper
and lower zone glandular epithelial expression of angi¬
opoietin 1 mRNA was retained (Fig. 3h,j). Grain density
increased in the stroma at this stage (Table 1; Fig. 3h,i).
By day 28, clear, punctate angiopoietin 1 mRNA local¬
ization was observed throughout the decidualized stroma
(Fig. 3k,I,n). In all sense slides, no specific signal was
detected above a low background.
Angiopoietin 2
Angiopoietin 2 mRNA was detected only in animals
at week 4 of pregnancy, and it was localized exclusively
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in endothelial cells of maternal vessels (Table 1; Fig. 4).
In all sense slides, no specific signal was detected above
a low background.
Tie-2
In non-pregnant late secretory endometrium Tie-2
mRNA was expressed predominantly in endothelial cells
throughout the stroma of all zones (Fig. 5a,b,I). At
week 2 of pregnancy (day 14), the generalized pattern of
stromal expression observed in the non-pregnant animals
was reduced but was still present (Table 1; Fig. 5d,e).
High grain density was observed in endothelium im¬
mediately surrounding the upper zone glands at this
time (Fig. 5d,e,j). By weeks 3 and 4 of pregnancy,
luminal epithelial expression of Tie-2 mRNA was not
observed but expression was still observed in upper
zone decidualized stroma (Fig. 5g). By comparison with
CD31 immunocytochemistry (Fig. 5i) and high power
haematoxylin-eosin-stained sections (insert Fig. 5h),
Tie-2 appeared to be expressed in blood vessels
throughout the decidua. In all sense slides, no specific
signal was detected above a low background.
Discussion
In the present study the spatial and temporal patterns
of expression of mRNAs for VEGF, angiopoietins and
their receptors in marmoset uterus were described during
the peri-implantation period, allowing us to begin to
construct a working hypothesis as to their potential role
in oxygen and nutrient exchange and maternal vascular
remodelling.
Implantation occurs on day 11 after ovulation in mar¬
mosets, 3 days later than in women, and the blastocyst
remains in loose attachment to the surface epithelium
without epithelial fusion. Penetration of trophoblast into
maternal vessels occurs quite late, at days 45-60 of
gestation, compared with about day 12 in women
(Enders, 1993). Therefore, fetal demand for nutrients and
oxygen during early pregnancy must be met by diffusion
across the fetomaternal interface, a process likely to be
critically dependent on vascular permeability. Increased
permeability is generally thought to accompany tissue
growth and remodelling (Dvorak et al., 1999; Dvorak,
2000; Rabbani and Rogers, 2001). VEGF is a vascular
permeability factor as well as a mitogen for endothelial
cells (Keck et al., 1989). Permeability and uterine
oedema mediated by VEGF are critical for successful
implantation in rodents, in which inhibition of VEGF
prevented implantation (Dvorak et al., 1999; Dvorak,
2000; Rabbani and Rogers, 2001). Our finding that
VEGF mRNA was localized to upper zone endometrium
of all groups, increasing during the first few weeks of
pregnancy, implies a role for VEGF as a permeability
factor at this time.
The presence of VEGF mRNA in upper zone glandular
epithelium and luminal epithelium of non-pregnant late
secretory endometrium, with mRNA for both VEGFR-1
and -2 in endothelial cells of blood vessels immediately
surrounding these glands, is indicative of a local action
of VEGF. This is also observed in endometrium at
weeks 2 and 3 of pregnancy where it may be involved
in promoting fenestration of these vessels, thereby facil¬
itating oxygen transfer to the avascular fetus. Although
fetal membranes positive for CD31 were observed, they
had no capillary formation. It may be that these cells are
destined to become differentiated endothelial cells and
thus already express CD31 surface antigens.
Upregulation of stromal VEGF mRNA was observed
at week 4 of pregnancy. It is likely that the permeability
role of VEGF is decreasing at this point, as glandular
secretions are reduced and maternal sinusoids, although
not yet invaded by trophoblast, have much more intimate
contact with the more closely attached blastocyst, thus
facilitating diffusion. Very strong expression of VEGFR-1
and -2 mRNA was also observed in endothelial cells of
large maternal vessels immediately beneath the luminal
epithelium where fetal VEGF could be acting to promote
vessel migration such that fetal metabolic demands can
be adequately met. The pattern of mRNA localization
of VEGF and its receptors observed in the present
study is consistent with findings in women, in whom
fetal VEGF expression in tripronuclear zygotes has been
implicated to induce neoangiogenesis at the site of
implantation (Krussel et al., 2000). VEGF expression
has been documented in human placenta and in other
species in the later stages of placentation where it is
expressed in maternal decidua, but unlike our findings,
its receptor VEGFR-1 appeared to be expressed in
invading syncytial trophoblast (Ahmed et al., 1995;
Cooper et al., 1995; Clark et al., 1996). It may be that
fetal VEGF receptors are present only at later stages in
marmosets, when a more intimate interplay between
maternal and fetal tissues occurs (Wulff et al., 2002).
Soluble Fit has been reported to be produced by human
trophoblast in pregnancy and is detectable in the serum
of pregnant women (Banks etal., 1998). It is possible that
this also occurs in marmosets; however, no hybridization
of the VEGFR-1 probe to trophoblast was observed in
the present study despite our probe detecting both the
soluble and full-length receptor. No serum analyses were
conducted.
The roles of the angiopoietins and their receptor Tie-2
in early pregnancy are just beginning to be explored.
In general, angiopoietin 1 acts on its receptor Tie-2 to
promote stabilization of the endothelial cell-vascular
smooth muscle structure (Suri et al., 1996), whereas an¬
giopoietin 2 acts as an antagonist by binding to the Tie-2
receptor without transmitting a signal (Maisonpierre
et al., 1997; Lobov et al., 2002). In marmoset uterus,
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Fig. 3 (a-p) In situ hybridization of angiopoietin 1 mRNA in marmoset (Callithrix jacchus) endometrium, (a) Dark-field
and (b) corresponding light-field images of non-pregnant late secretory phase endometrium. Note angiopoietin 1
expression in stroma and low expression in glands of the upper zone endometrium. LE: luminal epithelium, (c)
Haematoxylin-eosinstained section of upper zone and luminal epithelium (x40). (d-g) Day 14 pregnant marmoset
endometrium, (d) Dark-field and (e) corresponding light-field images of high expression of angiopoietin 1 mRNA in the
glandular epithelium of the lower zone (LZ). Insert in (d) is a low power image (x 10) to demonstrate absence of grains in
myometrium and mid-zone endometrium, (o) High power image (x 100) to confirm cellular localization to glands of the
lower zone (LZG). (f) Dark-field and (g) corresponding light-field images of angiopoietin 1 localization in the upper zone
(UZ). Note low glandular localization together with stromal expression. Angiopoietin 1 is absent from the fetal membranes
(FM) and blastocyst (B). (h-j) Angiopoietin 1 expression at day 21 of pregnancy, (h) Dark-field and (i) light-field images of
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angiopoietin 1 mRNA was the most abundantly ex¬
pressed angiopoietin localized to upper zone glands
and stroma, whereas Tie-2 mRNA was expressed in
endothelial cells. In menstruating species after an infertile
cycle, menstruation and shedding of the upper zones ot
the eildumeliium uccui. The luwei zone and uiyOi'iiftl-
rium are comparatively more stable compartments from
which a new vascular and new upper zone endometrium
IS supplied (hmRh, 2IJI.II) Although the marmoset does
not menstruate, in infertile cycles a degree of vascular
remodelling may occur in the upper zones, whereas the
lower zones remain more stable, implicating a role for
angiopoietin 1 in this region as was observed in the
present study. However, the fertility rate is extremely high
in marmosets (Rowe ef a/., 2002) and hence this species
may retain a stable upper zone endometrium without
remodelling in response to progesterone withdrawal,
associated with basal expression of angiopoietin 1 and
Tie-2 in preparation for pregnancy. In fertile cycles,
the endometrium is preparing to receive an implanting
blastocyst and, thus, would require a stable maternal
vasculature. It is possible that angiopoietin 1 mRNA may
be expressed in the lower zones to maintain core vessel
stability.
During the peri-implantation period, stromal angi¬
opoietin 1 and Tie-2 mRNA expression in the upper
zones adjacent to the site of implantation was increased
compared with non-pregnant endometrium. As ges¬
tation progressed into weeks 3 and 4, expression of
angiopoietin 1 and Tie-2 mRNA in upper zone stroma
and decidua was further increased. This corresponds
with a continued requirement for a stable vasculature
at the maternal-fetal interface and eventual placentation
and development of a haemochorial placenta. This role
appears to extend to later pregnancy in marmosets, in
which angiopoietin 1 mRNA is localized exclusively to
syncytial trophoblasl (Wulff el a/., 2002), indicating that
once the fetal vasculature begins to develop, there may
be a need for stabilization of newly formed fetal vessels.
The only site of localization of angiopoietin 2 mRNA
was in large maternal vessels immediately beneath the
luminal epithelium of animals at week 4 of pregnancy,
where it was co-localized with Tie-2 mRNA. This is
similar to the situation observed in later stages of placen¬
tation in marmosets (Wulff ef a/., 2002). The presence
of VECF mRNA in the decidualized upper zone endo¬
metrium with its receptors in endothelial cells of this
same region, including large maternal vessels, is indic-
Fig. 4 (a-c) In situ hybridization of angiopoietin 2 mRNA in
pregnant marmoset (Callithrix jacchus) endometrium at day 28.
(a) Dark-field (x20) and (b) light-field (x100) images of upper
zone endometrium. Note angiopoietin 2 expression in endothelial
cells (EC) of large maternal vessels (MV), as demonstrated by
CD31 immunocytochemistry in (c) and higher power image in (b).
Angiopoietin 2 was absent from all other stages studied. Scale bars
represent (a) 100 and (b) 25 pm.
ative of a similar paracrine modulation. It is thought
that angiopoietin 2, when expressed in conjunction with
VEGF, can be pro-angiogenic, promoting destabilization
of vessels and breakdown of basal lamina to allow mi¬
gration of endothelial cells and subsequent angiogenesis.
angiopoietin 1 expression in the upper zone. Note expression in glandular epithelium and to a greater extent in stroma. This is also
highlighted in (p), a high power (x 100) bright-field image. UZS: upper zone stroma, (j) Dark-field image of lower zone (LZ) endometrium.
Note glandular epithelial localization of angiopoietin 1. (k-m) Angiopoietin 1 expression at day 28 of pregnancy, (k) Dark-field and (I)
corresponding light-field images of decidualized endometrium and luminal epithelium (LE). Note punctate expression of angiopoietin 1
mRNA throughout decidualized stroma, not in endothelial cells, which is further illustrated in (n), a higher power (x 100) bright-field
image. MV: maternal vessel, (m) Haematoxylin-eosin-stained section to demonstrate decidual morphology. Scale bars represent (a) 100,
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Fig. 5. (a-l) In situ hybridization of Tie-2 mRNA in marmoset (Callithrix jacchus) endometrium, (a-c) Non-pregnant late secretory
phase endometrium, (a) Dark-field and (b) light-field images of Tie-2 expression in stroma throughout all zones of the non¬
pregnant endometrium. Note expression localized to endothelial cells as demonstrated by CD31 immunocytochemistry (c) taken
at x 40 objective and higher power (x 100) bright-field images in (I). The insert in (I) illustrates CD31 immunocytochemistry,
counterstained with haematoxylin. (d-f) Pregnant marmoset endometrium at day 14 after ovulation, (d) Dark-field and
(e) corresponding light-field images of upper zone endometrium. Note localization to endothelial cells (EC) immediately
surrounding upper zone glands as demonstrated by (f) CD31 immunocytochemistry and (j,k) higher power (x 100) bright-
field images, (k) CD31 immunocytochemistry counterstained with haematoxylin. LE: luminal epithelium, (g-i) Typical Tie-2
expression at day 21 and day 28 of pregnancy, (g) Dark-field and (h) light-field images of upper zone decidualized endometrium.
FM: fetal membranes Note punctate expression of Tie-2 probably localized to endothelial cells as demonstrated by (i) CD31
immunocytochemistry. Insert shows a haematoxylin-eosin-stained section. Note vessels similar to areas of grain localization in
(g). Scale bars represent (b) 100, (c,h insert) 50 and (j-l, I insert) 25 p,m.
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Our findings indicate that at week 4 of pregnancy, VEGF
and angiopoietin 2 may be working synergistically to
promote migration of these vessels and establishment of
an efficient interface for nutrient and oxygen exchange
between the fetal and maternal circulation.
Neither angiopoietin nor Tie-2 mRNA was detected
in blastocyst or fetal membranes. Their presence in first
trimester placenta has been reported in women; Tie-2
has also been localized to trophoblast cells, as well as
endothelial cells (Dunk et at., 2000). However, Tie-2
mRNA has been observed in trophoblast in later stages
of pregnancy in marmosets (Wulff et ai, 2002).
It is also of interest that angiopoietin 2 is expressed
by uterine natural killer cells in human endometrium,
particularly those situated beneath the luminal epithe¬
lium and around vascular smooth muscle cells (Smith,
2001). No evidence for such expression was observed
in marmosets, in which angiopoietin 2 mRNA was
found exclusively in endothelial cells of luminal maternal
vessels as confirmed by CD31 immunocytochemistry.
In conclusion, this study has described the molecular
regulation of angiogenesis associated with implantation
and vascular remodelling during the peri-implantation
period in marmosets. It provides evidence that VEGFR-
1 and -2 and angiopoietin 1, angiopoietin 2 and Tie-2
interactions may be involved in the preparation of endo¬
metrium for implantation, remodelling of the maternal
vasculature during the peri-implantation period and
trophoblast invasion. Taken together with our previous
report on the molecular angiogenic events occurring
from week 7 of pregnancy to term, a comprehensive
picture of implantation and placentation in this primate
species is provided. Having proposed putative roles
for these angiogenic regulators in this process, there is
potential for in vivo studies using specific antagonists to
determine their physiological function.
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BrdU
The antibody reacts with the thymidine analogue 5-bromo-2'-deoxyuridine
(BrdU) and also with cellular DNA containing incorporated BrdU; it shows no
crossreactivity with other cellular components. The antibody may be applied




Code No./ Code/ Code-Nr. M 0823
Edition/Ausgabe 06.02.03
Intended use For in vitro diagnostic use.
Monoclonal Mouse Anti-Human CD31, Endothelial Cell, Clone JC70A, is
intended for use in immunocytochemistry. The antibody primarily
labels endothelial cells, and is a useful tool for the identification of benign and
malignant vascular disorders, including angiosarcomas. In addition, the
antibody is valuable for the labelling of vessels when determining
angiogenesis in several types of tumours.
Reagent provided Monoclonal mouse antibody provided in liquid form as cell
culture supernatant dialysed against 0.05 mol/L Tris/HCI, pH 7.2, and
containing
15 mmol/L NaN3.
Clone: JC70A (1). Isotype: lgG1, kappa.
Mouse IgG concentration: see label on vial.
Immunogen Cell membrane preparation from the spleen of a patient with
hairy cell leukaemia.
Specificity The antibody was clustered as anti-CD31 at the Fifth International
Workshop and Conference on Human Leucocyte Differentiation
Antigens. The epitope recognized was found to be within the extracellular
domain 1.
In Western blotting of membrane preparations from a spleen rich in the
antigen or from normal platelets, the antibody labels bands of
respectively 100 kDa and 130 kDa, the latter corresponding to classic CD31.
The smaller band of 100 kDa observed with the splenic
preparation may be due to proteolytic breakdown or to variations in
glycosylation.
Specimen preparation Paraffin sections: The antibody can be used for
labelling paraffin-embedded tissue sections fixed in formalin. Pre-treatment of
tissues with heat-induced epitope retrieval is required.
Performance characteristics Cells labelled by the antibody predominantly
display staining of the cell membrane, with weaker cytoplasmic staining.
Normal tissues: The antibody labels endothelial cells in a wide range of
tissues, including endothelium in renal glomerular capillaries and
the endothelium of vasa vasorum. In addition, the antibody labels
megakaryocytes and occasional plasma cells in bone marrow. In
frozen sections of human tonsil and spleen the antibody labels some non-
endothelial cells, including some mantle zone B cells and T cells.
In blood smears, the antibody labels neutrophil polymorphs, 50% of the
lymphocytes, all of the monocytes, and platelets.
Smooth Muscle Actin (Pericytes)
Clone 1A4
Code No./ Code/ Code-Nr. M 0851
Intended use For in vitro diagnostic use.
Monoclonal Mouse Anti-Human Smooth Muscle Actin, Clone 1A4, is intended
for use in immunocytochemistry. The antibody labels smooth
muscle cells, myofibroblasts and myoepithelial cells, and is a useful tool for
the identification of leiomyomas, leiomyosarcomas and
pleomorphic adenomas. Differential identification is aided by the results from
a panel of antibodies. Interpretation must be made within
the context of the patient's clinical history and other diagnostic tests by a
qualified pathologist.
Reagent provided Monoclonal mouse antibody provided in liquid form as cell
culture supernatant dialysed against 0.05 mol/L Tris/HCI, pH 7.2, and
containing
15 mmol/L NaN3.
Clone: 1A4. The 1A4 clone is identical to the anti-asm-1. Isotype: lgG2a,
kappa.
Mouse IgG concentration: see label on vial.
Immunogen N-terminal synthetic decapeptide of alpha-smooth muscle actin
coupled to keyhole limpet haemocyanin (KLH).
Specificity In Western blotting and 20-PAGE immunoblotting of the alpha-
smooth muscle isoform of actin, the antibody labels a band corresponding to
alpha-smooth muscle actin.
As demonstrated by Western blotting and/or immunocytochemistry, the
antibody cross-reacts with the alpha-smooth muscle actin-equivalent






Monoclonal Anti-Cytokeratin, pan antibody produced in
mouse
Clone C-11 Ascites fluid
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keratin-enriched preparation from cultured human
epidermoid carcinoma cell line A431.
The antibody recognizes human cytokeratins 4, 5, 6, 8, 10,
13, and 18. A broad spectrum antibody that reacts with a
wide variety of normal, reactive, and neoplastic epithelial
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1:400 using protease-digested, formalin-fixed,
paraffin-embedded sections of human or animal
tissues
contains 15 mM sodium azide
Storage temp. 20°C
Shipped in dry ice
Species reactivity : human, bovine, frog, kangaroo rat, rat, mouse
Isotype lgG1
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PR (C-19) is an affinity purified rabbit polyclonal antibody raised
against a peptide mapping at the carboxy terminus of the
progesterone receptor of human origin (identical to corresponding
mouse sequence).
PRODUCT
Each vial contains 200 pg IgG in 1.0 ml of PBS contains
0.1% sodium azide and 0.2% gelatin.
Blocking peptide is available for competition studies (sc-538 P)
(100 pg peptide in 0.5 ml PBS with 0.1% sodium azide and
100 pg BSA).
Also available as PR (C-19) X TransCruz antibody: sc-538 X for
gel supershift studies; supplied as 200 pg IgG in 0.1 ml PBS
contains 0.1% sodium azide.
SPECtFtCtTY
PR (C-19) is recommended for the detection of the progesterone
receptor (PR-A and PR-B) of mouse, rat and human origin by
Western blotting, immunoprecipitation and immunohistochemistry
(including paraffin-embedded sections).
PR (C-19) X TransCruz antibody is recommended for gel
supershift studies.
Recommended dilution range for Western blot analysis:
1:200-1:1000. Recommended starting dilution: 1:200.
For research use only, not for use in diagnostic procedures.
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DEFINITION Human VEGF mRNA.
LOCUS E15157 1873 bp RNA PAT 28-JUL-1999
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1873)
AUTHORS Uchida.K. .
TITLE PREPARATION OF ANTISENSE NUCLEIC ACID
JOURNAL Patent: JP 1998052285-A 24-FEB-1998;
BASE COUNT 422 a 506 c 608 g 3371
ORIGIN
1 tcgcggaggc ttggggcagc cgggtagctc ggaggtcgtg gcgctggggg ctagcaccag
61 cgctctgtcg ggaggcgcag cggttaggtg gaccggtcag cggactcacc ggccagggcg
121 ctcggtgctg gaatttgata ttcattgatc cgggttttat ccctcttctt ttttcttaaa
181 catttttttt taaaactgta ttgtttctcg ttttaattta tttttgcttg ccattcccca
241 cttgaatcgg gccgacggct tggggagatt gctctacttc cccaaatcac tgtggatttt
301 ggaaaccagc agaaagagga aagaggtagc aagagctcca gagagaagtc gaggaagaga
361 gagacggggt cagagagagc gcgcgggcgt gcgagcagcg aaagcgacag gggcaaagtg
421 agtgacctgc ttttgggggt gaccgccgga gcgcggcgtg agccctcccc cttgggatcc
481 cgcagctgac cagtcgcgct gacggacaga cagacagaca ccgcccccag ccccagctac
541 cacctcctcc ccggccggcg gcggacagtg gacgcggcgg cgagccgcgg gcaggggccg
601 gagcccgcgc ccggaggcgg ggtggagggg gtcggggctc gcggcgtcgc actgaaactt
661 ttcgtccaac ttctgggctg ttctcgcttc ggaggagccg tggtccgcgc gggggaagcc
721 gagccgagcg gagccgcgag aagtgctagc tcgggccggg aggagccgca gccggaggag
781 ggggaggagg aagaagagaa ggaagaggag agggggccgc agtggcgact cggcgctcgg
841 aagccgggct catggacggg tgaggcggcg gtgtgcgcag acagtgctcc agccgcgcgc
901 gctccccagg ccctggcccg ggcctcgggc cggggaggaa gagtagctcg ccgaggcgcc
961 gaggagagcg ggccgcccca cagcccgagc cggagaggga gcgcgagccg cgccggcccc
1021 ggtcgggcct ccgaaaccat gaactttctg ctgtcttggg tgcattggag ccttgccttg
1081 ctgctctacc tccaccatgc caagtggtcc caggctgcac ccatggcaga aggaggaggg
1141 cagaatcatc acgaagtggt gaagttcatg gatgtctatc agcgcagcta ctgccatcca
1201 atcgagaccc tggtggacat cttccaggag taccctgatg agatcgagta catcttcaag
1261 ccatcctgtg tgcccctgat gcgatgcggg ggctgctgca atgacgaggg cctggagtgt
1321 gtgcccactg aggagtccaa catcaccatg cagattatgc ggatcaaacc tcaccaaggc
1381 cagcacatag gagagatgag cttcctacag cacaacaaat gtgaatgcag accaaagaaa
1441 gatagagcaa gacaagaaaa atgtgacaag ccgaggcggt gagccgggca ggaggaagga
1501 gcctccctca gggtttcggg aaccagatct ctcaccagga aagactgata cagaacgatc
1561 gatacagaaa ccacgctgcc gccaccacac catcaccatc gacagaacag tccttaatcc
1621 agaaacctga aatgaaggaa gaggagactc tgcgcagagc actttgggtc cggagggcga
1681 gactccggcg gaagcattcc cgggcgggtg acccagcacg gtccctcttg gaattggatt
1741 cgccatttta tttttcttgc tgctaaatca ccgagcccgg aagattagag agttttattt
1801 ctgggattcc tgtagacaca cccacccaca tacatacatt tatatatata tatattatat
1861 atatataaat taa
DEFINITION Human mRNA for FLT.
LOCUS E14000 2523 bp DNA PAT 24-JUN-1998
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2523)
AUTHORS Shibuya,M. .
TITLE POLYPEPTIDE CAPABLE OF BINDING TO VEGF
JOURNAL Patent: JP 1997255700-A 1 30-SEP-1997;
TOAGOSEI CO LTD
BASE COUNT 765 a 596 c 589 g 5731
ORIGIN
1 gcggacactc ctctcggctc ctccccggca gcggcggcgg ctcggagcgg gctccggggc
61 tcgggtgcag cggccagcgg gcctggcggc gaggattacc cggggaagtg gttgtctcct
121 ggctggagcc gcgagacggg cgctcagggc gcggggccgg cggcggcgaa cgagaggacg
181 gactctggcg gccgggtcgt tggccggggg agcgcgggca ccgggcgagc aggccgcgtc
241 gcgctcacca tggtcagcta ctgggacacc ggggtcctgc tgtgcgcgct gctcagctgt
301 ctgcttctca caggatctag ttcaggttca aaattaaaag atcctgaact gagtttaaaa
361 ggcacccagc acatcatgca agcaggccag acactgcatc tccaatgcag gggggaagca
421 gcccataaat ggtctttgcc tgaaatggtg agtaaggaaa gcgaaaggct gagcataact
481 aaatctgcct gtggaagaaa tggcaaacaa ttctgcagta ctttaacctt gaacacagct
541 caagcaaacc acactggctt ctacagctgc aaatatctag ctgtacctac ttcaaagaag
601 aaggaaacag aatctgcaat ctatatattt attagtgata caggtagacc tttcgtagag
661 atgtacagtg aaatccccga aattatacac atgactgaag gaagggagct cgtcattccc
721 tgccgggtta cgtcacctaa catcactgtt actttaaaaa agtttccact tgacactttg
781 atccctgatg gaaaacgcat aatctgggac agtagaaagg gcttcatcat atcaaatgca
841 acgtacaaag aaatagggct tctgacctgt gaagcaacag tcaatgggca tttgtataag
901 acaaactatc tcacacatcg acaaaccaat acaatcatag atgtccaaat aagcacacca
961 cgcccagtca aattacttag aggccatact cttgtcctca attgtactgc taccactccc
1021 ttgaacacga gagttcaaat gacctggagt taccctgatg aaaaaaataa gagagcttcc
1081 gtaaggcgac gaattgacca aagcaattcc catgccaaca tattctacag tgttcttact
1141 attgacaaaa tgcagaacaa agacaaagga ctttatactt gtcgtgtaag gagtggacca
1201 tcattcaaat ctgttaacac ctcagtgcat atatatgata aagcattcat cactgtgaaa
» 1261 catcgaaaac agcaggtgct tgaaaccgta gctggcaagc ggtcttaccg gctctctatg
1321 aaagtgaagg catttccctc gccggaagtt gtatggttaa aagatgggtt acctgcgact
• 1381 gagaaatctg ctcgctattt gactcgtggc tactcgttaa ttatcaagga cgtaactgaa
1441 gaggatgcag ggaattatac aatcttgctg agcataaaac agtcaaatgt gtttaaaaac
» 1501 ctcactgcca ctctaattgt caatgtgaaa ccccagattt acgaaaaggc cgtgtcatcg
1561 tttccagacc cggctctcta cccactgggc agcagacaaa tcctgacttg taccgcatat
1621 ggtatccctc aacctacaat caagtggttc tggcacccct gtaaccataa tcattccgaa
1681 gcaaggtgtg acttttgttc caataatgaa gagtccttta tcctggatgc tgacagcaac
» 1741 atgggaaaca gaattgagag catcactcag cgcatggcaa taatagaagg aaagaataag
1801 atggctagca ccttggttgt ggctgactct agaatttctg gaatctacat ttgcatagct
1861 tccaataaag ttgggactgt gggaagaaac ataagctttt atatcacaga tgtgccaaat
1921 gggtttcatg ttaacttgga aaaaatgccg acggaaggag aggacctgaa actgtcttgc
1981 acagttaaca agttcttata cagagacgtt acttggattt tactgcggac agttaataac
2041 agaacaatgc actacagtat tagcaagcaa aaaatggcca tcactaagga gcactccatc
2101 actcttaatc ttaccatcat gaatgtttcc ctgcaagatt caggcaccta tgcctgcaga
2161 gccaggaatg tatacacagg ggaagaaatc ctccagaaga aagaaattac aatcagagat
2221 caggaagcac catacctcct gcgaaacctc agtgatcaca cagtggccat cagcagttcc
2281 accactttag actgtcatgc taatggtgtc cccgagcctc agatcacttg gtttaaaaac
2341 aaccacaaaa tacaacaaga gcctggaatt attttaggac caggaagcag cacgctgttt
2401 attgaaagag tcacagaaga ggatgaaggt gtctatcact gcaaagccac caaccagaag




DEFINITION Homo sapiens vascular endothelial growth factor receptor 2 (KDR)
mRNA, complete cds.
LOCUS AF063658 4071 bp mRNA PRI 16-MAY-1998
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 4071)
AUTHORS Yu,Y„ Whitney,R.G. and Sato,J.D.
TITLE Coding region for human VEGF receptor KDR (VEGFR-2)
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 4071)
AUTHORS Yu,Y., Whitney,R.G. and Sato,J.D.
TITLE Direct Submission
JOURNAL Submitted (06-MAY-1998) Adirondack Biomedical Research Institute,
10 Old Barn Rd., Lake Placid, NY 12946, USA
BASE COUNT 1169a 894 c 1025g 9831
ORIGIN
1 atggagagca aggtgctgct ggccgtcgcc ctgtggctct gcgtggagac ccgggccgcc
61 tctgtgggtt tgcctagtgt ttctcttgat ctgcccaggc tcagcataca aaaagacata
121 cttacaatta aggctaatac aactcttcaa attacttgca ggggacagag ggacttggac
181 tggctttggc ccaataatca gagtggcagt gagcaaaggg tggaggtgac tgagtgcagc
241 gatggcctct tctgtaagac actcacaatt ccaaaagtga tcggaaatga cactggagcc
301 tacaagtgct tctaccggga aactgacttg gcctcggtca tttatgtcta tgttcaagat
361 tacagatctc catttattgc ttctgttagt gaccaacatg gagtcgtgta cattactgag
421 aacaaaaaca aaactgtggt gattccatgt ctcgggtcca tttcaaatct caacgtgtca
481 ctttgtgcaa gatacccaga aaagagattt gttcctgatg gtaacagaat ttcctgggac
541 agcaagaagg gctttactat tcccagctac atgatcagct atgctggcat ggtcttctgt
601 gaagcaaaaa ttaatgatga aagttaccag tctattatgt acatagttgt cgttgtaggg
661 tataggattt atgatgtggt tctgagtccg tctcatggaa ttgaactatc tgttggagaa
721 aagcttgtct taaattgtac agcaagaact gaactaaatg tggggattga cttcaactgg
781 gaataccctt cttcgaagca tcagcataag aaacttgtaa accgagacct aaaaacccag
841 tctgggagtg agatgaagaa atttttgagc accttaacta tagatggtgt aacccggagt
901 gaccaaggat tgtacacctg tgcagcatcc agtgggctga tgaccaagaa gaacagcaca
' 961 tttgtcaggg tccatgaaaa accttttgtt gcttttggaa gtggcatgga atctctggtg
1021 gaagccacgg tgggggagcg tgtcagaatc cctgcgaagt accttggtta cccaccccca
* 1081 gaaataaaat ggtataaaaa tggaataccc cttgagtcca atcacacaat taaagcgggg
1141 catgtactga cgattatgga agtgagtgaa agagacacag gaaattacac tgtcatcctt
► 1201 accaatccca tttcaaagga gaagcagagc catgtggtct ctctggttgt gtatgtccca
1261 ccccagattg gtgagaaatc tctaatctct cctgtggatt cctaccagta cggcaccact
# 1321 caaacgctga catgtacggt ctatgccatt cctcccccgc atcacatcca ctggtattgg
1381 cagttggagg aagagtgcgc caacgagccc agccaagctg tctcagtgac aaacccatac
» 1441 ccttgtgaag aatggagaag tgtggaggac ttccagggag gaaataaaat tgaagttaat
1501 aaaaatcaat ttgctctaat tgaaggaaaa aacaaaactg taagtaccct tgttatccaa
1561 gcggcaaatg tgtcagcttt gtacaaatgt gaagcggtca acaaagtcgg gagaggagag
1621 agggtgatct ccttccacgt gaccaggggt cctgaaatta ctttgcaacc tgacatgcag
1681 cccactgagc aggagagcgt gtctttgtgg tgcactgcag acagatctac gtttgagaac
1741 ctcacatggt acaagcttgg cccacagcct ctgccaatcc atgtgggaga gttgcccaca
1801 cctgtttgca agaacttgga tactctttgg aaattgaatg ccaccatgtt ctctaatagc
1861 acaaatgaca ttttgatcat ggagcttaag aatgcatcct tgcaggacca aggagactat
1921 gtctgccttg ctcaagacag gaagaccaag aaaagacatt gcgtggtcag gcagctcaca
1981 gtcctagagc gtgtggcacc cacgatcaca ggaaacctgg agaatcagac gacaagtatt
2041 ggggaaagca tcgaagtctc atgcacggca tctgggaatc cccctccaca gatcatgtgg
2101 tttaaagata atgagaccct tgtagaagac tcaggcattg tattgaagga tgggaaccgg
2161 aacctcacta tccgcagagt gaggaaggag gacgaaggcc tctacacctg ccaggcatgc
2221 agtgttcttg gctgtgcaaa agtggaggca tttttcataa tagaaggtgc ccaggaaaag
2281 acgaacttgg aaatcattat tctagtaggc acggcggtga ttgccatgtt cttctggcta
2341 cttcttgtca tcatcctacg gaccgttaag cgggccaatg gaggggaact gaagacaggc
2401 tacttgtcca tcgtcatgga tccagatgaa ctcccattgg atgaacattg tgaacgactg
2461 ccttatgatg ccagcaaatg ggaattcccc agagaccggc tgaagctagg taagcctctt
2521 ggccgtggtg cctttggcca agtgattgaa gcagatgcct ttggaattga caagacagca
2581 acttgcagga cagtagcagt caaaatgttg aaagaaggag caacacacag tgagcatcga
2641 gctctcatgt ctgaactcaa gatcctcatt catattggtc accatctcaa tgtggtcaac
2701 cttctaggtg cctgtaccaa gccaggaggg ccactcatgg tgattgtgga attctgcaaa
2761 tttggaaacc tgtccactta cctgaggagc aagagaaatg aatttgtccc ctacaagacc
2821 aaaggggcac gattccgtca agggaaagac tacgttggag caatccctgt ggatctgaaa
2881 cggcgcttgg acagcatcac cagtagccag agctcagcca gctctggatt tgtggaggag
2941 aagtccctca gtgatgtaga agaagaggaa gctcctgaag atctgtataa ggacttcctg
3001 accttggagc atctcatctg ttacagcttc caagtggcta agggcatgga gttcttggca
3061 tcgcgaaagt gtatccacag ggacctggcg gcacgaaata tcctcttatc ggagaagaac
3121 gtggttaaaa tctgtgactt tggcttggcc cgggatattt ataaagatcc agattatgtc
3181 agaaaaggag atgctcgcct ccctttgaaa tggatggccc cagaaacaat ttttgacaga
3241 gtgtacacaa tccagagtga cgtctggtct tttggtgttt tgctgtggga aatattttcc
3301 ttaggtgctt ctccatatcc tggggtaaag attgatgaag aattttgtag gcgattgaaa
3361 gaaggaacta gaatgagggc ccctgattat actacaccag aaatgtacca gaccatgctg
3421 gactgctggc acggggagcc cagtcagaga cccacgtttt cagagttggt ggaacatttg
3481 ggaaatctct tgcaagctaa tgctcagcag gatggcaaag actacattgt tcttccgata
3541 tcagagactt tgagcatgga agaggattct ggactctctc tgcctacctc acctgtttcc
3601 tgtatggagg aggaggaagt atgtgacccc aaattccatt atgacaacac agcaggaatc
3661 agtcagtatc tgcagaacag taagcgaaag agccggcctg tgagtgtaaa aacatttgaa
3721 gatatcccgt tagaagaacc agaagtaaaa gtaatcccag atgacaacca gacggacagt
3781 ggtatggttc ttgcctcaga agagctgaaa actttggaag acagaaccaa attatctcca
3841 tcttttggtg gaatggtgcc cagcaaaagc agggagtctg tggcatctga aggctcaaac
3901 cagacaagcg gctaccagtc cggatatcac tccgatgaca cagacaccac cgtgtactcc
3961 agtgaggaag cagaactttt aaagctgata gagattggag tgcaaaccgg tagcacagcc




DEFINITION Human angiopoietin-1 mRNA, complete cds.
LOCUS HSU83508 2149 bp mRNA linear PRI26-MAR-1997
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2149)
AUTHORS Davis,S., Aldrich,T.H., Jones,P.F., Acheson,A., Compton.D.L.,
Jain,V., Ryan,T.E., Bruno,J., Radziejewski,C., Maisonpierre,P.C.
and Yancopoulos,G.D.
TITLE Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by
secretion-trap expression cloning
JOURNAL Cell 87 (7), 1161-1169 (1996)
REFERENCE 2 (bases 1 to 2149)
AUTHORS Davis,S., Aldrich,T.H., Jones,P.F., Acheson.A., Compton,D.L.,
Jain,V., Ryan.T.E., Bruno,J., Radziejewski,C., Maisonpierre,P.C.
and Yancopoulos,G.D.
TITLE Direct Submission
JOURNAL Submitted (31-DEC-1996) Discovery, Regeneron Pharmaceuticals, 777
Old Saw Mill River Road, Tarrytown, NY 10591, USA
ORIGIN
1 cagctgactc aggcaggctc catgctgaac ggtcacacag agaggaaaca ataaatctca
61 gctactatgc aataaatatc tcaagtttta acgaagaaaa acatcattgc agtgaaataa
121 aaaattttaa aattttagaa caaagctaac aaatggctag ttttctatga ttcttcttca
181 aacgctttct ttgaggggga aagagtcaaa caaacaagca gttttacctg aaataaagaa
241 ctagttttag aggtcagaag aaaggagcaa gttttgcgag aggcacggaa ggagtgtgct
301 ggcagtacaa tgacagtttt cctttccttt gctttcctcg ctgccattct gactcacata
361 gggtgcagca atcagcgccg aagtccagaa aacagtggga gaagatataa ccggattcaa
421 catgggcaat gtgcctacac tttcattctt ccagaacacg atggcaactg tcgtgagagt
481 acgacagacc agtacaacac aaacgctctg cagagagatg ctccacacgt ggaaccggat
541 ttctcttccc agaaacttca acatctggaa catgtgatgg aaaattatac tcagtggctg
601 caaaaacttg agaattacat tgtggaaaac atgaagtcgg agatggccca gatacagcag
661 aatgcagttc agaaccacac ggctaccatg ctggagatag gaaccagcct cctctctcag
721 actgcagagc agaccagaaa gctgacagat gttgagaccc aggtactaaa tcaaacttct
781 cgacttgaga tacagctgct ggagaattca ttatccacct acaagctaga gaagcaactt
841 cttcaacaga caaatgaaat cttgaagatc catgaaaaaa acagtttatt agaacataaa
901 atcttagaaa tggaaggaaa acacaaggaa gagttggaca ccttaaagga agagaaagag
961 aaccttcaag gcttggttac tcgtcaaaca tatataatcc aggagctgga aaagcaatta
1021 aacagagcta ccaccaacaa cagtgtcctt cagaagcagc aactggagct gatggacaca
1081 gtccacaacc ttgtcaatct ttgcactaaa gaaggtgttt tactaaaggg aggaaaaaga
1141 gaggaagaga aaccatttag agactgtgca gatgtatatc aagctggttt taataaaagt
1201 ggaatctaca ctatttatat taataatatg ccagaaccca aaaaggtgtt ttgcaatatg
1261 gatgtcaatg ggggaggttg gactgtaata caacatcgtg aagatggaag tctagatttc
1321 caaagaggct ggaaggaata taaaatgggt tttggaaatc cctccggtga atattggctg
1381 gggaatgagt ttatttttgc cattaccagt cagaggcagt acatgctaag aattgagtta
1441 atggactggg aagggaaccg agcctattca cagtatgaca gattccacat aggaaatgaa
1501 aagcaaaact ataggttgta tttaaaaggt cacactggga cagcaggaaa acagagcagc
1561 ctgatcttac acggtgctga tttcagcact aaagatgctg ataatgacaa ctgtatgtgc
1621 aaatgtgccc tcatgttaac aggaggatgg tggtttgatg cttgtggccc ctccaatcta
1681 aatggaatgt tctatactgc gggacaaaac catggaaaac tgaatgggat aaagtggcac
1741 tacttcaaag ggcccagtta ctccttacgt tccacaacta tgatgattcg acctttagat
1801 ttttgaaagc gcaatgtcag aagcgattat gaaagcaaca aagaaatccg gagaagctgc
1861 caggtgagaa actgtttgaa aacttcagaa gcaaacaata ttgtctccct tccagcaata
1921 agtggtagtt atgtgaagtc accaaggttc ttgaccgtga atctggagcc gtttgagttc
1981 acaagagtct ctacttgggg tgacagtgct cacgtggctc gactatagaa aactccactg
2041 actgtcgggc tttaaaaagg gaagaaactg ctgagcttgc tgtgcttcaa actactactg
2101 gaccttattt tggaactatg gtagccagat gataaatatg gttaatttc
DEFINITION Homo sapiens angiopoietin 2 (ANGPT2), mRNA.
LOCUS NM_001147 2269 bp mRNA linear PRI20-DEC-2003
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2269)
AUTHORS Zhou,Y., Bellingard,V., Feng.K.T., McMaster,M. and Fisher,S.J.
TITLE Human cytotrophoblasts promote endothelial survival and vascular
•
remodeling through secretion of Ang2, PIGF, and VEGF-C
JOURNAL Dev. Biol. 263 (1), 114-125 (2003)
PUBMED 14568550
ORIGIN
1 tgggttggtg tttatctcct cccagccttg agggagggaa caacactgta ggatctgggg
61 agagaggaac aaaggaccgt gaaagctgct ctgtaaaagc tgacacagcc ctcccaagtg
121 agcaggactg ttcttcccac tgcaatctga cagtttactg catgcctgga gagaacacag
181 cagtaaaaac caggtttgct actggaaaaa gaggaaagag aagactttca ttgacggacc
241 cagccatggc agcgtagcag ccctgcgttt cagacggcag cagctcggga ctctggacgt
301 gtgtttgccc tcaagtttgc taagctgctg gtttattact gaagaaagaa tgtggcagat
361 tgttttcttt actctgagct gtgatcttgt cttggccgca gcctataaca actttcggaa
421 gagcatggac agcataggaa agaagcaata tcaggtccag catgggtcct gcagctacac
481 tttcctcctg ccagagatgg acaactgccg ctcttcctcc agcccctacg tgtccaatgc
541 tgtgcagagg gacgcgccgc tcgaatacga tgactcggtg cagaggctgc aagtgctgga
601 gaacatcatg gaaaacaaca ctcagtggct aatgaagctt gagaattata tccaggacaa
661 catgaagaaa gaaatggtag agatacagca gaatgcagta cagaaccaga cggctgtgat
721 gatagaaata gggacaaacc tgttgaacca aacagctgag caaacgcgga agttaactga
781 tgtggaagcc caagtattaa atcagaccac gagacttgaa cttcagctct tggaacactc
841 cctctcgaca aacaaattgg aaaaacagat tttggaccag accagtgaaa taaacaaatt
901 gcaagataag aacagtttcc tagaaaagaa ggtgctagct atggaagaca agcacatcat
961 ccaactacag tcaataaaag aagagaaaga tcagctacag gtgttagtat ccaagcaaaa
1021 ttccatcatt gaagaactag aaaaaaaaat agtgactgcc acggtgaata attcagttct
1081 tcaaaagcag caacatgatc tcatggagac agttaataac ttactgacta tgatgtccac
1141 atcaaactca gctaaggacc ccactgttgc taaagaagaa caaatcagct tcagagactg
1201 tgctgaagta ttcaaatcag gacacaccac aaatggcatc tacacgttaa cattccctaa
1261 ttctacagaa gagatcaagg cctactgtga catggaagct ggaggaggcg ggtggacaat
1 1321 tattcagcga cgtgaggatg gcagcgttga ttttcagagg acttggaaag aatataaagt
1381 gggatttggt aacccttcag gagaatattg gctgggaaat gagtttgttt cgcaactgac
» 1441 taatcagcaa cgctatgtgc ttaaaataca ccttaaagac tgggaaggga atgaggctta
1501 ctcattgtat gaacatttct atctctcaag tgaagaactc aattatagga ttcaccttaa
» 1561 aggacttaca gggacagccg gcaaaataag cagcatcagc caaccaggaa atgattttag
1621 cacaaaggat ggagacaacg acaaatgtat ttgcaaatgt tcacaaatgc taacaggagg
1681 ctggtggttt gatgcatgtg gtccttccaa cttgaacgga atgtactatc cacagaggca
1741 gaacacaaat aagttcaacg gcattaaatg gtactactgg aaaggctcag gctattcgct
> 1801 caaggccaca accatgatga tccgaccagc agatttctaa acatcccagt ccacctgagg
1861 aactgtctcg aactattttc aaagacttaa gcccagtgca ctgaaagtca cggctgcgca
1921 ctgtgtcctc ttccaccaca gagggcgtgt gctcggtgct gacgggaccc acatgctcca
1981 gattagagcc tgtaaacttt atcacttaaa cttgcatcac ttaacggacc aaagcaagac
2041 cctaaacatc cataattgtg attagacaga acacctatgc aaagatgaac ccgaggctga
2101 gaatcagact gacagtttac agacgctgct gtcacaacca agaatgttat gtgcaagttt
2161 atcagtaaat aactggaaaa cagaacactt atgttataca atacagatca tcttggaact
2221 gcattcttct gagcactgtt tatacactgt gtaaataccc atatgtcct
DEFINITION Homo sapiens TEK tyrosine kinase, endothelial (venous
malformations, multiple cutaneous and mucosal) (TEK), mRNA.
LOCUS NM 000459 4138 bp mRNA linear PRI20-DEC-2003
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 4138)
AUTHORS Cascone,!., Audero,E., Giraudo,E., Napione,L., Maniero,F.,
Philips,M.R., Collard.J.G., Serini,G. and Bussolino,F.
TITLE Tie-2-dependent activation of RhoA and Rac1 participates in
endothelial cell motility triggered by angiopoietin-1
JOURNAL Blood 102 (7), 2482-2490 (2003)
PUBMED 12816861
REMARK GeneRIF: Angiopoietin-1 is implicated in the maturation and
remodeling of the vascular network during embryo development and in
adult life through its tyrosine kinase receptor Tie-2 stimulates
endothelial cells to migrate and change shape.
ORIGIN
1 cttctgtgct gttccttctt gcctctaact tgtaaacaag acgtactagg acgatgctaa
61 tggaaagtca caaaccgctg ggtttttgaa aggatccttg ggacctcatg cacatttgtg
121 gaaactggat ggagagattt ggggaagcat ggactcttta gccagcttag ttctctgtgg
181 agtcagcttg ctcctttctg gaactgtgga aggtgccatg gacttgatct tgatcaattc
241 cctacctctt gtatctgatg ctgaaacatc tctcacctgc attgcctctg ggtggcgccc
301 ccatgagccc atcaccatag gaagggactt tgaagcctta atgaaccagc accaggatcc
361 gctggaagtt actcaagatg tgaccagaga atgggctaaa aaagttgttt ggaagagaga
421 aaaggctagt aagatcaatg gtgcttattt ctgtgaaggg cgagttcgag gagaggcaat
481 caggatacga accatgaaga tgcgtcaaca agcttccttc ctaccagcta ctttaactat
541 gactgtggac aagggagata acgtgaacat atctttcaaa aaggtattga ttaaagaaga
601 agatgcagtg atttacaaaa atggttcctt catccattca gtgccccggc atgaagtacc
661 tgatattcta gaagtacacc tgcctcatgc tcagccccag gatgctggag tgtactcggc
721 caggtatata ggaggaaacc tcttcacctc ggccttcacc aggctgatag tccggagatg
781 tgaagcccag aagtggggac ctgaatgcaa ccatctctgt actgcttgta tgaacaatgg
841 tgtctgccat gaagatactg gagaatgcat ttgccctcct gggtttatgg gaaggacgtg
901 tgagaaggct tgtgaactgc acacgtttgg cagaacttgt aaagaaaggt gcagtggaca
961 agagggatgc aagtcttatg tgttctgtct ccctgacccc tatgggtgtt cctgtgccac
1021 aggctggaag ggtctgcagt gcaatgaagc atgccaccct ggtttttacg ggccagattg
1081 taagcttagg tgcagctgca acaatgggga gatgtgtgat cgcttccaag gatgtctctg
1141 ctctccagga tggcaggggc tccagtgtga gagagaaggc ataccgagga tgaccccaaa
1201 gatagtggat ttgccagatc atatagaagt aaacagtggt aaatttaatc ccatttgcaa
1261 agcttctggc tggccgctac ctactaatga agaaatgacc ctggtgaagc cggatgggac
1321 agtgctccat ccaaaagact ttaaccatac ggatcatttc tcagtagcca tattcaccat
1381 ccaccggatc ctcccccctg actcaggagt ttgggtctgc agtgtgaaca cagtggctgg
1441 gatggtggaa aagcccttca acatttctgt taaagttctt ccaaagcccc tgaatgcccc
1501 aaacgtgatt gacactggac ataactttgc tgtcatcaac atcagctctg agccttactt
1561 tggggatgga ccaatcaaat ccaagaagct tctatacaaa cccgttaatc actatgaggc
1621 ttggcaacat attcaagtga caaatgagat tgttacactc aactatttgg aacctcggac
1681 agaatatgaa ctctgtgtgc aactggtccg tcgtggagag ggtggggaag ggcatcctgg
1741 acctgtgaga cgcttcacaa cagcttctat cggactccct cctccaagag gtctaaatct
1801 cctgcctaaa agtcagacca ctctaaattt gacctggcaa ccaatatttc caagctcgga
1861 agatgacttt tatgttgaag tggagagaag gtctgtgcaa aaaagtgatc agcagaatat
1921 taaagttcca ggcaacttga cttcggtgct acttaacaac ttacatccca gggagcagta




































ttggaccctt agtgacattc ttcctcctca accagaaaac atcaagattt ccaacattac
acactcctcg gctgtgattt cttggacaat attggatggc tattctattt cttctattac
tatccgttac aaggttcaag gcaagaatga agaccagcac gttgatgtga agataaagaa
tgccaccatc attcagtatc agctcaaggg cctagagcct gaaacagcat accaggtgga
catttttgca gagaacaaca tagggtcaag caacccagcc ttttctcatg aactggtgac
cctcccagaa tctcaagcac cagcggacct cggagggggg aagatgctgc ttatagccat
ccttggctct gctggaatga cctgcctgac tgtgctgttg gcctttctga tcatattgca
attgaagagg gcaaatgtgc aaaggagaat ggcccaagcc ttccaaaacg tgagggaaga
accagctgtg cagttcaact cagggactct ggccctaaac aggaaggtca aaaacaaccc
agatcctaca atttatccag tgcttgactg gaatgacatc aaatttcaag atgtgattgg
ggagggcaat tttggccaag ttcttaaggc gcgcatcaag aaggatgggt tacggatgga
tgctgccatc aaaagaatga aagaatatgc ctccaaagat gatcacaggg actttgcagg
agaactggaa gttctttgta aacttggaca ccatccaaac atcatcaatc tcttaggagc
atgtgaacat cgaggctact tgtacctggc cattgagtac gcgccccatg gaaaccttct
ggacttcctt cgcaagagcc gtgtgctgga gacggaccca gcatttgcca ttgccaatag
caccgcgtcc acactgtcct cccagcagct ccttcacttc gctgccgacg tggcccgggg
catggactac ttgagccaaa aacagtttat ccacagggat ctggctgcca gaaacatttt
agttggtgaa aactatgtgg caaaaatagc agattttgga ttgtcccgag gtcaagaggt
gtacgtgaaa aagacaatgg gaaggctccc agtgcgctgg atggccatcg agtcactgaa
ttacagtgtg tacacaacca acagtgatgt atggtcctat ggtgtgttac tatgggagat
tgttagctta ggaggcacac cctactgcgg gatgacttgt gcagaactct acgagaagct
gccccagggc tacagactgg agaagcccct gaactgtgat gatgaggtgt atgatctaat
gagacaatgc tggcgggaga agccttatga gaggccatca tttgcccaga tattggtgtc
cttaaacaga atgttagagg agcgaaagac ctacgtgaat accacgcttt atgagaagtt
tacttatgca ggaattgact gttctgctga agaagcggcc taggacagaa catctgtata
ccctctgttt ccctttcact ggcatgggag acccttgaca actgctgaga aaacatgcct
ctgccaaagg atgtgatata taagtgtaca tatgtgctgg aattctaaca agtcataggt
taatatttaa gacactgaaa aatctaagtg atataaatca gattcttctc tctcatttta
tccctcacct gtagcatgcc agtcccgttt catttagtca tgtgaccact ctgtcttgtg
tttccacagc ctgcaagttc agtccaggat gctaacatct aaaaatagac ttaaatctca
ttgcttacaa gcctaagaat ctttagagaa gtatacataa gtttaggata aaataatggg
attttctttt cttttctctg gtaatattga cttgtatatt ttaagaaata acagaaagcc
tgggtgacat ttgggagaca tgtgacattt atatattgaa ttaatatccc tacatgtatt
gcacattgta aaaagtttta gttttgatga gttgtgagtt taccttgtat actgtaggca
cactttgcac tgatatatca tgagtgaata aatgtcttgc ctactcaaaa aaaaaaaa
Homology of probes with marmoset
VEGF
VEGF probe 578 bp
Marmoset sequence ACCESSION AJ278192 374bp
Matches very well from 120 -422 of our probe, bases 1-303 of the
Marmoset sequence, with 6 mismatches, ie 98% homology.
The rest of the Marmoset 304 - 374 only gives 23% homology.
This corresponds to 1158 -1531 of the published Human
sequence ACCESSION E15157
FLT
Published Human sequence ACCESSION AJ278194
our probe 1507-1778
marmoset ACCESSION AJ278194
3592-3910 8 mismatches 98% homology
Our probe detects both sflt and Flt1
KDR
Published Human sequence ACCESSION AJ278193
our probe 1355-1767
marmoset sequence ACCESSION AJ278193
2491-2776 7 mismatches 97% homology
Ang-1, Ang-2 and Tie-2
No marmoset data available
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